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Summary
Dysbindin (dystrobrevin-binding protein 1; DTNBP 1) has been implicated as a 
schizophrenia candidate gene. However while numerous positive associations have 
been reported, no non-synonymous alleles have been found which account for the 
association. A number of recent studies suggest that altered dysbindin expression may 
be the mechanism by which DTNBP 1 variants confer susceptibility to schizophrenia. 
Therefore one objective of this study was to identify putative DTNBP 1 cis-acting 
variants and perform association analyses of these variants with schizophrenia and 
allelic expression differences observed at the DTNBP 1 locus.
While four variants were associated with schizophrenia, logistic regression suggested 
that the signal observed at these polymorphisms was not independent of the most 
associated SNP rs4715984. Comparison with the results of a DTNBP 1 allelic 
expression assay revealed that seven SNPs were associated with differential expression. 
Post hoc analysis revealed that the majority of the expression differences were 
accounted for by variation at two loci (rs2619538 and rsl 3198512), one of which 
(rsl3198512) was subsequently shown to directly affect transcription in vitro using a 
luciferase reporter gene assay. As rs4715984 was not correlated with allelic expression 
differences it implies that a reduction in dysbindin expression through cis-acting 
variation may not be the primary aetiological factor in schizophrenia pathogenesis. This 
was supported by further analysis of a schizophrenia risk haplotype previously reported 
to be associated with differential expression as the refined haplotype was no longer 
correlated.
A second objective of this thesis was to investigate the hypothesis that DTNBP 1 could 
cause susceptibility to schizophrenia through its role within the BLOC-1 complex. 
Association analysis was performed on BLOC-1 genes which displayed evidence of 
being under the influence of cis-acting regulation. MUTED, a BLOC-1 gene previously 
reported as associated to schizophrenia was also investigated. However association 
results provided no compelling support for the hypothesis that DTNBP 1 contributes to 
susceptibility to schizophrenia through the BLOC-1 complex.
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Chapter 1: Introduction
1.1 Schizophrenia
Schizophrenia is a severe psychiatric disorder with a lifetime risk of ~1% [1]. The 
disease is characterised by psychotic symptoms, apathy, altered emotional reactivity 
and disorganised behaviour [2]. Although subtle cognitive and behavioural symptoms 
are present from early childhood, onset of the more distinguishing features is 
commonly in the late teens and early twenties. These symptoms often result in impaired 
functioning in work, school, parenting, independent living and interpersonal 
relationships.
Although outcomes are variable, the typical course of schizophrenia is one of relapses 
followed by partial remission. Even with treatment, only 20%-40% of patients 
diagnosed with schizophrenia or schizophrenia spectrum disorder (SSD) have been 
found to show a substantial clinical improvement after 5-6 years of treatment [3].
Due to the pervasiveness of associated deficits and often life-long course, schizophrenia 
is among the top ten leading causes of disease related disability in the world [4]. 
Sufferers are often the most vulnerable, isolated and disadvantaged individuals in 
society [5]. In addition to the core symptoms which result in impaired functioning, 
schizophrenic patients are also at an increased risk of alcohol and drug problems, 
violent victimisation, post traumatic stress disorder, housing instability and 
homelessness, smoking-related illness’ and depression. The net result of exposure to 
these risks is an increased mortality due to suicide (estimated at 5%), accidents, or 
illness’ such as respiratory and cardiovascular diseases [6, 7].
In addition to the suffering caused to patients and their families, schizophrenia also has 
an enormous economic impact. In 1996 the cost of schizophrenia to the UK economy
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was estimated at £2.6 billion [8] and the combined economic and social costs of 
schizophrenia have been estimated to account for 2.3% of all burdens within developed 
countries [9].
At present schizophrenia cannot clearly be defined at a biological level and the disorder 
is inadequately treated by current therapies. Understanding schizophrenia from a 
genetic viewpoint will hopefully lead to a full understanding of the biological pathways 
involved in schizophrenia aetiology and as a result, successful treatment. The purpose 
of the following study was therefore to identify and understand genetic variants that 
influence schizophrenia susceptibility.
1.1.1 History of Schizophrenia
The condition now referred to as schizophrenia was first characterised in 1893 by the 
German psychiatrist Emil Kraepelin, under the name dementia praecox [10]. This 
disorder was established by grouping together several previously described syndromes 
which included hebephrenia, catatonia and paranoid dementia. The distinguishing 
features of dementia praecox were two fold. Firstly, Kraepelin noted that, unlike other 
dementia such as Alzheimer’s disease which occurred later in life, dementia praecox 
usually began in late teens or early adulthood. Secondly, Kraepelin described dementia 
praecox as a deteriorating psychotic disorder whose primary disturbance was not one of 
mood but of cognition [11].
In addition to dementia praecox, Kraepelin also characterised the disorder manic 
depressive illness. By reclassifying the majority of the previously described insanities 
as either dementia praecox or manic depressive illness, Kraepelin introduced 
considerable order to the previously confused field of psychiatric disease classification. 
However there were a number of objections to Kraepelin’s categorisations including his 
belief that dementia praecox was a form of dementia with a deteriorating course and no 
chance of recovery. To this end, dementia praecox was renamed by a Swiss psychiatrist 
Eugen Bleuler at the beginning of the 20th century. Bleuler realised that the illness was
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not a type of dementia as some patients did improve rather than continue to deteriorate 
as Kraepelin had suggested. In light of this, and other observations, Bleuler coined the 
term schizophrenia, from the Greek schizen ‘to split’ and phren ‘mind’, to emphasise 
the fact that the disorder produces a severe fragmentation of thinking and personality. 
Although it is now known that split personality disorder is actually a separate and 
relatively rare disease (dissociative disorder), the term schizophrenia has remained.
1.1.2 Symptoms of Schizophrenia
Schizophrenia is characterised by a diverse set of signs and symptoms which arise from 
almost all domains of brain function including language, emotion, reasoning, motor 
activity and perception [12]. Although highly varied, the majority of symptoms 
displayed by schizophrenics fall into three broad categories; negative symptoms -  the 
absence of certain functions or aspects of the mind that should be present in a normal 
individual, positive symptoms -  the presence of certain features which are not present 
in a normal individual and cognitive impairment [7, 13]. Negative symptoms include 
social withdrawal, disorganisation and reduced will. Positive symptoms comprise of 
disorders of perception (hallucinations), inferential thinking (delusions) plus 
involuntary movements or actions (catatonia) [2, 13]. Symptoms of cognitive 
impairment include deficits in attention, intelligence, memory and executive function 
[14].
1.1.3 Classification of the Phenotype
At present there is no objective diagnostic test or easily measurable biomarker available 
to provide a secure diagnosis of schizophrenia [15]. As a result diagnosis is based 
solely upon the symptoms presented and reported and consequently on detailed clinical 
observation.
Cross-national studies at the beginning of the 20th century suggested that, due to the 
complexity of schizophrenia, there were international differences in the breadth and
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style of schizophrenia diagnosis [16, 17]. In response to this the World Heath 
Organisation and the American Psychiatric Association produced criterion-based 
systems for the diagnosis of schizophrenia. Currently under the tenth and fourth 
revisions respectively, the International Classification of Disease (ICD) and the 
American Psychiatric Association’s Diagnostic and Statistical Manual (DSM) 
objectively define the symptoms and characteristic impairments of schizophrenia in a 
relatively similar way [2]. The major differences between each approach consist of the 
DSM-IV requirements for social or occupational dysfunction (not included in ICD-10) 
and a six month duration of illness (vs. one month duration in ICD-10). This results in a 
somewhat narrower definition of the disorder in DSM-IV. Nevertheless consistency 
between the two systems is high [18] and the introduction of both has been shown to 
substantially improve the reliability of diagnosis [2].
1.1.4 Epidemiology of Schizophrenia
The annual incidence of schizophrenia has recently been estimated at between 8 and 43 
per 100,000 individuals [19]. This level of incidence is relatively similar across a wide 
range of cultures and countries including developed and developing nations [15, 20]. 
The lifetime relative risk of developing schizophrenia ranges from 0.3-2% with an 
average o f-0.7% [21].
Previously it has generally been believed that the risk of developing schizophrenia over 
a lifetime is similar among males and females [22]. However gender differences in the 
clinical expression and outcome of schizophrenia have long been recognised [23] with 
women tending to have a later age of onset than men [24] and a more benign course of 
illness including fewer hospital admissions and increased social functioning [25]. Two 
recent meta-analyses have supported this observation and revealed a higher lifetime risk 
in males (relative risk male: female-1.4) [19, 26].
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1.1.4.1 Environmental Risk Factors
A proportion of the risk of developing schizophrenia is attributable to environmental 
factors [3, 7, 27]. Substantial evidence has been reported, although mainly in western 
countries, which shows individuals bom or brought up in an urban environment are 
more likely to develop schizophrenia than those in rural areas [28]. Migration has also 
been associated with an increased risk of schizophrenia. Other environmental risk 
factors include pre and perinatal events such as prenatal infections, famine during 
pregnancy, obstetric and perinatal complications and winter/spring births. More general 
environmental risk factors include lower social class, social stress, low IQ score and 
cannabis abuse [3, 29].
1.1.4.2 Genetic Risk Factors
Although several environmental risk factors have been implicated in schizophrenia, no 
one factor appears either necessary or sufficient to cause the disorder. In contrast, there 
is now overwhelming evidence that the risk of developing schizophrenia is largely 
attributable to genetic risk factors. This evidence comes in number of forms including 
family, twin and adoption studies.
By analysing over 40 family studies, Gottesman and Shields were able to show that 
schizophrenia runs in families [1]. In addition, it was observed that the risk of 
developing schizophrenia is increased in the relatives of affected individuals. The 
lifetime risk of developing schizophrenia in the general population is -1%. This 
contrasts with the average risk to siblings (9%) and offspring (13%) of affected 
probands. Furthermore an identical (monozygotic) twin who shares 100% of their genes 
with a proband has a risk of almost 50% (Figure 1.1).
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Figure 1.1. Risk o f developing schizophrenia, for relatives o f schizophrenia probands compared to the 
general population. The percentages indicated in the key refer to the proportion o f genes shared. Data 
based on reviews by Gottesman [1].
Although family studies suggest that genetic factors may play a role in the aetiology of 
schizophrenia, they do not provide any evidence about the relative contribution o f these 
factors. Twin studies can be used to determine whether familial clustering is due to 
genetic factors or the result of a shared environment. This class of family study 
compares the concordance rates of a disease between members of monozygotic (MZ) 
twin pairs who are genetically 100% identical and dizygotic (DZ) twins who share only 
50% of their genes. A greater concordance rate between MZ than DZ twins reflects a 
genetic influence. Conversely, if a disease is caused by environmental factors then the 
rate of concordance between MZ and DZ twins would be the same [30]. Cardno and 
Gottesman [31] combined data from five relatively recent twin studies [32-36] and 
found that the average concordance rate between MZ twins was 50% compared to 1% 
in DZ twins using DSM-IIIR criteria.
One criticism of twin studies is that they assume that both types of twins share 
environmental influences to the same extent. Adoption studies do not rely on this
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assumption but provid corroborative evidence that the increased risk of developing 
schizophrenia in biologically related individuals is due to a major genetic influence. 
Using a variety of designs (adoptee studies, cross-fostering and adoptee families) 
adoption studies have shown an increased risk of schizophrenia in biological first 
degree relatives of probands, though not in non-biologically related adopted or adoptive 
family members who share the same environment as probands [37-40]. These studies 
include Rosenthal and colleagues [39] who, examining subjects from Danish adoption 
registers, found 18.8% of adoptees whose biological parents were schizophrenic had 
schizophrenia spectrum disorder (SSD) compared with 10.1% of matched controls. 
Using an alternative design, Kety et al [38] reported that 20.3% of biological parents of 
affected individuals had SSD compared to 5.8% of adoptive parents or parents of 
control adoptees. Finally a more recent study showed a prevalence of schizophrenia of 
9.4% in adopted away offspring of schizophrenic parents compared to a lifetime 
prevalence of 1.2% in control adoptees [41].
1.1.5 Neurobiology of Schizophrenia
The clinical features of schizophrenia described in section 1.1.2 are highly suggestive 
of a neurobiological basis of the disorder. However while a large amount of literature 
has been published investigating the neurobiology of schizophrenia, the precise nature 
of schizophrenia pathogenesis is still unclear [42]. Nevertheless over the past two 
decades a number of advances have been made in this field, the majority of which have 
been achieved due to developments in neuroimaging, electrophysiological and 
neuropathological technologies [42].
One notable and consistent finding in schizophrenia is the absence of cortical gliosis 
[43]. Indeed a number of studies have observed a reduction in glial density in 
schizophrenic patients [43]. Gliosis, which consists of an increase in glial cells within 
damaged areas of the CNS, is seen in various neurodegenerative disorders such as 
Alzheimer’s disease [44]. The lack of gliosis in schizophrenia indicates that the 
cognitive impairments observed are not caused by a neurodegenerative process. This
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conclusion is supported by studies which report little evidence of large scale neuronal 
loss in schizophrenic brains.
In the absence of degenerative changes, the attention of researchers has focused on 
alterations in the cytoarchitecture of neurons within the schizophrenia brain. Analysis 
of synapse and dendrite morphology has produced converging lines of evidence which 
suggest that disrupted cortical synaptic circuitry is a central deficit in schizophrenia [43, 
45, 46]. MRI studies reveal subtle reductions in grey matter volume in the dorsolateral 
prefrontal cortex (DPFC) and hippocampus in subjects with schizophrenia [43, 45, 47]. 
While grey matter is composed primarily of neuropil and cell bodies, post-mortem 
studies suggests it is a decrease in neuropil that causes the reduction in grey matter as 
they show a decreased dendrite density along with normal or increased neurone density 
[43].
In addition to grey matter reductions a number of studies have reported a decrease in 
white matter in schizophrenic brains [42, 45, 46]. *H magnetic resonance spectroscopy 
(MRS) studies support this finding as they have identified lower N-acetylaspartate 
(NAA) levels in temporal and frontal cortex of patients with schizophrenia [48]. NAA 
is a putative measure of neuronal viability which includes the formation and 
maintenance of myelin. Furthermore a reduction in pre-synaptic markers such as 
synaptophysin indicates schizophrenics have a reduced number of axon terminals
o 1
compared to healthy controls. This is supported indirectly by P MRS which shows a 
decrease in phosphomonoester levels within the prefrontal and temporal cortices [43]. 
This decrease indicates a reduction in the synthesis of membrane phospholipids and 
consequently a decrease in the number of synapses.
If schizophrenia is a disorder of disrupted synaptic circuitry the underlying mechanism 
of susceptibility could be a malfunction in neurotransmitter chemistry. To date there 
have been a number of neurochemical theories which are based primarily on 
compounds that ameliorate or induce schizophrenia-like symptoms. These drugs have 
been shown to act on a number of neuronal receptors and affect neurotransmitter
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release. The most prominent of these theories are the dopamine and glutamate 
hypotheses; although other theories involving neurotransmitters such as GABA, 
serotonin and acetylcholine have also been postulated.
The dopamine hypothesis of schizophrenia remains the most studied neurochemical 
theory relating to the disorder [49]. The classical dopamine hypothesis suggests that 
dopamine neurotransmission is hyperactive in schizophrenics [50] and is based on the 
indirect evidence that some anti-psychotic drugs block central dopamine receptors 
while dopamine agonists such as amphetamine produce a psychomimetic effect [51]. 
Even though this theory has been studied in depth, direct evidence for the dopamine 
hypothesis is still sparse. Furthermore it has been difficult to separate any reported 
observations, such as an increase in D2 receptors in schizophrenic patients, from the 
effect of prior antipsychotic drug treatment. Another limitation of the classical 
dopamine hypothesis is that its explanatory power is stronger for positive symptoms 
than other aspects of the disease such as cognitive impairment which has a greater 
lifetime prevalence than most positive symptoms and often better predicts a patient’s 
outcome [42].
The abnormal cortical connectivity and functioning suspected to occur in 
schizophrenia automatically implicates another neurotransmitter, glutamate, due to the 
fact that majority of excitatory synapses in the brain are glutamatergic. Experimental 
evidence supports this association and suggests that schizophrenia may be related to 
deficient glutamate mediated excitatory neurotransmission via N-methyl-D-aspartic 
acid (NMDA) receptors. NMDA antagonists such as phencyclidine (PCP) and ketamine 
have been shown to trigger a number of schizophrenia-like symptoms including 
positive and negative symptoms along with cognitive deficits [51]. Furthermore post 
mortem studies of schizophrenia patients have reported, albeit not consistently, reduced 
expression of glutamate receptors, in particular NMDA receptors, in a variety of brain 
regions including the prefrontal cortex (PFC) and hippocampus [51].
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Another neurotransmitter implicated in schizophrenia is gamma amino butyric acid 
(GABA). There is now substantial evidence that abnormalities in cortical and limbic 
GABA neuronal populations are a feature of the neurobiology of schizophrenia [49, 52, 
53]. In addition, mRNA levels of glutamate decarboxylase, the major determinant of 
GABA synthesis have consistently been shown by post mortem studies to be reduced in 
schizophrenia patients, thus suggesting reduced GABA levels [54].
Although the majority of evidence is indirect, serotonergic and acetylcholinergic 
neurotransmission have also been suggested to be disrupted in schizophrenics.
Serotonin antagonists such as clozapine and risperidone have been shown to have 
therapeutic benefits for schizophrenia cases [42, 51]. Additionally it has been 
suggested that the high prevalence of cigarette smoking in schizophrenics could be a 
compensatory response to a deficit in nicotinic cholinergic receptors [42, 51].
In summary, rather than having a distinctive characteristic, the neuropathology of 
schizophrenia appears to consist of a number of subtle changes that indicate an 
alteration in neuronal circuitry. The increased advancement of imaging and 
neuropathological technologies will hopefully provide more direct and compelling 
evidence of the specific abnormalities in schizophrenia which will in turn provide a 
clearer picture of its neuropathology. However one question that will still need 
resolving is whether a given abnormality represents a primary pathogenic event (cause), 
a secondary deleterious event (consequence) or a homeostatic response intended to 
restore normal brain function (compensation) [45]. As susceptibility genes are thought 
to represent a primary pathological event [46], the identification of schizophrenia 
susceptibility genes is likely to be crucial to achieve a complete understanding of 
schizophrenia pathology.
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1.1.6 Modes of Inheritance
1.1.6.1. Polygenic Model
Evidence from family, twin and adoption studies has conclusively shown that genetic 
factors play a significant role in the aetiology of schizophrenia and the heritability of 
schizophrenia has been estimated to be >80% [55, 56]. However the almost exponential 
decline in relative risk observed as genetic distance from the proband increases (Figure 
1.1) is incompatible with the hypothesis that schizophrenia is a single gene disorder or a 
collection of single gene disorders, even when incomplete penetrance is taken into 
account [55]. This observation is supported by Risch [57] who demonstrated that the 
relative risk data observed for schizophrenia is not compatible with one locus with a 
relative risk (Xs) value of greater than 3.
Taken together, these findings suggest that the mode of inheritance for schizophrenia, 
like that of other common disorders such as Alzheimer’s disease, bipolar disorder and 
diabetes, is non-Mendelian, complex and involves more than one locus [58]. Models of 
genetic susceptibility which consist of more than one susceptibility locus include 
oligogenic, a few genes of moderate effect and polygenic, many genes of weak effect.
The frequency of discordance between MZ twins (-50%) suggests that inheritance of a 
particular genotype does not confer a certainty of developing schizophrenia but rather a 
susceptibility to the disorder. This inherited susceptibility can be explained by a 
polygenic model, also known as a multifactorial liability threshold (MLT) model [59, 
60]. In this situation the risk or liability of developing schizophrenia follows a 
continuous (normal) distribution in the general population (Figure 1.2a). Each 
susceptibility gene exerts a small effect and combines with other genetic and 
environmental risk factors in a predominantly additive manner. When the number of 
risk factors an individual possesses exceeds a critical threshold, the individual develops 
schizophrenia (or is diagnosed with the disorder). Furthermore an increase in risk 
factors past this threshold results in an increase in severity of the disease. The threshold
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for schizophrenia is determined by the lifetime morbid risk of developing the disorder; 
therefore -1%  of the population will achieve the threshold for schizophrenia diagnosis.
As affected individuals possess a higher proportion of susceptibility genes than 
unaffected individuals, relatives of a proband have a higher probability of inheriting 
susceptibility alleles than the general population and therefore their mean risk 
increases, as shown in Figure 1.2.b. As the critical threshold level remains unchanged 
this shift means a greater proportion o f siblings (-10%) exceed the threshold for 
schizophrenia diagnosis. This explains why the incidence o f schizophrenia is higher in 
relatives o f schizophrenics than in the general population and that the risk increases as 
the degree of genetic relatedness also increases as shown in Figure 1.1.
Threshold
Number
of
individuals
Average risk in 
general population
Average nsk in /  
sibs of probands
Lifetime morbid risk
Figure 1.2. The multifactorial-liability threshold model for schizophrenia. The disorder has a continuous 
distribution in the population due to multiple genetic and environmental risk factors contributing to the 
risk o f developing the disease. The lifetime morbidity risk o f schizophrenia in the general population is 
given in a) where 1% of individuals (shown in red) have a combination o f risk factors which produce a 
schizophrenia diagnosis. Unaffected individuals (shown in white) are under this threshold. The lifetime 
morbidity risk o f siblings o f schizophrenics is shown in b). As these individuals have a higher probability 
o f inheriting susceptibility genes, their average liability is increased and as a result a greater proportion 
exceeds the threshold for schizophrenia diagnosis. Adapted from [61, 62].
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In addition to an increased risk to those related to schizophrenic individuals, the MLT 
model can also explain why the risk for schizophrenia in an individual, increases with 
the number of affected relatives [56]. For example an individual with two affected 
siblings is more likely to develop schizophrenia than an individual with one affected 
and one unaffected sibling. This is because the parents of these offspring are likely to 
be closer to the critical threshold than parents of one proband and therefore are more 
liable to pass on risk genes to additional offspring. In addition, more severely affected 
schizophrenic individuals are more likely to have schizophrenic offspring due to the 
high number of risk factors they possess. Although a polygenic inheritance model 
implies multiple genes of weak affect, it should also be noted that even under this 
model, alleles of large effect are expected to occur by chance. Therefore the model can 
also account for families with a high density of illness whose susceptibility may be 
caused by alleles of large effect [63, 64].
1.1.6.2 Non-additive Effects
As discussed above, the polygenic or MLT model of complex diseases assumes that 
many genes of small effect contribute to disease susceptibility in an additive manner. 
However while the observed epidemiological data is best accounted for by the MLT 
model [65], the data does not fit a simple additive model particularly well [56]. One 
explanation for this, which is supported by recent twin analysis [33], is that the mode of 
transmission of schizophrenia is more complicated than a purely additive combination 
of risk factors [56].
Epistasis in general terms denotes the interaction between genes or gene products and 
historically was used to describe the masking effect of one genotype on another at 
separate loci. However epistasis in terms of genetic studies refers to two or more genes, 
each with their own susceptibility risk, acting in a multiplicative manner, whereby the 
total liability from n genes is greater than the sum of their individual susceptibilities 
[66].
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Accounting for possible epistatic effects is particularly challenging in complex 
genetics. Nonetheless, a number of methods have been developed to test for epistasis 
within association data. These methods use logistic regression to fit multiple genotypes 
to affection status [67]. A successful example of this approach identified epistatic 
interactions between OLIG2 and CNP plus OLIG2 and ERJBB4 [68]. These were 
independent of the main effects shown by each of the loci. Biological plausibility for 
these interactions was subsequently indicated by a correlation of the expression of these 
genes [68].
In addition to the gene-gene interactions involved in epistasis, gene-environmental 
interactions could also affect schizophrenia risk. A number of studies have been 
published which have investigated interactions between environmental risk factors and 
genetic susceptibility variants [69-73]. This includes the potential interaction between 
the COMT Val158Met polymorphism, cannabis use and the development of psychosis 
[69]. However, at this time there are no gene-environment interactions which are 
unambiguously associated with schizophrenia.
In general although some advances have been made in hypothesising the mode of 
inheritance of schizophrenia; the number of susceptibility genes involved, the disease 
risk conferred by each locus, the extent of genetic heterogeneity and the degree of 
interaction between loci all remain unknown [63].
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1.2 Identifying Complex Disease Genes
As the risk of developing schizophrenia is largely attributable to genetic risk factors a 
logical next step is to attempt to identify genes which confer susceptibility to 
schizophrenia. This in turn will hopefully lead to an understanding of the biological 
pathways involved in schizophrenia aetiology and as a result, successful treatment.
The two main methods employed to locate disease susceptibility genes are linkage and 
association analysis. Both methods depend on the existence of polymorphic genetic 
markers but do not require any prior knowledge of the pathogenesis of the disease [56]. 
Linkage analysis can detect susceptibility genes over large distances; however it is 
typically limited to detecting those of larger effect. In contrast, association analysis can 
detect genes of more moderate/minor effect although until recently with the advent of 
genome-wide association studies, only relatively small regions could be analysed at one 
time [56, 61, 62].
1.2.1 Linkage Analysis
The concept of linkage analysis, which has been particularly successful at detecting 
genes that cause Mendelian traits, is based on the phenomenon known as genetic 
linkage. Before cell division takes place during gametogenesis, homologous 
chromosomes pair up within a diploid cell. During meiosis these homologous pairs 
exchange genetic material in a process known as recombination which occurs at 
crossover points or chiasma. Therefore recombination produces new hybrid 
chromosomes where some loci originated from the maternal chromosome and some 
from the paternal. The process of recombination generates increased diversity among 
the human species and restructures genes and their alleles [56, 61, 62].
If two loci are on different chromosomes the probability that their alleles will be 
inherited together is 0.5. This is the phenomenon Mendel described as independent 
assortment. As a crossover point within a chromosome appears to occur in a random
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fashion this is also true for loci far apart on the same chromosome. However the nearer 
two genes are to one another the less likely it is that a crossover point will occur 
between them and the more likely that they will be transmitted together. Therefore the 
probability that they will be inherited together is greater than 0.5. This represents a 
departure from the law of independent assortment and is known as genetic linkage.
Linkage analysis aims to establish if a genetic marker co-segregates with a phenotype 
within many independent families or over many generations of an extended pedigree. 
Although the marker itself may not be causing the disease/phenotype, the phenomenon 
of genetic linkage indicates that a susceptibility locus causing the phenotype resides in 
the same chromosomal region as the segregating marker.
The traditional approach to calculating the statistical evidence for linkage is the LOD 
score [74]. A LOD score is a logarithm of the odds ratio of the likelihood that the 
observed co-segregation of marker and illness is due to linkage, against the likelihood 
that the observed co-segregation occurs by chance. Morton suggested that a cumulative 
LOD score exceeding 3 should be regarded as good evidence for linkage, while a 
cumulative LOD score below -2 should be regarded as strong evidence against linkage 
[74]. A LOD score of 3 represents an odds ratio of 1000:1 in favour of linkage and
“i
corresponds to a p value of 0.05. This means that the observed data is 10 -fold more 
likely to arise under the specified hypothesis of linkage than under the null hypothesis 
of no linkage [75].
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1.2.1.1 Parametric and Non-parametric Analysis
Classic linkage analysis, known as parametric analysis, follows the cosegregation of 
markers and disease over a number of generations in large multiplex families. It 
involves the specification of a genetic model and has proved to be a very powerful 
method for detecting loci segregating in a Mendelian fashion [61]. However for 
complex diseases such as schizophrenia, where the mode of transmission is unknown, 
parametric linkage analysis is more challenging. As a result non-parametric analysis, 
which does not require a mode of inheritance to be defined, is often used. The most 
popular design for non-parametric analysis is the affected sib pairs (ASP) method. 
Unlike parametric analysis, which compares affected and unaffected family members, 
ASP examines allele sharing in affected siblings only. This is particularly suited for the 
analysis of complex diseases where unaffected siblings may be non-penetrant carriers 
of the susceptibility allele. Allele sharing can be defined in two ways, identity-by-state 
(IBS) or identity-by descent (IBD). Two alleles are characterised as IBS if they both 
have the same DNA sequence at the polymorphic site. If these two alleles are also both 
descended from a recent common ancestor then they are said to be IBD. IBD is 
regarded as a superior measure of allele sharing as it is more informative and less 
dependant on the exact marker allele frequency being known [61].
1.2.1.2 Limitations of Linkage Analysis
Linkage analysis can be a powerful and robust method of identifying genes that cause 
Mendelian disorders. However for most common diseases linkage analysis has 
achieved only limited success [76, 77]. This lack of success has been attributed to a 
number of factors. Firstly linkage analysis has been found to be less powerful at 
identifying common genetic variants that have a modest effect size [78]. In addition the 
standard set of microsatellites used in linkage analysis, which are spaced ~10cM apart, 
are unlikely to extract complete inheritance information [77]. While these confounders 
could potentially be resolved by using a denser set of markers, larger sample sizes and 
larger pedigrees, Hirschhom and Daly [77] note that the Prol2Ala variant in the
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PPARG gene which affects the risk of type 2 diabetes would only be detected using 
linkage analysis of over 1 million affected sib pairs.
1.2.2. Association Studies
An association study compares marker allele or genotype frequencies in a group of 
affected cases against a group of unaffected controls. Unlike linkage, association 
studies have been used to identify genes of minor effect in a number of complex genetic 
disorders. This includes the glucokinase and glycogen synthase genes in non-insulin 
dependant diabetes (NIDDM) and insulin dependant diabetes (IDDM) respectively [79, 
80].
The term allelic association is used to describe a statistically significant difference in 
marker allele frequency between affected and unaffected individuals. Genotypic 
association refers to a significant difference in genotype frequency. An association 
between a marker and a certain disease can be explained by one of two genetic 
mechanisms: direct association, whereby the associated marker is the causal variant and 
indirect association due to linkage disequilibrium.
Linkage disequilibrium (LD) refers to the co-occurrence or correlation between two 
loci on the same chromosome. As discussed in section 1.2.1, a high correlation between 
two markers is likely to occur between loci that are close together (<50kb) as they are 
less likely to be separated by recombination during meiosis. The degree of LD between 
two loci is usually calculated by one of two measures, D’ or r [81, 82]. Both measures 
are based on the pairwise-disequilibrium coefficient D which is a measure of the co- 
variance between two loci. The value of D between two alleles (i.e. A and B) is 
calculated using the frequency of the two alleles (pA and qe) and the haplotype 
frequency ((X a b ) -
D Ab =  &ab " Pa ^b
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A limitation of using D as the degree of LD between two markers is that its possible 
value is constrained by the frequencies of each marker allele. Therefore in order to 
compare values of D between different pairs of markers with different allele 
frequencies, D is normalised to D’ [82]. Unlike D, D’ lies on a scale of 0-1 and is 
calculated using the theoretical maximal value of D (Dmax) [81, 82].
D’ = D/Dmax
A D’ value of 0 denotes no correlation between two loci while a value of 1 indicates 
complete LD. Complete LD between two loci indicates that one allele of a marker 
always occurs with an allele of the other marker. However a limitation of D’ is that 
where a difference in allele frequency between two markers exists, a D’ of 1 can occur 
even though the two markers are not in perfect correlation. For example, Allele A of 
locus 1 may always occur with allele B of loci 2. However allele B of locus 2 may 
occur with both allele A and a of the first polymorphism.
An alternative measure of LD which accounts for the above scenario is r2. r2 is 
measured using D plus the product of the allele frequencies at the two loci:
f(A,)f(A2)f(B,)f(B2)
9  9As with D’, r values lie between 0 and 1 however in this instance an r value of 1 
indicates a perfect correlation between the genotypes of two markers where the alleles 
of both markers always co-occur and therefore have the same frequency [83]. Because 
the genotype of one marker can be determined by the genotype of the second marker, 
two markers with an r =1 are termed proxies.
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1.2.2.1 Association Study Design
In designing an association study for a particular gene or genomic region a number of 
so called “tag markers” are identified which account for all the known genetic variation 
at a particular locus under analysis, or at least to a specified minor allele frequency 
(MAF). If an association signal is detected then the polymorphisms tagged by the 
significant marker must be considered as potential risk variants along with the 
significant marker itself. Tagging a gene or genomic region poses a number of 
advantages. Firstly, by using tag markers a locus can be assayed without genotyping 
every polymorphism in the region, thereby dramatically reducing costs. In addition, no 
prior knowledge of the functional variants is needed as a functional role can be 
hypothesised, or investigated further, after putative risk allele(s) have been identified. 
Furthermore, all common, known genetic variation in a region will be assayed thereby 
reducing false negative rates. However there are limitations to a tagging approach. Rare 
variants are unlikely to be covered by this strategy. In addition, further analysis such as 
sequencing and extra genotyping, may be needed to find the causal variant(s).
1.2.2.1.1 Tag Marker Selection
In order to identify tag markers it is first necessary to genotype all polymorphisms at a 
locus within either a subset of your association sample or a representative population. 
From this the LD structure of the association sample can be estimated and tag markers 
selected. The HapMap database (www.hapmap.org) is a primary research tool which 
often allows the researcher to avoid this initial genotyping step. This publicly available 
database was created by the International Haplotype Map Consortium [84]. It contains 
details of over 5.5 million single nucleotide polymorphisms (SNPs) (HapMap phase II) 
which have been genotyped in 270 individuals from four populations (West European 
n=90, West African n=90, Han Chinese n=45, Japanese n=45).
Tag SNP selection is based on a number of factors. Firstly a researcher needs to decide 
how much of the genetic variation in a region to cover (i.e. to what MAF) and how
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thoroughly (the degree of LD between the genotyped marker and the tagged SNP). Due 
to the large sample sizes needed to detect an association with rare events, a MAF >0.05 
is often selected.
The two most common methods of tagging a locus involve the use of either haplotype 
tag SNPs (htSNPs) or pairwise tag SNPs (tag SNPs). Identifying htSNPs involves 
taking the haplotype diversity of a population in account rather than just a single 
marker-marker correlation. While this strategy can result in a reduction in the number 
of SNPs to be genotyped, and therefore a reduction in costs, interpreting the results can 
be problematic. Consequently a standard method of tag SNP selection has become 
pairwise analysis which involves measuring marker-marker (pairwise) LD via r2 and 
subsequently selecting a set of independent markers. The ideal pairwise tag SNP
-*y
selection strategy would be to genotype all markers where alleles were not in an r of 1 
with any other genotyped marker. However this threshold is often relaxed, i.e. r >0.8, 
to reduce the number of SNPs genotyped.
1.2.2.2 Family Based Association Studies
In addition to being the causal variant, or being in LD with the causal variant, a marker 
allele may also appear associated with disease if cases and controls are not ethnically 
comparable. In such a situation, known as population stratification, differences in allele 
frequency will emerge at all loci that differentiate between these two populations 
whether the alleles are causally related or not. Population stratification can also mask a 
true causal effect and produce a false negative result. It is therefore vital to ensure cases 
and controls are well matched for ethnicity. One strategy often employed is to use 
unaffected family members as controls, such as parents or siblings. The most popular 
family based association study design uses parent-proband trios, where both parents 
and their affected offspring are genotyped [61, 85]. If there is a distortion in the number 
of times an allele is transmitted to the affected offspring from a heterozygote parent, 
that is greater then expected by chance, then the allele is said to be associated. There
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are numerous statistical methods to test for such an association, although the 
transmission/disequilibrium test (TDT) is the most widely used [85, 86].
Although family-based studies account for population stratification, a major drawback 
of this kind of sample is the difficulty in sample ascertainment. This can be particularly 
true of late onset disorders. Another limitation of the trio design is that at least two out 
of each trio needs to be genotyped for each variant. In addition, using unaffected 
siblings as controls results in a loss of power as they are over-matched to the cases [61].
1.2.2.3 Case Control Association Studies
A case control study design involves assaying the frequency of alleles or genotypes in a 
sample of affected individuals (cases) and comparing this with the frequency in a set of 
unaffected individuals (controls) from the same population. The main advantage of this 
design is the relative ease of sample collection compared to familial approaches which 
allows the construction of large sample sizes. In addition, as the analysis of each case is 
not reliant on an exact control (such as a parent or sibling) a large genotyped sample is 
often available for analysis which has greater power to detect real effects (see section 
1.2.2.4). As discussed, population stratification is the main drawback of a case control 
study design. To protect against this, it is desirable that the sample is a homogenous 
population of similar ancestry [87]. Furthermore, a process of matching cases to 
controls for possible confounding factors such as age and sex is advantageous.
1.2.2.3.1 Statistical Evidence for Association in Case Control Studies
Statistical evidence for association in case-control studies comes from an estimation of 
the odds ratio or chi square statistic which are determined using a contingency table of 
either allele or genotype counts in cases and controls. Usually, the statistic is converted 
into a probability or p value. Typically a p value of 0.05 or less is used to indicate that 
the null hypothesis of no association can be rejected [61, 88] as such a value will occur 
by chance on only 5% of occasions, assuming all SNPs are independent. However as
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many association studies test >20 SNPs such a p value can be expected to occur by 
chance for at least one variant. There are several methods that attempt to adjust the 
probability estimate for multiple comparisons, the most prominent of which are 
Bonferroni correction, experiment or gene wide adjustments and permutation methods 
[77]. Although statistical attempts to correct for multiple testing are justified in order to 
reduce the amount of false positives, it is highly likely these methods are over 
conservative in the presence of weak but true genetic effects [89]. Therefore the ideal 
method for assessing whether a reported association is a true effect is for it to be 
replicated in an independent sample [5].
1.2.2.4 Power of Association Studies
The major factors affecting the power of an association study to detect a susceptibility 
variant is the effect size, as well as the frequency, of the disease risk allele(s) [77, 90]. 
The more common a risk allele and/or the larger the effect size, the greater the power a 
study of fixed sample size has to find an association with that variant. The odds ratio 
(OR) of a variant is a measure of its effect size. It is defined as the odds of exposure to 
a susceptibility variant in cases compared to controls. For example, if a variant has an 
odds ratio of three, the odds of an individual with one copy of the risk allele being a 
case is three times higher than that of a control and the odds of an individual 
homozygote for the risk allele being a case compared to control are 9:1. Figure 1.3 
illustrates the effect of both the OR and MAF of a disease susceptibility variant on the 
sample size required to provide 80% power to detect such variants at a p<0.05 level.
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Figure 1.3. Effects o f allele frequency and OR on sample size requirements. The total number o f 
individuals (equal number o f cases and controls) that are required in an association study to detect 
disease variants with allelic odds ratios o f 1.2 (red), 1.3 (blue), 1.5 (green) and 2 (black) at various MAFs 
are shown. Numbers given are for a statistical power o f 80% at a significance level o f p<0.05. Adapted 
from [91] using Power and Sample Size Calculations software [92],
As can be seen from Figure 1.3 a sample of just under 500 cases and 500 controls (or 
500 families with 2 parents and an affected offspring) is needed to have an 80% chance 
of detecting a risk allele with an OR of 1.5 and a MAF of 0.1. However to have the 
same level of power a sample of 4000 cases and 4000 controls would be required to 
detect a variant with the same effect size but a MAF of 0.01. In addition, although a 
sample of 500 cases and 500 controls have an 80% chance of detecting a risk allele 
with a MAF of 0.1 and an OR of 1.5, the sample size would need to be more than 
doubled to have the same chance of detecting a variant with an OR of 1.3.
It must also be noted that these figures assume a multiplicative model for risk and that 
either the disease variant is assayed itself or that there is perfect linkage disequilibrium 
between the test marker and disease variant. If this is not the case then even larger 
sample sizes may be required to achieve the same power.
As the allelic architecture of schizophrenia is completely unknown, the power of an 
association study to detect a risk variant can only be speculated. Two polarised views
25
have dominated much of the literature on the allelic frequency and risk affect of the 
variants that cause common diseases [91]. The common disease common variant 
(CDCV) hypothesis of schizophrenia and other complex disorders assumes that genetic 
variants that alter disease risk occur at relatively high frequency (MAF>0.05). Under 
this model, disease susceptibility is suggested to result from the joint action of several 
common variants and unrelated affected individuals share a significant proportion of 
disease alleles [93]. However, due to their common nature these variants are also likely 
to be of weak effect (see section 1.1.6.1). The extreme alternative to the CDCV 
hypothesis is the multiple rare variant hypothesis in which disease susceptibility is due 
to distinct genetic variants in different individuals and disease susceptibility alleles 
have low population frequencies (MAFO.Ol) [94-98]. It is highly likely that both 
common alleles with a weak effect (0R<1.5) and rare variants (MAF<0.05) explain the 
instances of schizophrenia and therefore both need to be detected. As discussed above, 
this will require large sample sizes.
The advent of genome-wide association studies (GWAS) has also highlighted the need 
of increased samples sizes. GWAS studies have the capacity of assay over 500,000 
polymorphisms at a time. Analysis of this number of variants necessitates that only a p 
value <5x10'8 can be confidently reported as an association [99] and production of this 
level of significance requires large samples. It is therefore now becoming commonplace 
for research centres to form collaborations in order to produce sample sizes large 
enough to detect an effect. A case in point is the Wellcome Trust Case Control 
Consortium (WTCCC) which examined -2,000 individuals for each of seven major 
complex diseases (bipolar disorder, coronary artery disease, Crohn's disease, 
hypertension, rheumatoid arthritis, and type 1 and type 2 diabetes) plus a shared set of 
-3,000 controls [58]. However GWAS studies are aimed at detecting common variants 
only and therefore additional analysis, involving sequencing a large number of 
individuals, will be needed to investigate rare variants and schizophrenia.
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1.3 DTNBP1 and Schizophrenia
The combination of linkage and association analyses has implicated a number of genes 
in the susceptibility of schizophrenia. These include neuregulin (NRG1) [100], D- 
amino oxidase (DAO) [101], D-amino oxidase activator (DAOA) [101], disrupted in 
schizophrenia 1 (DISCI) [102], catechol-O-methyltransferase (COMT) [103] and 
regulatory of G-protein signalling 4 (RSG4) [104]. However one of the most 
convincing susceptibility genes to date is DTNBP1.
The DTNBP1 gene encodes for the dystrobrevin binding protein 1 (commonly known 
as dysbindin) and is located on 6p24-22. Chromosome 6p24-22 is a well established 
schizophrenia linkage region [105-109] and DTNBP1 was first identified as a 
schizophrenia susceptibility gene through association analysis of this linkage region 
[109]. In this initial study Straub and colleagues typed 17 SNPs, plus an additional 3 
simple sequence-length polymorphic markers (SSLPs) within 270 families from the 
Irish Study of High Density Schizophrenia Families (ISHDSF) [110] who had 
previously shown linkage to 6p24-21 [109, 111]. The 20 markers analysed at 6p22 
spanned DTNBP1 (chr6:15,631,018-15,771,250), JARID2 (chr6:15,354,506- 
15,630,232) a gene 3’ to DTNBP1, plus the 5’ region proximal to DTNBP1. Significant 
evidence for association was observed between schizophrenia and a number of single 
markers within DTNBP1 (p<0.01). This evidence for association was further 
strengthened via haplotype analysis where several 3-marker haplotypes showed 
association (0.001<p<0.008) [112]. Although the association data was complex these 
results identified DTNBP1 as a susceptibility gene for schizophrenia which at least 
partly explained the linkage signal observed at 6p24-22. Reanalysis of this data, with 
the addition of extra markers, attributed the association signal to a single 8-marker 
haplotype spanning the DTNBP1 locus via a pedigree disequilibrium test (rs3213207, 
rslOl 1313, rs2619528, rs2005976, rs760761, rs2619522, rsl018381, rsl474605, 
GGAATGCG, PDT=0.002) [113].
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Since the original report, 25 replication studies have been published to date. While 
some studies have failed to replicate the initial findings [114-128], further support for 
DTNBP1 as a schizophrenia susceptibility gene has been reported in Caucasian [117, 
121, 127, 129-134], Asian [121, 135-138], African American [129] and Hispanic [117] 
populations. A summary of these positive associations are given in Table 1.1, while the 
more specific details of each study are described below.
The association between DTNBP1 and schizophrenia was first replicated in another 
family based association study [131] where six of the most significant SNPs reported in 
the initial study (rs3213207, rslOl 1313, rs2619528, rs760761, rs2619522, rs l018381) 
were genotyped in two independent samples, a sib-pair sample consisting of 78 families 
of German and Israeli origin and a sample of 127 German and Hungarian parent 
proband trios. Single marker association was reported in both samples separately and 
within the combined sample (rs3213207 p=0.0052, rs 1011313 p=0.0092, rs2619528 
p=0.140, rs760761 p=0.0007, rs2619522 p=0.030). Six-marker haplotype analysis 
revealed that 97% of the observed marker distributions could be explained with seven 
different haplotypes. Of these only one haplotype had a larger frequency of transmitted 
(T) rather than non-transmitted (NT) haplotypes (Trios: T=0.738, NT=0.594, Sib pairs: 
T=0.731, NT=0.566). This haplotype consisted of the common allele at each locus 
(AGGCTC). However as no formal association test was reported for this haplotype the 
single marker results are presented in Table 1.1.
A number of other family based studies have also observed an association between 
DTNBP1 and schizophrenia. Kirov and colleagues [130] genotyped 8 SNPs 
(rs2619539, rs3213207, rslOl 1313, rs2005976, rs2743852, SNP002901727/rs9476858, 
rs2619538 and rs909706) within a sample of Bulgarian trios (n=488) with 
schizophrenia or schizoaffective disorder. Over transmission of two markers 
(rs3213207 p=0.009 and rs2005976 p=0.0013) was observed and analysis of two, three 
and four marker haplotypes produced numerous positive results (p<0.001). The most 
significant of these was a two marker haplotype which included rs2619539 and 
rs3213207 (p=0.00027). However due to the number of different significant haplotypes,
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a specific haplotype(s) carrying the susceptibility/protective alleles in the population 
could not be determined.
The first study to examine DTNBP1 and schizophrenia in an Asian population 
investigated seven SNPs previously typed in the Straub study (rs742105, rs760666, 
rs2619539, rs2619522, rsl018381, rs909706, rs3213207) in 233 Han Chinese trios 
[137]. Two of these SNPs (rs760666, rs3213207) were not included in any further 
analysis because both SNPs had a minor allelic frequency of <5% in the population 
sample. Although no significant association was found for any individual SNP, 4 
marker haplotype analysis identified the haplotype GTCA (rs2619539, rs2619522, 
rslOl8381, rs909706) which was significantly over-transmitted to affected individuals 
(p=0.00091).
Fallin et al genotyped 440 SNPs from 64 schizophrenia and bipolar candidate genes in 
a sample of 274 schizophrenic or schizoaffected Ashkenazi case-parent trios [139]. 
These candidate genes included DTNBP1 where 16 SNPs were selected for analysis on 
the basis of previous linkage or association and/or biological relevance. DTNBP1 met 
the criteria for a suggestive association (empirical p<0.05) to schizophrenia with both 
single marker and haplotypic associations observed. While SZgene [140] reports that 
the 16 markers genotyped were rs 1047631, rs2619539, rs3213207, rs760666, rs766761, 
rslOl 1313, rsl018381, rs2619538, rs2619522, rs2619528, rs742106, rsl040410, 
rs2056942, rs760665, rsl018382 and DTNBP1 unknown , no specific details of the 
SNPs genotyped or the significant markers are given in the report. The results have 
therefore not been included in Table 1.1.
The most recent family based DTNBP1 association study involved association analysis 
of DTNBP1 polymorphisms in two USA based samples [129]. Duan and colleagues 
genotyped 26 DTNBP1 SNPs in a total of 646 subjects from 136 families, of which 
72% were of European ancestry and 18% were African American. The SNPs examined 
included those previously reported as associated with schizophrenia (n=9), a number of 
coding SNPs (n=7), previously untested SNPs (n=7), plus three additional SNPs which
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had previously shown no evidence of association but would allow the gene to be tagged 
at an r2>0.8. rs7758659 showed single marker association in both the European 
(p=0.03) and the African American (p=0.045) samples. Both samples had the same 
overtransmitted allele (G) and therefore the combined sample showed even greater 
significance (p=0.004). This association was further strengthened by the addition of 
rs3213207 to form a two marker haplotype between rs7758659 and rs3213207 (GA, 
p=0.0015).
Although the initial association study plus a number of replication studies have been 
family based, a significant proportion of replication studies have been of case control 
design. The first case control study of DTNBP1 and schizophrenia was performed by 
Van den Bogaert and colleagues [127] who analysed five SNPs within three samples 
containing schizophrenic individuals and unaffected controls of German (418 cases,
285 controls), Polish (294 cases, 113 controls) and Swedish (142 cases, 272 controls) 
descent. While the German and Polish samples did not show a significant difference 
between cases and controls, a 5-marker haplotype was significantly associated in the 
Swedish sample (rs3213207, rslOl 1313, rs2005976, rs760761, rsl018381, AGATT, 
p=0.0098). This association became even more significant after a separate analysis of 
cases with a positive family history of schizophrenia was performed (p=0.00009).
Analysis of six previously tested DTNBP1 SNPs (rs909706, rsl018381, rs2619522, 
rs760761, rs2691528, rs 1011313) in 524 individuals with schizophrenia or 
schizoaffective disorder and 573 controls also revealed evidence for association 
between DTNBP1 and schizophrenia [117]. Although no association was observed in 
the African American subset of the sample (215 cases, 74 controls), three SNPs 
(rsl018381, rs2619522 and rs2619528) were positively associated in the Caucasian 
subset (258 cases and 467 controls) as well as a smaller Hispanic subset (51 cases and 
32 controls). Haplotypic analysis of the Caucasian sample identified a six-marker risk 
haplotype (rs909706, rs l018381, rs2619522, rs760761, rs2691528, rs l011313, 
GATGTG p=0.005). Combined analysis of both the Caucasian and Hispanic subsets
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identified four significant markers (rs2619528, rs760761, rs2619522, rslOl 8381) with 
the greatest single marker association shown by rs l018381 (p=0.0006).
An association analysis between DTNBP1 and schizophrenia in a UK based case 
control sample (708 cases and 711 controls) [134] attempted to confirm DTNBP1 as a 
schizophrenia susceptibility gene by replicating the association observed in the initial 
Straub study [112] and/or by identifying other risk variant(s) through screening the 
exonic and putative promoter regions of DTNBP1. No evidence of single marker 
association between schizophrenia and a number of previously studied markers 
(rs2619539, rs3213207, rslOl 1313, rs2005976) was observed. The study also failed to 
replicate both the initial haplotypic association [112] and the association reported after 
reanalysis of the original data [113]. However Williams and colleagues did determine 
significant evidence for association in one new risk (rs2619539, rs3213207, rs2619538, 
CAT p=0.01) and two protective haplotypes (CAA p=0.006, GGT p<0.001). These 
haplotypes consisted of markers previously reported as associated as well as a novel 
SNP (rs2619538) which was identified through mutation detection of DTNBP1 and 
located within a putative promoter region. When this marker was typed in a sample that 
previously did not show association [123] the specific risk and protective haplotypes 
reported by Williams et al were also significantly associated with schizophrenia in the 
independent sample (CAT p=0.02, CAA p=0.047, GGT p=0.006) [134].
Two other case control studies of Caucasian origin have also provided evidence of an 
association between DTNBP1 and schizophrenia. A case control study of 80 cases and 
106 controls of Italian origin identified significant haplotypes which also included 
rs2619538 (rs2619538, rs909706, AA p=0.048, rs2619538, rs909706, rsl018381, 
global p=0.040). However their most significant result was observed with the two 
marker haplotype containing rs760761 and rs2005976 (CA, p=0.034) [132].
A report into the association between DTNBP1 and schizophrenia in a Spanish sample 
(589 cases and 617 controls) identified both risk and protective haplotypes [133]. In 
addition to polymorphisms from other putative schizophrenia candidate genes, Vilella 
and colleagues genotyped 12 DTNBP1 SNPs, six of which had previously been typed
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in other studies [112, 118]. Two single markers and four 3-marker haplotypes showed 
evidence for association. However, only one haplotype survived correction for multiple 
testing by permutation analysis. This 3-marker haplotype included three previously 
untyped markers rs875462, rs l040410 and rs6926401 (Risk haplotype TTT, corrected 
p=0.015). However rs875462 is in high LD (^=0.94) with rs7758659. rs7758659 is part 
of the 2-marker (rs7758659, rs3213207) risk haplotype identified in the Duan study 
(GAp=0.0015) [129].
In addition to the family based study by Tang and colleagues in Han Chinese trios 
[137], there have been four additional studies which have investigated DTNBP1 as a 
schizophrenia susceptibility gene in the Asian population. Three of these used a case 
control design [135, 138] and a further study analysed DTNBP1 in both an Asian 
family and Scottish case control sample [121].
Numakawa et al [135] genotyped six polymorphisms previously found to be associated 
with schizophrenia (rs2619539, rs3213207, rslOl 1313, rs760761, rs2619522, 
rs2619538) in a Japanese population of 670 cases and 588 controls. Four of these SNPs 
showed evidence of association (rs3213207 p=0.013, rs760761 p=0.027, rs2619522 
p=0.022, rs2619538 p=0.025). The most significant of which, rs3213207, was further 
strengthened in haplotype analysis where a 2-marker haplotype containing rs3213207 
showed the most significant association (rs3213207, rslOl 1313, GG p=0.00028).
Li and colleagues [121] examined 10 SNPs that were identified in the original report of 
association [112] plus rs2619538, in a sample of 638 Chinese trios and a Scottish 
sample consisting of 580 cases and 620 controls. Two polymorphisms (rs3213207 and 
rs2619528) showed single marker association with schizophrenia in the trio sample 
(p=0.02 and p=0.002 respectively). Further analysis also identified a 2-marker 
haplotype overtransmitted to affected individuals (rs2005976, rs2619528, GG corrected 
p<0.001). In contrast to the trio sample, no single marker was found to be significantly 
associated with schizophrenia in the Scottish case control sample. However one risk
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haplotype (rs760761, rs2005976, CA p=0.0066) and one protective haplotype 
(rs2619538, rs909706, AT p=0.003) were identified.
In a response to the inconsistencies in the risk alleles reported in the two previous Asian 
studies, as well as earlier Caucasian studies, Tochigi et al examined 12 DTNBP1 SNPs 
in a Japanese sample of 314 cases and 314 controls [138]. Of the 12 SNPs studied, nine 
were common with the initial Straub study [112] and all the SNPs from the previous 
Asian studies [135, 137], except rs2619538, were included. No single marker 
association was observed however permutation tests detected a significant difference 
between cases and controls of several 10-marker haplotypes. In addition, haplotypic 
analysis of markers which had shown an association in previous Asian studies [135, 
137], identified the risk haplotype TCTCG (rs742105, rs2619539, rs2619522, 
rsl 018381, rs909706 p=0.0076). While this consisted of the same markers as the 
associated haplotype reported by Tang and colleagues [137] the risk haplotypes 
reported by each were different (Table 1.1).
The most recent study of DTNBP1 in an Asian population genotyped four of the six 
SNPs analysed in the Numakawa study [135] (rs3213207, rs 1011313, rs760761, 
rs2619522) in a Korean sample of 908 cases and 601 controls [136]. Although no 
significant difference was observed in the allelic or genotypic distributions between 
cases and controls, haplotype analyses revealed a significant association with 
schizophrenia (p<0.0001). Two protective haplotypes were identified ACCC and 
ACTA (p=0.00014 and p<0.001 respectively). Sliding analysis showed that the markers 
rs760761 and rs2619522 exerted major contributions to this haplotype with the two 
protective haplotype (CC p=0.0003, TA p=0.0001) plus a significant associated risk 
haplotype (CA p=0.013).
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dbSNP ID rs875462 r s l040410 rs742105 rs6926401 rs7758639 rs2619539 rs3213207 rs1011313 rs2619528 rs2005976 re760761 rs2619522 rs1018381 rs1474605 rs909706 rs2619538
Alternative name - - P1333 - P1655 P1635 P1325 P1765 P1757 P1320 P1763 P1578 P1792 P1583 SNP A
Chromosome Position (March 2006) 15646415 15655455 15681053 15693988 15701219 15728834 15736081 15741411 15757808 15758781 15759111 15761628 15765049 15766191 15768850 15773188
Alleles T/C c n T/C T/G G/A G/C A/G G/A G/A G/A c / r T/G C/T A/G G/A T/A
Study Year Population Sample Association
Straub/
Van den Oord 2002/3 Irish Family Haplotype G G A A T G C G
German
Schwa rb 2003 and Israeli Family Single Marker A G G c T
Kirov 2004 Bulgarian Family Single Marker A G
U 2005 Scottish Family Haplotype A c
European and
Duan 2007 African American Family Haplotype G A
Van den Bogaert 2003 Swedish Case/Control Haplotype A G A T T
Funke 2004 Caucasian Case/Control
and Hispanic Single Marker A T G T
Caucasian Case/Control Haplotype G A T G T G
Williams 2004 UK Case/Control Haplotype C A T
Morris* 2003/4 Irish Case/Control Haplotype C A T
Tosato 2007 Italian Case/Control Haplotype A c
Vilella 2007 Spanish Case/Control Haplotype T T T
Tang 2003 Chinese Family Haplotype G T C A
Li 2005 Chinese Family Haplotype G G
Numakawa 2004 Japanese Case/Control Haplotype G G
Tochigi 2006 Japanese Case/Control Haplotype T C T C G
Pae 2009 Korean Case/Control Haplotype c T
Table 1.1. Summary of positive association studies between DTNBP1 and schizophrenia (studies that have reported an association with a specific phenotype are 
summarised in Table 1.2). SNPs genotyped by each study are given in grey. The alleles of SNPs reported as associated either on their own or as part o f a multi­
marker haplotype are given. For clarity the strand o f the reported allele may have been changed. Adapted from Williams et al and Mutsuddi et al [134, 141]. 
♦Significant haplotypic association only observed in the Irish population after additional genotyping of rs2619538.
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1.3.1 Negative Association Studies
While the majority of publications have reported an association between DTNBP1 and 
schizophrenia, some studies have failed to observe an association [114-128]. These 
negative studies have mainly been performed with Caucasian samples and involved a 
case control design. Van den Bogart and colleagues were the first group to report a 
negative association between DTNBP1 and schizophrenia [127]. They examined 5 
DTNBP1 SNPs (rs3213207, rslOl 1313, rs2005976, rs760761, rsl018381) in three 
samples containing schizophrenic individuals and unaffected controls of German (418 
cases, 285 controls), Polish (294 cases, 113 controls) and Swedish (142 cases, 272 
controls) descent. As mentioned previously, while a significant association was 
observed in the Swedish sample, no significant difference was observed between the 
cases and controls in either the German or Polish samples.
Other Caucasian case control samples which have failed to find an association between 
DTNBP1 and schizophrenia include a Scottish sample of 580 cases and 620 controls 
[121], a US sample of 451 schizophrenic or schizoaffective cases and 291 controls 
[128], a Dutch sample of 273 schizophrenic patients and 580 controls [114] and a UK 
sample of 450 cases and an equal number of controls [115]. A study of eight DTNBP1 
SNPs in an Irish sample of 219 schizophrenia cases and 231 controls also failed to find 
an association [123]. Three of these SNPs were selected due to their significant 
association in the initial Straub study (rs3213207, rs2005976, rs760761). The remaining 
five SNPs (rsl047631, rs760666, rs2619539, rs2619542 and rs2619550) were 
identified from the NCBI dbSNP database. No association was observed with any of 
the markers analysed, even when cases positive for a family history of schizophrenia 
(n=65) were compared against controls. However as discussed in section 1.3, when an 
additional SNP s2619538 was genotyped within their sample, they were able to 
replicate the haplotypic associations reported by Williams et al[ 134].
Two studies have also failed to find an association after examining DTNBP1 SNPs in 
Caucasian family samples. The first by Hall et al investigated five SNPs in 210 US
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trios plus 233 South African Afrikaner families [118]. The second study analysed 
DTNBP1 variants within 441 Finnish families which included 865 affected individuals 
[126].
Holliday and colleagues examined several DTNBP1 SNPs in both a case control (194 
cases, 180 controls) and two family based samples (41 Australian and 197 Indian 
pedigrees but failed to find an association in any sample [119]. Two other studies also 
failed to observe an association between DTNBP1 and schizophrenia in the Asian 
population. The first examined DTNBP1 variants within a sample of 693 Taiwanese 
families [122]. The second was of case control design and analysed DTNBP1 in 194 
Korean schizophrenic cases and 351 controls [120].
Finally, while DTNBP1 is associated with schizophrenia in one African American 
sample [129], analysis of DTNBP1 in another case control sample of African 
American origin (215 schizophrenic cases and 74 controls) failed to find an association 
[117].
It must be noted that the majority of these studies analysed very few DTNBP1 SNPs 
(nine out of the 15 negative studies genotyped <10 DTNBP1 polymorphisms). In order 
to avoid this caveat Peters and colleagues analysed 39 SNPs which tagged the DTNBP1 
locus, in an Anglo-Irish case control sample of 336 schizophrenia cases and 172 
controls [124]. However, again no association was observed.
Another possibility for the negative reports including the study by Peters et al [124] is 
the relatively low sample sizes analysed. One study which attempted to resolve the 
potential limitations of either low gene coverage or small sample sizes, investigated 
DTNBP1 along with another 13 of the best supported schizophrenia candidate genes 
within a large sample of 1870 cases and 2002 controls [125]. Sanders and colleagues 
genotyped a dense set of SNPs, which included previously associated polymorphisms 
as well as tagging markers, for each gene. In total 38 DTNBP1 SNPs were genotyped. 
Twelve of these had previously been reported as associated with schizophrenia, the
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remainder tagged -84% of the DTNBP1 locus (HapMap phase II, r2>0.8, MAF>0.05). 
In addition to single marker analysis, haplotypic analysis was performed which 
included the examination of previously reported haplotypes. HapMap phase II SNPs 
that were not genotyped were imputed. No DTNBP1 SNPs showed a significant 
association with schizophrenia. However neither did any of the other 13 genes after 
experiment-wide correction for multiple testing. Sanders and colleagues suggest a 
number of reasons for their failure to find an association, including an atypical sample. 
However they also suggest that the odds ratios observed in their analysis are in a 
plausible range (1.10-1.23) for small susceptibility effects but below what would 
produce significant p values in their sample.
Despite these negative association results DTNBP1 markers show a significant 
association to schizophrenia after meta-analyses by two different groups [140, 142]. Li 
and colleagues analysed 9 SNPs from 12 DTNBP1 association studies [117, 121, 123, 
127, 134, 135, 137, 143] which consisted of 3429 cases, 3376 controls and 721 trios 
[142]. Four out of the nine SNPs analysed showed a significant association to 
schizophrenia however, the authors note that the results from Funke and colleagues 
[117] appeared to account for the association signal at three of these variants and none 
survived correction for multiple testing. However, this study did not include all 
DTNBP1 association studies. In contrast the SZgene database contains an up to date 
collection of all published genetic association studies on which a continuously updated 
meta-analysis is performed on polymorphisms that have been genotyped in four or 
more independent case-control samples [140]. Genes that contain SNPs which posses a 
significant OR after meta-analysis, such as DTNBP1, are classed as “Top Results” and 
listed on the SZgene homepage.
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1.3.2 DTNBP1 and Endophenotypes
In addition to reports of a general association between DTNBP1 and schizophrenia, 
several studies have also observed an association between DTNBP1 markers and 
specific schizophrenic disease correlates, often termed endophenotypes. These are 
summarised in Table 1.2.
The first report between DTNBP1 and a specific phenotypic variable was published by 
Williams and colleagues who observed that a protective haplotype (rs2619539, 
rs3213207, rs2619538, CAA p=0.006) was significantly associated with higher 
education achievement (corrected p=0.02) [134]. While higher education achievement 
would not meet the standard criteria for an endophenotype, it is often used as a proxy 
for IQ and cognitive function. In support of the link between DTNBP1 and cognition, 
Donohoe et al [144] reported that schizophrenic patients carrying the risk haplotype 
from the Williams study (CAT), which was also significant in their own case control 
sample, showed impaired spatial working memory (mean errors = 65) compared to 
patients without the risk haplotype (mean errors=50, p=0.009) [144]. Working memory 
has been consistently demonstrated to be impaired in schizophrenic patients and 
variations in working memory have been shown to be associated with general cognitive 
performance [145].
Risk haplotypes from other studies have also been found to be associated with 
endophentypes relating to cognition. Since the identification of their GATGAG 
(rs909706, rs l018381, rs2619522, rs760761, rs2619528, rslOl 1313) risk haplotype 
[117], Funke and colleagues have reported an association between this haplotype and a 
reduced general cognitive ability in both healthy volunteers (p=0.04) and 
schizophrenics (p=0.035) [146]. A more recent report by the same group found that 
carriers of the GATGAG risk haplotype also demonstrated a significantly greater 
decline in IQ than non-carriers (p=0.05) [147]. The individual alleles of DTNBP1 
markers which form part of either the Williams [134] or Funke [117] risk haplotypes 
have also been shown to be significantly associated with IQ scores in a combined
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sample of patients, siblings and controls (rs760761 p=0.026, rs2619522 p=0.025, 
rs2619538 p=0.038) [148]. A further study also found an association between 
rs2619528 and rs760761 and changes in prefrontal brain function [149]. However 
disturbed prefrontal brain function was observed in healthy individuals carrying the G 
and C alleles of rs2619528 and rs760761 respectively (p=0.0068) which are the 
opposite alleles to those found in the Funke risk haplotype. However these alleles were 
found to be associated with schizophrenia in the Schwab study [108].
In addition to comparing spatial working memory in schizophrenia patients with and 
without the CAT risk haplotype [144], Donohoe and colleagues have also reported 
significantly reduced PI amplitudes in individuals carrying the CAT haplotype (n=14) 
than those not (n=12) [150]. PI performance is a measure of early visual processing. 
Other studies have also suggested a more generalised role for dysbindin in brain 
function than solely cognitive function.
Kircher et al analysed DTNBP1 genotypes and cognitive function as well as personality 
traits in a sample of healthy volunteers (n=521) [151]. Individuals carrying the common 
C allele of rsl018381 had a significantly higher total schizotypical personality 
questionnaire (SPQ-B) scale score compared to individuals carrying the T allele 
(p=0.0005). The SPQ-B is a 22 item self report screening instrument for schizophrenia 
spectrum disorder according to DSM-IV [152]. On the subscale score, although no 
association between rs l018381 and cognitive deficits were observed, the C allele 
carriers did show a significantly higher interpersonal deficit factor score (p=0.0005). 
This score describes negative symptoms such as social anxiety, no close friends, 
blunted affect and paranoid ideation. As the T allele of rsl 018381, which tags the 
GATGAG risk haplotype, scored lower on the SPQ-B sum and the interpersonal deficit 
sub-score this suggests a protective effect by this allele. Although this is in the opposite 
direction to what would be expected it must be noted that the C allele of rs 1018381 has 
been also been reported as associated with schizophrenia, including within the original 
Straub study [113, 137, 138].
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In contrast the Kircher study, the Funke GATGAG risk haplotype has been shown to be 
associated with negative symptoms by DeRosse and colleagues [153]. In this study the 
risk haplotype was tested for association with the lifetime history of negative symptoms 
in 181 Caucasian patients with schizophrenia. Post hoc t test analysis revealed that 
carriers of the risk haplotype (n=26) had significantly higher ratings than non-carriers 
on avolition (p<0.04), alogia (p<0.02) and flattened affect (p<0.02). This resulted in a 
significantly higher overall negative symptom rating in carriers (p=0.001).
The risk haplotype demonstrated to account for all the association reported in the initial 
study by Straub et al (rs3213207, rsl011313, rs2619528, rs2005976, rs760761, 
rs2619522, rsl018381, rsl474605, GGAATGCG) has also been shown to be associated 
with high levels of negative symptoms in patients with schizophrenia (p=0.004) [154]. 
Furthermore, Pae et al [155] reported that a haplotype consisting of rs3213207 and 
rs 1011313 is associated with higher positive and negative syndrome scale (PANSS) 
scores in 240 Korean schizophrenic inpatients. However subsequent analysis of the 
association identified that the major contributor to the association was a higher positive 
subscale score (AG p=0.009).
Several other studies have also reported an association between DTNBP1 and positive 
symptoms. Stefanis et al [156] examined 18 SNPs within a number of schizophrenia 
susceptibility genes, including DTNBP1, in 2243 male military conscripts. They 
observed a single marker association with the minor alleles of both rs2619522 and 
rs760761 with positive and paranoid schizotypy scores. These two alleles (G and T 
respectively) are on the GATGAG risk haplotype background. In addition they 
observed an association between these alleles and lower attention capacity supporting 
the link between DTNBP1 and cognitive deficits.
Three other studies have investigated variation at the DTNBP1 locus with 
schizophrenia psychotic symptoms [157-159]. Firstly, rsl 1558324 has been reported 
associated with child-onset psychosis (risk allele A, p=0.014) in a cohort of 102 
children with onset of psychosis before age 13. The same report also showed an
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association between several DTNBP1 SNPs (rsl047631, rs6924627, rs760761, 
rs2619522, rsl 1558324) and a number of endophenotypes measured by the premorbid 
adjustment scale (PAS) (0.001 <p<0.046) suggesting DTNBP1 may contribute to early 
neurodevelopmental impairment [158]. Secondly Kishimoto and colleagues analysed 
the three markers that constitute the CAT risk haplotype in a Japanese cohort of 197 
individuals with methamphetamine psychosis (MP) and 243 controls [159]. The 
psychotic symptoms shown in MP are close to those observed in schizophrenia and MP 
is considered a pharmacological model of schizophrenia [160]. In addition to a 
significant allelic association at rs3213207 (p=0.00003), the three marker haplotype 
was also significantly associated with MP (p= 0.0005). Specific haplotype analysis 
identified CAA as a protective haplotype (p= 0.0013). This is consistent with the 
Williams study which identified CAA as a schizophrenia protective haplotype [134].
Corvin and colleagues also investigated the impact of the CAT haplotype on clinical 
symptomatology in psychosis within 262 schizophrenic and schizoaffective patients of 
Irish descent [157]. Means scores were compared for risk haplotype carriers (n=70) 
against non-risk carriers (n=123) for principle components determined from 30 PANSS 
items. A significant difference was observed between groups for the 
hostility/excitability score (p=0.004) with risk haplotype carriers producing lower 
scores than non-risk carriers. Hostility/excitability has been identified as a mania-like 
factor by studies of functional psychosis [161] and in a recent study was shown to be 
the best factor at distinguishing between the schizophrenia and affective psychotic 
disorders [14]. It has therefore been suggested that the lower score observed in risk 
haplotype carriers indicates that DTNBP1 could contribute susceptibility to a 
“prototypical” schizophrenia, as described by Craddock et al [162], rather than 
affective symptoms on the mood psychosis spectrum.
An association between DTNBP1 and schizophrenia endophenotypes could suggest 
possible mechanism(s) through which pathogenesis could be mediated. However as 
with the general association data the studies described above are difficult to interpret as 
risk alleles and haplotypes have been reported to be associated with multiple
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schizophrenia endophenotypes including cognition, positive and negative symptoms. A 
limitation of most studies that have attempted to investigate the relationship between 
DTNBP1 and specific endophenotypes relating to schizophrenia is that the sample sizes 
have been relatively small. In addition, a number of studies have only examined one 
risk haplotype often with only one endophenotype. These issues may have contributed 
to why the specific relationship between SNPs and haplotypes and certain symptoms 
remains unclear. A recent study by Lucinao and colleagues [163] tried to address some 
of these issues by investigating the association between several DTNBP1 
polymorphisms and cognitive function in three large population samples (1054 
Scottish, 1806 Australian, 745 English). Within each cohort a battery of well validated 
cognitive tasks were performed which included measurements of IQ, verbal ability and 
several memory functions. In total 12 markers were genotyped which included those 
within the Williams and Funke risk haplotypes (CAT and GATGAG respectively) plus 
six SNPs from the original Straub study. A number of single polymorphisms showed 
association with several cognitive abilities including executive function, processing 
speed, verbal declarative memory and freedom from distractibility. However the only 
association to survive correction for multiple testing was that of the CAT risk haplotype 
and verbal ability (p<0.001).
Overall the link between DTNBP1 risk alleles and haplotypes, particularly the Williams 
risk haplotype, appears to be strongest with an impaired cognitive ability. While the 
Funke risk haplotype shows association to both cognitive deficits and negative 
symptoms, these findings could be related, as negative symptoms and cognitive 
function have been shown to be highly correlated [164].
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dbSNP ID rs1047631 rs2619539 rs3213207 rs1011313 rs6924627 rs2619528 rs2005976 rs760761 rs2619522 r$1018381 rs1474605 rs909706 rsl 1558324 rs2619538
Alternative name P3230 P1655 P1835 P1325 P3762 P1765 P1757 P1320 P1763 P1578 P1792 P1583 P3521 SNP A
Chromosome Pos 15631080 15728834 15736081 15741411 15741601 15757808 15758781 15759111 15761628 15765049 15766191 15768850 15771097 15773188
Alleles A/G G/C A/G G/A G/A G/A G/A C/T T/G C/T A/G G/A A/G T/A
Study Year Phenotype Association Original SZ Association Study
Williams 2004 Higher Educational Attainment Protective Haplotype Williams 2004 C A A
Donohoe 2007 Impaired Spatial Working Memory Risk Haplotype Williams 2004 C A T
Donohoe 2008 Early Visual Processing Risk Haplotype Williams 2004 C A T
Corvin 2008 Hostility/Excitability Risk Haplotype Williams 2004 C A T
Lucinao 2009 Verbal Ability Risk Haplotype Williams 2004 C A T
Burdick 2006 General Cognitive Ability Risk Haplotype Funke 2004 G A T G T G
DeRosse 2006 Negative Symtoms Risk Haplotype Funke 2004 G A T G T G
Burdick 2007 Cognitive Decline Risk Haplotype Funke 2004 G A T G T G
Kircher 2009 Higher SPQ-B Total score and Risk Allele
Interpersonal Defects Funke 2004 C
Fanous 2005 Negative Symtoms Risk Haplotype Straub/Vanden Oord 2002/03 G G A A T G C G
Gomlck 2005 Child onset psychosis Slnle Marker A
PAS Total Single Marker G A T G A
Falgatter 2006 Disturbed Prefrontal Risk Allele
Brain Function G C
Stefanis 2007 Lower Attention Capacity Risk Allele T G
Lower positive and Risk Allele
paranoid schizotypy scores T G
Zin stock 2007 Full S ad e  IQ Risk Allele T G T
Pae 2008 Psychotic Positive Symtoms Haplotype A G
Table 1.2. Summary of association studies between DTNBP1 and schizophrenia related phenotypes. The table has been divided into four sections. The first three 
give details o f the associations observed with specific risk haplotype (Williams [134], Funke [117] and Straub [112, 113] respectively). The final section gives 
associations o f individual risk alleles with different endophenotypes. Alleles or haplotypes are determined as risk if they have previously been reported as associated 
with schizophrenia (see Table 1.1 for details).
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1.3.3 DTNBP1 and Bipolar Disorder
In light of the reports that DTNBP1 is associated with schizophrenia, a number of 
research groups have investigated variants at the DTNBP1 locus with bipolar disorder 
[139, 165-169]. The first association study of DTNBP1 markers and bipolar disorder 
was performed by Raybould and colleagues [169] who investigated the three marker 
schizophrenia risk haplotype reported by Williams et al [134] in a Caucasian case 
control sample of 726 bipolar cases and 1407 controls. Although they did not find any 
evidence that DTNBP1 influences risk to bipolar disorder in general, DTNBP1 was 
found to be nominally significantly associated in a subset of the bipolar cases (n=133) 
with predominantly psychotic episodes of mood disturbance. In these individuals 
rs2619538 was significantly associated with bipolar disorder with psychosis as well as 
the three marker schizophrenia risk haplotype CAT (p=0.004 and p<0.042 
respectively). This is consistent with Corvin and colleagues who showed carriers of 
CAT had lower mania-like scores [157] and two studies that have observed significant 
association between DTNBP1 haplotypes and psychosis in schizophrenia patients [158, 
159]. However it must be noted that these findings by Raybould et al were not 
significant after correction for multiple testing.
Breen and colleagues investigated 11 DTNBP1 SNPs within 213 bipolar patients and 
197 controls [165]. Ten of these polymorphisms were those genotyped by the Straub 
study. The 11th SNP chosen for analysis was rs2619538. Although single marker 
association analysis revealed nominal significance, the greatest association was 
observed with haplotypic analysis. While a number of three marker haplotypes were 
identified that were significantly associated with bipolar (p=0.006-0.008), the most 
significant result was observed with the four marker haplotype (rs2619522, rs760761, 
rs2005976, rs2619528, p=0.005). Within this 4 marker haplotype, the allele 
combination TCGG was found to be protective (p=0.028). No association, either allelic 
or haplotypic, was observed with rs2619538, the only SNP which was also genotyped 
in the Raybould study [169].
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The most recent case control study of DTNBP1 and bipolar disorder in a Caucasian 
sample was performed in a sample of 515 bipolar patients and 1316 control 
subjects[166]. A total of seven DTNBP1 SNPs were analysed directly and rs2619522 
was imputed. The majority of these SNPs were chosen based on their inclusion in either 
the Straub [112] or Williams [134] studies. A number of allelic and genotypic 
associations were observed, however apart from the allelic association for rs3213207 
(p=0.006) none survived correction for multiple testing. The most significant result was 
produced via haplotypic analysis where a 4 marker haplotype consisting of rsl 6876571, 
rs2619539, rs3213207 and rs760761 was significantly associated with bipolar (GCGT,
p=0.02).
In addition to case control studies there has been one family based study of DTNBP1 
and bipolar disorder in a Caucasian sample [170]. This study investigated several genes 
previously associated with schizophrenia in 379 bipolar patient-affected offspring trios. 
This included DTNBP1, where 19 markers were genotyped which tagged 87% of the 
DTNBP1 locus at an r2>0.8. These SNPs also captured 8 out of the 11 SNPs previously 
reported as associated with schizophrenia at an r =1. However analysis using gene- 
based tests revealed no significant evidence for association between DTNBP1 and 
bipolar disorder.
A second family based study analysed DTNBP1 with bipolar disorder in a population 
isolate sample [139]. In addition to analysing DTNBP1 for an association with 
schizophrenia, Fallin and colleagues also genotyped several DTNBP1 polymorphisms 
in 323 bipolar disorder Ashkenazi case-parent trios. As with the schizophrenia trio 
sample analysed in the same study, DTNBP1 met the criteria for a suggestive 
association. Several single markers were reported to show an association (0.01<p<0.05) 
although no specific details are given. In light of the Raybould study [169] it may be of 
note that 67% of the bipolar affected cases had psychosis.
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Along with publications using Caucasian and population isolate samples there have 
been two studies which have investigated DTNBP1 and bipolar disorder in the Asian 
population. Pae and colleagues [168] analysed five SNPs (rs3213207, rs l011313, 
rs2005976, rs7607961, rs2619522) in a Korean sample of 155 bipolar cases and 478 
controls. Although no single marker association was observed, the 5 marker haplotype 
was found to be significantly associated (global p=0.009) which appeared to be in part 
due to the protective effect of the ACGTA haplotype (p=0.00016). Additional sliding 
window analysis identified the GTA alleles of the haplotype to be the major 
contributors (p=0.00006).
Joo and colleagues genotyped rs2619538, rs2619522 and rs760761 in a sample of 163 
patients and 350 controls again of Korean descent [167]. A genotypic association was 
observed for both rs2619522 and rs760761 (p=0.014 and p=0.026 respectively). 
However these did not remain significant after Bonferroni correction for multiple 
testing.
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1.3.4 DTNBP1 and Major Depressive Disorder
A number of studies have examined DTNBP1 variants with major depressive disorder 
(MDD) [171-175]. Kim et al analysed 4 SNPs (rs3213207, rslOl 1313, rs760761 and 
rs2619522) in a Korean sample of 188 MDD patients and 350 controls [172]. A 
significant association (p=0.0014) was observed via 4-marker haplotype analysis with 
the protective haplotype ACTA showing the greatest association (p=0.002). Sliding 
window analysis revealed that the major contribution was due to the rs761761 and 
rs2619522 haplotype (p=0.000026). Although neither of these SNPs showed single 
marker association with MDD, rs760761 had previously been reported by the same 
group to show allelic association, along with rs2005926, with antidepressant response 
(p=0.00055 and p=0.0058 respectively) [173].
Three studies have analysed DTNBP1 in MDD case control samples of Caucasian 
origin [171, 174, 175]. None of these observed a significant association either at a 
single marker or haplotype level. However a number of factors may explain why the 
Caucasian studies reported a negative association with MDD. Two of the studies [171, 
174] did not genotype all markers from the associated 4 marker haplotype reported by 
Kim et al. In addition the protective haplotype ACTA previously reported was not 
observed in the case control sample analysed by Zill et al [175]. Nevertheless, it must 
be noted that all studies analysing DTNBP1 and MDD have examined only a limited 
number of DTNBP1 variants (range=4-6 markers) and the majority of studies [171, 
172, 174, 175] are likely to be underpowered due to small sample sizes.
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1.4 Possible Explanations for Inconsistent Association Results
While the association studies reported in sections 1.3 and 1.3.2 provide strong support 
for DTNBP1 as a schizophrenia susceptibility gene, this data is by no means 
conclusive. Even allowing for the fact that many of the studies reporting a positive 
association have not analysed the same genetic markers, there is considerable 
disagreement between publications with respect to the associated markers and 
haplotypes reported. For example the initial replication study by Schwab and 
colleagues [131], which genotyped 6 SNPs from the 8-marker risk haplotype described 
by Van den Oord et al [113], determined that the 6-marker haplotype consisting of the 
common alleles at each locus (rs3213207, rslOl 1313, rs2619528, rs760761, rs2619522, 
rsl018381, AGGCTC) was the only 6-marker haplotype to occur at a larger frequency 
in transmitted than non-transmitted haplotypes. Although this observation was 
consistent with their single marker results (See Table 1.1), it was in contrast to the 
results reported in the Van den Oord reanalysis [113] of the Straub study [112] where 
the rare alleles were preferentially associated with schizophrenia in the 8-marker risk 
haplotype (gGantgCn, rare alleles are depicted in lower case and those not typed in the 
Schwab study are given as N). Even more generally, as can be seen from Table 1.1, the 
associated alleles reported tend to “flip-flop” between studies.
One potential explanation for the differences observed is that the design of the majority 
of the association studies to date makes it improbable that the significant SNPs reported 
have a direct pathogenic role in the function of DTNBP1. The original study selected 
SNPs from public databases and relied on these SNPs to be in sufficient LD with the 
actual functional variant(s) for an association signal to be detected. Most replication 
studies have not attempted to identify these functional variants but have typed SNPs 
previously reported as associated. Therefore these studies also rely on the fact that the 
SNPs examined are in LD with the functional variant(s) in their sample.
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One study that did attempt to identify DTNBP1 causal variants undertook a direct 
approach by screening all exons and putative promoters for sequence polymorphisms
[134]. However even here haplotypic analysis yielded a more significant association 
than single markers, suggesting the true causal variants have yet to be identified.
It should therefore be noted that the degree of correlation between two SNPs is highly 
population dependant. In addition the effect size of a single variant can also vary 
between populations. The potential differences in the genetic architecture of a sample 
could possibly explain the patterns of association observed. However some of the 
differences reported, such as those between the Straub/Van den Oord and Schwab 
studies are within relatively related populations. Furthermore, a recent report argues 
against the hypothesis of sample variation [141]. Mutsuddi et al identified the single 
marker or haplotype that best captured the association signal in six studies which had 
investigated DTNBP1 in samples of European ancestry [112, 117, 127, 130, 131, 134]. 
From this, the tag SNP(s) for each risk haplotype were determined and genotyped 
through the HapMap CEU sample. Mutsuddi and colleagues observed that the 
haplotypes frequencies reported in each study were broadly similar to their frequency in 
the CEU population. This suggests that the European samples studied are genetically 
similar and that population stratification cannot explain the differences observed.
Consequently, one of the more likely explanations for the disagreement between studies 
is that there are multiple risk variants at the DTNBP1 locus (known as allele 
heterogeneity). This hypothesis is supported by the Mutsuddi study [141] which, using 
a high density reference map also demonstrated that the associated haplotypes reported 
in each study was inconsistent with one common causal variant contributing to 
schizophrenia at the DTNBP1 locus as all of the five supposed replication studies [117, 
127, 130, 131, 134] defined a different associated haplotype than the haplotype 
originally reported [112, 113]. Another possibility is that there is a single susceptibility 
allele, which has yet to be identified and is carried on a remarkable diversity of 
haplotypes even in closely related populations [5].
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1.5 Altered Expression of Dysbindin in Schizophrenia
Of all the studies to date between DTNBP1 and schizophrenia, no non-synonymous 
alleles have been shown to account for any of the association reported. This suggests 
that the causal variant(s) within DTNBP1 may either be as yet unidentified non- 
synonymous SNPs or polymorphisms which function by a mechanism other than 
altering protein structure. The later possibility is supported by molecular genetic studies 
into other complex disorders where several susceptibility genes have been identified but 
no obvious pathogenic mutations have been found [112, 176-179]. Possible alternative 
mechanisms by which DTNBP1 could confer susceptibility to schizophrenia include 
enhancing or inhibiting alternative spicing, altering the expression of dysbindin or a 
particular dysbindin transcript, or affecting mRNA stability or processing. A number of 
recent studies have provided evidence that altered dysbindin expression may be the 
mechanism by which DTNBP1 confers susceptibility to schizophrenia. These have 
included observations of a reduction in dysbindin expression in schizophrenic patients 
compared with controls [180-183] and evidence that variation in dysbindin expression 
within the brain is the result of genetic variation [184-186]. Details of these findings are 
summarised in section 1.5.1 below.
1.5.1 Dysbindin Expression in Schizophrenic Patients
Brain imaging and cognitive assessments consistently show a dysfunction in the 
dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia [187, 188]. In 
addition the poor performance on working memory tasks observed in schizophrenia 
have been associated with reduced activation of the DLPFC [144]. As a result,
Weickert and colleagues investigated the levels of dysbindin mRNA within the DLPFC 
of schizophrenic patients [183]. Comparison of 7 schizophrenic cases and 13 controls 
revealed a 15-20% reduction in dysbindin mRNA levels within the patient group 
(p=0.04).
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Corroborative results for this finding have been reported in similar studies which have 
measured dysbindin mRNA and protein levels in the hippocampal formation (HF). The 
HF has an important role in mediating cognitive and behavioural aspects of 
schizophrenia and shows frequent synaptic abnormalities in patients with the disorder 
[189, 190]. The first study to look at dysbindin levels in the HF compared dysbindin 
protein levels within post-mortem tissue from two sets of schizophrenic patients (n=17 
and 15 respectively) plus matched non-psychiatric controls [181]. A presynaptic 
reduction in dysbindin protein was reported at hippocampal formation sites of both sets 
of schizophrenic patients (average reductions of 18-42%, p=0.027-0.0001). The 
schizophrenic cases showed no loss or shrinkage of DGh neurons, no loss of DGiml 
thickness and no loss of the synaptic markers synaptophysin or synapsin-1 in the 
DGiml, thereby suggesting that the reduced presynaptic dysbindin observed within the 
HF was associated with schizophrenia rather than general differences in the HF [181]. 
Corroborative evidence for these findings was reported in a follow up study by the 
same group which observed reduced dysbindin mRNA in the HF of schizophrenics 
(n=10) compared with matched controls (20-40% reductions, p=0.04) [182].
While great care is taken when sample matching, measuring gene expression using 
post-mortem tissue is susceptible to confounding influences arising from characteristics 
of the tissues themselves (for example RNA quality, cellular heterogeneity) as well as 
demographic and environmental confounds (such as the effects of medication). 
Although the reduction in dysbindin expression detailed above was not significantly 
correlated with age, sex, PMI, or antipsychotic exposure, it’s worth noting that a 
reduction in dysbindin RNA, similar to that observed in the post mortem studies, has 
also been observed in peripheral blood lymphocytes (PBL) of 12 schizophrenic patients 
compared to controls (28% reduction, p=0.02) [180]. The measurement of gene 
expression in PBL removes the influence of neurohormonal, medication and 
environmental factors by several passages of cell culture [180].
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1.5.2 Cis-acting Variation of DTNBP1
If DTNBP1 does confer susceptibility through altered expression then this could be 
facilitated in a number of ways. Expression of human protein-encoding genes can be 
regulated at a number of different stages including the control of chromatin structure, 
initiation of transcription, mRNA processing, transport of mRNA to the cytoplasm, 
mRNA stability, translation of mRNA and protein activity [191, 192]. Altered 
dysbindin expression in schizophrenics has been detected at both the mRNA and 
protein level and in some instances reduction of these two forms has been shown in the 
same region of the brain, for example the dentate gyrus of the HF [181, 182]. This 
suggests that the mechanism by which dysbindin expression is reduced involves a 
reduction in dysbindin transcript levels or mRNA stability as opposed to degradation of 
the protein.
Factors that affect the transcription or mRNA stability of DTNBP1 can be genetic or 
environmental. Genetic influences on gene expression fall into two categories, cis or 
trans-acting. Cis-acting factors are located on the same chromosome as the target gene 
and although they are more likely to be close to their target i.e. within the promoter, cis- 
acting regulatory regions can be some distance from the coding sequence [191]. Trans­
acting factors can be situated anywhere in the genome and influence the expression of a 
target gene through interaction with cis-regulatory sequences. While the post-mortem 
and PBL analyses described in section 1.5.1 cannot distinguish between these genetic 
influences, one method that can determine whether a gene is under the influence of cis- 
acting regulation is the allelic expression assay.
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1.5.2.1. Relative Allelic Expression Analysis
Allelic expression (AE) analysis can determine whether the expression of a gene is 
under the influence of either polymorphisms within regulatory elements or other cis- 
acting phenomena such as epigenetic modification. In the absence of cis-acting 
influences that differentially effect the transcription or stability of the two copies of 
mRNA of an autosomal gene, both mRNA copies will be equally expressed. However 
if an individual is heterozygous for any cis-acting polymorphisms, or where one copy 
of a gene is systematically affected by epigenetic modification, then the mRNA from 
each chromosome will be expressed at different levels.
The relative expression of each copy of a specific gene can be measured with 
quantitative allele discrimination of a coding SNP within the assayed gene. This coding 
SNP is used as a copy-specific tag for any cis-acting regulatory SNPs (also known as 
eSNPs). Individuals heterozygous for the coding SNP are analysed. If any individuals 
are also heterozygote for a regulatory polymorphism, the presence of cis-acting 
regulatory variation will be detected in a significant departure from the expected 1:1 
allele ratio in a sample (Figure 1.4) [193]. This ‘within-subjecf approach means that 
each allele acts as an internal control for the other. Only cis-acting factors will be 
detected and other influences, such as differences in tissue preparation, mRNA quality, 
environmental factors and trans-acting regulatory influences are controlled for [193].
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Figure 1.4 Principle of relative allelic expression analysis. A) An individual who is heterozygote for an 
exonic A/G polymorphism is also heterozygous for an unknown regulatory SNP denoted a/p. B) One 
allele of the regulatory polymorphism (denoted P) results in lower expression o f the gene copy 
containing the G allele, with which it is in phase. C) The relative under expression of the G allele (and 
thus the presence of the regulatory polymorphism) is detected by applying a quantitative method of allele 
discrimination to the cDNA and comparing this with the relative representation of the two alleles 
observed in genomic DNA. Adapted from [193].
54
1.5.2.2 Allelic Expression Analysis of DTNBP1
Using allelic expression analysis Bray and colleagues showed that DTNBP1, along 
with 6 out of 15 other assayed genes, is under the influence of cis-acting variation
[184]. For DTNBP1, two SNPs were analysed, chr6:15580740A->G and 
chr6:15643772 T->C (genomic sequence, June 2002) with nine heterozygotes assayed 
for each SNP. For the A->G SNP six individuals showed allelic expression differences 
>20% with an average difference in allele representation of 66% (p<0.01). For the T->C 
SNP three individuals showed differential expression >20% with an average difference 
of 36% (p<0.01). It is interesting to note that DTNBP1 showed the greatest differential 
expression out of the 15 genes examined as DTNBP1 was the only gene selected for 
allelic expression analysis under a specific a priori hypothesis due to the absence of 
non-synonymous changes in DTNBP1 that explain its association with schizophrenia.
A more in depth analysis by the same group confirmed the influence of cis-acting 
variation on DTNBP1 [186]. Allelic expression analysis of DTNBP1 was performed 
using rsl 047631, an expressed SNP located within the 3’UTR of the majority of 
predicted DTNBP1 transcripts (Figure 1.5) [134]. 149 Caucasian individuals were 
genotyped for rsl 047631. 31 of these individuals were heterozygous and therefore 
informative for allelic expression analysis. Primer extension analysis using SNaPshot 
chemistry, was performed on two cDNA samples and one corresponding gDNA sample 
for each individual. Bray and colleagues reported a significant reduction in expression 
of the cDNA carrying the common A-allele of rsl 047631 relative to the cDNA carrying 
the G-allele (p<0.0001) with a mean A/G ratio of 0.86 (Figure 1.6). This deviation from 
a 1:1 ratio provided evidence that unknown DNA variants in cis to the DTNBP1 gene 
are causing variation in DTNBP1 expression.
Although a statistically significant reduction was observed, there was considerable 
variability in the cDNA ratios between the individuals assayed which ranged from 0.64, 
a 36% reduction of allele A, to 1.07, a 7% increase in allele A. Sample variance was
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discounted as firstly repeat assays showed good reproducibility between individual 
cDNA ratios (SD/mean = 0.05) and secondly 15 extra samples were analysed from two 
brain regions and within subject comparisons between these regions indicated no 
significant differences (paired t  test p=0.61). It was therefore suggested that the spread 
of data could potentially reflect multiple cis-acting variants influencing expression, 
interactive effects between a cis-acting variant and other trans-acting factors or 
environmental effects.
15631 000I
r s l 0 4 7 6 3 1 |
156315001 156320001 156325001 156330001
f l l i e  1 i c .E x p re s s io n _ S N P
UCSCKnown G en es ( J u n e .  0 5 ) B ased  o n  Un i P r o t ,  R e f Sect. an d  GenBanK mRNfl
156335001
DTNBP1
Figure 1.5. Chromosomal location of the allelic expression assay SNP rsl 047631. rsl 047631 is located 
in the 3 ’UTR o f three DTNBP1 transcripts, DTNBPla, DTNBPlc and AF061734. Differential 
expression of the transcript DTNBPlb was not captured by this assay.
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Figure 1.6. Comparison between corrected genomic and cDNA allele ratios in heterozygotes for SNP 
rsl 047631. Data are represented as a ratio of A/G alleles. Significant under-representation of the A allele 
is observed in cDNA (p< 0.0001).
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1.5.2.3 Other Evidence of Cis-acting Variation
The allelic expression results of DTNBP1 have been further corroborated by a recent 
study whose primary focus was to identify trans-acting loci on DTNBP1 expression
[185]. This analysis involved using gene expression as a quantitative trait for linkage 
analysis to map polymorphic regulatory loci. Real time quantitative PCR measures of 
lymphoblastoid DTNBP 1 expression were obtained from 200 individuals, consisting of 
26 CEPH sibships, which were then used for genome-wide quantitative linkage 
analysis. A linkage peak was observed on chromosome 8p (28.1Mb-32.2Mb, max 
lod=2.77) suggesting trans-acting factors in this region. However the strongest evidence 
for linkage was observed on chromosome 6p (14.8Mb-16.9Mb, max lod=3.2). This 
peak is at the DTNBP1 locus (15.6Mb-15.8Mb) and is therefore consistent with cis- 
acting influences. 56 out of the 200 individuals that constituted the linkage sample were 
heterozygous for the coding SNP rs l047631 and allelic expression analysis on the 
lymphoblastoid cDNA from these individuals confirmed variable cis-acting influences 
on DTNBP1 expression operating in the lymphoblastoid cells [185].
1.5.3 Cis-acting Variation in Schizophrenia
Although there is evidence that dysbindin mRNA expression is reduced in 
schizophrenics and DTNBP 1 is under cis-acting variation, this is not enough to infer 
decreased expression of dysbindin by cis-acting variants is a primary aetiological 
mechanism in schizophrenia. For example reduced mRNA expression could be a 
compensatory mechanism for enhanced dysbindin function. Ideally any schizophrenia 
risk SNPs and/or haplotypes need to be shown to affect the expression of DTNBP 1. 
However given the complex pattern of associations in the literature as well as the 
difficulty in replicating complex systems such as the human brain in vitro, direct 
analysis is difficult. In an effort to prove that the reduction of dysbindin expression is 
relevant to schizophrenia pathophysiology two studies attempted to link the 
observations of low dysbindin expression with genetic associations reported.
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A preliminary study by Weickert and colleagues [183] looked into whether the altered 
expression in dysbindin seen in the DLPFC could be linked to DTNBP 1 genotypes. 
When individuals were stratified by genotype a significant difference in dysbindin 
expression was observed with 4/11 SNPs examined (rsl047631, p=0.048, rs2743864, 
p=0.04, rsl 1558324, p=0.004, rs2619537, p=0.05). These four SNPs were located in 
the promoter, 3’UTR and 5’UTR of DTNBP 1 and, although the study involved 
relatively few individuals, the results suggested that variation in dysbindin mRNA 
levels in schizophrenics may be due to altered transcription rates caused by cis-acting 
factors.
To investigate whether cis-acting influences are relevant to the aetiology of a particular 
disease, allelic expression data can be stratified by the genotypes of an associated 
SNP/haplotype to determine whether this DNA variant is correlated with differential 
expression. Allelic expression ratios of individuals with one copy of a risk 
allele/haplotype are compared against individuals with zero or two copies of the risk 
allele/haplotype. Individuals with two copies of the risk allele/haplotype are grouped 
with individuals with no copies due to the nature of allelic expression data. As results 
are given in the form of a ratio even if an individual has two copies of a variant that 
alters mRNA expression they would give an allelic expression ratio of 1. Hence it is 
only individuals heterozygous for a risk allele/haplotype that will show a difference in 
expression if that risk allele/haplotype is also associated with altered expression.
In previous studies this strategy has been used to establish that a COMT haplotype 
associated with schizophrenia, is correlated with reduced COMT expression (p= 0.003) 
[194]. It has also been reported that mRNA carrying the e4 allele of APOE, a risk allele 
for Alzheimer’s disease, has significantly increased expression compared to mRNA 
carrying either the e3 or e2 alleles (p<0.0001) [195]. Consequently, this approach was 
applied to DTNBP 1 allelic expression ratios using schizophrenia association data 
previously reported [134]. Firstly, Bray and colleagues carried out a comprehensive re­
analysis of previous case control genetic association data [134] to identify the risk
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haplotype that included phase information for rs l047631. As described above, this 
coding SNP had been used by the group to perform the allelic expression analysis. As a 
result a 3-marker haplotype, TAA (T allele of rs2619538, A allele of rs3213207 and A 
allele of rsl 047631) was identified that maximally differentiated the cases and controls 
(5.2% increase in the cases). Individuals assayed in the allelic expression analysis were 
genotyped for this 3-marker haplotype and the allelic expression data stratified by 
individuals heterozygous for the risk haplotype and individuals carrying no copies of 
the risk haplotype. The relative expression of the A-allele of rsl 047631 was shown to 
be significantly lower when it was carried on the risk haplotype (TAA AE ratio=0.79) 
compared with when it was carried on the non-risk haplotypes (Non risk AE ratio=0.92, 
p=0.002, see Figure 1.7).
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Figure 1.7. Allele ratios at SNP r s l047631, stratified by heterozygosity for the defined 3-marker 
schizophrenia risk haplotype. Data represented as a ratio o f A/G alleles o f rsl 047631.
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This observation suggests that variants associated with schizophrenia could be causing 
differential expression of DTNBP 1. Nevertheless, Bray and colleagues note that it 
cannot be assumed that any of the SNPs within the risk haplotype analysed have direct 
effects on DTNBP 1 expression. This is illustrated by the fact that the risk haplotype 
does not account for all the cis-acting variation observed (Figure 1.7). Individuals who 
do not carry the risk haplotype have an average allelic expression ratio of 0.95 and 
three individuals show a relative decrease in expression of greater than 20%. There may 
therefore be functional variants unidentified in the original case control study.
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1.6 The Dysbindin Protein and Putative Function
When DTNBP 1 was first identified as a schizophrenia susceptibility gene little was 
known about the dysbindin protein. However although its specific function is still 
unclear, evidence from a number of sources, such as interacting proteins and animal 
models, has provided some clues as to the function of dysbindin and how reduced 
expression of the protein could confer susceptibility to schizophrenia.
The gene DTNBP 1 encodes dysbindin, a ubiquitously expressed protein with the 
highest levels of expression detected in the testis, liver, kidney, brain, heart and lungs 
[196]. Immunohistochemical studies have shown that dysbindin is expressed in 
multiple regions in the brain including the hippocampal formation and frontal cortex. 
Within these regions dysbindin is located in a diverse set of neuronal populations, 
within cell bodies as well as both pre and post synaptic sites. Multiple protein isoforms 
of dysbindin have been reported, reflecting alternative splicing within the gene. At 
present three mRNA transcripts (NM 032122, NM_183040 and NM_183041) have 
been validated according NCBI’s Reference Sequence (RefSeq) [197] which encode 
the proteins dysbindin-1 A, dysbindin-IB and dysbindin-1C respectively. Bioinformatic 
analysis suggests that many more mRNAs exist and 13 other alternative splice variants 
of DTNBP 1 are listed on the AceView database (www.ncbi.nlm.nih.gov/AceView) 
[198]. However whether these encode active proteins remains to be seen. The three 
validated isoforms appear to be commonly expressed and have a molecular mass of 
48kDA, 36kDA and 32kDA [199]. Computer aided sequence analysis of the three 
protein isoforms shows all contain a predicted coiled-coil region which spans 89 amino 
acids (See Figure 1.8) [196]. Coiled coils are bundles of intertwined alpha-helices that 
provide protein-protein interaction sites for the dynamic assembly and disassembly of 
protein complexes [200].
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Figure 1.8. Structural comparison of the three major dysbindin isoforms. Numbers below each variant 
gives the amino acid sequence location beginning at the C-terminus. CCD = coiled coil domain. DD = 
dysbindin domain. PD = PEST domain. LZM = leucine zipper motif. Adapted from [199].
1.6.1 Dysbindin and the Dystrophin-associated Protein Complex
Dysbindin is known to interact with the dystrophin-associated protein complex (DPC), 
specifically the a- and (3-dystrobrevins [196]. In fact, dysbindin was originally 
discovered by a yeast-two hybrid screen designed to identify (3-dystrobrevin interacting 
proteins, hence dysbindin’s full name dystrobrevin binding protein. The DPC, also 
known as the dystrophin glycoprotein complex (DGC), is a multi-protein complex 
comprised of three distinct components: the sarcoglycans, the dystroglycans and the 
cytoplasmic complex which includes the sytrophins and the dystrobrevins [201]. The 
correct assembly o f the DPC is vital for the normal function of muscle and disruption of 
the complex causes muscular dystrophy, a disorder characterised by progressive muscle 
wasting [202]. Duchenne muscular dystrophy (DMD) is the most common and severe 
form of the disease. Patients are usually confined to a wheelchair by the age of 12 and 
die in their late teens or early 20s due to respiratory failure. DMD is caused by 
mutations in the DMD gene which encodes the 427-kDa cytoskeletal protein 
dystrophin. A milder form of the disease, Becker muscular dystrophy (BMD) is also 
caused by mutations in the DMD gene but the disorder has a much later onset and a 
longer lifespan [203].
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1.6.2 The DPC and Schizophrenia
As well as being located within the sarcolemma of muscle the DPC is also found in 
postsynaptic densities in a number of brain areas. In addition to muscle disorders, 
mutations in dystrophin are also associated with a range of developmental cognitive 
and behavioural disabilities. These include attention difficulties, verbal short term 
memory deficits and problems in phonological language processing [203-205]. These 
observations are consistent with the DPC having a functional role within the brain. 
Furthermore, it has suggested that DMD has a neuropathology reminiscent of 
schizophrenia i.e. frontal temporal distribution, cortical heteropias and reduced 
dendritic arborisation of pyramidal neurons [46, 206].
Nonetheless, although there is some evidence that dysbindin could confer susceptibility 
to schizophrenia through the interaction with the DPC, additional studies do not support 
this hypothesis. Firstly, while the power to detect an association was relatively low, a 
study which analyzed of a number of DPC genes for an association to schizophrenia, 
including p-dystrobrevin (DTNB), 6-sarcoglycan (SGCD) and £-sarcoglycan (SGCE) 
produced negative results [207]. Secondly, although dysbindin and p-dystrobrevin co- 
localise in the mossy fibres of brain neurons, P-dystrobrevin is located postsynaptically 
[196]. In vitro studies have shown that dysbindin can be detected presynaptically in 
regions of the HF known to receive intrinsic glutamate input and importantly where p- 
dystrobrevin is not expressed [181]. As discussed previously, Talbot and colleagues 
reported a significant reduction in presynaptic dysbindin expression in several 
hippocampal regions [181], suggesting that dysbindin might influence schizophrenia 
risk through presynaptic mechanisms that are independent of the DPC.
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1.6.3 Dysbindin and the BLOC-1 Complex
In addition to the DPC, dysbindin is also a component of the biogenesis of lysosome 
related organelles complex 1 (BLOC-1) [208]. This is a ubiquitously expressed 
complex, located at both post and crucially presynaptic sites. The BLOC-1 complex is 
approximately 200kDa and consists of at least eight proteins; dysbindin, muted, 
pallidin, cappuccino, snapin and BLOC-1 subunits 1, 2 and 3 [208-211]. Within BLOC- 
1, dysbindin has been shown to interact directly with pallidin, muted and snapin [212] 
(See Figure 1.9). This interaction has been shown to be facilitated through the coiled 
coil region of the dysbindin protein [212].
Pallidin
Dysbindirp ^ Snapin BL0S1
(Cappuccin<
BL0S3
BL0S2
Figure 1.9. Illustration o f  the reported interactions between BLOC-1 proteins. Adapted ffom[211].
Although the exact molecular function of BLOC-1 remains unknown, evidence 
suggests that the complex is involved in the formation, development or maintenance of 
lysosome related organelles. Mutations in a number of the BLOC-1 genes, including 
DTNBP1, have been shown to cause various forms of Hermansky-Pudlak syndrome 
(HPS). HPS is the general term given to a collection of related autosomal recessive 
disorders which are characterised by the hypopigmentation of hair, skin and eyes and 
prolonged bleeding time [213]. These symptoms are caused primarily by defects in 
intracellular protein trafficking which results in the dysfunction of melanosomes and 
platelet dense granules. Melanosomes and platelet dense granules are intracellular 
organelles which act as catabolic compartments within the cell [214]. While 
melanosomes are involved in melanin synthesis and storage, platelet dense granules
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have a role in the activation of platelet aggregation. Both organelles are referred to as 
lysosome-related organelles due to genetic and morphological evidence that supports 
the idea that their biogenesis pathway is analogous to that of lysosomes [211, 214].
Other lysosome-related organelles include azurophil granules (in neutophils), lytic 
granules (in cytotoxic T lymphocytes and natural killer cells) and lamellar bodies (in 
epithelial cells) [211]. Interestingly additional manifestations, such as pulmonary 
fibrosis [215] and defective lysosomal enzyme secretion [216], which can be ascribed 
to defects in lysosome or related organelles other than melanosomes or platelet dense 
granules [211], have been observed in subsets of HPS patients and HPS mouse models. 
This suggests that BLOC-1 genes may function in a more general way than simply 
regulating the biogenesis of melanosomes and platelet dense granules. This hypothesis 
is supported by the fact that BLOC-1 genes are expressed in a wide variety of cell types 
[208,217].
Apart from BLOC-1 there are four other distinct complexes which are thought to be 
involved in the biogenesis of lysosome-related organelles, the AP-3 complex, BLOC-2, 
BLOC-3 and the HPS (homotypic vacuolar protein sorting) complex. Mutations of 
genes within these complexes cause similar phenotypic defects to the BLOC-1 genes 
and analysis of these complexes, in particular AP-3, has provided further evidence of 
the cellular function of the BLOC-1 complex. In fibroblasts the AP-3 complex traffics 
lysosome-associated membrane proteins (LAMPs) from early-associated tubules to late 
endosomes and lysosomes. In melanocytes AP-3 mediates the trafficking of the key 
melanogenic enzyme, tyrosinase, to maturing melanosomes. BLOC-1 has been shown 
to reside on micro vesicles that contain AP-3 [218]. In addition the BLOC-1 complex 
can facilitate the trafficking of known AP-3 cargoes through interaction with AP-3 and 
BLOC2 [218, 219]. It has therefore been suggested that, like AP-3, BLOC-1 may 
function in membrane protein sorting.
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The analysis of another BLOC-1 protein SNAPAP suggests that dysbindin may also 
have a specific role within the brain. SNAPAP (chrl: 153,631,145-153,634,325) 
encodes the 15kDa protein snapin which is a binding protein of SNAP25 (synaptosomal 
associated protein). SNAP25 belongs to the family of soluble N-ethylmaleimide- 
sensitive-factor attachment protein receptor (SNARE) proteins. The primary role of 
SNARE proteins is to mediate the fusion of cellular transport vesicles with the cell 
membrane. SNAP25 is one the best studied SNARE proteins and is involved in the 
fusion or exocytosis of synaptic vesicles with the plasma membrane which results in the 
release of neurotransmitters. SNAREs can be divided into two categories, vesicle or v- 
SNARES, which are incorporated into the membranes of transport vesicles during 
budding and target or t-SNARES, which are located in the membrane of target 
compartments and the plasma membrane. SNAP25 is a t-SNARE and along with 
syntaxin (another t-SNARE) and a v-SNARE synaptobrevin, also known as VAMP 
(vesicle associated membrane protein), form the SNARE complex. Correct assembly of
0A- lA -this complex is required for Ca dependent exocytosis and Ca dependent regulation 
of the SNARE fusion machinery is provided by the synaptotagmins. Investigations into 
the function of SNAPAP provided evidence that the gene may be an important 
regulator of neurosecretion as snapin has been shown to enhance the association 
between synaptotagmin and the SNARE complex [220]. Corroborative evidence of this 
has been found in SNAPAP mutant mice, where the association between 
synaptotagmin-1 and SNAP25 in brain homogenates was markedly decreased 
compared to the wild type mice, and in cultured cells where the knockdown of 
SNAPAP led to a significant reduction of vesicles residing in releasable pools [221].
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1.6.4 The Sandy (sdy) Mouse
Alterations in the expression levels of dysbindin shown in schizophrenic patients [181, 
183], could potentially disrupt the assembly and function of BLOC-1, thereby affecting 
intracellular lysosomal trafficking and possibly neurotransmitter release. To date, no 
major psychiatric manifestations have been documented in HPS patients, including type 
7 which is caused by mutant dysbindin [208]. However behavioural analyses of the 
sandy mouse mutant, which lacks dysbindin owing to a deletion in the DTNBP1 gene, 
report a number o f behavioural abnormalities in the mouse which have been associated 
with schizophrenia [222-226]. Morphological analyses of the sandy mouse [224, 225, 
227, 228], plus several in vitro studies [135, 229-231] have also provided evidence of 
potential functional mechanisms.
The sandy (sdy) mouse mutant, which originally arose on the DBA12J inbred strain, 
carries a spontaneously occurring deletion of the DTNBP1 gene. This large deletion 
(38,129bp) spans intron 5 to intron 7 and results in the loss of 51 amino acids from the 
dysbindin protein and the complete knockdown of dysbindin expression (see Figure 
1. 10 ).
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Figure 1.10. Dysbindin deletion in the Sdy mouse. nt=nucleotide. E=exon. Adapted from [208].
Recent behavioural assessments of the sdy mouse have observed a number of 
schizophrenia-like characteristics including cognitive and negative symptoms. Two 
studies which analysed the social interaction of sdy mice found they displayed reduced
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social contact compared to wild type mice [224, 225]. This suggests that knockout of 
the DTNBP1 gene leads to social withdrawal which mimics negative symptoms 
exhibited in schizophrenia. Furthermore Hattori et al observed anxiety-like symptoms 
in the sdy mouse including decreased arm entries into an elevated maze and less time 
spent in the centre o f an open field [225]. However other studies using similar tests 
failed to find a significant difference between sdy mutants and control mice [223, 224, 
226]. Conflicting results have also been observed for locomotor activity. Hyperactivity 
is considered to be a proxy for positive symptoms displayed in schizophrenia such as 
delusions and hallucinations [225]. While studies by Bhardwaj and Cox [222, 223] both 
observed hyperactivity in sdy mice, two other studies reported a decrease in locomotor 
activity [225, 226] and one study found no significant difference between sdy mice and 
controls [224].
Although there are some disagreements between publications, all studies which tested 
for habituation found that sdy mice showed reduced habituation compared to control 
mice [222, 223, 225, 226]. It has been suggested that the impaired habituation of sdy 
mice resembles the decreased habituation to diverse stimuli reported in schizophrenia 
[223],
Studies which tested for cognitive function in sdy mice have also all reported deficits 
including reduced working memory [226], impaired long term recognition [222, 224] 
and impaired spatial memory [223, 226]. Deficits in cognitive functions related to the 
prefrontal cortex and hippocampus/medial temporal lobe such as recognition memory 
and other forms of declarative memory have been described in schizophrenia subjects. 
In addition, mice heterozygous for the DTNBP1 deletion also displayed significant 
impairments in some behavioural tests such as recognition memory [222] indicating 
that not only complete absence but also smaller variations in the expression of 
dysbindin, as seen in schizophrenia patients, can generate behavioural deficits related to 
schizophrenia and other psychotic disorders.
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1.6.5 Putative Function of Dysbindin
The characteristics observed in the sdy mouse, such as hyperactivity, reduced 
habituation plus spatial learning and memory deficits are consistent with dysfunction of 
the hippocampal formation [223]. For example spatial learning deficits similar to those 
observed in the sdy mouse have also been shown in mice with hippocampal legions
[232]. More specifically, evidence suggests that the dentate gyrus and mossy fibre 
terminus play important roles in working memory and long term memory retention
[233]. The dentate gyrus is activated in spatial working memory tasks [234] and studies 
have reported a highly positive correlation between spatial working memory 
performance and the size of the mossy fibre terminals [235, 236]. Although 
abnormalities in the dentate gyrus have not been reported in the sdy mouse, dysbindin 
could play a critical role in memory disturbance in schizophrenia via these regions of 
the hippocampal formation. Dysbindin is expressed at high levels in both the dentate 
gyrus and mossy fibres [181, 237]. Moreover, as previously discussed, dysbindin levels 
have been shown to be reduced in both the dentate gyrus and the mossy fibre terminus 
of patients with schizophrenia [181-183].
Further evidence suggests that the behavioural deficits observed in sdy mice and 
potentially schizophrenic patients could, at least in part, be due to a dysfunction in 
neurotransmitter release. Dysbindin is located in synaptic vesicles [237] which share 
common features with lysosome related organelles [238]. As discussed above, 
SNAPAP, another BLOC-1 gene is involved in synaptic vesicle priming through its 
interaction with the SNARE complex [220, 221]. A recent study by Chen et al [227] 
reported that sdy mice exhibit abnormal neurotransmitter release and that this is likely 
to be caused by abnormal vesicle priming and fusion. A follow-up study by the same 
group [224] observed a 25% reduction of the steady state levels of snapin in the sdy 
mouse (p<0.05). In contrast overexpression of dysbindin in primary cortical neuronal 
cells induces the expression of two members of the SNARE complex, SNAP25 and 
synapsin 1 [135]. As dysbindin has been shown to directly interact with snapin both in
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humans [211,212, 237] and in mice [224] it has been hypothesised that dysbindin has 
an upstream regulatory role on neurotransmitter release via an interaction with snapin 
which facilitates correct vesicle priming and stabilises ready releasable pools [224].
In vitro studies suggest that dysbindin, through this role in neurotransmitter release, 
may modulate the secretion of glutamate and/or dopamine. Abnormal transmission of 
both of these neurotransmitters has already been implicated in the neuropathology of 
schizophrenia [51, 239, 240] and the decreased habituation shown in mice and 
schizophrenic patients may indicate a problem with dopaminergic or glutamate 
processing [222].
Talbot and colleagues were first to provide evidence of a role for dysbindin in 
glutamate neurotransmission [181]. They reported that the presynaptic reduction in 
dysbindin protein, observed in patients with schizophrenia, was specifically located 
within regions of the HF known to receive intrinsic glutamate input. In addition, the 
reduction in dysbindin was inversely correlated with increased expression of vesicular 
glutamate transporter 1 (VGlut-1), the main vesicular glutamate transporter present in 
the HF [241]. This inverse relationship suggests an effect of dysbindin on VGlut-1 
expression, synthesis or degradation within the HF.
The hypothesis of a role for dysbindin in glutamate neurotransmission is also supported 
circumstantially by the demonstration that overexpression o f dysbindin increases 
extracellular basal glutamate levels and glutamate release while the knockdown of 
endogenous dysbindin protein by siRNA results in a reduction of glutamate release
[135]. Deficiency in dysbindin could therefore cause glutamatergic dysfunction in the 
dentate gyrus (DG) and mossy fibres which in turn could underpin the cognitive deficits 
related to the DG in both schizophrenia and sdy mice.
In addition to being located within glutamatergic regions of the HF, dysbindin is also 
highly expressed in dopaminergic nuclei [183, 231]. Cell culture studies have shown
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that knockdown of DTNBP1, or its BLOC-1 binding partner MUTED, can affect 
dopamine D2 receptor internalisation and signalling [229]. It is therefore interesting to 
note that like sdy, mice overexpressing D2 receptors show working memory deficits 
[242]. Consequently it been hypothesised that dysbindin, via its role in the BLOC-1, 
may regulate the recycling of dopamine D2 receptors in post synaptic targets of 
dopaminergic synapses [226]. However the role of dysbindin in dopamine 
neurotransmission still remains unclear. Although sdy mice have been shown to have 
lower levels o f dopamine in the cerebral cortex, hippocampus and hypothalamus 
compared to wild type mice [225, 228], cell culture experiments in PC 12 cells suggests 
a decrease in dysbindin expression causes an increase in dopamine release [231].
Overall cell culture studies and biochemical analysis of the sdy mouse mutant suggests 
several putative functional mechanisms by which dysbindin could confer susceptibility 
to schizophrenia. While these hypotheses are supported by behavioural analysis of the 
sdy mouse, it must be noted that similar behavioural effects can be seen in other mice 
mutants following the disruption of genes thought to have little to do with 
schizophrenia [226]. Notwithstanding the phenotypes of the sdy mice and cell culture 
studies provide evidence that dysbindin may have a role in neurotransmitter release and 
more specifically dopamine and glutamate processing.
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1.7 Thesis Aims and Objectives
Identifying DTNBP1 causal variants would confirm DTNBP1 as a schizophrenia 
susceptibility gene and allow more accurate predictions as to the nature of the 
pathogenic function of these variants. It would also help determine the true magnitude 
of effect of DTNBP1 on the susceptibility to schizophrenia.
As previously discussed, current data suggests that dysbindin could promote 
susceptibility to schizophrenia through altered gene expression. In an attempt to link the 
genetic association data with the post mortem findings, Bray and colleagues identified a 
DTNBP1 risk haplotype correlated with reduced allelic expression [186]. However this 
risk haplotype does not account for all of the reduced expression and it is therefore 
highly possible that some or all of the cis-acting functional variants that cause altered 
dysbindin expression have not been identified. It is plausible that SNPs within the 
correlated risk haplotype may not affect dysbindin expression at all and are in LD with 
the actual functional variants or that there are unidentified functional variants that work 
in conjunction with SNPs within the risk haplotype to alter DTNBP1 expression.
Consequently one aim of the research presented within this thesis was to refine the 
findings of Bray et al and determine DTNBP1 causal variants by identifying and 
characterising both DTNBP1 schizophrenia risk variants and putative regulatory 
polymorphisms. This included identifying putative DTNBP1 regulatory regions and the 
sequence variants within these regions. Detected polymorphisms were then subjected to 
association analyses with both schizophrenia and DTNBP1 expression differences. 
Potential regulatory variants were verified using an in vitro luciferase expression assay.
In addition to identifying DTNBP1 functional variants, the biological pathway by 
which dysbindin could confer susceptibility to schizophrenia was also investigated 
further. Firstly, an attempt was made to replicate any previous positive associations 
reported of the BLOC-1 genes. Secondly this research set out to determine whether any 
other BLOC-1 genes like DTNBP1 are under the influence of cis-acting variation. If
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evidence of differential expression was observed these genes were subjected to 
association analysis with schizophrenia.
73
Chapter 2: Materials and Methods
2.1 DNA samples
2.1.1 UK Schizophrenia Case Control Association Sample
All subjects were unrelated, Caucasian, resident in the British Isles, and had provided 
written informed consent to participate in genetic studies. Protocols and procedures 
were approved by relevant ethical review panels including the UK Wales Multi-centre 
Research Ethics Committee (Cardiff, Wales).
All 709 cases met DSM-IV criteria for schizophrenia and consisted of 483 males and 
226 females. The mean age at interview was 44.5 years ± 14.6 years. Diagnosis was 
made by two raters from all available information following a semi-structured 
interview, Schedules for Clinical Assessment in Neuropsychiatry (SCAN) or Present 
State Examination (PSE) [17, 243] plus examination of case notes. Formative team 
reliability meetings took place weekly throughout recruitment.
716 control individuals (482 males, 234 females, mean age 41.5 years ± 11.5 years) 
were group matched to cases for age, sex, and ethnicity from more than 1400 blood 
donors from the British Blood Transfusion Service. Controls were not specifically 
screened for psychiatric illness but individuals were not taking regular prescribed 
medications. In the UK, blood donors are not remunerated even for expenses and are 
not over-represented for indigents or the socially disadvantaged in whom the rate of 
psychosis might possibly rise above a threshold that would influence power [88, 244].
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2.1.2 Caucasian Brain Samples
Genomic DNA and total RNA was extracted from post-mortem brain tissue (frontal, 
temporal or parietal cortex) of 149 unrelated, anonymised Caucasians (86 males. 63 
females; mean age = 58, standard deviation (SD)=19). Of these. 86 had received no 
psychiatric or neurological diagnosis at the time of death, 22 had a diagnosis of 
Alzheimer's disease, 12 had a diagnosis of schizophrenia, 14 had a diagnosis of bipolar 
disorder and 15 had a diagnosis of major depression. Details such as the cause of death 
and post-mortem interval were also recorded. These samples were obtained from four 
sources (The MRC London Neurodegenerative Diseases Brain Bank. UK.; The Stanley 
Medical Research Institute Brain Bank, Bethesda, USA; the Mount Sinai School of 
Medicine, New York, USA and The Karolinska Institute, Stockholm. Sweden).
2.1.3 Mutation Screening Sample
Mutation screening was performed using a sample of 14 unrelated schizophrenic 
subjects selected from the UK case control sample described in section 2.1.1. 
Individuals were chosen that met DSM-IV criteria for schizophrenia and had at least 1 
affected sibling. 14 unrelated individuals from the same population allows 95% power 
to detect alleles with a MAF>0.1 and 80% power to detect alleles with a MAF of 0.05.
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2.2 DNA/RNA Extraction and Quantification
2.2.1 DNA Extraction and Storage
All DNA samples used in this study were extracted by members of the Department of 
Psychological Medicine within Cardiff University. For allelic expression assays 
(section 2.9) genomic DNA (gDNA) was extracted from neuronal tissue by Dr. 
Nicholas Bray.
All other gDNA samples were obtained as high molecular weight DNA fractions from 
either lymphocytes in venous whole blood or from buccal cavity epithelial cells via 
saline mouthwash. Each sample was prepared via standard phenol/chloroform DNA 
extraction followed by ethanol precipitation. Stock and diluted samples were stored in 
water at -20°C.
2.2.2 RNA Extraction and cDNA synthesis from Total RNA
Neuronal tissue RNA extraction was performed by Dr. Nicholas Bray using the 
Ambion RNAqueous-Midi kit. cDNA was synthesised from total RNA (DNase treated) 
by reverse transcription (RT) using a RETROscript kit (Ambion). All RTs were 
performed by either Dr. Nicholas Bray or Dr. Liam Carroll as described in the 
RETROscript guidelines. In order to detect any genomic DNA contamination RNA 
samples underwent PCR amplification prior to complementary DNA (cDNA) synthesis.
2.2.3 Spectrophotometer Quantification
Extracted DNA was initially quantified using a Beckman DU 640B spectrophotometer 
(Beckmann Instruments). Each DNA sample was diluted to a 5% solution in sterile 
water (i.e. 5pl DNA sample in 95pl of water). The absorbance (A) of UV light at 
260nm and 280nm wavelengths (>.) was measured, and DNA concentrations were
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calculated on the assumption that an A260nm value of 1 was equivalent to 50pg of DNA. 
A ratio o f A260nm to A280nm above a value of 1.8 indicated a suitable level of DNA and 
the absence of contaminating protein.
RNA concentrations were measured by Dr. Nicholas Bray using an Amersham 
Ultrospec 2100 pro UV/Visible spectrophotometer.
2.2.4 Pico Green DNA Quantification
A more accurate quantification of DNA samples was performed using a Fluoroskan 
Ascent fluorometer (Thermo Labsystems) and pico green (Invitrogen). Samples were 
first diluted to less than 50ng/pl based on spectrophotometer readings in a lOOpl 
volume. Aliquots o f the samples were then diluted with IX TBE in a white 96 well 
cliniplate so that the final DNA concentration was 0.6-1.2ng/ul. A pico green working 
solution was prepared in parallel by adding 5pl o f pico green to 995pl of IX TE.
In order to measure DNA concentration, lOOpl of the pico green working dilution was 
dispensed into each diluted sample. The fluorometer measures the concentration of a 
sample using an UV excitation wavelength of 485nm and an emission wavelength of 
538nm. A standard curve (prepared by Dr. Nadine Norton) was then used to calculate 
the concentration o f DNA for each sample. The original samples were then adjusted so 
that each was at a concentration of 4ng/ml ± 0.5ng.
2.3 Polymerase Chain Reaction
The polymerase chain reaction (PCR) is an enzymatic in vitro cycling technique for the 
amplification o f a specific region of DNA that lies between two regions of known 
sequence. Thermostable Taq polymerase enzyme was used which synthesises a 
complementary strand from the DNA template in the presence of suitable buffers and a 
mix of adenine (abbreviated A), cytosine (C), guanine (G) and thymine (T)
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deoxyribonucleotide triphosphates (dNTPs). Two oligonucleotide primers are designed 
to flank the specific region of DNA to be amplified. These primers provide the double 
stranded starting point for Taq polymerase to begin 5’ to 3’ synthesis. A PCR reaction 
is comprised of three steps, a denaturation step which produces a single stranded DNA 
template, a primer annealing step where the primers bind their complementary 
sequence and an elongation step when the synthesis of DNA occurs. Each step is 
accompanied by controlled temperature changes and there are typically 30-45 cycles 
per reaction.
2.3.1 PCR Primer Design
PCR primers were designed in silico using the Primer 3 web resource (http/Avww- 
genome.wi.mit.edu/cgi-bin/primer/primer3-www.cgi). If possible PCR primers were 
designed using the default Primer 3 settings of an average length of 20bp, an annealing 
temperature of ~60°C and a GC content less than 80%. In general, and specifically 
where PCR products were required to be sequenced, amplimeres were restricted to 
<500bp.
2.3.2 PCR Optimisation
All PCRs were performed on MJ thermocyclers. Three types o f Taq polymerase were 
used in this study: HotStarTaq (Qiagen), Titanium Taq (BD Biosciences) and Expand 
High Fidelity Taq (Roche). Titanium Taq was used for Amplifluor based genotyping 
(see section 2.7.3), Expand High fidelity Taq was used for amplification of regions for 
cloning (section 5.2.2.2). HotStarTaq (Qiagen) was used in PCRs for mutation 
detection (section 2.5), sequencing (section 2.6) and genotyping (section 2.7). As the 
exact PCR conditions and reagents were dependant on the specific methodology, the 
optimised PCR conditions are given in the relevant sections below.
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2.4 Agarose Gel Electrophoresis
The negative phosphate groups within DNA allow DNA fragments to be separated 
electrophoretically. When a potential difference is applied through a porous substance 
such as an agarose gel, DNA will move towards the anode, at a rate dependent on the 
fragment size. Analysis of pre or post PCR samples was performed using 1-2% agarose 
gels, depending on the fragment size and resolution required.
To construct a 1% gel, lg  o f agarose (Sigma-Aldritch) was dissolved in 100ml 0.5x 
TBE buffer (Ultra pure electrophoresis grade, National Diagnostics). The solution was 
heated until it became clear. Once the solution had cooled slightly, lpl Ethidium 
Bromide solution (lOmg/ml) was added. This solution was then poured into a gel- 
former with appropriate gel combs added and left to cool until it formed a solid.
In order to run a specific sample in a gel, each PCR product was mixed with loading 
buffer. 6x loading buffer was made by creating a solution of 15% ficoll, 0.25% 
bromophenol blue, 0.25% xylene cyanel in water. An appropriate volume of PCR 
product was mixed with loading buffer and pipetted into a formed well. 3pi of size 
standard (for example lkb plus DNA ladder, Invitrogen) was also run alongside 
samples to allow size comparison. Each gel was run at between 100-120V in an 
electrophoresis tank for the appropriate amount o f time needed to see the DNA size 
expected. Samples were visualised using a UV transilluminator (UVP) and photographs 
taken using Kodak Electrophoresis Gel analysis system.
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2.5 Mutation Detection
Mutation detection was performed using either Denaturing High Performance Liquid 
Chromatography (dHPLC) or High Resolution DNA Melting Analysis (HRMA). 
Details of both are given below. The PCR products of any individuals showing 
alternative profiles detected by either dHPLC or HRMA were then sequenced in order 
to identify DNA variants.
2.5.1 Denaturing High Performance Liquid Chromatography
Denaturing High Performance Liquid Chromatography (dHPLC) is an automated 
technology based on the separation of heteroduplex PCR products from their 
corresponding homoduplexes via an ion-pair reversed-phase liquid chromatography 
system. The hydrophobic stationary phase consists of alkylated nonporous 
poly(strene/divinylbenzene) particles and the mobile phase consists of 
triethylammonium acetate (TEAA) and acetonitrile (ACN). The column is maintained 
at a set temperature to partially denature DNA molecules. Under these conditions, 
heteroduplexs attributable to mismatch pairing will form weaker interactions with the 
hydrophobic matrix. Due to the use of a linear acetronitrile gradient, heteroduplexes are 
eluted earlier than homoduplexes. Samples containing a heterozygous mutation form 
both homoduplexes and heteroduplexes, and (theoretically at least) two peaks are 
observed (Figure 2 .IB). In reality, resolution is not optimal and it is more common to 
see one peak with a “shoulder” (Figure 2.1C). Samples that give a single peak (Figure
2.1 .A) could either be wild type sequence or contain a homozygous mutation.
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A B C
Figure 2.1. Representation o f  dHPLC traces (Absorbance vs. Retention Tim e) for A. homozygote B. 
heterozygote (theoretical) and 
C. heterozygote (realistic) samples.
2.5.1.1. Heteroduplex Formation and Analysis Parameters
For each fragment the 14 DNA samples of the mutation screening sample were PCR 
amplified in a 24pl PCR reaction. This consisted of 4pl o f genomic DNA (4ng/pl),
1.12pl of each primer (5pmol), 1.92jil dNTPs (5mM each), 2.4pl lOx buffer, 0.12pl 
HotStarTaq (10U/pl) and 14.44pl of water. If required 1.44pl o f Dimethyl sulfoxide 
(DMSO) was added to the PCR reaction and the volume of water reduced. DMSO is 
used in PCR to inhibit secondary structures in the DNA template or the DNA primers 
Each DNA fragment amplification was optimised to one of the four PCR cycling 
conditions outlined below (A,B,D,E).
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A1. 95°C for 15 minutes
2. 94°C for 5 seconds
3. 56°C for 5 seconds
-0.5 per cycle
4. 72°C for 10 seconds
5. Go to step 2 for 11 cycles
6. 94°C for 5 seconds
7. 50°C for 5 seconds
8. 72°C for 10 seconds
9. Go to step 6 for 22 cycles
10. 72°C for 10 minutes
11. 15°C forever
B
1. 95°C for 15 minutes
2. 94°C for 5 seconds
3. 61°C for 5 seconds
-0.5 per cycle
4. 72°C for 10 seconds
5. Go to step 2 for 11 cycles
6. 94°C for 5 seconds
7. 57°C for 5 seconds
8. 72°C for 10 seconds
9. Go to step 6 for 22 cycles
10. 72°C for 10 minutes
11. 15°C forever
D
1. 95°C for 15 minutes
2. 94°C for 20 seconds
3. 50°C for 30 seconds
4. 72°C for 20 seconds
5. Go to step 2 for 34 c
6. 72°C for 10 minutes
7. 15°C forever
E
1. 95°C for 15 minutes
2. 94°C for 20 seconds
3. 5 5 °C for 30 seconds
4. 72°C for 20 seconds
5. Go to step 2 for 34 cycles
6. 72°C for 10 minutes
7. 15°C forever
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To form heteroduplexes, PCR products were heated to 94°C and then gradually 
reannealed by cooling at a rate o f 1°C for 40minutes. Optimal temperatures and 
corresponding elution gradients for each PCR fragment were selected using DHPLC 
Melt (http://insertion.stanford.edu/melt.html). In addition to the temperature suggested 
by the software (n°C), each fragment was also run at n+2°C to ensure maximum 
sensitivity.
2.5.I.2. dHPLC Analysis
dHPLC analysis was performed using the WAVE™ DNA Fragment Analysis System 
(Transgenomic) [245]. 5pl of heterodulpexed PCR product was injected onto a 
DNASep column. Hetero- and homoduplexes were then eluted with a linear acetonitrile 
gradient formed by mixing buffer A (0.1 TEAA, pH 7.0) and buffer B (0.1 TEAA, pH 
7.0, containing 25% ACN) at a constant flow rate of 0.9ml/min. DNA was detected at 
260nm. The analytical gradient was 4 minutes long with the concentration of buffer B 
increased at 2% per/min. For each fragment the initial and final concentrations of buffer 
B were adjusted to obtain a retention time between 3 and 5minutes. Between samples, 
the column was cleaned with 100% buffer B for 30seconds and equilibrated at starting 
conditions for 2 minutes. When all samples had been processed, the resultant 
chromatograms were compared, with a shift in trace pattern indicative of a 
heteroduplex.
2.5.2 High Resolution DNA Melting Analysis
High Resolution DNA Melting Analysis (HRMA) is based on the observation that the 
melting temperature (Tm) of a PCR amplimere can be largely dependent on its specific 
sequence composition [246]. By slowly melting a PCR amplimer in the presence of a 
suitable fluorescent dye, which binds specifically to double stranded DNA (dsDNA), it 
is possible to monitor the amplimere’s melting curve via the change in fluorescence as 
the dye is released. When compared with a wild type sequence, the presence of both 
homo and heteroduplexes (caused by PCR products with heterozygous loci) can 
generate detectable changes in the shape of the melting curve [247]. The fluorescent
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dye LC green is particularly suited to HRMA because it can be used at concentrations 
high enough to saturate the dsDNA binding sites during PCR without inhibiting Taq 
polymerase [248]. Saturation of the dsDNA reduces the potential of dye molecules 
released during HRMA being redistributed to dsDNA. This increases the sensitivity of 
the HRMA to detect subtle changes in fluorescence and LC green can efficiently detect 
single nucleotide variants in PCR products [249].
2.5.2.1. HRMA PCR
PCRs were performed in a 12pl reaction using 4pl o f genomic DNA (4ng/pl), 0.56pl of 
each primer (5pmol), 0.96pl dNTPs (5mM each), 1.2pl of lOx LCgreen Plus (Idaho 
Technologies) and 1.2pl of 10X LCgreen Plus PCR buffer (20mM MgCl, Idaho 
Technologies) and 0.06pl of HotStarTaq polymerase (10units/pl, Quiagen). Fragments 
with a GC content o f >60% were amplified in the presence of 10% (1.2pl) DMSO.
The PCR cycling parameters were as follows:
1. 95°C for 10 minutes
2. 94°C for 20 seconds
2. 56-66°C for 30 seconds (depending on amplimer)
3. 72°C for 1 minute
4. Go to step 2 for 44 cycles
5. 72°C for 10 minutes
6. 15°C forever
2.5.2.2 Mutation Detection by HRMA
HRMA was performed according to the manufactures instructions: each 12ul sample 
was denatured by increasing the temperature to 98°C at a rate of 0.1°C/s with 
fluorescent data points being acquired continuously at a rate o f 14 points/°C.
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Melting profiles were analysed using a semi-automated analysis [250]. This involved 
normalising the melting curves by manually defining the temperature interval before 
and after the major change in fluorescence that corresponds to 100% and 0% 
fluorescent respectively. The samples were then analysed using the Lightscanner 
HRMA software Call-IT™ (Idaho Technologies) using the high sensitivity setting. The 
automatic calls o f the software were inspected by the user and manually clustered 
according to the similarity of the ‘difference curve’ plots.
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2.6 Sequencing
PCR products from individuals showing alternative melt profiles, either by dHPLC or 
HRMA (and therefore suggestive of heteroduplex formation) were sequenced in both 
directions using the fluorescent Sanger sequencing method via Big-Dye termination 
chemistry.
The fluorescent sequencing reaction involves the incorporation of four fluorescently 
labelled dideoxynucleotides (ddATP, ddCTP, ddGTP, ddTTP) in addition to unlabelled 
dNTPs. Unlike dNTPs, ddNTPs terminate after extending one base during a primer 
extension reaction. After an appropriate number of cycles, such a reaction produces a 
series o f DNA fragments which have been terminated at each successive base position. 
When these fragments are electrophoresed in a capillary sequencer, such as the 
ABI3100, each base o f the sequence will be fractionated by size and under laser 
detection, fluoresce according to the base at that site.
In order to reduce errors and improve consistency an Agencourt semi-automated 
protocol was employed for the clean up of PCR and Sequencing products using the 
Beckman-Coulter NX liquid handler.
2.6.1.1 PCR Clean-up
PCR clean-up is needed when the product to be sequenced has been amplified via a 
PCR reaction as it removes unincorporated dNTPs, primers, DNA polymerase and 
salts. If a mini-prep product is to be sequenced this step can be omitted. The PCR 
product (10pl) is mixed with 21.6pl of AMPure reagent (Agencourt). This reagent 
contains magnetic beads which adhere to the DNA. The products not fixed to the beads 
are removed by successive 85% ethanol wash steps. The PCR amplimeres are then 
eluted in 195pl H20 in a new 96-well skirted plate.
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2.6.1.2 Sequencing Reaction
5|il o f the cleaned PCR or mini-prep product ws added to a 5pi sequencing reaction mix 
which consists of: 1.917pl 5X BigDye sequencing buffer, 0.116pl BigDye termination 
mix, 1 pi o f either the forward or reverse PCR primer (4pmol/pl) and 1.917pl H20. The 
BigDye reaction mix contains the four fluorescently labelled ddNTPs, unlabelled 
dNTPs and a Sequenase enzyme. The sequencing reaction was performed on a MJ 
thermocycler using the following conditions:
1. 96°C for 2 minutes
2. 96°C for 30 seconds
3. 55°C for 15 seconds
4. 60°C for 4 minutes
5. Go to step 2 24 times
6. 4°C for 4 minutes.
2.6.1.3 Post-sequencing Clean-up
The post-sequencing clean-up removes any unwanted impurities from the sequencing 
reaction such as unincorporated ddNTPs. The post-sequencing clean-up involves a 
CleanSEQ chemistry protocol which like the AmPure reagent used in the PCR clean-up 
contains magnetic beads. lOpl of sequencing product was added to 7.5pl of CleanSEQ 
reagent along with 36.39pl of 85% ethanol. As with the AMPure protocol the 
sequencing product binds to magnetic beads and the non-bound contaminants are 
removed by successive 85% ethanol wash steps. The cleaned sequencing product is 
eluted in 75pl of H20 which can be read directly via a capillary sequencer.
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2.6.1.4 Sequencing Analysis
Samples were run on the ABI3100 PRISM through a 36cm capillary using 
polyacrylamide POP6 (Applied Biosystems). The ABI3100 PRISM genetic analyser 
automatically analyses the raw data generated through electrophoresis using its 
Sequence Analysis Software (Applied Biosystems). This software calls each nucleotide 
based on the fluorescence at each base.
A combination of the sequence analysis software packages Sequencher (Gene Codes) 
and NovoSNP [251] were used to identify any polymorphisms within the amplimeres. 
Both packages align multiple sequencing traces and will highlight differences between 
the traces and/or a reference sequence. The user can then manually inspect these 
differences to judge whether a polymorphism exists.
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2.7 Genotyping
The majority o f genotyping was performed using the MassARRAY genotype platform. 
Where this failed or did not pass the stringent quality control (QC) checks SNaPshot or 
Amplifluor were attempted.
2.7.1 Sequenom MassARRAY
The Sequenom MassARRAY genotyping system allows the highly accurate genotyping 
of simple polymorphisms by combining iPlex GOLD primer extension chemistry with 
MALDl-ToF (Matrix Assisted Laser Desorption Ionisation -  Time of Flight) Mass 
Spectrometry (MS). iPlex GOLD involves primer extension over the polymorphism of 
interest and the examination of the mass of the extended product to discern the 
genotype of the sample. Results are stored and analysed using the software Typer 
(Sequenom). The main advantage of this genotyping system is the high accuracy 
combined with a high multiplexing level (up to a 40-plex).
The initial step of MassARRAY genotyping involves the design of a multiplex assay 
using Sequenom Design Assay software. For each polymorphism the flanking DNA 
sequence is obtained and additional features of the sequence that may confound any 
assay are highlighted (for example known SNPs or repetitive sequence) to prevent 
assay design over these regions. From this information the Sequenom Assay Design 
software designs PCR and extension primers to the highest multiplex level possible. 
Details o f these are provided in the design output file. In order to ensure extension 
peaks are detected at the MALDI-Tof MS stage, the design software may add a non­
specific sequence to the extension primer. A lObp non-specific tag sequence is also 
added to the 5’ end of the PCR primers to ensure they are detected in the MADLI-ToF 
MS spectrum.
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2.7.1.1 Sequenom PCR and Extension
The software designs the PCR primers so as to create the shortest amplimere possible 
that will allow efficient PCR at an annealing temperature of 56°C. This allows a 
universal PCR condition to be used. Each PCR is performed with 3pl of dried genomic 
DNA (4ng/pl) in a 384 microtitre plate (ABgene) with the addition of a 5pi PCR mix. 
This PCR mix consists of: 3.35pl water, 0.625pl 10X PCR buffer, 0.323pl MgC12 
(25mM), 0.1 pi dNTPs (25mM), 0.1 pi HotStarTaq and 0.5pl PCR primer mix (forward 
and reverse PCR primers at lpmol/pl)
The following PCR is then performed:
1. 95°C for 15 mins
2. 94°C for 20s
3. 56°C for 30s
4. 72°C for 1 min
5. Repeat steps 2-6 for 44 cycles
6. 72°C for 3 mins
7. 15°C for 10 minutes
A number of genomic DNA positive control samples and negative control samples 
were electrophoresised on a 2% gel to check for both PCR efficiency and 
contamination. Should the assay pass this QC, a 2pl Shrimp Alkaline Phosphatase 
(SAP) mix was added to the 5pl PCR reaction. The SAP mix consists of:
SAP 0.3pl
SAP Buffer 0.17pl
Water 1.53pl
90
This 7|j.l reaction mix then undergoes the following thermocyclic conditions:
1. 37°C for 30 minutes
2. 85°C for 10 minutes
3. 95°C for 5 minutes
4. 15°C for 10 minutes
The extension reaction involves the addition of optimised concentrations of unextended 
extension primers, along with ddNTPs, to the 7pl PCR and SAP reaction product. The 
extension primer mix containing a mix of all unextended extension primers is defined 
by an optimisation procedure involving a small number of DNA samples. The 
extension primers are split into four groups dependent upon their mass (lowest to 
highest mass) which are diluted initially to final concentrations of 0.938pM, 1.17pM,
1.425pM and 1.875pM. The extension primers are divided in this way as lower mass 
products generate a lower signal to noise ratio when detected by MALDI-ToF. After an 
initial test run the extension primer concentrations are adjusted according to their peak 
height. For example if a peak height is low then the final concentration is increased. At 
the optimisation stage failed or abnormal assays (for example self priming assays) are 
also removed.
The 2pl extension mix consists of:
iPlex GOLD reaction buffer 0.2pl
iPlex GOLD termination mix 0.2pl
iPlex GOLD enzyme 0.041 pi
Adjusted unextended primer mix 1.559pl
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The extension reaction was then carried out as follows:
1. 94°C for 30 seconds
2. 94°C for 5 seconds
3. 52°C for 5 seconds
4. 80°C for 5 seconds
5. Go to step 3, 4 times
6. Go to step 2, 39 times
7. 72°C for 3 minutes
8. 4°C for 10 minutes
After the extension reaction, desalting of the solution using Clean Resin (Sequenom) 
was performed by the addition of 6mg of the resin using the Sequenom dimple plate 
followed by 25pl of water to the reaction mix. The reaction sample is then mixed on a 
rotor for ~1 hour. The resin removes all ions that may alter the spectra of the sample 
and therefore affect the subsequent analysis. After mixing the samples are spun in 
centrifuge for 15minutes at 3000rpm to separate the resin from the solution.
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2.7.1.2 Sequenom Analysis
Samples are automatically spotted onto the Sequenom MassARRAY SpectroCHIP 
using a nanodispenser liquid handler (Sequenom). Each chip contains 384 spots which 
are composed of a combustible matrix (3-hydroxypicolinic acid) that allows ionisation 
of the product when excited by a laser [252]. Each ionised extended and unextended 
MassEXTEND primer product differs in mass and is therefore amenable to MALDI- 
ToF MS analysis using MassARRAY RT software (SpectroAcquire, Sequenom). The 
software estimates genotypes for each sample based upon the assay design output and 
certain parameters such as the peak heights (intensity of mass signal) of each allele and 
also the extension primer yield (successful extension of the unextended primer 
compared to residual unextended primer). These genotypes can then be viewed and 
manually revised by the user using the Typer software (Figure 2.2).
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Figure 2.2. Screenshot from Typer analysis software (Sequenom) for rs9296985. TT homozygotes are 
shown in green, C homozygotes in blue and CT heterozygotes in yellow. No Calls are given in red.
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2.7.1.3 Accurate Genotyping
All assays were initially optimised by genotyping DNA from 30 CEPH parent-offspring 
trios. All plates for genotyping contained a mixture of cases, controls, blanks, and 46 
C h i' samples. "Double-genotyping", where another experienced user of the Sequenom 
genotyping system and Typer software checks the genotypes for every assay, was used. 
Genotypes were called blind to sample identity, affected status, and blind to the other 
rater. Genotypes of CEU samples were compared to those available on the HapMap to 
provide a measure of genotyping accuracy. Genotyping assays were only considered 
suitable for analysis if a) during optimisation, genotypes for CEU individuals were the 
same as those in the HapMap when available and b) all subsequent duplicate genotypes 
from the CEU samples were consistent with the HapMap data.
2.7.2 SNaPshot
A polymorphism which varies at one particular nucleotide can be genotyped via 
oligonucleotide primer mediated extension of a single fluorescently labelled ddNTP 
using SNaPshot chemistry (Applied Biosystems). The SNaPshot reaction consists of 
the PCR of a sample of interest, which is then cleaned before primer extension by a 
single fluorescent ddNTP (ddATP, ddCTP, ddGTP, ddTTP) corresponding to the next 
3* base (the polymorphic site of interest). This is followed by another clean-up step to 
remove excess ddNTPs and analysis using an ABB 100 PRISM Genetic Analyser 
(Applied Biosystems). Genotyping was performed by manual inspection of the 
extension peaks using Genotyper software (Appied Biosystems). Oligonucleotide 
extension primers were designed using the internet based algorithm FP primer designed 
by Dobril Ivanov (http://m034.pc.uwcm.ac.uk/FP_Primer.html.).
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For individual SNaPshot genotyping, each sample underwent a standard 12pl PCR 
reaction using 3pl of genomic DNA (4ng/pl), 0.28pl of each primer (5pmol), 0.96pl 
dNTPs (5mM each), 1.2pl lOx buffer, 0.06pl HotStarTaq (lOU/pl) and 6.22pl of water. 
The PCR cycling conditions are outlined below:
1. 94°C for 15 minutes
2. 94°C for 20 seconds
3. Tm°C for 20 seconds
4. 72°C for 30-45 seconds
5. Repeat steps 204 for 35-45 cycles
6. 72°C for 10 minutes
7. 15°C forever
Tm°C was determined by the annealing temperature of each primer set.
Shrimp Alkaline Phosphatase (SAP) (Amersham) and exonuclease I (Amersham) was 
then added to each PCR product to degrade unincorportated dNTPs and unextended 
primers. The reaction involved the addition of a 5 pi Sap mix described below to the 
12pl PCR product.
SAP 0.5pl
Hxonuclease I 0.1 pi
Water 4.4pl
The reaction conditions were as follows:
1. 37°C for 1 hour
2 80°C for 15mins
3. 15°C for ever
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For SNaPshot primer extension an 8pl reaction mix consisting of 1.25pl SNaPshot 
reagent (containing fluor-labelled ddNTPs and a sequenase), 3.75pl reaction buffer, 2pl 
water and 1 pi of extension primer diluted to the appropriate concentration, was added 
to 2pl of the cleaned PCR product.
T y p i c a l l y  extension primers were used at a 0.5pmol/pl concentration, although this was 
altered in same cases to obtain optimum peak heights using the equation
Concentration = Y7(YX) 
where Y' is the required peak height (typically 3000 fluorescence intensity units as 
displayed by the Genotyper software (Applied Biosystems), Y is the initial peak height 
and X is the initial primer concentration [253].
The following reaction was then performed:
1. 96°C for 2 minutes
2. 96°C for 5 seconds
3. 43°C for 5 seconds
4. 60°C for 5 seconds
5. Repeat steps 2-4 for 24 cycles
6. 15°C forever
A further stage of SAP clean-up was then performed to degrade the unincorporated 
ddNTPs. A 5pl reaction mix comprising of 0.5pl SAP and 4.5pl water was added to the 
SNaPshot reaction product and the same conditions as the SAP PCR clean-up were 
performed. After this reaction, 3pl of the product was added to lOpl of HiDi 
formamide. The samples were then run through a 36cm capillary using POP4 
polyacrylamide (Applied Biosystems). The raw data was analysed using the Genescan 
Analysis v3.7 software (Applied Biosystems) and imported into Genotyper software 
(Applied Biosystems)
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The Genotyper software allows firstly the discrimination of correct genotypes and 
secondly the amount of each allele present in a sample. The latter is indirectly measured 
via the peak height of the fluorescence. The amount of each allele present is given as a 
numerical value (arbitrary absorbance units) and can be exported to an Excel file for 
further analysis. Individual samples are then genotyped based on the presence of 
fluorescence for the corresponding nucleotide (Figure 2.3). Along with genomic DNA, 
negative controls are added at the PCR and SNaPshot stages to check for 
contamination.
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Figure 2.3. Individual genotyping via Snapshot using Genotyper software (Genecodes). 
A GG homozy gote B GC heterozygote.
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2.7.3 A m plifluor
The Amplifluor Uniprimer assay involves an allele specific PCR using a common anti­
sense reverse PCR oligonucleotide primer and two sense forward primers which differ 
at their 3 ’ ends corresponding to the complimentary base for each allele of a SNP. The 
forward primers also differ at the 5’ end of the oligonucleotide, where each allele 
specific primer has a ~20bp stretch of nucleotides complimentary to two universally 
fluorescently labelled primers (Uniprimers). Each of the uniprimers is labelled either 
with a green or red fluorophore. However these do not fluoresce due to a hairpin 
structure that brings a quencher into contact with the fluorophore.
The unlabelled forward primers initiate a competitive allele-specific PCR. These allele 
specific amplimeres serve as templates for the binding of the labelled uniprimers. The 
incorporation of the uniprimer into the allele-specific amplimere displaces the hairpin 
structure o f  the uniprimer, releasing the fluorphore from its quencher and generating 
fluorescence. The resulting levels of red and green fluorescence can distinguish the 
levels o f each allele in an individual sample and therefore the genotype.
The assays are designed using the internet based software Amplimfluor Assay Architect 
(https://apps.serologicals.com/AAA). The design process requires the input of the SNP 
alleles with flanking DNA sequence. The software then designs two forward and one 
reverse primer.
For each Amplifluor reaction a SNP specific PCR primer mix was made which was 
added to the general PCR reaction mix. The primer mix consisted of:
Forward Primer (Allele 1) lOOpmol/pl 2.5pl
Reverse Primer (Allele 2) lOOpmol/pl 2.5pl
Reverse Primer lOOpmol/pl 25pl
Water 470pl
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This primer mix was then used in the PCR reaction mix as follows. All reagents except 
the primer mix are supplied by BD Biosciences.
For some assays 0.625pl of Reaction Mix S can be added (water reduced to 3.21 5 j j .1)  to 
improve the assay such as genotype clusters.
The total reaction volume of 5pl was added to 12ng of dried genomic DNA in a black 
96 or 384 well microtitre plate (ABGene). The cycling conditions, for the Amplifluor 
reaction are as follows:
1. 96°C for 4 minutes
2. 96°C for 10 seconds
3. 5 8 °C for 5 seconds
4. 72°C for 10 seconds
5. Repeat steps 2-4 for 20 cycles
6. 96°C for 10 seconds
7. 55°C for 20 seconds
8. 72°C for 40 seconds
9. Repeat steps 6-8 for 18-30 cycles depending on assay
10. 68°C for 7 minutes
11.15°C for 10 minutes
lOx Titanium Taq Buffer 
dNTPs (2.5pl each)
0.5pl
0.4pl
0.07pl
0.07pl
0.07pl
0.05pl
3.84pl
Primer mix
SR labelled primer
FAM
Titanium Taq Polymerase 
Water
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The first stage of the reaction conditions (steps 1-5) involves the denaturation of the 
target DNA sample, the annealing of the allele specific primers and the elongation of 
the fragments which include the complimentary tails for the universal uniprimer. The 
second stage (6-11) involves the denaturation of the PCR product, the annealing of the 
fluorescently labelled primers to the complimentary sequence in the PCR product.
When the fluorescently labelled primers bind to the complimentary sequence within the 
allele specific PCR products fluorescence occurs.
The fluorescence of each sample was analysed using an Analyst HTS Assay Detection 
Platform (LJT Biosystems) at the wavelengths shown below for each fluorophore:
FAM Excitation at 485nm Emission at 520nm
SR Excitation at 580nm Emission at 620nm
The results are given as the signal intensity for the two fluorophores which can be 
plotted on a graph program (https://apps.serologicals.com). The clusters of individual 
fluorescent points correspond to three genotype classes which can be assigned manually 
by the user (Figure 2.4). The output of the graph program is in the form of 11, 12, 22 
where 1 corresponds to the FAM allele and 2 to the SR allele.
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Figure 2.4. Cluster plot o f  individuals from an Amplifluor assay.
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2.8 Sample Processing
For large scale PCR and post-PCR reactions involving many DA, samples, reagent 
master mixes and samples were aliquoted using robotic liquid kindling systems. DNA 
samples were typically stored within shallow well DNA boxes ii^ Bgene). These are 
compatible with the Beckman-Coulter FX and NX microdispeisers. DNA samples 
were aliquoted into suitable (96 or 384 well) microtitre plates (%ene). Both machines 
were also used to dispense reaction master mixes in the same mner. All programs for 
use with the Beckman-Coulter FX and NX were written by Sai Dwyer.
i
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2.9 Relative Allelic Expression Assay
To assay gene transcripts for factors regulating steady-state mRNA levels in an allelic- 
specific manor (such as cis-acting factors) a quantitative assay of allelic expression has 
been developed in house [184]. The principle o f the assay is that in any given tissue the 
relative level o f steady state mRNA (as transcribed from each chromosome) should 
have a 1:1 ratio unless factors regulating the levels of the mRNA differentially affect 
the two autosomal transcripts. A transcribed heterozygote marker can be used to 
measure for such differences. PCR primers are designed which will encompasses the 
variant in question, and which will amplify the genomic DNA (gDNA) and 
complimentary' DNA (cDNA) equally (i.e. primers are within an exon boundary). Any 
divergence o f the 1:1 allelic ratio of gDNA observed in cDNA samples is indicative of 
an allele-specific regulation of steady-state mRNA levels in the tissue examined, such 
as a cis-acting regulatory polymorphism regulating transcription.
To study specific genes for allelic expression differences, polymorphisms were selected 
that were located within predicted mRNA sequence and had a high minor allele 
frequency (to maximise the number of heterozygotes studied). All markers were 
assayed using “universal” primers based on single exonic sequence capable of 
amplifying genomic and complementary DNA. The same analytical conditions were 
used for both genomic and cDNA. This enabled the average of the ratios observed from 
genomic DNA (representing a 1:1 ratio of the two alleles) to be used to correct allele 
ratios obtained from cDNA analysis for any inequalities in allelic representation 
specific to each assay [184]. As a result a divergence from the 1:1 allelic ratio by cDNA 
samples could be indicative of an allele-specific regulation of steady-state mRNA 
levels in the tissue examined, (Figure 2.5).
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Figure 2.5. Illustration o f  a SNaPshot assay result for a heterozygote individual who A) shows no cis- 
acting variation and B) is under the influence o f  cis-acting variation. gDNA ratios are 1:1 however where 
cis-acting variation is influencing transcription o f  one mRNA strand the intensity o f each allele will show 
a divergence from the 1:1 ratio in the cDNA. The florescence intensity readings are taken and a ratio o f 
Major allele/Minor allele is then calculated.
All allelic expression assays were performed using the Caucasian Brain samples 
(described in section 2.1.2). Each cDNA sample was assayed alongside the 
corresponding heterozygous genomic DNA to ensure uniformity o f conditions.
PCR amplification and primer extension was carried out with SNaPshot chemistry 
(Applied Biosystems) as described in section 2.7.2. Aliquots o f 3pl SNaPshot reaction 
product were combined with 8jil HiDi formamide and loaded onto an ABB 100 PRISM 
Genetic Analyser (Applied Biosystems). Peak heights representing allele-specific 
extended primers were determined by using Genotyper software (Applied Biosystems) 
and were used to calculate the ratio o f allelic representation for each sample. All peak 
heights were between 550-6000 fluorescence intensity units and assays showing 
genotypes for blank samples were excluded.
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2.9.1 Allelic Expression Analysis
The following protocol was used to analyse relative differential allelic mRNA 
expression. gDNA and cDNA from individuals heterozygous for the assay SNP were 
analysed in parallel. Duplicate cDNA samples (independent reverse transcription (RT) 
reactions for the same sample) were used to increase assay confidence. Raw data from 
Genotyper software was collated for each gDNA and cDNA sample. To obtain an allele 
ratio the fluorescence intensity value for the common allele was divided by the 
fluorescence intensity value of the rare allele. The mean of all the gDNA ratios was 
taken and each gDNA and cDNA ratio corrected by this mean (thereby adjusting the 
gDNA average ratio to 1). Samples showing a standard deviation of ±0.2 between 
duplicate RTs were removed. The average corrected cDNA ratio from two duplicate 
RTs was then calculated. The average standard deviation over all corrected duplicate 
RT standard deviations was recorded as a quality score for the assay.
Evidence for differential allelic expression was deduced if an assay met the following 
criteria. Firstly, one of more samples had to show a differential expression of greater 
than 20% after correction using the average genomic ratio. Yan and colleagues [254] 
analysed allelic expression of the APC tumour suppressor gene in 17 HapMap CEU 
individuals plus a familial adenomatous polyposis (FAP) patient, previously shown to 
have decreased expression of one allele. As no significant variation in expression of 
APC was detected in the 17 CEU individuals, they concluded that there was little 
common variation in APC expression and that APC could thereby be used to model 
analysis of other genes. Analysis of the 95% confidence intervals of the APC allelic 
expression ratios in the 17 individuals resulted in Yan et al estimating that a variation in 
expression could be confidently identified when the expression of the two mRNA 
copies, and therefore the corrected cDNA ratio, differed by more than 20% (outside the 
corrected ratio o f 0.8-1.2).This criterion has been used in several subsequent allelic 
expression analyses [184, 186, 194, 195, 255] and therefore was also used in this study. 
Secondly, a statistically significant difference (p<0.05) needed to be observed. To 
determine the statistical significance of any differences observed, all ratios (corrected 
genomic or cDNA) were normalised via a natural log transformation. After
104
confirmation by the Kolmogorov-Smimov test that the transformed gDNA and cDNA 
data followed a normal distribution, gDNA and cDNA values were compared by a 2 
independent sample t-test. To account for the possibility o f weak LD between the 
assayed SNP and a potential regulatory SNP and/or multiple cis-acting variants, the 
spread of the cDNA ratios and gDNA ratios were compared using the Levene’s test.
2.10 Bioinformatic and Statistical Analysis
Several types of statistical analyses were performed in this thesis. The majority were 
carried out using the analysis software PLINK
(http://pngu.mgh.harvard.edu/purcell/plink) [256]. This included tests for single marker 
association in cases and controls (allelic and genotypic) and haplotypic analysis. 
Analysis o f variants for deviations from Hardy-Weinberg were also performed using 
PLINK. Statistical analyses that did not use the PLINK software are outlined below or 
are found within the methods section of the relevant chapter.
2.10.1 LD Estimation and Tag SNP Determination
Determination of the LD between markers and tag SNP identification was performed 
using Haploview (http://www.broad.mit.edu/haploview/haploview), a software program 
designed for genetic association studies [257]. The program allows the user to import 
marker genotype data such as a CEU HapMap dataset or case-control genotype data. 
The quality o f this data can then be assessed via a display of the percentage of 
individuals genotyped, Hardy-Weinberg equilibrium p values and non-Mendelisations. 
The LD (r2 and D’) between markers can also be identified. The Tagger function within 
Haploview uses the LD values to select “tag” markers for an association study via user 
defined parameters (r2, MAF and the type of analysis to be performed; pairwise, 
haplotype). In addition to LD analysis Haploview can also be used test for marker or 
haplotype association.
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2.10.2 Sample Size Power Calculations
Power calculations for the mutation detection samples were determined using the 
equation: l-(l-f)n, where f  = minor allele frequency and n = number of chromosomes 
examined (i.e. 2x number of individuals).
The power o f an association sample to detect susceptibility variant(s) with a specific 
MAF and OR at a given p value were calculated using the software PS Power and 
Sample Size Calculations [92].
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Chapter 3: The Identification of Putative DTNBP1 
Regulatory Regions and Association Analysis of SNPs 
with Schizophrenia
3.1 Introduction
Allelic expression analysis has determined that DTNBP1 is under the influence of cis- 
acting regulatory variant(s). As dysbindin expression has been show n to be altered in 
schizophrenic patients compared to controls it has been suggested that this cis-acting 
variation may also confer susceptibility to schizophrenia. However while determining 
that DTNBP1 is under the influence of cis-acting variation is relatively straightforward, 
identifying the cis-acting variants provides a greater challenge.
Although some studies have screened predicted promoter regions in addition to the 
analysis of DTNBP1 coding regions [113, 134, 258], there has been  no comprehensive 
analysis of genomic sequences that may have a cis-acting regulatory influence on 
dysbindin expression. This chapter describes the identification o f  putative DTNBP 1 cis- 
regulatory regions, the screening of these regions for polymorphisms and the 
subsequent analysis of variants for association with schizophrenia.
While determining regulatory variants, particularly those distal to  the target gene 
remains a challenge, there are a number of different approaches that can be used to 
identify genomic sequence that has a potential regulatory function. These, plus a brief 
overview of transcription and the different types of cis-regulatory elements, are 
described below.
107
3.1.1 Categories of Cis-acting Regulatory Elements
The initiation and regulation of transcription is a complex process, which involves the 
assembly of a number of proteins known as transcription factors (TFs). TFs bind to 
specific DNA sequences which are organised into a series of regulatory elements. 
Consequently the molecular basis for the transcriptional regulation of gene expression 
involves the binding of trans-acting proteins (transcription factors) to cis-acting 
sequences (binding sites) [192].
Cis-acting regulatory elements can be split into two groups based primarily on their 
distance from the transcription start site (TSS) of a gene (See Figure 3.1). The promoter 
is usually directly upstream of the TSS and contains core and proximal promoter 
elements. This group of elements provide the basal transcription levels for a gene.
Distal regulatory elements often modulate this basal transcription. They contain 
enhancers and silencers which act independently of their distance from, and orientation 
to, the target gene.
D istal R eg u la to ry  E le m e n ts
Locus Control Regon lnsulator Enhancer Silencer
Core PromoterProximal Promoter
I ■ I Downstream Enhancer
S p a c e r  DNA 1___________________________________________________I
P ro m o te r  (< 1 kb)
Figure 3.1. The complex arrangement o f the regulatory elements for a typical gene. Regulatory elements 
include the promoter, which is composed o f core promoter and proximal promoter elements and typically 
spans less than lkb. Distal (upstream or downstream) regulatory elements, which can include enhancers, 
silencers, insulators and local control regions, can be located up to 1Mb from the promoter. Adapted 
from [191, 192, 259].
108
3.1.1.1 The Promoter: Core and Proximal Elements
The core promoter, also known as the minimal promoter, describes the region at the 
start of a gene that serves as the docking site for the basic transcriptional machinery. In 
the case of protein encoding genes this includes general transcription factors (GTFs) 
and RNA polymerase II. GTFs assemble in an ordered fashion on the core promoter to 
form the preinitiation complex (PIC). The PIC recruits RNA polymerase II to the 
promoter and therefore defines the start and direction of transcription. The first step in 
PIC assembly is the binding of transcription factor TFIID; a multi-subunit consisting of 
the TATA box binding protein (TBP) and a set o f tightly bound TBP associated factors 
(TAFs). The TBP subunit binds to the consensus DNA sequence TATA(A/T)A(A/T), 
known as the TATA-box. In addition to the TATA box, metazoan core promoters can 
be composed of a number of recognition elements including initiator element (Inr), 
downstream promoter element (DPE), downstream core element (DCE), TFIIB- 
recognition element (BRE) and motif ten element (MTE). Except for BRE, which binds 
TFIIB, all other known core promoter elements bind TFIID [259]. It is therefore likely 
that many features o f the core promoter have yet to be discovered. It is also possible 
that known core promoter elements are not as common as previously thought.
Statistical analysis o f -10,000 predicted human promoters for the four core promoter 
elements TATA, BRE, Inr and DPE found that TATA boxes were present in only 1/8 of 
promoters and over a quarter of the promoters analysed did not include any of the four 
elements [260].
The proximal promoter is found upstream of the core promoter and typically contains 
recognition sites for sequence specific ubiquitous transcription factors. These 
recognition sites can include GC boxes, as well as CCAAT boxes. GC boxes bind the 
TF Spl and are often within lOObp of the transcription initiation site. CCAAT boxes 
are typically located at -75bp and are recognised by CTF and CBF (also known as 
Nuclear Factor I (NFI) and NFY respectively) [261].
The transcription factors which bind to both core and proximal promoter sequences are 
traditionally thought to promote basal transcription. However recent experiments [262-
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264] have suggested that recognition sites in these regions may also bind proteins that 
are used as tethering elements to recruit distal regulatory elements to the core promoter.
3.1.1.2 Distal Elements
Distal cis-acting regulatory elements are so called as they can be located several 
kilobases away from their target gene [191, 192, 259]. Some distal elements have even 
been found at distances o f up to 1Mb from the gene they regulate [265, 266]. Unlike 
promoter elements, distal regulatory elements function independently of both distance 
and orientation from the gene and as a result can be 3’, 5’ or within an intron of the 
regulated gene or even a neighbouring gene [259]. It is commonly thought that distal 
regulatory elements typically regulate transcription in a spatial and temporal specific 
manner. They come in the form of enhancers, silencers and insulators and the average 
gene is likely to have several of these regulatory elements.
As the name suggests enhancers are involved in the increased expression of their target 
gene. They are recognised by transcription factors known as activators. Activators can 
be distinguished by their different DNA binding domains. Specific activator families 
contain domains such as a cysteine-rich zinc finger, homeobox, helix-loop-helix (HLH) 
or basic leucine zipper (bZIP) [261]. Each binding domain has its own specific 
enhancer DNA sequence with which to bind. Enhancer sites are generally small (6- 
12bp) and specificity is usually dictated by no more than 4-6 positions [259].
Silencers are bound by TFs known as repressors which confer a negative effect on 
transcription. They can confer a negative effect through direct competition with an 
enhancer for the binding of a transcription factor [267] or by binding a repressor which 
blocks the binding of an activator to a nearby enhancer [268]. Consequently silencer 
sequences are often found with enhancers within clusters of transcription factor binding 
sites (TFBSs). Enhancers and silencers can also be found within proximal promoter 
regions and therefore the distinction between promoter and distal elements can become 
blurred.
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There have been a number of theories as to how distal elements could affect 
transcription over such large physical distances. Recent in vivo experiments on 
Drosophila melanogaster [263, 269] have provided evidence that distal regulatory 
elements could function via chromatin looping whereby the distal regulatory unit is 
brought into close proximity to the promoter by looping out the intervening DNA (see 
Figure 3.2). In addition in vivo footprinting and chromatin immunoprecipitation has 
shown RNA polymerase II binding to distal enhancer elements which suggests the PIC 
may initially form at a distal enhancer rather than at the core promoter [270]. This 
could occur where rapid gene activation is required as it would allow precise regulation 
of transcription initiation.
Enhancer with 
bound Activator
Core Promoter
Figure 3.2. DNA looping model for distal regulatory element action. Distal (upstream or downstream) 
regulatory elements, which can include enhancers, silencers, insulators and local control regions, can be 
located up to 1 Mb from the promoter. These distal regulatory regions may gain contact with the core or 
proximal promoter through a mechanism that involves looping out the intervening DNA. Adapted from 
[269].
Due to the long distances involved in enhancer and silencer action, they have the 
potential to activate several neighbouring genes. Although a number of enhancers have 
been reported to show a preference for core and proximal promoter elements of specific 
genes this does not always appear to be the case [262, 271]. Therefore the action of 
enhancers and silencers needs to be restricted to prevent the activation/inactivation of 
non-target genes. This role is performed by a third class of distal cis-acting regulatory 
elements known as insulators. They can be between 500bp and 3kb in length and 
evidence suggests they can function in two ways. An insulator can be located between 
enhancers and promoters to block the enhancer-promoter communication [272] or they 
can flank a gene and prevent the spread of repressive chromatin [273].
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3.1.2 The Identification of Putative Regulatory Regions
Several techniques have been developed in order to identify genomic regulatory 
regions. These include electrophoretic gel-mobility shift assays (EMSA), DNA 
footprinting, chromatin immunoprecipitation (ChIP), DNase hypersensitivity analysis 
and reporter gene assays [274, 275].
EMSA allows the analysis of protein-DNA interactions in vitro. Radio- or fluorescent- 
labelled oligonucleotide probes are used as bait for transcription factors. The binding of 
transcription factors to a probe is detected by gel electrophoresis as bound probes will 
migrate slower through a gel than unbound probes. A limitation of EMSA is that the 
DNA region of interest must be known and the length of probe used needs to be 
relatively short (20-30 nucleotides) to allow good resolution on the gel. DNA 
footprinting also detects protein-DNA interactions but does not have the limitations of 
EMSA. DNA footprinting is based on the cleavage of DNA sequence by either a 
chemical or enzyme. In the presence of a protein-DNA interaction the DNA will be 
protected from cleavage and these uncut regions or “footprints” can be observed by gel 
electrophoresis.
Unlike in vitro binding assays such as EMSA and DNA footprinting, chromatin 
immunoprecipitation (ChIP) allows the identification of endogenous DNA-protein 
complexes. Cells are treated with formaldehyde in order to “fix” the DNA-protein 
interactions via cross-linking. These DNA-protein complexes are subsequently 
immunoprecipitated from nuclear extracts by an antibody specific to the protein of 
interest [276]. After reverse cross-linking, the DNA with which the protein of interest 
has been bound can be determined.
A further method of identifying regulatory regions is the reporter gene assay. In these 
experiments a genomic sequence of interest is inserted into a reporter gene construct. 
The expression of the reporter gene can then be compared between reporter gene 
constructs with and without the inserted sequence.
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The mapping of DNase hypersensitive sites has also been used to identify the location 
of regulatory elements [277, 278]. DNA is packaged in chromatin which generally 
adopts a highly condensed structure that is relatively inaccessible to proteins. As a 
result, at any given time, most of the human genome is a poor template for biochemical 
reactions such as transcription. However the loss or remodelling of one or more 
nucleosomes, the basic repeating unit of chromatin, at a given genomic location 
produces hotspots of accessibility around regions important for gene regulation such as 
promoters. The increased availability of the DNA to transcription factors and other 
regulatory proteins also increases its sensitivity to digestion by nucleases such as 
DNase 1. This is especially true of locus control regions which are often marked by 
clusters of DNase 1 hypersensitive sites [259].
While these “wet-laboratory” methods have been successful in identifying regulatory 
sequence, they often require significant optimisation, are labour intensive and time 
consuming. In silico analysis can be used to identify putative regulatory regions which 
can then be investigated further. In silico methods either analyse a particular sequence 
for certain features, such as TFBS motifs, or utilise previous wet-laboratory results, for 
example DNase 1 hypersensitivity experiments. The former of these methods are 
described below.
3.1.2.1 Promoter Regions
The simplest and most logical starting point for the identification of polymorphisms 
that could have an affect on transcription is to analyse the sequence immediately 3 ’ and 
5’ of the TSS of the gene of interest. Reporter gene analysis of over 700 unique gene 
promoters revealed that sequence variants which altered gene expression by more than
1.5 fold were strongly biased towards the core and proximal promoter regions with 
75% within the first 200 bases 5’ to the TSS [279]. Therefore genomic sequence 
immediately 5’ and 3’ of a gene’s TSS is an ideal region to screen for eSNPs, 
particularly if the sequence contains transcription factor binding sites (TFBSs) or is 
near a CpG island. A CpG island is a relatively short stretch of DNA (500bp-2kb) 
which has a high G+C content and a high frequency of CpGs (a dinucleotide consisting
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of a cytosine nucleotide next to a guanine separated by a phosphate group). CpGs are 
scattered throughout the genome and are methylated at the 5th carbon position of the 
cytosine base. Approximately 60% of all human gene promoters fall near a CpG island 
and methylation status (the default of which is unmethylated) can be correlated with 
gene expression [280, 281].
3.1.2.2 Transcription Factor Binding Site Clusters
Individual TFs generally bind to DNA with relatively low specificity. Thus, the precise 
control o f gene transcription requires a higher degree of specificity than that typically 
afforded by the binding if a single transcription factor to a single DNA recognition site 
[282]. Regulatory elements accomplish this desired control by being composed of 
relatively closely grouped clusters of TFBSs. A cluster of several recognition sites 
would rarely be encountered in the genome whereas a single recognition site of only 4- 
8bp could potentially be quite common. These clusters are also beneficial as multiple 
TFs bound to a cis-regulatory cluster typically function synergistically and activate 
transcription more strongly than a single factor alone [282, 283].
Other areas of the genome which contain clusters of TFBSs are locus control regions 
(LCRs). LCRs are a feature of long distance cis-acting regulation and are involved in 
the regulation of a group of genes [284]. They are often composed of multiple cis- 
acting elements including enhancers, silencers as well as insulators. LCRs are typically 
located upstream of the target gene(s). However they can also be found within introns 
of a target gene [285], downstream [286, 287] or even within an intron of a 
neighbouring gene [288].
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3.1.2.3 Evolutionary Conserved Regions
Identifying regions that contain clusters of TFBSs can be a successful way of finding 
regulatory regions [289-292]. However a limitation in identifying clusters of TFBSs is 
that it relies on the knowledge of the transcription factor binding sequence. It has been 
shown that the majority o f sequence variants within promoter regions that alter 
expression are not within predicted TFBSs [279]. This suggests there may be many 
recognition sites, or other unknown factors that may affect transcription, yet to be 
identified. One method of identifying putative regulatory sequence that does not require 
prior knowledge of transcription factor binding site sequence motifs is the identification 
of evolutionary conserved sequence.
It is reasonable to hypothesise that conserved sequence would be more likely to contain 
functional elements than the rest of the genome. A total of 5% of bases within the 
genome can be confidently identified as under evolutionary constraint in mammals 
[293]. However coding regions only comprise -1.5%  of the genome and comparisons 
of mammalian and non-mammalian genomes demonstrate that -3%  of non-coding 
sequence is strongly conserved. Therefore, these conserved non-coding regions 
(CNCs), also known as conserved non-genic regions (CNGs) [294], could potentially 
be functionally relevant.
By comparing distant species such as D. melanogaster and D. virilus scientists have 
been able to identify regulatory regions in the Drosophila genome [295, 296]. 
Consequently several attempts have been made in mammals, in particular the mouse, to 
identify regions of regulatory function by means of sequence conservation. Initial 
studies which have attempted to determine regulatory regions in the human genome 
characterised a region as conserved if the sequence contained at least 1 OObp of 
ungapped genomic sequence which was at least 70% identical between the human and 
mouse genome [297-300]. These criteria are above the average level of neutral 
sequence conservation between human and mouse genomes where only 40% of the 
mouse genome can be aligned to the human genome, of which an average of 67.2% of 
nucleotides are identical [301].
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To increase the sensitivity of selecting functionally relevant sequence more recent 
studies have compared either a third species, usually the dog [302-305], or several 
mammalian species [306-308] simultaneously. These regions are often referred to as 
ultraconserved regions [309]. Sequence identified by comparing the human and mouse 
genomes appears to show a uniform distribution within intergenic sequences whereas 
ultraconserved regions appear to cluster around genes [266, 309]. Therefore, if only a 
minority of CNCs are cis-transcriptional regulators then it is likely to be these 
ultraconserved sequences.
While the most common hypothesis for the role o f CNCs within the human genome is 
that this conserved sequence contains cis-acting regulatory sequence but it is possible 
that they have a different function, especially CNCs within so-called gene deserts. A 
recent study has suggested that up to 10% of CNCs may be matrix-attachment regions 
[310] which regulate the conformation of chromatin through the binding of particular 
proteins. They might also participate in inter-chromosomal interactions that are 
mediated through protein bridges and bring chromosomes together in the nucleus [311, 
312].
3.1.3. Aims of This Chapter
The objective of this chapter was to identify DTNBP1 putative functional SNPs 
associated with schizophrenia. This involved the identification of putative regulatory 
regions at the DTNBP1 locus. As knowledge of gene regulatory mechanisms is 
incomplete and each approach to identifying cis-acting regulatory regions (and 
therefore potential regulatory polymorphisms) has numerous caveats, a combination of 
a number of in silico methods was used to identify putative regulatory sequence. The 
regions identified were subsequently screened for variants. The SNPs detected, plus any 
additional SNPs required to tag the DTNBP1 gene itself, were subjected to association 
analysis with schizophrenia.
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3.2 Methods
3.2.1 Putative Regulatory Region Identification
Evidence suggests that there are at least four transcription variants of DTNBP1 (UCSC, 
May 2004). Details of these transcripts are given in Figure 3.3. Three of these isoforms 
have supportive evidence of one GenBank RNA sequence plus at least one additional 
line of evidence from RefSeq, CCDS or Uniport. DTNBPla (NM 032122) encodes the 
longest isoform (chr6:15631018-15771250) and contains 10 exons. Compared to 
DTNBPla, DTNBPlb (NM_183040) contains additional coding sequence in exon 9 but 
has a shorter and distinct C terminus. DTNBPlc (NM_183041) contains an alternative 
splice site in the 5’ coding region, uses a downstream start codon and has a shorter N- 
terminus compared to DTNBP1 variants a and b [313]. Another transcript AF061734, 
often called the alternative transcript or short isoform, has less conclusive experimental 
evidence but has supporting data of a GenBank mRNA [314]. Its mRNA is 104kb 
compared to the 138-140kb of DTNBPla, b and c and contains an alternative 
transcription start site.
A
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B
Transcnot mRNA ID T ranscnpt sequence mRNA Length Total exon count Coding sequence Number of AAs Number of coding exons
DTNBPla NM 032122 chr6 15631018-15771250 140233 10 chr6: 15631185-15771079 352 10
DTNBPlb NM 183040 ctuB 15632635-15771250 139464 9 chr6: 15632635-15771079 304 9
DTN8P1C NM 183041 chr6 15631018-15771250 140233 10 chr6 15631185-15735644 271 6
AF061734 AF061734 chr6 15631020-15735583 104563 6 chr6:15631185-15735578 165 6
Figure 3.3. A Alternative DTNBPl transcripts. Exons in blue are coding, grey regions are non-coding. B 
Transcript specifics (May 2006 Freeze). AA = amino acids. Sources [198, 3 13].
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Due to limitations on the number of regions that could be screened for putative eSNPs, 
a “window” of genomic sequence around the longest DTNBP1 variant (DTNBPla) was 
determined which was then subjected to in silico analysis to identify putative regulatory 
elements. Using this “window” maximised the chance of discovering DTNBP1 
regulatory regions while reducing the number of false positives identified (for example, 
regions with no regulatory effect or no regulatory effect on DTNBP1 expression). In 
total, the derived genomic sequence from 75kb 5’ to lOkb 3’ of DTNBPla 
(chr6:15,621,018-15,844,250) was analysed in silico in order to identify putative cis- 
acting regulatory regions. A cut-off point of 75kb upstream of DTNBP1 was chosen 
although the nearest gene 5’ to DTNBP1 is 465kb upstream, due to time and funding 
constraints, analysis o f this entire region was unfeasible within this study. Another 
gene, JARID2 is situated only 1 kb 3’ to DTNBPla. As regulatory elements within the 
JARID2 gene are more likely to regulate JARID2 expression rather than DTNBP1 only 
lOkb of genomic sequence 3’ to DTNBPla was selected. Details on the four different 
strategies for identifying putative regulatory regions are given below.
3.2.1.1 Core and Proximal Promoter
Most core and proximal promoter elements are located adjacent to the TSS of their 
target gene [279]. The transcription start sites of the four main DTNBP1 transcripts 
were identified using the genome browser UCSC (May 2004 freeze). The mRNA 
transcript of DTNBPla, DTNBPlb and DTNBPlc starts at the same point 
(chr6:15771250). As these isoforms are likely to share the same core promoter region, 
5kb 5’ and 3’ of transcription start site of these three isoforms (chr6: 15,765,956- 
15,776,344) was included for polymorphism screening.
The TSS of the alternatively spliced transcript AF061734 is situated at the beginning of 
exon 5 of the other DTNBP1 iso forms and consequently AF061734 is likely to be 
regulated by a separate promoter region. A smaller lkb window 5’ and 3’ of the TSS of 
AF061734 (chr6:15,763,611-15,736,610) was screened for putative regulatory 
polymorphisms.
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3.2.1.2 Transcription Factor Binding Sites Clusters
Regions containing multiple transcription factor binding sites (TFBSs) were identified 
in silico using the web based algorithm Cluster Buster (http://zlab.bu.edu/cluster- 
buster/cbust.html). Cluster Buster employs a probabilistic model to search for regions 
in a sequence that greater resembles a transcription factor binding site motif cluster 
more than background DNA [315]. Sequences that pass the likelihood ratio threshold 
(default =5) are displayed in an overview diagram where potential individual TFBSs 
are listed.
To identify clusters of TFBSs at the DTNBP1 locus the genomic sequence 
chr6:15,621,018-15,844,250 was analysed for the 16 TFBS motifs listed on the Cluster 
Buster website (TATA, Spl, CRE, ERE, NF-1, E2F, Mef-2, Myf, CCAAT, Ap-1, Ets, 
Myc, GATA, LSF, SRF, Tef). Default parameters were used (gap parameter=5, cluster 
score threshold=5, motif score threshold=6) so as to balance the sensitivity between 
tight clusters with weak motifs and loose clusters with strong motifs [315].
3.2.1.3 Regions of High Conservation
Non-coding regions o f high conservation between species (CNCs) were identified for 
chr6:15,621,018-15,844,250 in silico using two approaches originally described by 
Drake et al [316]. Firstly CNCs were identified using ECR (Evolutionary Conserved 
Regions) browser [317] (www.ECRbrowser.com). This database displays conservation 
profiles between multiple genomes such as human, rodent or fish (See Figure 3.4).
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Figure 3.4. Conservation profile from ECR browser which depicts conserved regions between the human 
and the mouse genome plus the human and the dog genome at the DTNBP1 locus. Annotated genes are 
depicted as a horizontal blue line above the graph. Conserved regions within coding exons are coloured 
blue and conserved regions within UTRs are coloured yellow. Evolutionary conserved regions that do not 
correspond to transcribed sequences are highlighted in red if they are intergenic or pink if they lie within 
an intron.
Drake et al used a variety o f different analysis parameters to detect CNCs across the 
entire genome by identifying conserved regions between the human and mouse genome 
and the human and dog genomes. As this study aimed to identify regulatory regions 
solely at the DTNBP1 locus, a less stringent set o f criteria was used than that 
recommended by Drake et al. CNCs were defined as non-coding sequence with a 
minimum length o f 100 bases and a minimum identity o f 80% between the human 
genome and both the mouse and dog genome.
Secondly, CNCs were determined using the UCSC track “most conserved”, May 2004 
freeze (See Figure 3.5). This track catalogues conserved non-coding regions identified 
through analyses designed to extract the top 5% o f the conserved genome. This analysis 
examined the conservation between vertebrate, insect, worm and yeast genomes [318]. 
For the DTNBP1 locus 145 coding and non-coding conserved regions were stored on 
this track. In order to prioritise these regions for further analysis, non-coding sequence 
with a lod threshold level o f >40 was selected.
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Figure 3.5. Conserved regions around the DTNBP1 locus identified from the comparison of vertebrate, 
insect, worm and yeast genomes. Non-coding regions with a lod score >40 were subsequently identified 
for further analysis.
3.2.1.4 DNase Hypersensitive Regions
DNase HS regions were determined using experimental data previously reported [319]. 
Conventionally, DNase 1 hypersensitive sites (HS) have been detected by subjecting 
isolated nuclei to DNase treatment with subsequent digested genomic DNA detected 
via Southern blotting. This can reveal the extent to which DNase 1 cleavage occurs in a 
specific genomic region near a selected probe. Crawford and colleagues [320] 
published a protocol that dramatically scaled up this method by using high throughput 
sequencing to sequence regions flanked by DNAsel hypersensitive sites. The results of 
which were deposited on the UCSC track NHGRI DNasel-HS track (May 2004). The 
data from this track has since been merged with a follow up study by the same group 
[319] which aimed to create a more accurate, high throughput system to identify valid 
DNasel HS sites across the genome by improving the signal to noise ratio. This merged 
data can be found on a new UCSC track Duke/NHGRI DNasel-Hypersensitivity (May 
2004). Both tracks were mined for DNase 1 HS regions around the DTNBP1 locus.
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3.2.2 Samples
3.2.2.1 Mutation Screening Sample
Mutation screening of putative regulatory regions was performed in 14 unrelated 
schizophrenics (described in chapter 2.1.3) plus 13 other individuals. These 13 
individuals included 7 individuals previously reported to have DTNBP1 allelic 
expression differences >20% [186]. The remaining six samples comprised of three sets 
of parents whose offspring had been included in a previous study which measured total 
DTNBP1 expression by real time PCR using Taqman Gene Expression Assays [185]. 
The parents o f these individuals were chosen rather then the offspring themselves as the 
genetic variation of multiple siblings who showed altered total expression could be 
analysed by including just the two parents. Of the three sets of parents two pairs were 
included as their offspring showed the lowest DTNBP1 expression in the previous 
study and two individuals (one set of parents) were chosen as their offspring had the 
highest total DTNBP1 expression.
3.2.2.2 Schizophrenia Case Control Sample
The schizophrenia case control sample used in this chapter consisted of 709 
schizophrenic patients and 716 controls. Specific details of this sample are given in 
chapter 2.1.1.
3.2.3 Mutation Screening of Putative Regulatory Regions
All putative regulatory regions, identified by the methods described above, were 
screened for polymorphisms using the Lightscanner software (Idaho Technologies) and 
BigDye Sanger sequencing. The protocols for these methods are described in chapter
2.5.2 and 2.6 respectively.
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3.2.4 SNP Selection
All DNA variants detected were genotyped in the 30 CEPH parent-offspring trios that 
constitute the HapMap CEU sample. Detected SNPs were combined with all SNPs 
(n=216) of HapMap phase II (Jan 06) that span the DTNBP1 locus (Chr6:15621211- 
15780522, March 2006 freeze). Pairwise tagging via the Tagger function of Haploview 
was then used to select a non-redundant set of SNPs which captured all the alleles at the 
DTNBP1 locus at a MAF >0.001 and at an ^>0.95. In addition any putative regulatory 
variants with a MAF>0.001 were captured with an r2= l .
3.2.5 Genotyping
All SNPs were genotyped by primer extension using Sequenom MassARRAY as 
described in the chapter 2.7.1. Genotyping was performed either by myself or Dr. Liam 
Carroll. If genotyping failed using Sequenom Mass Array, genotyping was attempted 
using Amplifluor (see chapter 2.7.3).
3.2.6 Statistical Analysis
3.2.6.1 Association Analysis
All statistical analysis was performed using plink software [256]. This included 
association, Hardy-Weinberg equilibrium (HWE) and haplotypic analysis. Each marker 
was tested for allelic association using the Armitage trend test. Genotypic association 
was performed using %2 2degrees of freedom (df) tests. For SNPs whose genotype 
counts were less than 5 genotypic association analysis was performed using CLUMP 
where tests of significance are achieved by permutation. In this instance 10000 
permutations were performed [321]. Goodness of fit tests for HWE were performed in 
the cases and controls separately. Analysis of all combinations of 2 and 3 marker 
haplotypes was also performed using Plink as was the specific analysis of previously 
reported risk and protective haplotypes [134] in this extended case control sample.
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3.2.6.2 Logistic Regression of Association Signal
Logistic regression analysis of the association signal was performed in SPSS. The 
genotypes of each SNP showing an allelic association were coded as 0, 1 or 2 based on 
the number of copies of the risk allele. For the logistic regression analysis case control 
status was selected as the dependant variable and the genotypes of all associated SNPs 
were selected as covariates.
Logistic regression was performed three times using the enter method plus the forward 
and backward stepwise logistic regression methods. Probability of stepwise thresholds 
used in this analysis were entry=0.05 and removal=0.08.
The enter method determines whether any SNPs show a significant association after p 
values are adjusted for the correlation between the test SNP and all other SNPs in the 
model. The forward stepwise logistic regression identifies the most associated SNP 
using the enter method then determines whether any other SNP remains significant 
after taking the correlation between the test SNP and the most significant SNP into 
account. If they still show a significant association they are added to the model. The 
backward stepwise logistic regression begins with all SNPs within the model. SNPs 
with non-significant adjusted P values are removed in a stepwise manner with the 
logistic regression repeated after each SNP is removed.
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3.3 Results
3.3.1 Identification o f Putative Regulatory Regions
As no one conclusive in silico method to identify cis-acting regulatory sequences has 
been described, a complimentary set of different methods was devised for determining 
putative regulatory regions at the DTNBP1 locus. This consisted of determining 
putative promoter regions, regions containing clusters of TFBSs, DNase HS sites plus 
evolutionary conserved sequence. Analysis of chr6:15,621,018-15,844,250 identified 
21 putative regulatory regions (Figure 3.6). The exact chromosomal position of the 
regions identified and primers designed for mutation screening are given in Appendix 
Tables 9.1.1 and 9.1.2.
Two putative promoter regions for the four main DTNBP1 transcripts were identified 
(Figure 3.6). O f the remaining 19 regions, 5 were highly conserved regions determined 
using either ECR browser (n=3), USCS “most conserved” track (n=l) or both (n=l). 
Analysis using the web based program Cluster Buster predicted 13 regions to contain 
clusters o f TFBSs and one DNase hypersensitive region was identified using the track 
NHGRI DNasel-HS (May 2004).
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Figure 3.6. Chromosomal location o f putative DTNBP1 regulatory regions.
Genomic sequence identified as putative regulatory regions by a combination of methods are shown. 
Sequence immediately surrounding the transcription start site o f the three o f the main DTNBP1 isoforms 
plus AF061734 are illustrated under the track named “Promoters” . Evolutionary conserved regions, as 
well as DNase hypersensitive regions, are given within the “Conserved Regions” and “DNase 
Hypersensitive Regions” tracks respectively. Regions identified by Cluster Buster to contain clusters o f 
TFBSs are shown under the track name “TFBS”.
3.3.2 Comparison of Regulatory Region Detection Methods
Although ECR browser and UCSC use different methods to identify regions of 
conservation (see section 3.2.1.3) it could be expected that there would be some overlap 
in the regions identified by the two methods. While this is the case for the sequence 
chr6:15820928-15821304 (region 15 on Figure 3.6) which is identified by both ECR 
browser and UCSC to be a highly conserved region, there is no overlap in the other four 
regions identified by these methods.
It could also be hypothesised that there would be additional overlap in the genomic 
regions identified as conserved, or regions containing putative promoter regions,
TFBSs or DNase HS sites. For example, both putative promoter regions and regions of 
high conservation could be expected to contain TFBSs or promoter regions could show 
high conservation between species. Furthermore methods that identify sequence 
containing TFBSs and DNase HS sites could potentially identify the same sequence. 
However as can be seen it Figure 3.6 this is not the case, as each method identifies 
unique sequence not determined by another in silico analysis.
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3.3.3 Polymorphism Detection within Regulatory Regions
Screening all putative DTNBP1 regulatory regions identified 56 SNPs, 24 of which 
were novel (Table 3.1.) 32 of these SNPs are located within the core promoter region of 
either the main (n= 26) or alternative transcripts (n= 6). Five DNA variants were 
identified in regions of high conservation, 17 within sequence predicted to contain 
clusters o f TFBSs and two polymorphisms were observed in the area of DNase 
hypersensitivity.
Of the 56 SNPs identified, 39 had not been previously genotyped as part of the 
HapMap project. Therefore an attempt was made to genotype these 39 SNPs through 
the HapMap CEU sample in order to determine the MAF and the LD structure of these 
variants. However 8 of these 39 polymorphisms (rsl 2194321, DTNBP1-C13 SNP1, 
DTNBP1 -C24b_SNP 1, DTNBP1-C26_SNP1, rsl0949310, DTNBPl-R16_microsat, 
rs5874525, rs3070184) failed to be genotyped either by Sequenom or SNaPshot or 
Amplifluor. Therefore these have not been captured in the following association 
analysis.
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SN P No SN P ID C hrom osom al Position SN P Major/Minor MAF Region
1 r s 1076636 15623763 c / t 0.24 TFB S cluster
2 r s 1076635 15624057 A/G 0.22 TFBS cluster
3 rs1 7470454 15631177 G/A 0.05 TFB S cluster
4 rs2743548 15691803 T/G 0.08 CNC
5 rs9464802 15703383 A/G 0.08 TFBS cluster
6 rs13217513 15731386 G/A 0.20 TFBS cluster
7 A lt_ trans_S N P _p l 15735080 C/A 0 Alt T ranscript Putative Prom oter
8 rs1 6876738 15735532 G/C 0.17 Alt T ranscript Putative Prom oter
9 r»12525702 15735750 C/T 0.09 Alt T ranscript Putative Prom oter
10 rs3 2 13207 15736081 A/G 0.12 Alt T ranscript Putative Prom oter
11 Alt_trans_.SNP_ p4b1 15736141 C/T 0.03 Alt T ranscript Putative Prom oter
12 Alt_trans__SNP_ p5 15736261 T/G 0.09 Alt T ranscript Putative Prom oter
13 rs1 474605 15766191 A/G 0.19 Main T ranscript Putative Prom oter
14 DTNBP1-C1 SNP1 15766308 T/C 0 Main T ranscript Putative Prom oter
15 DTNBP1-C2 SNP1 15766584 C/T 0.09 Main T ranscript Putative Prom oter
16 rs1 2196958 15766584 T/A 0.01 Main T ranscript Putative Prom oter
17 rs1 997679 15766884 C/T 0.28 Main T ranscript Putative Prom oter
18 rs13192791 15767518 C/T 0.20 Main T ranscript Putative Prom oter
19 rs909706 15768850 C/T 0.37 Main T ranscript Putative Prom oter
20 rs2619516 15768930 A/G 0.08 Main T ranscript Putative Prom oter
21 DTN BP1-C9b SNP1 15769372 G/C 0.09 Main T ranscript Putative Prom oter
22 rs9476886 15769440 C/T 0.25 Main T ranscript Putative Prom oter
23 rs1 2194321 15769507 C/T N/A Main T ranscript Putative Prom oter
24 D TN BP1-C9b SN P2 15769573 T/C 0.03 Main Transcript Putative Prom oter
25 DTN BP1-C12 SNP1 15770552 G/C 0 Main Transcript Putative Prom oter
26 DTN BP1-C13 SN P1 15770555 G/C N/A Main Transcript Putative Prom oter
27 D TN BP1-C13 SN P2 15770558 C/G 0 Main T ranscript Putative P rom oter
28 rs9476887 15770870 C/T 0 Main T ranscript Putative P rom oter
29 r s 1 1558324 15771097 T/C 0.22 Main T ranscript Putative Prom oter
30 DTN BP1-C16 SNP1 15771705 C/G 0 Main T ranscript Putative Prom oter
31 rs2 6 19536 15771826 T/C 0.09 Main Transcript Putative Prom oter
32 DTN BP1-C16 SN P2 15771883 C/T 0.09 Main T ranscript Putative Prom oter
33 rs2619537 15772392 A/G 0.16 Main T ranscript Putative Prom oter
34 rs1 2204704 15773184 G/A 0.16 Main T ranscript Putative Prom oter
35 rs2 6 19538 15773188 T/A 0 39 Main T ranscript Putative Prom oter
36 DTN BP1-C23 SNP1 15774468 C/G 0 Main T ranscript Putative Prom oter
37 D T N B P1-C 24b SNP1 15774812 G/T N/A Main T ranscrip t Putative Prom oter
38 DTN BP1-C26 SNP1 15775663 G/A N/A Main T ranscript Putative Prom oter
39 D TNBP1-dhyp SNP1 15784456 T/C 0.01 D N ase HS
40 rs1 7407828 15784456 G/C 0.29 D N ase HS
41 DTN BP1-R10 SNP1 15794357 T/C 0 22 TFBS cluster
42 DTN BP1-R10 indell 15794358 C/T 0.28 TFBS cluster
43 D TN BP1-R10 inde!2 15794409 A/G 0.29 TFBS cluster
44 rs9296989 15794678 A/G 0.43 TFBS cluster
45 rs6906528 15798293 G/A 0.28 TFBS cluster
46 rs10949310 15800916 C/G N/A TFBS cluster
47 rs7450621 15806527 C/T 0.45 CNC
48 r» 1 2 2 l2 4 7 7 15820927 C/A 0.43 CNC
49 D TN BP1-R16 m icrosat 15841789 ACn N/A CNC
50 DTN BP1-R16 SNP1 15841944 C/T 0.02 CNC
51 DTN BP1-R17 SNP1 15843067 C/T 0 02 TFBS cluster
52 rs2025926 15843264 G/T 0.03 TFBS d u s te r
53 D TN BP1-R17 SN P2 15843267 G/A 0.02 TFBS d u ste r
54 rs5874525 15843366 GI­ N/A TFBS d u s te r
55 rs3070184 15843367 G/A N/A TFBS d u s te r
56 rs2619514 15843987 T/C 0.06 TFBS d u ste r
Table 3.1. Sequence variants identified within putative DTNBP1 regulatory regions.
SNP positions are according to UCSC human genome chromosome 6 reference sequence (March 2006  
freeze). Minor allele frequencies (M AF) in the HapMap CEU sample are shown. 24 novel 
polymorphisms were identified during this study. N/A indicates not available and is given where a DNA  
variant failed to be typed through the CEU population.
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3.3.4 Tag SNP Selection
Tag SNP selection was performed in two stages. Firstly, a non-redundant set of SNPs 
was selected which captured the 48 variants (with CEU genotype data) identified within 
the putative regulatory regions at a MAF >0.001 and at an r2= l. Secondly, extra SNPs 
were selected that would tag the core DTNBP1 locus (Chr6:15621211-15780522) at a 
MAF >0.001 and at an ^>0.95. This combined tagging was employed due to the 
potential ambiguity of the regulatory region identification methods. It was hoped that 
tagging the core DTNBP1 locus in addition to the putative regulatory variants would 
maximise the chance of identifying DTNBP1 risk variant(s) and more specifically 
functional variant(s). Supplementing tagging of the core DTNBP1 locus with the 
variants identified by direct screening also has a number of advantages over solely 
selecting tag SNPs for the core DTNBP1 locus using the HapMap database alone.
Firstly, direct sequencing of putative regulatory regions identified variants not 
deposited in the HapMap database. Secondly, the "window” of genomic sequence 
screened for putative regulatory regions covered a much larger area than the tagged 
DTNBP1 region (Figure 3.7). While tagging the larger region at the high density 
employed for the core DTNBP1 locus would have greatly increased the number of tag 
SNPs to be genotyped, including the putative regulatory variants increased coverage 
and enriched the SNPs analysed for putative regulatory variants while keeping the 
number of tag SNPs to be genotyped to a realistic level.
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Figure 3.7. Comparison o f the genomic sequence screened for putative regulatory regions 
(chr6:15,621,018-15,844,250) and the core DTNBP1 locus (chr6:15621211-15780522) tagged at an 
^<0.95 MAF<0.001.
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Pairwise tagging selected a set of 66 tag SNPs which captured 100% of the variation at 
chr6:15621211-15780522 with an ^>0.95 and MAF>0.001 plus all putative regulatory 
variants at an r2= l. However due to genotyping failure (using both Sequenom and 
Amplifluor) a final set of 64 tag SNPs were genotyped which captured 94% of the 
variation at an ^>0.95 and MAF>0.001. Of the 48 putative regulatory SNPs, 37 were 
either genotyped themselves or tagged at an 1^ =1 with a SNP typed through the 
association sample. Of the remaining of 11 putative regulatory variants, 7 had 
M AF0.001 and 4 SNPs (rsl076635, alt_trans_SNP_p4bl, DTNBPl-C9b_SNP2, 
DTNBP1-R10SNP1) failed to be typed by Sequenom or Amplifluor and no proxies 
were available.
33.5 Association Analysis
Of the 64 tag SNPs genotyped across the DTNBP1 locus and putative regulatory 
regions, all had a call rate o f >95%. Individuals were only included in analysis if they 
had genotypes for over 80% of the 64 SNPs analysed, therefore 18 individuals were 
removed from the sample prior to association analysis. All markers were in HW 
equilibrium at p>0.001 for both cases and controls. However to compensate for even 
small deviations in HW, the Armitage trend test was used to test for allelic association 
(Table 3.2).
Three polymorphisms showed nominal allelic association with schizophrenia 
(rs4715984 p=0.001, rs2619538 p=0.024, rs9296989 p=0.017), although rs4715984 
was the only SNP to survive correction for multiple testing after 10,000 permutations 
(p=0.04). All three of these polymorphisms also showed genotypic association 
(rs4715984 corrected p=0.003, rs2619538 p=0.016, rs9296989 p=0.038). One SNP 
rs3778651 showed genotypic (corrected p=0.011) but not allelic association.
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No rsID Chrom Pos Alleles Freq Cases
Freq
Controls Arm Trend P
Arm Trend Emp 
P (10000) Counts cases
Counts
Controls
HW Cases & 
Controls HW Cases HW Con Genotypic p
Clump P 
10000
1 rs2235258 15621461 G/A 02301 0.2323 0 8901 1 45/210/397 38/253/417 0 127 0 026 1.000 0.250 N/A
2 rs9396589 15621723 T/G 0.2709 02876 0 3248 09999 45/266/346 55/299/357 0 383 0.555 0.522 0.616 N/A
3 rs9654600 15622092 A/T 0.0699 0.0777 0.4378 1 7/78/573 2/107/605 0 552 0.032 0.302 NA 0.052
4 rs9396590 15622478 G/A 0.2753 0 2922 0.3247 09999 45/269/338 59/294/352 0 505 0.433 0.856 0.546 N/A
5 rs1076636 15623763 T/C 02096 0.2202 0.5186 1 36/195/406 36/227/416 0.072 0056 0.502 0.546 N/A
6 rs9396591 15624264 A/G 0.2733 02894 0.3403 09999 44/270/341 55/301/354 0229 0.376 0.466 0.627 N/A
7 rs742102 15624612 A/G 0.0320 0.0358 0.5979 1 2/38/616 2/47/664 0.067 0.137 0.224 NA 0.870
8 rs1474587 15624688 T/C 0.1508 0.1474 0.8063 1 21/155/477 20/169/520 0.025 0 066 0.178 0.913 N/A
9 rs909626 15625663 T/C 0.1368 0.1299 0.6071 1 14/152/492 19/147/546 0.046 0.619 0.029 0.467 N/A
10 rs3778651 15626511 T/C 0.0578 00721 0.1306 0.9731 5/66/586 1/101/612 0.826 0058 0.165 NA 0.011
11 rs13213814 15627355 C/T 02656 02588 0.6843 1 49/251/357 45/279/389 1 0.617 0.627 0.693 N/A
12 rs13198512 15627864 T/C 0.5046 0 4846 0.2927 0.9999 169/323/163 161/368/183 0.705 0.755 0.369 0.385 N/A
13 rs13201824 15628757 T/G 0.2647 0.2556 0.594 1 49/244/353 46/270/392 0.621 0.479 1.000 0.736 N/A
14 rs1047631 15631080 C/T 0.1415 0.1421 0.963 1 13/158/479 9/183/515 0.266 1.000 0.123 0.479 N/A
15 rs17470454 15631427 A/G 0.0631 0.0497 0.1308 0.9736 2/79/577 3/65/646 0.613 1.000 0.410 NA 0.206
16 rs742106 15632459 A/G 0.3548 0.3622 0.6835 1 78/306/267 83/349/279 0.099 0.549 0.105 0.741 N/A
17 rs2056943 15632542 C/T 0.0464 0.0337 0.0855 0.913 1/59/597 0/48/664 0.721 1.000 1.000 NA 0.141
18 rs16876571 15632658 A/G 0.0130 0.0179 0.3005 0.9999 0/17/636 0/25/673 1 1.000 1.000 NA 0 349
19 rs16876575 15633136 T/C 0.1438 0.1273 0.2031 0.9961 15/159/483 8/165/538 0.729 0.635 0.310 0.215 N/A
20 rs6937379 15633976 A/G 0.2344 0.2525 0.2604 0.9991 36/236/385 34/292/387 0.107 1.000 0.029 0.156 N/A
21 rs4712253 15634396 T/C 0.4085 0.3787 0.1098 0.95 115/306/235 96/348/269 1 0.375 0.340 0.114 N/A
22 rs9464795 15638143 A/G 0.0809 0 0848 0.7192 1 6/93/550 6/106/584 0.285 0.298 0.622 0.893 N/A
23 rs9370822 15652715 C/A 0.3941 0.3827 0.5318 1 102/313/241 86/373/253 0.041 1.000 0.004 0.099 N/A
24 rs12527121 15654192 T/C 0.0968 0.0850 0.2791 0.9996 6/115/535 4/113/595 0.869 1.000 0.809 NA 0.560
25 rs9370823 15658637 G/A 0.2874 0.2956 0.6293 1 49/275/325 51/313/338 0.056 0.443 0.070 0.714 N/A
26 rs9296983 15663405 A/G 0.2266 0.2464 0.2195 0.9977 32/232/389 36/272/390 0.259 0.823 0.221 0.384 N/A
27 rs4715984 15669870 A/G 0.1107 0.0756 0.0013 0.0471 6/133/516 2/103/603 0.330 0.552 0.417 NA 0.003
28 rs9358063 15673010 T/C 0.4671 0.4698 0.8865 1 141/315/183 136/382/178 0.088 0.812 0.008 0.124 N/A
Table 3.2. Case/Control association analysis of 64 tag SNPs spanning the DTNBP1 locus and putative regulatory regions. SNP positions are according to UCSC
human genome chromosome 6 reference sequence (March 2006 freeze). Alleles given as Minor/Major alleles. N/A= not analysed.
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No rsID Chrom Pos Alleles Freq Cases
Freq
Controls Arm Trend P
Arm Trend Emp 
P (10000) Counts cases
Counts
Controls
HW Cases &
Controls HW Cases HW Con Genotypic p
Clump P 
10000
29 rs7771339 15677985 A/G 0.04497 0.0407 0 5823 1 1/57/598 1/56/655 1 1.000 1.000 NA 0.636
30 rs2743548 15691803 G/T 0.07840 00898 0.2895 09999 6/91/560 6/116/591 0384 0.276 0.820 0.457 N/A
31 rs9296985 15697994 C/T 0 0804 0.0878 0.4959 1 6/93/554 6/110/579 0.376 0.295 0.641 0.716 N/A
32 rs12203173 15705548 G/A 0.1476 0.1239 0 0695 0.8675 16/161/477 7/163/544 0.729 0.537 0.226 0.070 N/A
33 rs12199640 15706859 T/C 0.0356 0.0437 0.2953 0.9999 3/39/590 1/59/638 0.153 0.039 1.000 NA N/A
34 rs7752070 15712898 G/A 0.0810 0.0915 0.3539 1 9/88/557 11/107/587 0 002 0 029 0.037 0.630 0.224
35 rs3829893 15723616 A/G 0.1549 0.1377 0.2087 0.9966 19/159/458 10/175/523 0.913 0.287 0.343 0.134 N/A
36 rs2619539 15728834 C/G 04765 0.4601 0.3916 1 150/307/180 135/376/191 0 381 0.384 0.048 0.084 N/A
37 rs3213207 15736081 C/T 0.1133 0.1075 0.6289 1 7/131/502 4/143/555 0.164 0 843 0.118 NA N/A
38 Alt trans_p5 SNP1 15736261 A/C 0.0338 0.0459 0.1203 0.9633 2/40/609 3/58/637 0.059 0.162 0.171 0.120 0.593
39 rs1011313 15741411 T/C 0.1000 0.0821 0.1080 0.9487 9/113/533 6/105/602 0.248 0.277 0462 0.268 0.273
40 rs13212086 15742115 T/C 0.2395 0.2518 0.4533 1 35/238/370 39/276/388 0304 0.746 0.316 0.677 N/A
41 rs2619528 15757808 T/C 0.1888 0.1923 0.8186 1 22/203/429 23/227/460 0.483 0.800 0.471 0.931 N/A
42 rs760761 15759111 A/G 0.1940 0.1987 0.753 1 22/209/421 24/235/453 0.303 0.616 0.410 0.931 N/A
43 rs2619520 15764134 C/A 0.1107 0.0906 0.0857 0.9126 12/121/522 6/117/589 0.228 0.113 0.822 0.154 N/A
44 rs1018381 15765049 A/G 0.0790 0.0845 0.6033 1 6/91/555 5/108/585 0.467 0.279 1.000 0.682 N/A
45 rs1474605 15766191 C/T 0.1948 0.1959 0.9411 1 22/212/423 23/233/456 0.230 0.535 0.342 0.979 N/A
46 rs12196958 15766584 ATT 0.0084 0.01471 0.1313 0.9766 1/9/648 0/21/693 0.167 0.041 1.000 NA N/A
47 rs 1997679 15766884 A/G 0 3208 0.3411 0.2604 0.9991 72/275/306 76/331/301 0.903 0.419 0.316 0.212 0.054
48 DTNBP1 c9b SNP1 15769372 C/G 0.0898 0.0870 0.7877 1 4/110/543 1/122/590 0.063 0.810 0.033 NA N/A
49 rs9476886 15769440 T/C 0.2676 0.2433 0.1484 0.9843 52/245/355 40/263/402 0.617 0.317 0.838 0.217 0.396
50 rs11558324 15771097 C/T 0.2393 0.2661 0.1069 0.9469 35/242/375 49/273/375 0.773 0.668 1.000 0.259 N/A
51 rs2619536 15771826 C/T 0.0919 0.1023 0.3656 1 9/102/542 6/133/570 0.535 0.101 0.685 0.213 N/A
52 DTNBP1 c16 SNP2 15771883 T/C 0.0395 0.0413 0.8170 1 3/46/609 3/53/658 0.021 0.074 0.113 NA N/A
53 rs2619537 15772392 G/A 0.1322 0 1457 0.3117 0.9999 14/146/498 14/180/520 0.736 0.395 0.880 0.419 0.924
54 rs 12204704 15773184 A/G 0.1816 0.1548 0.0630 0.8369 26/187/445 17/187/510 0.384 0.293 1.000 0.133 N/A
55 rs2619538 15773188 A/T 0.4698 0.4264 0.0238 0.5134 151/305/190 121/361/225 0.869 0.180 0.282 0016 N/A
Table 3.2 cont. Case/Control association analysis of 64 tag SNPs spanning the DTNBP1 locus and putative regulatory regions. SNP positions are according to 
UCSC human genome chromosome 6 reference sequence (March 2006 freeze). Alleles given as Minor/Major alleles. N/A= not analysed.
132
No rsID Chrom Pos Alleles Freq Cases
Freq
Controls Arm Trend P
Arm Trend Emp 
P (10000) Counts cases
Counts
Controls
HW Cases 
& Controls HW Cases HW Con Genotypic p
Clump P 
10000
56 DTNBP1_Dhypsnp1 15784456 C/T 0.0129 0 0098 0 4549 1 1/15/642 0/14/699 0158 0 099 1.000 NA N/A
57 rs17407828 15784456 C/G 0.3113 0.3379 0.1439 0.982 69/268/315 77/317/303 0.664 0.315 0.735 0 194 0.377
58 DTNBP1_r10_SNP1 15794357 C/T 0.1370 0.1419 0.7086 1 9/162/486 12/178/522 0259 0.324 0.541 0.879 N/A
59 rs9296989 15794678 G/A 0 4648 0.4195 0.0175 0.4253 145/317/191 120/354/234 1 0.530 0.537 0.038 N/A
60 rs7450621 15806527 T/C 0.4977 0.4651 0.0918 0.9222 165/318/168 151/352/200 0.744 0.583 0.940 0.209 N/A
61 rs12212477 15820927 A/C 0.4363 0.4105 0.1791 09933 128/312/211 120/338/246 0 540 0.524 0.876 0.385 N/A
62 DTNBP1_r16_SNP1 15841944 T/C 0.0626 00509 0.1876 0.9946 2/77/568 2/68/637 1 1.000 0.701 NA 0.424
63 rs2025926 15843264 A/C 0.0123 0.00945 0.4701 1 0/16/633 0/13/675 1 1.000 1.000 NA 0.576
64 rs2619514 15843987 G/A 0 0965 0.0765 0.0660 0.8511 8/110/535 3/101/595 0.729 0.368 0.789 NA 0.129
Table 3.2 cont. Case/Control association analysis of 64 tag SNPs spanning the DTNBP1 locus and putative regulatory regions. SNP positions are according to 
UCSC human genome chromosome 6 reference sequence (March 2006 freeze). Significantly associated SNPs highlighted in red. The most significantly associated 
SNP rs4715984 is in bold and highlighted in red. Alleles given as Minor/Major alleles. N/A= not analysed.
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3.3.6 Location of Associated SNPs
The chromosomal location of all significant polymorphisms and their proxies (r2>0.95) 
are given in Figure 3.8A. The SNP showing the greatest association to schizophrenia, 
rs4715984, is an intronic SNP not located within a previously identified putative 
regulatory region. However rs 12525702, a proxy of rs4715984, is located within the 
putative promoter region of the alternative transcript AF061734 and only 200bp 
upstream of the TSS (Figure 3.8B). Therefore rsl 2525705 could potentially have a 
regulatory effect on this DTNBP1 transcript. Both rs2619538 and rs9296989 are also 
within putative regulatory regions. As can be seen from Figure 3.8A, rs2619538 is 
located ~1.8kb upstream of the TSS of the three main DTNBP1 transcripts. Although 
not as close to the TSS as r s l2525702, this SNP could also potentially have a 
regulatory effect on one or all of these transcripts. The polymorphism rs9296989 is 
within a region determined by the Cluster Buster program. However reanalysis showed 
that rs9296989 is not located within any of the predicted TFBSs within this region. 
rs3778651 which shows a genotypic association to schizophrenia is not located with 
putative regulatory regions, nor is its proxy rs9296975.
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Figure 3.8.
A. Chromosomal position o f significant SNPs and proxies (^>0.95) plus putative regulatory regions 
previously identified, r s l2525705, a proxy for rs4715984 (p=0.001) is located within the putative 
promoter region o f the alternative transcript AF061734. rs2619538 and rs9296989 are also located within 
putative regulatory regions. rs4715984 is not located with any putative regulatory regions, nor is 
rs3778651 or its proxy rs9296975. Based upon May 2004 UCSC freeze.
B. Chromosomal location o f rsl 2525702 on a narrowed scale, rsl 2525702 is a proxy for rs4715984 
(p=0.001) and, is ~200bp upstream o f the alternative transcript AF061734. Based upon May 2004 UCSC 
freeze.
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3.3.7 Further Analysis of the Allelic Association Signal
A high-density tagging strategy was used for this study (^>0.95). As a result the 
significant SNPs may be reporting the same association signal. LD analysis, illustrated 
in Table 3.3, shows that rs2619538 and rs9296989 are in a high LD (D’=l, r2=0.92). 
However the LD between rs4715984 and rs2619538/rs9296989 is lower (D’=0.46/0.43, 
1^=0.04/0.02).
rs4715984 rs2619538 rs9296989
rs4715984 0.04 0.02
rs2619538 0.46 0.92
rs9296989 0.43 1
Table 3.3. LD analysis o f all significantly associated SNPs. The top half o f the table shows r2 values and 
D’ values are given in the bottom half o f the table.
In order to discern whether rs2619538 or rs9296989 show an association over and 
above rs4715984 (the most associated SNP) logistic regression was performed. Firstly 
the p value of each SNP was adjusted for the correlation between itself and all other 
associated SNPs. As can be seen from Table 3.4 only rs4715984 remains significant 
after this analysis (Enter Logistic Regression p=0.011).
Forward and backward stepwise logistic regression confirmed that the association 
observed by rs9296989 and rs2619538 shows no evidence for independence from 
rs4715984 as neither remain significant after adjustment for their correlation with 
rs4715984 (Stepwise Logistic Regression p=0.095 and p=0.107 respectively). Further 
details of the enter and stepwise logistic regression results are given in the Appendix 
(Tables 9.1.3-9.1.5).
SNP ID Arm Trend 
P Value
Enter LR 
P Value
Stepwise LR 
P Value
rs4715984 0.001 0.011 -
rs9296989 0.018 0.656 0.095
rs2619538 0.024 0.919 0.107
Table 3.4. Logistic Regression Analysis o f SNPs showing an allelic association. LR = Logistic 
Regression. Arm = Armitage. Enter LR p value refers to p values adjusted for the correlation between the 
test SNP and all other significant SNPs. Stepwise LR p values are adjusted for the correlation between 
the test SNP and rs4715984.
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3.3.8 Haplotype Analysis
Haplotype analysis was performed on the 64 markers genotyped at this locus. Analysis 
of all 2 and 3 marker haplotypes (45,760 phased haplotypes) revealed the strongest 
evidence for association with a three marker haplotype composed of the SNPs 
rs 17470454, rs4715984 and rs2619520 (global p=0.00025). Analysis of the specific 3 
marker haplotypes formed by these SNPs identified both a risk haplotype (GAA 
p=0.0014, case frequency = 0.11, control frequency = 0.076) plus a protective 
haplotype (GGA p=0.00002, case frequency = 0.71, control frequency = 0.78). 
However the risk haplotype does not refine the allelic association observed with 
rs4715984 alone (p=0.001, cases frequency (A) = 0.11, control frequency = 0.076). In 
addition as ~45,000 two and three marker haplotypes were analysed, the best p values 
shown here would not survive a Bonferroni correction for multiple comparisons 
(p> 0.05).
3.3.8.1 Analysis of Previous Risk Haplotype
The association sample used in this chapter is an extended but largely overlapping 
version of the UKCC sample analysed by Williams et al [134]. Therefore in addition to 
identifying new risk variants the significant results reported in the previous study were 
analysed in this extended sample. Williams et al determined significant evidence for 
association in one risk haplotype (rs2619538, rs3213207, rs2619539 TAC, p=0.01) and 
two protective haplotypes (AAC p=0.006, TGG p<0.001). Analysis of these three risk 
haplotypes in this extended case control sample are given in Table 3.5. While the rare 
protective haplotype is no longer associated with schizophrenia (TGG p=0.758) the 
other protective haplotype still shows an association in this sample (AAC p=0.016). 
Furthermore the original risk haplotype is also associated with schizophrenia in this 
extended sample (TAC, p=0.048).
rs4715984 the most significantly associated SNP in this study was not genotyped in the 
original publication by Williams and colleagues. Haplotype analysis was therefore 
performed with the previous three markers and rs4715984. As can be seen in Table 3.5
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the four marker haplotype combination (rs2619538, rs3213207, rs2619539, rs4715984) 
has a globally significant p value (p=0.016). The addition o f rs4715984 splits 
individuals carrying the risk TAC haplotype into carriers o f the TACT or TACC 
haplotypes. The associated allele o f rs4715984 (T) occurs on the same haplotype 
background as the risk haplotype TAC and refines the association (TACT p=0.005). 
The protective haplotype also shows a refined signal as the protective allele of 
rs4715984 is found on the AAC haplotype (AACC p=0.003).
However it must be noted that while addition o f rs4715984 refines the risk haplotype 
association, only 2%  o f the 3% difference observed for the TAC haplotype is seen for 
the TACT haplotype. The remaining 1% difference, while not great enough for a 
significant association, is shown by the TACC haplotype.
A
Markers Haplotype Case Control P Value
rs2619539-rs3213207-rs2619538 Global N/A N/A 0.100
rs2619539-rs3213207-rs2619538 TAC 0.19 0.16 0.048
rs2619539-rs3213207-rs2619538 AAC 0.34 0.38 0.016
B
— Markers Haplotype Case Control P Value
rs2619538-rs3213207-rs2619539-rs4715984 Global N/A N/A 0.016
rs2619538-rs3213207-rs2619539-rs4715984 TACT 0.09 0.07 0.005
rs2619538-rs3213207-rs2619539-rs4715984 TACC 0.10 0.09 0.588
rs2619538-rs3213207-rs2619539-rs4715984 AACT 0.02 0.01 0.303
rs2619538-rs3213207-rs2619539-rs4715984 AACC 0.32 0.37 0.003
Table 3.5. A Haplotype analysis results for the previously identified risk haplotype [134] with the 
extended association sample. B. The refinement of the risk haplotype association by the addition of 
rs4715984. Given are the marker IDs, haplotypes, case and control frequencies and an association p 
value. Risk haplotypes are given in red, protective haplotypes in blue.
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3.4 Discussion
Recent studies suggest that complex diseases may be caused by the variation in 
expression of multiple genes and that pathogenic mutations will function not by altering 
the protein structure, but by affecting the levels of specific susceptibility genes [192, 
322, 323]. The gene dysbindin (DTNBP1) shows all the features of a gene that could 
promote susceptibility to schizophrenia through altered expression. Firstly, while 
DTNBP1 has been widely reported as associated with schizophrenia, no obvious 
pathogenic mutations have been found [324]. Secondly dysbindin expression, both at 
the mRNA and protein level, is reduced in schizophrenic brains [181-183]. Finally, 
reductions in dysbindin mRNA have been shown to be associated with a DTNBP1 
schizophrenia risk haplotype [186]. This evidence suggests that the causal variants 
within DTNBP1 could be located in cis-acting regulatory elements.
To date there has been no comprehensive study o f the DTNBP1 locus for genomic 
sequence that may have a regulatory effect on the expression of dysbindin. This chapter 
describes the screening of a “window” around the DTNBP1 gene for functional 
variants. This involved the initial identification of putative regulatory regions followed 
by polymorphism detection within these regions. In silico analysis for regulatory 
sequence identified 21 putative regulatory regions and mutation screening of these 
regions detected 56 polymorphisms. These were combined with 216 SNPs at the 
DTNBP1 locus (Chr6:15621211-15780522) which had been genotyped in HapMap 
phase II. A defined a set of highly informative SNPs that captured the majority of 
common variation at this locus was then genotyped in a relatively ethnically 
homogeneous schizophrenia case control sample.
Allelic and genotypic analysis identified four SNPs associated with schizophrenia. 
However logistic regression analysis determined that the allelic association observed 
with rs2619538 and rs9296989 is not independent of the association signal detected at 
rs4715984. While this indicates a single association signal in this case control sample, it 
is worth noting that rs9296989 shows a trend towards a signal independent of 
rs4715984 (p=0.095). rs9296989 may therefore be in partial LD with another SNP, not
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typed in this analysis, which shows an association independent of rs4715984. However, 
identifying this hypothetical SNP is beyond the scope of this thesis.
rs4715984 itself survives correction for multiple testing. It has also been found to 
refine the risk haplotype previously reported by Williams et al [134]. While rs4715984 
does not reside within a putative regulatory element, analysis of the LD structure across 
DTNBP1 identified a proxy, rs l2525702, which is found within the putative promoter 
region of the DTNBP1 isoform AF061734. rsl 2525702 is only 200bp upstream of the 
transcription start site of AF061734 and therefore an ideal candidate to cause cis-acting 
variation. As well as altering the binding of a transcription factor rsl 2525702 could 
cause expression differences by other mechanisms. Sequence variants that lie outside of 
transcription factor binding site may exert their effect by either altering the bending of 
DNA towards (or away from) its optimum configuration or by altering the flexibility of 
the DNA [322]. If this is the case it would make it equally likely that rs4715984 may be 
the causal variant.
While it is promising that a SNP located within a predicted regulatory region has been 
found to be associated with schizophrenia, there are many question marks over whether 
the determination of putative regulatory regions by the methods described, will be 
successful in identifying functional SNPs. The overlap in the regulatory regions 
identified by the different methods described in this chapter was relatively low. This 
may suggest that one or all of the methods used are not exceptionally efficient at 
determining regulatory elements and are producing a high number of false positives 
and/or negatives. However the pattern of regions could also be explained if each 
method is detecting a different type of regulatory element.
Another caveat of this study is that the analysis of the DTNBP1 locus for regulatory 
variants has only screened a small fraction of sequence that could potentially affect 
DTNBP1 expression. For example while it was decided to limit the sequence analysed 
3’ to DTNBP1 to lOkb, due to the presence of the gene JARID2 1 kb 3’ to DTNBP1, 
there have been reports o f a number of regulatory elements for specific genes have been 
found within neighbouring genes [288]. Secondly, cis-acting variants have been
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observed over 1Mb away from the target gene [265], however screening this amount of 
genomic sequence for putative DTNBP1 regulatory regions would have been 
unfeasible.
In order to establish whether identifying putative regulatory elements via the in silico 
analysis used in this chapter is a successful way of determining cis-acting variants, and 
also whether the risk polymorphisms identified in this chapter are causal variants, 
further investigation is needed. Therefore all informative SNPs examined in this 
chapter have been subjected to additional analysis which was designed to verify 
whether any of these SNPs could affect dysbindin expression. This consisted of 
association analysis with the DTNBP1 allelic expression data previously described 
[186]. In addition SNP(s) showing association with the allelic expression data, and 
deemed most likely to be influencing the expression differences observed, were 
examined in a functional reporter gene assay. These analyses are described in chapters 
4 and 5 respectively.
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Chapter 4: Association Analysis of DTNBP1 Putative 
Regulatory SNPs with cortical Dysbindin mRNA 
Levels
4.1 Introduction
As described in Chapter 1, Bray et al previously provided evidence that DTNBP1 is 
under the influence of cis-acting variation [184]. As reduced DTNBP1 expression had 
also been reported in post mortem brains of schizophrenic patients [181-183], it was 
suggested that cis-acting variation may be relevant to schizophrenia aetiology and that 
unidentified sequence variants in regulatory regions of DTNBP1, might promote 
susceptibility to schizophrenia by altering expression of the gene. In an attempt to link 
the observations of cis-acting variation with the genetic association previously reported 
between DTNBP1 and schizophrenia [134], Bray and colleagues showed that the 
relative expression of the A-allele of the exonic SNP rsl 047631, used in the allelic 
expression assay, was significantly lower when it was carried on the schizophrenia risk 
haplotype TAA (T allele of rs2619538, A allele o f rs3213207 and A allele of 
rs l047631, p=0.01) compared with when it was carried on the non-risk haplotypes 
[186].
However the report also noted that the risk haplotype did not account for all the cis- 
acting variation in DTNBP1 expression as a proportion of samples that did not carry the 
risk haplotype showed allelic distortion (Figure 4.1). In light of this it was suggested 
that the risk haplotype was unlikely to have a direct effect on DTNBP1 expression and 
may be in LD with the actual functional variant(s).
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Figure 4.1. Allele ratios at SNP r s l047631, stratified by heterozygosity for the defined 3-marker 
schizophrenia risk haplotype. Data represented as a ratio o f  A/G alleles. The risk haplotype includes the 
reduced expression A-allele o f  rsl 047631. cDNA samples from individuals who are heterozygous for the 
risk haplotype show lower expression o f  the A-allele than those from individuals who carry no copies o f  
the risk haplotype (p=0.002). However a number o f  individuals homozygous for the risk haplotype also 
show allelic expression differences (average allelic expression ratio =0.95) including three individuals 
with a relative decrease in expression o f  greater than 20% [186].
Chapter 3 describes the identification of a set o f SNPs that would allow the high density 
mapping of the DTNBP1 locus and putative DTNBP1 regulatory regions. The initial 
aim of this chapter was to identify potential cis-acting variants by determining which of 
these SNPs best correlate with the allelic expression data reported by Bray et al [186]. 
The second phase of the analysis was to determine whether any of these SNPs were 
also associated with schizophrenia. Of particular interest was rs4715984 which was 
observed in chapter 3 to show the greatest association with schizophrenia (p=0.0013) 
and survived correction for multiple testing (p=0.0471). Moreover, this SNP was found 
to refine the association of the schizophrenia risk haplotype, originally identified by 
Williams and colleagues [134], which was subsequently shown to also be associated 
with reduced DTNBP1 expression. In light of this the refined risk haplotype was also 
analysed for correlation with allelic expression differences.
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4.2 Methods
4.2.1 Caucasian Brain Samples
Details of the 149 individuals which form the Caucasian brain sample used in this 
chapter are given in chapter 2.1.2. The extraction protocols used for these samples are 
described in chapter 2.2.
4.2.2 Identification of Putative Regulatory Regions, Polymorphism Detection and 
Tag SNP Identification
The identification of putative regulatory regions and the screening of these regions is 
described in chapter 3. The criteria used to determine the tag SNPs analysed in this 
chapter is also given. Briefly SNPs were selected that would tag variants located within 
the putative regulatory regions at an 1^=1. In addition extra polymorphisms were chosen 
which would tag the DTNBP1 locus (Chr6:15621211-15780522) at an ^>0.95. Both 
criteria had a MAF>0.001.
4.2.3 Genotyping
Tag SNPs were genotyped through the Caucasian brain sample using the Sequenom 
MassARRAY genotyping system. Details of this protocol are given in chapter 2.7.1.
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4.2.4 Allelic Expression Analysis
Allelic expression analysis of DTNBP1 was performed by Dr. Nicholas Bray using the 
coding SNP rsl047631, the results of which have previously been published [186]. 
Details of allelic expression protocol can be found in the chapter 2.9.
DNA samples from heterozygous subjects were assayed twice, with each assay 
consisting of two separate cDNA samples and one gDNA sample for each 
heterozygote. As a result, the genomic DNA ratios reported in this chapter are the 
average of two measurements and cDNA ratios given for each sample are the averages 
of four measurements. Samples were amplified using primers based on exonic sequence 
capable of amplifying both genomic DNA or cDNA:
5 ’ -GTGGTGAGGACAGCGACTCT-3 ’ and
5,-GCTGTTCTTTAAGTTTCTCACACA-3’. Allele representation was measured by 
primer extension and SNaPshot chemistry (Applied Biosystems) using the extension 
primer 5’-TTCTCACACATTATTGGCAATTA-3’.
4.2.5 Normalisation of Allelic Expression Data
All prior statistical analysis o f the allelic expression data has been performed using 
non-parametric tests for example Mann-Whitney U [186]. Non-parametric tests are 
used when a numerical outcome is produced but the dataset is not normally distributed. 
In these situations, non-parametric analysis, such as the Mann-Whitney U, can be more 
robust than parametric tests as they are less affected by extreme observations. However 
on normally distributed data parametric analysis has greater power as all information 
within a dataset is conserved, unlike non-parametric tests where numerical variables are 
converted into ranks. For this reason steps were taken to normalise the allelic 
expression data so subsequent analyses could be performed using parametric tests. 
Allelic expression ratios (n=31) were transformed by taking the natural log of each 
ratio. Histogram and Q-Q plots of the transformed ratios as well as statistical tests for 
normality (Figure 4.2) illustrate that the log transformation of the allelic expression
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ratios follows a normal distribution. Subsequent analysis of stratified ratios was 
therefore achieved via parametric tests.
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Figure 4.2. Normality tests on transformed (logarithmic) allelic expression ratios determined by analysis 
o f  individuals heterozygous for the SNP rsl 047631. The results shown are A) Histogram B) Normal Q-Q 
plot o f  LogExp C) Statistical test results.
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4.2.6 Statistical Analysis
Association analyses between cortical dysbindin mRNA levels and DTNBP1 tag SNP 
genotypes were performed on normalised allelic expression ratios (n=31) previously 
reported [186]. A statistically significant correlation was determined in two phases 
using the software package SPSS. Details of these analyses are given below.
4.2.6.1 Independent Samples T-test
Firstly, for each test SNP the relative expression o f mRNA from each chromosome 
were compared between heterozygous and homozygous individuals. This was 
performed by comparing the normalised allelic expression ratios using an independent 
samples t-test. To determine whether equal or unequal variance should be assumed the 
Levene’s test for homogeneity of variance was used. Homozygotes (whether major or 
minor alleles) were grouped together in this analysis as it would be expected that all 
individuals homozygous for a variant, whether functional or not, would show a relative 
allelic expression ratio of 1.
4.6.2.2 Direction of Effect Analysis
Where a significant difference was observed, the direction of effect (whether an allele 
is associated with reduced or increased expression) was established. This was 
determined by calculating the most probable diplotype between the test SNP and the 
allelic expression SNP rsl 047631 for each individual. The probability of an individual 
carrying a particular diplotype was estimated using a diplotype probability algorithm 
designed by Dr. Valentina Moskvina. An example of the output from the diplotype 
probability program is given in Table 4.1. This program determines diplotype 
probabilities by summing the probabilities of the two relevant haplotypes. The 
probability of each haplotype is calculated by dividing the frequency of the given 
haplotype by the sum of the frequencies for all possible haplotypes, given the observed 
genotypes at each locus [195]. Haplotype frequencies were predicated with EH+ [325],
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using genotypes from all 149 individuals of the allelic expression sample. Genotypes 
were entered into EH+ in a numerical format (i.e. common allele = 1, minor allele=2).
Frequencies
Haplotype Cases+Controis
AG 0.124
AA 0.413
TG 0.006
TA 0.457
Genotypes Individual haplotype Probabilities (rs2819538, rs1047631) Diplotype Probabilities
rs1047631 r*2619538 TC TT AC AT Dip 1 Probabilty Dip 2 Probablity
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG N/A N/A N/A N/A N/A N/A
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4796 0.0204 0.0204 0.4796 TA.AG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG AA 0.5 0.5 0 0 AAAG 1
AG TA 0.4798 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
AG TA 0.4796 0.0204 0.0204 0.4796 TAAG 0.9592 AATG 0.0408
Table 4.1. Data output from the diplotype probability program for rs2619538. The original output o f  
numerical genotypes has been amended to give actual nucleotides. Haplotype frequencies are provided 
from EH+. Individuals heterozygous for rs2619538 and rsl0 4 7 6 3 1 are 96% likely to carry the TA/AG  
diplotype and only 4% likely to carry the AA/TG diplotype.
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4.6.2.3 Linear Regression Analysis
By grouping all heterozygotes together the independent t-test method assumes that 
double heterozygote individuals (those heterozygous for the test SNP and the allelic 
expression SNP rs l047631) all carry the same diplotype. The most probable diplotype 
is then calculated to determine the direction of effect. However some test 
polymorphisms may not be in high linkage disequilibrium with the allelic expression 
SNP and therefore the two possible diplotypes may have similar probabilities. For 
example, an individual heterozygous at marker A and B (Aa, Bb) may have diplotype 
probabilities of AB, ab = 45% and Ab, aB = 55%. In these instances grouping 
heterozygotes together may not be suitable as some individuals may carry one 
diplotype (i.e. AB, ab) and other individuals may carry the alternative diplotype (i.e. 
Ab, aB).
In order to account for the possibility of nominal linkage disequilibrium between a tag 
SNP and rsl 047631, and therefore the potential switching of phase in double 
heterozygotes, stepwise linear regression analysis was performed on the probability 
estimates for all haplotype combinations between the specified test SNP and 
rsl 047631.
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4.3 Results
4.3.1 Single Marker Correlation Analysis
To assess the correlation between DTNBP1 SNPs and cortical dysbindin mRNA levels, 
tag markers were genotyped in the 149 individuals that constitute the Caucasian brain 
sample. In total 60 of the 64 tag SNPs were successfully genotyped which captures 
93% of the genetic variation of DTNBP1 locus and putative regulatory regions at 
^>0.95 MAF>0.001. All SNPs had a called rate >90% in the whole Caucasian brain 
sample (n=149) and a call rate >80% in the individuals with allelic expression data 
(n=31). Single marker analysis of association for these 61 SNPs and allelic expression 
ratios was subsequently performed using independent samples t-test and logistic 
regression. The results of this analysis are given in Table 4.2.
In total 7 SNPs were significantly associated with differential allelic expression. All 
markers, except DTNBPl_R16snpl were non-significant for the Levene’s test for 
homogeneity of variance, therefore equal variance was assumed for 59/60 t-tests. Five 
SNPs showed significant evidence for association by means of the independent t-test 
analysis (rs9370822 p=0.03, rs9358063 p=0.003, rs2619539 p=0.001 and rs2619538 
p=0.001, rs9296989 p=0.003). Three of these were also significantly associated with 
allelic expression differences when variation in phase was taken into account using 
linear regression (rs9370822 p=0.03 and rs2619538 p=0.001, rs9296989 p=0.003). Two 
markers were significantly associated using the linear regression only (rs2235258 
p=0.045 and rsl 3198512 p=0.007). The allelic expression ratios stratified by the 
genotypes of SNPs associated with allelic expression differences can be seen in Figure 
4.3.
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No SNP T-Test P Levene’s Test LR P
1 rs2235258 0.167 0.766 0.045
2 rs9396589 0.334 0.466 N/S
3 rs9654600 0.890 0.777 N/S
4 rs9396590 0.086 0.979 N/S
5 rs l076636 0.582 0.955 N/S
6 rs9396591 0.114 0.992 N/S
7 rs742102 Non Poly N/A N/A
8 rsl 474587 0.149 0.639 N/S
9 rs909626 0.628 0.577 N/S
10 rs3778651 0.832 0.787 N/S
11 rs13213814 0.128 0.493 N/S
12 rs13198512 0.198 0.942 0.007
13 rsl 3201824 0.153 0.219 N/S
14 rsl 047631 Non Poly N/A N/A
15 rs l7470454 0.103 0.060 N/S
16 rs742106 0.905 0.337 N/S
17 rs2056943 Non Poly N/A N/A
18 rs l6876571 0.355 0.832 N/S
19 rs l6876575 0.769 0.268 N/S
20 rs6937379 0.107 0.451 N/S
21 rs4712253 0.888 0.196 N/S
22 rs9464795 0.655 0.795 N/S
23 rs9370822 0.030 0.482 0.030
24 rs12527121 0.157 0.853 N/S
25 rs9296983 0.372 0.509 N/S
26 rs4715984 0.769 0.268 N/S
27 rs9358063 0.003 0.171 N/S
28 rs7771339 Non Poly N/A N/A
29 rs2743548 0.611 0.780 N/S
30 rsl 2203173 0.769 0.268 N/S
31 rsl 2199640 Non Poly N/A N/A
32 rs3829893 0.961 0.278 N/S
33 rs2619539 0.001 0.580 N/S
34 rs3213207 0.076 0.315 N/S
35 Alt trans snp p5 0.185 0.862 N/S
36 rs1011313 0.324 N/A (Only 1 het) N/S
37 rs2619528 0.251 0.884 N/S
38 rs2619520 0.305 N/A (Only 1 het) N/S
39 rs1018381 0.655 0.795 N/S
Table 4.2. Single marker allelic expression correlation results. Shown for each SNP is chromosomal 
position (March 2006), independent t-test p value (T-test P), Levene’s test from homogeneity o f variance 
(Levene’s Test), stepwise linear regression p value (LR P). Significantly associated SNPs are highlighted 
in red. Non-poly - the SNP was non-polymorphic through the 31 informative individuals. N/S -  non 
significant. N/A = Not analysed.
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40 rsl 474605 0.251 0.884 N/S
41 rs l2196958 Non Poly N/A N/A
42 rsl 997679 0.268 0.613 N/S
43 DTNBP1 C9b SNP1 0.176 0.821 N/S
44 rs9476886 0.113 0.650 N/S
45 r s l1558324 0.377 0.774 N/S
46 rs2619536 0.325 0.667 N/S
47 DTNBP1_C16_SNP2 0.718 0.921 N/S
48 rs2619537 0.895 0.475 N/S
49 rs l2204704 0.197 0.390 N/S
50 rs2619538 0.001 0.839 0.001
51 DTNBP1 Dhyp SNP1 Non poly N/A N/A
52 rs l7407828 0.415 0.395 N/S
53 DTNBP1 R10 SNP1 0.829 0.879 N/S
54 rs9296989 0.003 0.926 0.003
55 rs7450621 0.325 0.312 N/S
56 DTNBP1_R16_SNP1 0.207 0.012 N/S
57 rs2025926 0.839 0.787 N/S
58 rs2619514 0.086 0.154 N/S
59 rs9296985 0.655 0.778 N/S
60 rs7752070 0.611 0.750 N/S
40 rsl 474605 0.251 0.884 N/S
Table 4.2 cont. Single marker allelic expression correlation results. Shown for each SNP is 
chromosomal position (March 2006), independent t-test p value (T-test P), Levene’s test from 
homogeneity o f  variance (Levene’s Test), stepwise linear regression p value (LR P). Significantly 
associated SNPs are highlighted in red. Non-poly - the SNP was non-polymorphic through the 31 
informative individuals. N/S -  non significant. N/A = Not analysed
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Figure 4.3. Allelic expression ratios (A/G) at SNP rsl 047631 stratified by the genotypes o f a) rs2235258 
(Logistic Regression (LR) p=0.045) b) r s l3198512 (LR p= 0.007) c) rs9370822 (independent samples t- 
test and LR p = 0.03) d) rs9358063 (t-test p =0.003) e) rs2619539 (t-test p = 0.001) f) rs2619538 (t-test 
and LR p= 0.001) g) rs9296989 (t-test and LR p = 0.003). Ratios are stratified by all genotypes unless 
statistical analysis o f a SNP was only significant via t-test. In these cases ratios are stratified by 
heterozygosity.
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4.3.2 LD between Significantly Associated SNPs
The LD between the SNPs significantly correlated with differential allelic expression is 
given in Table 4.3. The greatest LD between correlated SNPs is shown between 
rs2619538 and rs9296989 (^=0.92, D’=l). There is also relatively high LD between 
rs2619539, rs9370822 and rs9350863 (O.Sl^rSO.VS, 0.95<D’<1).
rs2235258 rsl 3198512 rs9370822 rs9358063 rs2619539 rs2619538 rs9296989
rs2235258 0.22 0 0.01 0.02 0 0
rs13198512 0.84 0.37 0.09 0.15 0.03 0.04
rs9370822 0.03 0.8 0.51 0.62 0.17 0.21
rs9358063 0.17 0.32 1 0.78 0.12 0.15
rs2619539 0.25 0.42 0.95 1 0.06 0.07
rs2619538 0.03 0.22 0.43 0.46 0.29 0.92
rs9296989 0.05 0.26 0.52 0.5 0.3 1
Table 4.3. LD between SNPs significantly associated with differential allelic expression, r values are 
given above the grey boxes, D ’ values are given below.
154
4.3.3 Location of Significant SNPs and Proxies
As this analysis uses a tag SNP approach it is important to note the proxies of the 
significantly associated SNPs. These are given in Table 4.4. Five of the 7 SNPs do not 
have any proxies (r2>0.95), however rs9370822 and rs2619539 have five and four 
proxies respectively.
rsID
Chromosomal
Position Proxy
Chromosomal
Position r2
rs9370822 15652715 rs909706 15768850 1
rs7383568 15725911 1
rs9396592 15646989 1
rs6909929 15712434 0.963
rsl 2207867 15699482 0.961
rs2619539 15728834 rs4715988 15726088 0.967
rs2743868 15733787 0.967
rs9476864 15719806 1
rs4236167 15641930 0.967
rs2619538 15773188 No Proxy ^>0.95
rs9296989 15794678 No Proxy ^>0.95
rs2235258 15621461 No Proxy ^>0.95
rs13198512 15627864 No Proxy ^>0.95
rs9358063 15673010 No Proxy ^>0.95
Table 4.4 Proxies o f  SNPs significantly associated with differential expression.
The location of the SNPs significantly associated with allelic expression differences 
and their proxies is given in Figure 4.4. The locations of the putative regulatory regions 
identified in chapter 3 are also given.
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Figure 4.4 Location o f significantly associated SNPs and proxies
O f the seven SNPs significantly correlated with allelic expression data and their nine 
proxies only three are located within putative regulatory regions identified in chapter 3. 
rs2926989 is within a region predicted to contain a cluster o f TFBSs. However as 
described in chapter 3, rs9296989 is not predicted to disrupt any of the TFBSs detected 
by Cluster Buster within this region. rs2619538 is within the putative promoter region 
o f three main DTNBP1 transcripts (DTNBPla, DTNBPlb and DTNBPlc). This is also 
the case for rs909706 which is in an i^=l with rs9370822 (p=0.030).
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4.3.4. Further Analysis of rs2619538 and rs2619539
If a SNP is a cis-acting variant, which causes the altered DTNBP1 expression observed 
in the rs l047631 allelic expression assay, it would be expected that this SNP would 
show the greatest association to allelic expression differences. It would also follow that 
individuals who are heterozygous for this SNP would display greater relative 
differences in the expression of each gene copy than those who are homozygous. The 
two SNPs most significantly associated with allelic expression differences were 
rs2619538 and rs2619539 (independent samples t-test p=0.001). However when allelic 
expression ratios are plotted against the genotypes of rs2619539 (Figure 4.3e), it is 
individuals homozygous for rs2619539 which show the greatest allelic distortion 
(homozygote mean cDNA ratio = 0.782, heterozygote mean cDNA ratio = 0.93). It is 
therefore unlikely that rs2619539 itself is the SNP causing the variation in DTNBP1 
expression captured by this assay.
In contrast, individuals heterozygous for rs2619538 show the greatest differential 
expression (Figure 4.3f). Individuals heterozygous for rs2619538 are predicted to carry 
the diplotype TA/AG with a diplotype probability of 0.96 (see Table 4.1). 
Consequently, the mean reduction in expression of mRNA carrying the TA haplotype 
compared to mRNA carrying the AG haplotype is 22% (mean cDNA ratio = 0.78, 
range: 0.99-0.64). Therefore, in addition to being one of the two SNPs showing the 
greatest association to differential expression, unlike rs2619539, the pattern of the 
association of rs2619538 is consistent with the SNP having a cis-acting influence on 
expression.
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4.3.5 Multi-locus Analysis
Although rs2619538 appears the most likely to be a cis-acting variant based on the 
correlation data, it is of note that the allelic variation at rs2619538 does not account for 
all the cis-acting variation observed. As with the schizophrenia risk haplotype initially 
shown to be correlated with reduced expression, some individuals homozygous for 
rs2619538 show differences in allelic expression (Figure 4.3f). This observation 
suggests a number of possibilities. There could be a single functional variant, as yet 
unidentified, that rs2619538 is in partial LD with. However for this to be the case the 
polymorphism would have to have been missed by our screening described in chapter 3 
or be distal to the DTNBP1 locus (over 73kb 5’ or lOkb 3’ to the DTNBP1 gene). 
However as five of the seven SNPs associated with differential expression are outside 
the putative regulatory sequence identified in chapter 3, and high density tagging the 
DTNBP1 locus only included ±10kb of the gene, this is a possibility.
A second possibility is that the combination of rs2619538 and another DNA variant is 
causing the allelic expression differences observed. Since Bray and colleagues note that 
the spread of the allelic expression data could potentially reflect multiple cis-acting 
variants [186] the allelic expression data was reanalysed to determine whether 
rs2619538 could be affecting expression of mRNA in combination with other 
polymorphism(s). If rs219538 is working in conjunction with another cis-acting variant 
captured in this study, then it would be likely that this other variant would show some 
degree of correlation with allelic expression differences. Therefore haplotypes between 
rs2619538 and each of the other six significant SNPs were subjected to association 
analysis with allelic expression differences.
All haplotypes between rs2619538 and the other significantly correlated SNPs 
(rs2235258, rsl3198512, rs9370822, rs9358063 and rs2619539, rs9296989) were 
systematically analysed. Phase information for the allelic expression SNP rs l047631 
was also included in the analysis so a direction of effect could be determined. As this 
analysis created multiple diplotype combinations, a two sample independent t-test
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analysis could not be performed. Therefore the resulting haplotype probabilities were 
subjected to stepwise linear regression analysis. The results of this analysis, along with 
the single marker association results, are summarised in Table 4.3.
The most significant linear regression result is shown for the combination of rs2619538 
and rsl 3198512 (p=0.001). The genotypes of these two markers accounts for 74% of 
the variation in allelic expression. This is 21% greater than rs2619538 on its own which 
accounts for only 53% of the variation. The 2-marker combination of rs2619538 and 
rs2619539 is also calculated to account for 74% of the variation although the 
association shown for these two SNPs is less significant (p=0.003) than the haplotypes 
involving rsl 3198512. Further details on these two 2-marker combinations with phase 
information for r s l047631 are given below.
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Single Marker 
T-Test P Value
Single Marker 
Regression P Value
Single marker 
R value
Multilocus Linear 
Regression P value
rs2619538 haplotype 
R value
rs2235258 0.167 0.045 0.412 0.001 0.648
rs13198512 0.198 0.007 0.532 0.0001 0.741
rs9370822 0.030 0.030 0.428 0.0041 0.543
rs9358063 0.003 N/S N/A 0.001 0.699
rs2619539 0.001 N/S N/A 0.0003 0.743
rs2619538 0.001 0.001 0.560 N/A N/A
rs9296989 0.003 0.003 0.537 0.002 0.58
Table 4.3. Results of both the single marker and mulilocus analysis for rs2619538 with each of the other SNPs associated with allelic expression differences. R 
values are also given which show the proportion of the data (1 = 100%) explained by genotypes of each SNP/haplotype. N/S = Non-significant (p>0.05). N/A = Not 
analysed.
4.3.5.1 rs2619538 and rsl3198512
The allelic expression data stratified by the most probable diplotypes for rs2619538, 
r s l047631 and rs l3198512 are given in Figure 4.5. As can be seen, there is no one 
haplotype that accounts for all the allelic variation; therefore, if both rs2619538 and 
rsl 3198512 are functional variants, the stratified ratios suggest that the two 
polymorphisms have independent effects on mRNA expression. This is further 
supported by the location of the two polymorphisms, rsl 3198512 is located -3  kb 3’ to 
the four main DTNBP1 transcripts whereas rs2619538 is ~1.8kb 5’ to the gene (Figure 
4.6). As discussed in section 4.3.3 neither rs2619538 nor rsl 3198512 have any proxies 
at an ^>0.95.
As suggested from the single marker correlation analysis, rs2619538 appears to have 
the greatest influence on allelic expression differences as individuals heterozygous for 
rs2619538 (diplotypes TAA/AGA, TAG/AGG, TAG/AGA) show the largest deviation 
from the 1:1 ratio (Combined average ratio =0.75, independent t-test against gDNA 
p=0.0000015). r s l3198512 also appears to influence allelic expression differences as 
individuals homozygous for rs2619538, but heterozygous for rs l3198512 (AAG/AGA, 
n=6), show a difference in allelic expression (average A/G ratio =0.91). Although the 
individuals carrying this diplotype are not significantly different from the corrected 
genomic DNA ratios they do show a trend (independent t-test p=0.08). Furthermore, 
individuals heterozygous for both rs2619538 and r s l3198512 (TAG/AGA, n=8) show 
the greatest allelic expression differences (average A/G ratio =0.74). Also of note is 
that, unlike individuals homozygous for rs2619538 alone, individuals homozygous for 
rs2619538 and rs l3198512 (AAA, AGA, n=5) show no expression differences except 
one individual carrying the AAG/AGG haplotype which shows an AE ratio o f -0.72. 
Therefore, the addition of rsl 3198512 accounts for more of the allelic variation than 
rs2619538 on its own. This is reflected in the linear regression analysis (rs2619538 
linear regression model R= 0.560, rs2619538 and rs l3198512 model R=0.741).
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If these two SNPs are two independent cis-acting variants then it is the T allele o f 
rs2619538 and the G allele of r s l3198512 which cause a relative reduction in mRNA 
expression compared to the mRNA carrying their alternate alleles.
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4.3.5.2 rs2619538 and rs2619539
Linear regression analysis of rs2619538 and rs2619539 calculated that this two marker 
haplotype combination accounted for the allelic expression data as well as the two 
marker haplotype containing rs2619538 and r s l3198512 (R=0.74 respectively). 
However single marker analysis of rs2619539 suggested that variation at this locus is 
unlikely to have a cis-acting influence of DTNBP1 expression (section 4.3.4). 
Stratifying the allelic expression data by the most probable diplotypes for rs2619538, 
rs2619539 and rs l047631 (shown in Figure 4.7) further advocates this hypothesis.
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Figure 4.7 Allelic ratios at SNP r s l047631 stratified by the predicted 3-m arker diplotype for SNPs 
rs2 6 19538, rs2 6 19539 and r s l047631. Average diplotype probability = 83%.
In the three marker combination described in section 4.3.5.1, individuals homozygous 
for rs2619538, but heterozygous for rsl 3198512, were found to show allelic expression 
differences. This was not the case for rs2619539. Individuals homozygous for 
rs2619538 but heterozygous for rs2619539 (ACA/AGG, n=7) show the least 
differential expression (average A/G ratio = 0.97) whereas individuals homozygous for 
both SNPs (ACA/ACG, n=4) do show allelic expression differences (average A/G ratio 
= 0.83). Furthermore, unlike rs l3198512 and rs2619538, the double heterozygotes of 
rs2619538 and rs2619539 (TGA/ACG, n=7) do not show the greatest allelic expression 
differences. Therefore, detailed analysis of the allelic expression data stratified by
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rs2619538 and rs2619539 indicates that the genotypes of rs2619538 and rs2619539 do 
not explain the spread of the data any better than rs2619538 alone.
43.6 UKCC Association Data and Correlation Analysis
In order to determine whether possible DTNBP1 cis-acting variants are relevant to 
schizophrenia aetiology, the UKCC association data, described in chapter 3, was 
reviewed for the SNPs showing association to differential expression and vice versa. 
All SNPs showing a significant association to either schizophrenia or allelic expression 
differences are given in Table 4.4.
SNP Chromosomal Position T-Test P LR P Arm Trend P Genotypic P
rs2235258 15621461 0.167 0.045 0.890 0.250
rs3778651 15626511 0.832 N/S 0.131 0.011*
rs13198512 15627864 0.198 0.007 0.293 0.385
rs9370822 15652715 0.030 0.030 0.532 0.099
rs4715984 15669870 0.769 N/S 0.001 0.003*
rs9358063 15673010 0.003 N/S 0.887 0.124
rs2619539 15728834 0.001 N/S 0.392 0.084
rs2619538 15773188 0.001 0.001 0.024 0.016
rs9296989 15794678 0.003 0.003 0.017 0.038
Table 4.4. SNPs with a significant association to either allelic expression differences or schizophrenia 
are shown. The t-test and linear regression (LR) results for the association with differential expression 
are given. The A rm itage trend (Arm  Trend) and genotypic p values are given for the schizophrenia 
association analysis. *designates where a genotypic p value has been determ ined using CLUM P with 
10000 perm utations.
Four SNPs showed a significant association with schizophrenia (rs3778651, rs4715984, 
rs2619538 and rs9296989). Of these two do not show an association with allelic 
expression differences (rs3778651 p=0.832, rs4715984 p=0.769). Two schizophrenia 
risk variants, rs2619538 and rs9296989 also show an association to differential 
expression (p=0.001 and p=0.003 respectively). However the association to 
schizophrenia observed by these two SNPs was not found to be independent of 
rs4715984, which was found to show the greatest association to schizophrenia and was 
the only SNP to survive correction for multiple testing.
Of the seven SNPs significantly associated with allelic expression difference only 
rs2619538 and rs9296989, mentioned above, are also associated with schizophrenia.
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rsl 3198512, which along with rs2619538, appears to explain the majority of the altered 
mRNA expression, is not associated with schizophrenia (p=0.311). Neither is the 3- 
marker haplotype between rs2619538, r s l047631 and r s l3198512 (TAG p=0.229, 
Table 4.5) which shows the greatest relative reduction in DTNBP1 expression.
Haplotpye Case Frequency Control Fequency P Value
Global N/A N/A 0.154
TAA 0.188 0.166 0.126
TAG 0.275 0.255 0.229
AGA 0.096 0.091 0.634
AGG 0.036 0.043 0.342
AAA 0.221 0.229 0.642
AAG 0.183 0.216 0.029
Table 4.5. A ssociation analysis o f  3-m arker haplotype rs2 6 19538, r s l 047631, rs2 6 19538 within the 
schizophrenia case control sam ple. N/A = N ot applicable.
4.3.7. Analysis of the Refined Schizophrenia Risk Haplotype
Bray and colleagues have shown that a schizophrenia risk haplotype previously 
reported by Williams et al [134] (TAC: rs2619538, rs3213207, rs2619539, p=0.04163) 
is also significantly associated with reduced DTNBP1 expression [186]. The high 
density mapping of the DTNBP1 locus, described in chapter 3, illustrated that 
rs4715984 refines the association of this risk haplotype with schizophrenia in the 
extended UK case control sample (TACT: rs2619538, rs3213207, rs2619539, 
rs4715984, p=0.005).
In the initial investigation between the schizophrenia risk haplotype TAC and DTNBP1 
expression, a post-hoc reanalysis was performed on the association data to identify the 
risk haplotype that included phase information with respect to rs l047631 and that 
maximally differentiated cases and controls. This was achieved by a 3-marker haplotype 
comprising of the T-allele of rs2619538, the A-allele of rs3213207 and the A-allele of 
rsl 047631 (TAA frequency in cases = 45.6%, frequency in controls = 40.4%). It was 
subsequently shown that the relative expression of the A-allele of rsl 047631 was 
significantly lower when it was carried on the risk haplotype compared with when it 
was carried on the non-risk haplotypes (Figure 4.8).
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Figure 4.8. Allele ratios at SN P r s l 0 47631, stratified by heterozygosity for the defined 3-marker 
schizophrenia TAA risk haplotype. Data represented as a ratio o f  A/G alleles. The risk haplotype 
includes the reduced expression allele o f  rs l 047631. cD N A  sam ples from individuals who are 
heterozygous for the risk haplotype show low er expression o f  the A-allele than those from individuals 
who carry no copies o f  the risk haplotype (p=0.002).
To determine whether the refined association signal is still associated with reduced 
expression, the refined risk haplotype which contains phase information for the allelic 
expression SNP (TATA: T-allele of rs2619538, the A-allele of rs3213207 and the T- 
allele of rs4715984, A-allele of rsl 047631) was analysed.
To assess the effect of the refined TATA haplotype on allelic expression of DTNBP1, 
diplotype probabilities were determined for all 31 individuals informative for the allelic 
expression assay. 15 of the 31 individuals were originally predicted to be heterozygous 
for the 3-marker risk haplotype TAA (average diplotype probability =0.97, range 0.73- 
1). Following genotyping of rs4715984 through the allelic expression sample, 12 of 
these 15 individuals were predicted to be heterozygous for the non-associated TACA 
haplotype (T-allele of rs2619538, the A-allele of rs3213207 and the C-allele of 
rs4715984, A-allele of rsl 047631 p=0.405) with an average diplotype probability of 
0.88 (range = 0.6-0.99), while two were predicted to be heterozygous for the associated 
(p=0.0037) TATA haplotype (average diplotype probability = 0.63). One of the 31 
informative individuals failed genotyping for rs4715984. Subsequently the allelic 
expression ratios of individuals heterozygous for the TAA haplotype were stratified 
into individuals carrying the TATA haplotype and the TACA haplotype (Figure 4.9). If
I
♦
gONA cDNA: cDNA:
Non Risk Risk Het
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the association signal is linked to reduced expression, we would expect individuals 
carrying the TATA risk haplotype to still show a reduction in allelic expression. 
However as Figure 4.9 shows, although a significant association with allelic expression 
differences is still observed (p=0.0003), the relative expression of the A-allele of 
rsl 047631 is significantly lower when it is carried on the TACA non-risk haplotype.
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Figure 4.9. Individuals carrying the original TAA risk haplotype are further separated into those 
heterozygous for the associated TATA (p=0.0037) haplotype and those heterozygous for the non­
associated TACA haplotype (p=0.405). The 4-marker haplotype includes the reduced expression allele o f  
rs l047631. cDNA samples from individuals who are heterozygous for the non-associated haplotype 
TACA show lower expression (p=0.0003) than both the individuals carrying no copies o f  the original 
risk haplotype and those heterozygous for the new refined risk haplotype TATA.
Although this suggests that our refined schizophrenia association signal is not 
associated with reduced expression, the relatively low diplotype probability estimates 
mean the data are not conclusive. For example the most likely diplotype for two 
individuals who show allelic expression differences (allelic expression ratios 0.781 and 
0.639) is TACA/AATG (probability = 0.6). However these same individuals also have 
a 39% chance of carrying the TATA/AACG diplotype and therefore the associated 
haplotype (See Table 4.6).
Nevertheless, in order for the TATA risk haplotype to be associated with reduced 
expression one or both of these two individuals would have to be TATA/AACG and 
two individuals most likely to carry TATA/AGCG (63%) that do not show allelic 
expression differences would have to actually carry the TACA/AGTG (probability
♦
gDNA cDNA: 
Non Risk
cDNA:
TATA
cDNA:
TACA
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36%). The probability o f all four individuals carrying the less likely diplotype is 2% 
and the probability o f one of the individuals showing allelic expression differences 
carrying TATA and the other three carrying TACA is 5%. Therefore although the data 
is not conclusive, it is highly unlikely that the new refined risk haplotype is associated 
with reduced expression.
Genotypes Diplotype Probabilities
ID AE Ratio A/G rs2619538 rs3213207 rs4715984 rsl 047631 Diplotype 1 Probability Diplotype 2 Probability
A283/96 1.073 AA GA CT GA AACA AGTG 0.82
A74/90 1.070 AA GA N/A GA
G44 1.050 N/A GA N/A GA
A248/97 1.037 AA AA CC GA AACA AACG 1
G30 1.034 AA GA c c GA AACA AGCG 0.99
G39 1.014 AA N/A CC GA
S-9 0.985 TA GA CT GA TATA AGCG 0.63 TACA I AGTG 0.36
A009/99 0.965 AA GA CT GA AACA AGTG 0.82
G35 0958 AA GA CC GA AACA AGCG 0.99
G53 0.924 AA GA CC GA AACA AGCG 0.99
G26 0 920 AA GA CC GA AACA AGCG 0.99
A272/93 0.894 TA GA CT GA TATA AGCG 0.63 TACA AGTG 0.36
G54 0.874 TA AA CC GA TACA AACG 0.82
S-24 0.873 TA GA c c GA TACaI  AGCG 0.99
G42 0.863 AA GA c c GA AACA AGCG 0.99
7dx 0.852 AA GG c c GA AACA AGCG 0.99
A285/95 0.833 TA AA N/A GA
G37 0.829 TA AA CC GA TACA AACG 0.82
A136/90 0.820 AA AA N/A GA
71dx 0.799 TA GA CC GA TACA AGCG 0.99
A145/90 0.787 AA AA N/A GA
G21 0.781 TA AA CT GA TACA AATG 0.6 TATA AACG 0.3946
A17/90 0.780 AA AA CC GA AACA AGCG 1
A94/93 0.779 TA GA CC GA TA C /fl AGCG 0.99
A190/94 0.766 TA GA CC GA T A C *  AGCG 0.99
G55 0.725 AA AA CT GA AACA AATG 0.93
A206/90 0.720 TA GA CC GA TACA AGCG 0.99
A389/94 0.693 TA AA CC GA TACA AACG 0.82
A215/90 0.689 TA GA CC GA TACA^ AGCG 0.99
A 98/89 0.639 TA AA CT GA TACA AATG 0.6 TATA AACG 0.3946
A 99/89 0.636 TA GA CC GA TACA AGCG 0.99
Table 4.6. Refined Risk Diplotype Probabilities
31 individuals heterozygous for r s l047631, and therefore informative for the allelic expression sample 
are shown with the individual genotypes for the four markers that constitute the refined schizophrenia 
risk haplotype TATA (T allele rs2619538, A allele rs3213207, T allele rs4715984, A allele r s l047631) 
as well as possible diplotypes and probabilities. Four individuals carry the genotypes which make the 
associated TATA (shown in yellow) possible. However the two individuals which show allelic 
expression differences are predicted to carry the non associated TACA (shown in purple) haplotype.
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4.4. Discussion
The aim of this chapter was to identify putative DTNBP1 cis-acting variants by 
determining whether any SNPs which tag the DTNBP1 locus and putative regulatory 
regions were associated with reduced cortical dysbindin mRNA levels. Seven 
polymorphisms were found to be associated with the allelic expression differences first 
reported by Bray and colleagues [186]. Of these SNPs the two most significantly 
associated were rs2619538 and rs2619539 (p=0.001). Further analysis of the pattern of 
association shown by these two SNPs suggests that rs2619538 is the SNP most likely to 
have a cis-acting influence on DTNBP1 expression. The mean reduction of mRNA 
carrying the TA haplotype (T-allele rs2619538, A-allele rsl047631) compared to 
mRNA carrying the AG haplotype was 22%. However some individuals showing 
allelic expression differences were homozygous for rs2619538 therefore variation at 
this locus does not account for all of the expression differences observed. The spread of 
the data itself suggests that multiple cis-acting variants may be working in combination 
to cause the expression differences illustrated. In investigating this possibility the 
combination of two polymorphisms, rs2619538 and rsl3198512, were found to show 
the most correlation with allelic expression differences (p=0.0001), accounting for 74% 
of the expression differences. rs2619538 is ~1.9kb upstream of the TSS of three of the 
main DTNBP1 transcript variants, rs l3198512 is ~3kb downstream of DTNBP1, within 
an intron of JARID2.
If reduced DTNBP1 expression is a primary aetiological mechanism in the physiology 
of schizophrenia, it is likely that these cis-acting variants would also be associated with 
schizophrenia. However further investigation indicates that the reduction of DTNBP1 
expression through cis-acting variation may not be a primary aetiological factor in 
schizophrenia. While rs2619538 is weakly associated with schizophrenia, previous 
analysis has determined that the genetic association signal shown by this SNP is not 
independent of the more associated SNP rs4715984. rs4715984 shows no association 
with allelic expression differences (p=0.769). Furthermore neither s i3198512 nor the 
TAG haplotype (T allele rs2619538, A-allele of rsl047631, G allele of rs!3198512)
169
which is associated with the greatest relative reduction in DTNBP1 expression, are 
associated with schizophrenia (p=0.2927 and p=0.229 respectively).
The hypothesis that DTNBP1 cis-acting variation may not cause susceptibility to 
schizophrenia is further supported by the reanalysis of a schizophrenia risk haplotype 
previously shown to be associated with significantly reduced DTNBP 1 expression. The 
addition of rs4715984 to this risk haplotype refines the original association to 
schizophrenia. However when this refined haplotype is analysed in phase with 
rs l047631 the risk haplotype TATA is no longer correlated with reduced expression.
As with all studies of this nature there are a number of limitations to the analysis 
presented. The correlation analysis performed in this chapter consisted of a two step 
approach employing both independent t-tests and linear regression. By analysing all 
haplotype probabilities, linear regression analysis was included in order to take into 
account instances of nominal linkage disequilibrium between the test SNP and the 
allelic expression SNP which could result in the “flipping” of phase within double 
heterozygotes. While this two step analysis accounts for linkage disequilibrium 
differences to some extent, it is possible that the logistic regression might not be able to 
compensate for very low LD between a test SNP and the allelic expression SNP. In 
these instances the level of false negatives may be inflated.
Another caveat of this analysis is that the allelic expression assay described analyzes 
multiple DTNBP 1 transcripts simultaneously and therefore findings relate to net effects 
of those transcripts. Consequently the effects of SNPs/haplotypes on specific transcripts 
may have gone undetected. This is potentially especially true of DTNBP lb as the 
allelic expression assay used in the chapter does not assay variation from this transcript.
Another caveat of the analysis reported in this chapter is that it has been performed on a 
relatively small number of individuals. As a result although a relatively high 
genotyping call rate was employed for the 31 informative individuals (>80%), even one 
missing genotype has the potential to affect the association results. It is also worth 
noting that the diplotype probabilities calculated are an estimate based on an estimate of
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population haplotype frequencies. Therefore the diplotype probabilities (especially 
where relatively low) should be taken with caution. This is especially relevant in 
relation to the refined risk haplotype correlation analysis where the most probable 
diplotypes are as low as 60%.
This analysis also suggests that the identification of putative regulatory sequence by the 
methods described in chapter 3 may not be an effective way of detecting cis-acting 
variants. Five of the seven SNPs associated with allelic expression differences are not 
found within the putative regulatory sequence determined in chapter 3. This includes 
rsl 3198512, one of two SNPs most likely to cause cis-acting variation. However the 
most significantly correlated SNP rs2619538 was identified through the screening of 
the predicted promoter region for three of the main DTNBP 1 transcripts DTNBP la, 
DTNBP lb and DTNBP lc.
While correlation with differential expression suggests a SNP may be a cis-acting 
variant, it is possible that the SNP is in LD with the actual functional variant. In order 
to determine whether rs2619538 or rsl 3198512 have a direct effect on expression, both 
SNPs were subjected to functional analysis by luciferase reporter gene assay. The 
results of this assay are described in chapter 5.
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Chapter 5: Functional Analysis of rs2619538 and 
rs!3198512
5.1 Introduction
The previous chapter determined that the polymorphisms rs2619538 and rs l3198512 
are associated with differences in allelic expression at the DTNBP 1 locus, implying that 
they may have a cis-acting regulatory influence on dysbindin expression. Alternatively, 
it is possible that one or both of rs2619538 and r s l3198512 are not functional variants 
but are in strong LD with the actual regulatory polymorphisms.
A functional assay could help establish whether rs2619538 and/or rs l3198512 do have 
a cis-acting regulatory influence on gene expression. In addition, prior to correlation 
analysis with the allelic expression data, rs2619538 was identified as a potential 
regulatory variant (due to its location within a putative regulatory region) while 
rs l3198512 was not. Consequently, a functional assay may also help determine whether 
identifying putative regulatory variants, via the methods described in chapter 3, is a 
useful tool in identifying polymorphisms likely to have a regulatory influence.
Currently a common approach used to investigate the effects of a specific SNP on gene 
expression is the reporter gene assay. This in vitro technique utilises a plasmid which 
contains the coding sequence of a reporter gene (Figure 5.1). Putative regulatory 
sequence(s) are cloned into this reporter vector and the transcriptional activity of the 
inserted sequence can be indirectly estimated through quantification of the reporter 
gene protein.
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Figure 5.1. Principles o f a reporter vector. The antibiotic resistance gene and prokaryotic origin of 
replication permit propagation and selection o f the vector in E. coli. Putative regulatory sequences can be 
cloned either 5’ or 3’ to the reporter gene (depicted by A . )  Expression o f the reporter gene is detected 
by enzymatic or immunological means. PolyA = polyadenylated. Adapted from Promega technical 
manual TM033..
Although the reporter gene assay is an in vitro experiment, it presents a number of 
advantages. Firstly, it is a relatively simple and rapid experiment. In addition, genetic 
and environmental factors, which may complicate the results o f an in vivo assay, can be 
controlled. Finally, as well as determining whether a region of sequence has a 
regulatory effect on transcription, the reporter gene assay is sensitive enough to detect 
variation in expression caused by a single base change within the inserted sequence.
Over 100 SNPs, associated with a range o f behavioural traits, physiology and disease 
susceptibility within several organisms, have been shown to affect gene expression 
using the reporter gene assay [326]. These include variants within the Duffy blood 
group [327], the lactose gene [328] and the 5-HTT gene. The 5-HTT gene modulates 
serotoninergic neurotransmission by the active reuptake o f serotonin from the synaptic 
cleft [329] and is associated with a variety o f different behaviours, psychological 
processes (such as social behaviour, aggression, anxiety) and psychiatric disorders 
[330]. A number of allelic variants that differentially modulate 5-HTT transcription 
have been identified within the promoter o f the 5-HTT gene using luciferase reporter
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gene assay. This altered expression has been shown to affect the rate of serotonin (5- 
HT) uptake [331].
The luciferase reporter gene assay is a frequently used reporter gene assay. The firefly 
luciferase gene (Photinus pyralis) produces a 61kDA monomeric protein whose 
enzymatic activity oxidises beetle luciferin in a luminescent reaction (Figure 5.2). The 
light emitted from the reaction is quantified using a luminometer [332] which allows 
for an extremely sensitive assay [333].
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Figure 5.2. The oxidation o f  beetle luciferin by firefly luciferase.
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One problem often encountered with reporter gene assays is that variation in 
transfection efficiency can cause a high degree of variability in results. To normalise 
transfection efficiency within and between experiments, co-transfection of a control 
reporter gene vector can be used. Renilla luciferase (Renilla reniformis) is employed as
(K)control gene for the firefly luciferase assay in Promega’s dual-luciferase reporter assay 
system. The Renilla luciferase gene produces a 36kDA protein which utilises O2 and 
coelenterazine (Figure 5.3) [334]. Although both quantifiable by light emission, Renilla 
luciferase has a dissimilar enzyme structure and substrate requirement to firefly 
luciferase. These differences make it possible to selectively discriminate between the 
two bioluminescence assays.
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Figure 5.3. The oxidation o f  coelenterazine by Rennila luciferase.
The luciferase reporter vector system allows the analysis of both 5’ and 3’ flanking 
regions/SNPs [333] and therefore is an ideal assay to determine whether rs2619538 or 
rs l3198512 have a cis-acting regulatory influence on transcription in vitro. As a result, 
the aim of this chapter was to determine whether rs2619538 or rsl 3198512 have a 
functional affect on transcription through the use of the dual-luciferase® reporter assay 
system (Promega). Any differences in transcription were compared with the results 
identified in the previous chapter in order to establish whether the two sets of analyses 
depict the same allele(s) associated with a reduction in dysbindin/luciferase expression.
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5.2. Methods
5.2.1 Cell Strains and Media
5.2.1.1 Bacterial Strains
For the general expression of recombinant DNA plasmids, Escherichia coli XL 1-Blue 
cells were used (Stratagene) [335].
Genotype: recAl endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [F'proAB lacFZAMIS 
TnlO (Tef)].
5.2.1.2 Mammalian Strains
Functional analysis was performed using HEK 293 (Human embryonic kidney) cells 
[336]. These were obtained from the European Collection of Cell Cultures (ECACC). 
Although of epithelial origin, the biochemical chemistry of HEK293 cells is capable of 
carrying out most of the post-translational folding and processing required to generate 
functional mature protein from a wide spectrum of both mammalian and non- 
mammalian DNA [337]. The HEK293 cell line also has a number of other advantages 
that make it a popular choice for a variety of expression studies. Firstly, HEK293 cell 
lines have low maintenance costs and rapid cell division (24-36h). In addition, HEK293 
cells have a high transfection efficiency using a variety of methods which leads to a 
high protein production. The use of HEK293 cells also produces faithful translation.
5.2.1.3 Bacterial Media
All solutions were prepared and sterilised as appropriate. Media were autoclaved for 30 
mins at 115°C and cooled to below 50°C before use. Antibiotics were dissolved in 
water, filtered sterilised (0.2pM) and stored at -20°C.
All bacterial Escherichia coli (E. coli) strains were grown in Luria-Bertani (LB) Media 
containing 10g/l tryptone, 5g/l yeast extract and 10g/l NaCl. Solid media plates were
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prepared by adding 18.75g/l Bacto-agar prior to autoclaving. Antibiotic selection was 
provided by adding carbenicillin to either LB media or LB-agar solution at a final 
concentration of 50pg/ml.
5.2.1.4 Growth and Storage of Bacterial Cell Lines
E. coli strains were initially grown on LB solid media for 18-24h and stored at 4°C for 
up to one month. Before specific colonies were picked, agar plates were removed from 
storage two hours before use and allowed to dry. Selected E. coli strains were grown up 
in LB for 16-20 hours at 37°C with shaking at 200rpm. Longer term storage of E. coli 
was achieved by storing cells in 15% v/v glycerol at -80°C.
5.2.1.5 Growth of Mammalian Cell Lines
HEK 293 cells were grown in 25cm2 tissue culture flasks containing MEM Glutamax 
media supplemented with 10% FBS, 1% glutamine and 1% NEM (non-essential amino 
acids). Cells were incubated at 37°C in 5% CO2 and passaged at 70% confluence to 
maintain healthy cultures. Passaging was performed by first removing the cell culture 
media. Cells were then gently washed twice with phosphate buffered saline (PBS) and 
detached from the flask by incubation with 1ml o f trypsin/EDTA for 1 minute at 37°C. 
This was followed by gently tapping the flask to dislodge the cells. To re-suspend the 
cells 15mls of pre-warmed media were added to the flask. From this stock solution 
2mls were used to re-seed a new 25cm culture flask containing 14mls of fresh pre­
warmed media.
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5.2.2 Molecular Biology
5.2.2.1 Primer Design for Cloning
PCR primers for the desired genomic region were designed to include the amplification 
sequence plus a specific restriction enzyme (RE) recognition sequence. The RE 
recognition sequence was incorporated into the primer in order to allow cloning of the 
putative regulatory region into a pGL3 luciferase vector. The restriction enzyme site 
was chosen based on a number of factors. Firstly the RE recognition site needed to be 
located only once within the required pG13 luciferase vector and in an appropriate 
position for cloning, for example immediately 5’, upstream or downstream to the 
luciferase gene. Secondly, the RE recognition site could not occur within the putative 
regulatory sequence to be inserted. As each cloning strategy required a combination of 
two restriction enzymes, it was also advantageous if the two restriction enzymes were 
functional with the same reagents and reaction conditions. Where there was the 
potential for subcloning (multiple sequences inserted into the same plasmid) all 
sequences were checked for recognition sites for each selected restriction enzyme.
5.2.2.2 PCR Conditions
In order to ensure sequence specificity high fidelity taq was used for all PCR reactions. 
A typical PCR reaction was as follows:
Volume
High fidelity buffer 1.2pl
Forward primer (lOOng/pl) 0.5 pi
Reverse primer (lOOng/pl) 0.5pl
dNTP mix (lOmM) lpl
DNA Template (4ng) 3 pi (dried)
High fidelity Taq polymerase 0.2pl
Sterile molecular grade water 5.60pl
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The PCR cycling parameters were as follows with annealing temperature dependant on 
the amplimer:
X 40
94°C 94°C 56°C-66°C 72°C 72°C
2 minutes 15 s 30 s 1 min/kb 7 min
Where the fragment generated was >3kb an extension temperature of 68°C was used 
rather then 72°C.
5.2.2.3 Site-directed Mutagenesis
In order to introduce specific mutations into the inserted sequence site directed 
mutagenesis (SDM) was performed. SDM involved a standard PCR reaction except 
PCR primers were designed to incorporate the desired base change. Primers were 
designed by Primer 3 web resource (http//www-genome.wi.mit.edu/cgi- 
bin/primer/primer3-www.cgi). For increased specificity the polymerase Pfu-Ultra 
(Stratagene) was used. A typical mutagenesis reaction was as follows:
Volume (pi)
10 x polymerase chain buffer 5pl
Forward primer (lOOng/pl) 1.5pl
Reverse primer (lOOng/pl) 1.5(4.1
Deoxynucleotide mix (lOmM) 2.5pl
DNA Template (5-50ng) 3 pi
Pfu DNA polymerase 2.5pl
Sterile molecular grade water 34pl
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The PCR cycles were as follows:
X 20
95°C 95°C 55°C 68°C 68°C
2 minutes 30 s 1 min 1 min/kb 7 mins
lOjxl of PCR product was run on a 1.5% agarose gel to confirm DNA amplification. 2pl 
of Dpnlvtas then added to the remaining 40pl of PCR mix and incubated at 37°C for 
1.5hrs to digest the template super-coiled double stranded DNA.
5.2.2.4 Gel Extraction of DNA
For the extraction of DNA from agarose gels, the QIAquick Gel Extraction Kit 
(Qiagen) was used according to the manufacturers’ instructions. Samples were eluted 
either in 30pl-50jil of either elution buffer or molecular biology grade water. Prior to 
gel extraction, gels were blotted with Whatman Grade 1 (3mm) paper in order to avoid 
contamination of the extracted product.
5.2.2.5 Mutation Screening
Regions of sequence were screened for polymorphisms using the Lightscanner software 
(Idaho Technologies) and BigDye Sanger sequencing. The protocols for these methods 
are described in chapter 2.5.2 and 2.6 respectively.
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5.2.3 Cloning
5.2.3.1 Plasmids
Plasmid Description Selection Supplier
pGEM-T ‘T’ overhang cloning vector that 
allows direct insertion of PCR 
products.
Ampicillin Promega
pGL3-basic Luciferase reporter vector lacking any 
eukaryotic promoter or enhancer 
sequences. Allows for quantitative 
analysis of factors that could 
potentially regulate expression.
Ampicillin Promega
pGL3-promoter pGL3-basic backbone with the 
addition of S V40 promoter for the 
analysis of putative regulatory 
elements outside of the promoter 
region.
Ampicillin Promega
Table 5.1 Description o f  Plasmids used in this chapter for luciferase reporter gene assays.
5.2.3.2 Cloning into a pGEM-T® Vector
In order to ensure precise cloning of putative regulatory regions/SNPs into a pGL3 
luciferase vector, PCR products were first cloned using a pGEM-T® vector (Promega). 
The pGEM-T® vector consists of a pGem-57f(+) plasmid DNA which has been cleaved 
at the EcoR V site and had a single 3’ terminal deoxy-thymidine added to both ends. As 
Taq DNA polymerase adds a deoxy-adenosine to the 3’-termini of any amplification 
product [338], ligation between a desired insert and the pGEM-T® vector can take place 
via TA ligation.
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3 pi of purified PCR product was ligated with 1 pi of pGEM-T® vector (50ng) using T4 
DNA ligase and ligase buffer. A control insert was ligated in parallel as a positive 
control. A negative control was also performed with water. All reactions were 
incubated at 4°C overnight. Products were then visualised on a 1.5% agarose gel to 
check ligation.
5.2.3.3 Preparation of Chemically Competent E. coli XL 1-Blue Cells
Competent cells were prepared from XL 1-blue E. coli by either Dr Caroline Tinsley or 
Matthew Lock using a standard protocol [339].
5.2.3.4 Preparation of Electrocompetent E. coli XLl-Blue Cells
Electrocompetent cells were prepared from XL 1-blue E. coli by either Dr Caroline 
Tinsley or Matthew Lock.
5.2.3.5 Transformation of Bacteria by Heat-shock
50pl of chemically competent cells were thawed on ice and mixed thoroughly. 5pi of 
ligation/SDM mix or lp l of control plasmid pUC18 (lOng/pl) were then mixed with the 
competent cells in a chilled eppendorf tube and incubated on ice for 30 mins. Cells 
were then heat-shocked for 45-50s at 42°C exactly and cooled on ice for a further 2 
mins. After the addition of 950pl of LB media to each ligate/cell mix, cells were 
incubated at 37°C for 30-60 mins to allow recovery. The transformed cells were spun 
for 1 min at 13000rpm with the resulting pellet resuspended in 200pl of LB media. The 
resuspended cells were plated onto LB agar plates supplemented with carbenicillin, left 
to dry for 5-10 minutes, and subsequently incubated overnight at 37°C.
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5.2.3.6 Transformation of Bacteria by Electroporation
5 pi of ligation product was mixed with 40pl of electrocompetent cells on ice for 5 mins 
before transferring to an ice cold cuvette (0.2 cm electrode gap). After which cells were 
transformed by a pulse of electricity, 2.5kV, lOpF, 600D, 5msec (BioRad 
MicroPulser™ electroporator machine) and resuspended immediately in 1ml LB in a 
Falcon 2059 polypropylene tube. The cells were allowed to recover at 37°C for 30-60 
minutes, spun for lmin at 13,000rpm and the resulting pellet resuspended in 200pl of 
LB media. The resuspended cells were then plated onto LB agar plates supplemented 
with carbenicillin, left to dry for 5-10 minutes and subsequently incubated overnight at 
37°C.
5.23.1 Blue/white Screening of pGEM-T® Vector
Successful cloning of an insert into a pGEM-T® vector interrupts the coding sequence 
of the lacZ gene which produces p-galactosidase. p-galactosidase cleaves X-gal to 
produce galactose and 5-bromo-4-chloro-3-hydroxyindole. 5-bromo-4-chloro-3- 
hydroxyindole then is oxidized into 5,5'-dibromo-4,4,-dichloro-indigo, an insoluble 
blue product. As a result clones that contain PCR products, produce white colonies 
while blue colonies correspond to reformed pGEM-T® vectors. Recombinant clones 
can therefore be identified by colour screening on indicator plates containing Xgal. 
Indicator plates were prepared by spreading 20pl Xgal and lOpl Isopropyl p-D-1- 
thiogalactopyranoside (IPTG) across a solid media plate.
5.2.3.8 Preparation of Plasmid DNA
Desired colonies were picked from the solid media plate and suspended in 5mls of LB 
media plus 5pl of carbenicillin. The cells in solution were incubated overnight at 37°C. 
For all plasmid preparations DNA was then isolated using the QIAGEN Spin Miniprep 
kit according to the manufacturers’ instructions. DNA was quantified using a 
spectrophotometer (BioPhotometer, Eppendorf) at 260nm/280nm (A260).
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5.2.3.9 Restriction Digestion
The restriction enzymes used in this chapter, plus their reaction conditions are given in 
Table 5.2.
RE Recognition Sequence Buffer Incubation Temperature
Mlu ACGCGT NEBuffer 3 37°C
Ncol CCATGG NEBuffer 3 37°C
BamHI GGATCC NEBuffer 3 + BSA 37°C
Sail GTCGAC NEBuffer 3 + BSA 37°C
Fsel GGCCGGCC NEBuffer 4 + BSA 37°C
Table 5.2 Restriction Enzymes used in this chapter plus reaction conditions. All restriction enzymes 
were purchased from New England Biolabs (NEB).
Typical reactions contained 250ng-2pg DNA in a final reaction volume of 50pl. These 
reactions contained 10% buffer, lx  BSA (if required), the desired restriction enzyme 
(<10% total volume) plus sterile molecular biology grade water. Typically 10 units of 
enzyme were added per pg of DNA. The mixture was incubated for 4h at 37°C, then 
heat inactivated at 65-80°C depending of restriction enzyme used. For reactions 
comprising of more than one restriction enzyme, the buffer suggested by the 
manufacturer to be compatible with both enzymes was used. Enzymes were either 
added together at the start of the reaction or sequentially to improve efficiency.
After endonuclease digestion of the pGL3 vector, dephosphorylation of the 5’ DNA 
termini was performed in order to prevent the relegation of the 5’ and 3’ ends of the 
vector. Vector DNA was treated with lpl (lunit/pl) of calf intestinal alkaline phosphate 
(CAP) for 1 h at 37°C.
All digested products were then run on a 2% agarose gel in order to separate digested 
bands. Digests of a different nature, such as pGL3 vector and PCR product digests, 
were run in separate tanks to avoid cross contamination. The appropriate DNA 
fragment was then gel extracted as previously described (chapter 5.2.2.4).
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5.2.3.10 Ligation of Digested Insert into pGL3
Ligation of digested DNA and digested pGL3 vector was performed using T4 DNA 
ligase (Promega). A typical reaction was carried out in a skirted 96-well plate using a 
range of ratios of PCR insert to pGL3 vector (3:1-14:1). A lOpl or 20pl reaction was set 
up using lpl or 2pi 10X ligation buffer (Promega) plus 1-2 units of T4 DNA ligase. 
Negative ligations were also carried out simultaneously to confirm the complete 
digestion and dephosphorylation of the vector. Reactions were mixed thoroughly and 
centrifuged briefly before incubating either at room temperature for 1 Omins, 16°C for 4 
hours or overnight at 4°C.
5.2.3.11 Digestion and Sequencing of Construct
Confirmation of a successful ligation between insert and vector was two fold. Firstly 
plasmid DNA extracted using a miniprep kit, as described in 5.2.3.8, was subjected to 
digestion by the appropriate restriction enzymes. Digested products were then run on an 
agarose gel and the product size(s) checked against those expected. Secondly, the 
junctions between insert and vector were sequenced using sequencing primers designed 
approximately lOObp away, 5’ and 3’ respectively, from the two cloning sites.
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5.2.4 Dual-luciferase® Assay
5.2.4.1 Plating of HEK 293 Cells
The plating density of HEK 293 cells for the reporter assay was 10,000 cells per well in 
lOOpl volume. This was achieved by counting cells using a haemocytometer (Figure
5.4).
1mm
comer square
• Middle square
F igure 5.4. Standard Haemocytometer chamber.
To calculate the number of cells present the middle square was counted (N). When the 
coverslip is in the correct position the depth of the chamber is 0.1mm. Therefore the 
volume of one square is 0.1mm (depth of the chamber 0.1mm x area of square 1mm ) 
and the number of cells in lcm3= NxlO4. If the number of cells in the square (N) was 
less than 100 then the number of cells within all five squares were counted. In this case:
No of cells/ml = Total no counted x 10
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The plating density of HEK 293 cells for the reporter assay was 10,000 cells per well in 
lOOpl volume. This was achieved by counting cells using a haemocytometer (Figure
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Figure 5.4. Standard Haemocytometer chamber.
To calculate the number of cells present the middle square was counted (N). When the 
coverslip is in the correct position the depth o f the chamber is 0.1mm. Therefore the 
volume of one square is 0.1mm (depth of the chamber 0.1mm x area of square 1mm ) 
and the number of cells in lcm 3= NxlO4. If the number of cells in the square (N) was 
less than 100 then the number of cells within all five squares were counted. In this case: 
No of cells/ml = Total no counted x 104 
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5.2.4.2 Transfection of HEK 293 Cells
HEK293 cells were plated out at 10,000 cells/ml into a 96-well flat bottomed tissue 
culture treated sterile plate (Greiner Bio One) and incubated overnight at 37°C with 5% 
CO2. Transfection was carried out with 500ng of transformed pGL3 reporter vector and 
5ng of the control reporter vector. For each set of 6 replicates a transfection master mix 
was made which consisted of 1.5pl of fugene and 97pi of MEM glutaMAX media. This 
solution was briefly vortexed then incubated at room temperature for 5 minutes. 5 pi of 
the control reporter vector was added to each master mix at a concentration of lng/pl. 
Apart from the negative control, 5pi of pGL3 luciferase reporter construct (lOOng/pl) 
was also added. All tubes were vortexed briefly and incubated at room temperature for 
30 minutes. lOpl of this solution was then added directly to the cells of each replicate 
within the 96 well plate. The plate with lid was swirled gently and returned to the 
incubator overnight.
5.2.4.3 Detection of Reporter Proteins
Reporter gene expression of pGL3 recombinants was performed using the dual- 
luciferase® reporter assay system (Promega). In this system both firefly and Renilla 
luciferase are detected. The dual-luciferase reporter assay system was used following 
the manufacturers instructions. Briefly, media was gently aspirated from the 
transformed HEK cells. Cells were then washed in 50pl of PBS and lysed in 20pl lx 
passive lysis buffer (PLB). The plate was swirled gently on a bell-dancer platform for 
15-30 minutes and then assayed using a dual injecting plate reading lumininometer 
(MicroLumat Plus LB96V, Berthold technologies). The firefly and Renilla luciferase 
catalysed reactions were activated through the addition of lOOpl of LARII to detect 
firefly luciferase activity followed by the addition of lOOpl stop and glo to detect the 
Renilla activity. An overview of the chemistry is given in chapter 5.1 and a 
comprehensive explanation supplied in Part #TM040 (Promega).
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5.2.4.4 Statistical Analysis of Luciferase Reporter Assay
Light emission (Relative light units, RLU) proportional to the expression of firefly and 
Renilla luciferase expression was collected using a dual injecting plate reading 
luminometer ((MicroLumat Plus LB96V, Berthold technologies) at interval time points 
1 and 2 respectively. In order to account for the variation in transfection efficiency 
between samples, a ratio of firefly expression/KewY/a expression was taken for each 
sample.
To allow for comparison between assays, the average ratio for all control (pGL3- 
Promoter) replicates from one assay were taken and ratios from the assay normalised 
with respect to this average. In each assay six technical replicates were performed for 
each vector construct, so an average from the six normalised ratios was taken for each 
construct.
Initially, in order to confirm that any differences detected were reproducible and not 
due to experimental variability, 18 technical replicates were performed for each 
construct (6 replicates per assay, 3 assays). A second set of experiments were then 
carried out with 1 -2 biological replicates of each recombinant to determine whether any 
differences observed were due to a specific clone artefact.
For comparative analysis of constructs, all technical replicates of the same construct 
were averaged and regarded as one biological replicate. To determine whether there 
were any differences in luciferase expression between constructs, a one way ANOVA 
was performed on the luciferase expression levels of all biological replicates of the 
recombinant constructs. Where appropriate an independent samples t-test was then 
performed. A Levene’s test for homogeneity of variance was used to establish whether 
unequal or equal variance should be assumed. Standard error of the mean 
(STDEV(V(n)) was also calculated.
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5.3. Results
In order to examine whether genomic variation at rs2619538 or rsl3198512 affects 
gene expression, an attempt was made to clone each SNP plus surrounding sequence 
into a suitable firefly luciferase reporter gene vector (pGL3). The cloning of each SNP 
involved a number of steps including; determining the appropriate amount of 
surrounding sequence to clone for each SNP, identifying individuals homozygous for 
all variants within the region, PCR amplification and ligation of the region into a 
pGEM-T® vector, digestion of the recombinant pGEM-T® vector with suitable 
restriction enzymes, ligation of the digested insert with a suitable pGL3 vector, site 
directed mutagenesis of the pGL3 construct to create all common haplotype 
combinations within the inserted sequence and finally, quantification of luciferase 
expression for each construct. Details of each of these steps are given below.
5.3.1 Primer Design
PCR primers were designed for both rs2619538 and rsl 3198512 which would amplify 
the sequence spanning each SNP. If a SNP was near or within a potential regulatory 
region, for example the sequence immediately 5’ to the DTNBP1 transcription start site, 
then this sequence was also included in the amplification product. Each set of primers 
also incorporated recognition sites for restriction enzymes (RE) that would allow the 
cloning of the PCR product into a pGL3 vector. REs selected were dependent on the 
luciferase cloning vector used and the designated position of cloning within the vector. 
Both these aspects were determined by the genomic location of rs2619538 and 
rs l3198512 relative to the DTNBP1 gene.
rs2619538 is 1868bp upstream of the DTNBP1 coding sequence. Therefore PCR 
primers were designed to amplify a 2.2kb region which included rs2619538 plus the 
sequence immediately 5’ to DTNBP1 (chr6: 15771090-15773323, see Figure 5.5A). 
These primers also included RE sites (Mlul and Ncol in the forward and reverse 
primers respectively) which would allow the insertion of the DTNBP1 putative 
promoter region immediately upstream of the luciferase gene within a pGL3-Basic
189
reporter vector (Promega). The pGL3-Basic vector lacks any eukaryotic promoter or 
enhancer sequences, therefore any luciferase expression detected will be due to the 
inserted sequence. Consequently the pGL3-Basic vector is commonly used for the 
insertion of putative promoter regions. The cloning of the 2.2kb region 5’ of DTNBP1 
will allow the effect of SNPs such as rs2619538 plus any other potential variants 
subcloned into the vector to be analysed with a native DTNBP1 promoter rather than an 
artificial simian virus (SV) promoter. The position of cloning and the major features of 
the pGL3-Basic vector are given in Figure 5.5B.
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Figure 5.5. A. Chromosomal location o f rs2619538 and the putative promoter sequence to be inserted 
into a pGL3-Basic luciferase vector. B. Basic structure o f the pGL3-Basic luciferase vector (Promega 
technical manual TM033). The DTNBPl 5’ flanking region will be inserted 5’ to luciferase vector 
between the Ncol and Mlu sites (shown in red and blue respectively).
rsl 3198512 is 3154bp downstream of the DTNBPl a coding sequence. PCR primers 
were designed to amplify a 3.6kb region which included r s l3198512 plus the 3’UTR of 
DTNBPl (chr6: 15,627,534-15,631,184, see Figure 5.6A). PCR primers were designed 
to include RE recognition sites (Fsel and BamHI in the forward and reverse primers 
respectively) which would allow this 3’flanking region to be inserted downstream of 
the luciferase gene within a pGL3-Promoter (pGL3-P) reporter vector (Promega). The 
pGL3-Promoter vector contains a SV40 promoter upstream of the luciferase gene. As a 
result this vector can be used to study potential regulatory elements away from the 
sequence immediately 5’ of the gene of interest. Digestion of the pGL3-P vector with
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Fsel and BamHI, followed by the subsequent ligation of the DTNBPl 3’ flanking 
region, will remove the native pGL3 polyA signal and replace it with the DTNBPl 
3’UTR (Figure 5.6B).
It is generally suggested that the regions selected for PCR amplification and subsequent 
cloning should be kept under 3kb as regions larger than this have a higher rate of failure 
at the ligation stage [340]. As the DTNBPl 3’flanking region is >3kb, PCR primers 
were also designed to amplify a smaller, distal region immediately spanning 
r s l3198512 (chr6: 15,627,534-15,628,278, see Figure 5.6A). PCR primers for this 
750bp region were designed to include REs that would allow cloning of the region 3’ to 
the luciferase gene again within a pGL3-Promoter vector. However as this region does 
not contain the DTNBPl 3’UTR, RE sites were chosen downstream of the poly A signal 
(BamHI and Sail in the forward and reverse primers respectively, Figure 5.6B).
A.
chr6;
JN R ID 2
1 5 6 2 6 0 8 0 1 1 5 6 2 7 0 0 0 1
3 'D R _ I n s e r t
3 'F R _ l r » s e r t
1 5 6 2 8 0 8 0 1
I n s e r t
1 5 6 2 9 0 0 0 1 1 5 6 3 0 0 0 0 1 1 5 6 3 1 0 0 0 |
> > » » » » » » » » > » » » » » > » » » > » » > » » » » » » » > » » » » » » » > > >
SN Ps
r s l 3 1 9 8 5 1 2 |
UCSC Know n G e n e s  ( J u n e ,  0 5 )  B a s e d  o n  u n i P r o t , R e f S e q ,  a n d  G en B an k  mRNfl
D T N B P l 
D T N B P l
8F  06173-4 b H H S ’
Synthetic poly(A)
hiyiKii / u d iis tn y u O n tl
pause site
(for background
reduction)
pGL3-Promoter
Vector
(501 Obp)
SV40 late 
poly(A) signal 
dfor k>c* reporter)
'SV40 Promoter
Figure 5.6. A. Chromosomal location o f the two regions, 3 ’ Flanking region (FR) and 3’distal region 
(DR), which include r s l3 198512, to be inserted into pGL3-Promoter luciferase vectors (Promega).
B. Basic structure o f the pGL3-Promoter luciferase vector (Promega technical manual TM033). The 
DTNBPl 3’ flanking region will be inserted 3 ’ to luciferase gene between the Fsel (green) and BamHI 
(red) sites replacing the native polyA signal. The 3 ’distal region will be inserted 3’ to luciferase gene 
between the Sail (blue) and BamHI (red) sites.
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A detailed overview of the positions of cloning and the restriction enzyme recognition 
sites within the pGL3-Basic/Promoter reporter vectors discussed are given in Figure 
5.7. The PCR primers designed and the reaction conditions for the incorporated 
restriction enzymes are given in Table 5.3.
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5' CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGATAGTACCGAGCTC
SV40 Promoter
TyACGCGTpCTAGCCCGGGCTCGAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCCA
Mlul
Luc+ coding region SV40 late poly(A) signal
Start Start____________
CCATGGAAGACGCCAAAAACATAAAG.. (1644bp). G G C C GG C CG CTTCGAGC AGACATGATAAGATACATTGAT
I   I I_______ I
Ncol Fsel
GAGTTT GGAC AAACCAC AACTAG AAT GCAGT G AAAAAAAT GCTTTATTT GT GAAATTT GT GAT GCTATTGCTTTATTT
GTAACCATT ATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTT AT GTT CAGGTT CAGGGGGAGGT G
T GGGAGGTTTTTT AAAGCAAGT AAAACCT CTAC AAAT GT GGT AAAAT CGATAApG AT CCpT CG A<pCG AT G 3’
BamHI Sail
Figure 5.7. Restriction enzyme sites within pGL3-Basic luciferase vector. DTNBPl 5’ flanking region including rs2619538 incorporates the RE sites Mlul and 
Ncol. DTNBPl 3’ flanking region incorporates the RE sites Fsel and BamHI.
Region Chromosomal Position Size PCR Primer Sequence RE site
5’ Flanking Region chr6:15,771,090-15,773,323 2233 Forward ACGCGT cccccagctacaagctaag Mlu
Reverse CCAT GGCCggtctcctctcctca Ncol
3' Flanking Region Chr6:15,627,534-15,631,184 3650 Forward GGATCCtgtttgggggtgaaagga BamHI
Reverse GT CG ACcgaaggcacctttaactt Sail
3' Distal Region chr6:15,627,534-15,628,278 744 Forward GGCCGGCCattgggacatgggcgttg Fsel
Reverse GGATCCgaaggcacctttaacttg BamHI
Table 5.3. PCR primer sequence for 5’ flanking region, 3’ flanking region and 3’distal region. RE recognition sites are also given in capitals. DTNBPl 3’ distal 
region including r s l3198512 incorporates the RE sites BamHI and Sail.
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5.3.2 Genomic Screen of rs2619538 and rs!3198512 Flanking Sequence
In order to perform a luciferase reporter assay comparing the regulatory affect of each 
allelic variant of a SNP, constructs need to prepared which contain all haplotypic 
combinations within the inserted sequence. Production of these constructs can be done 
in one of two ways. Either, individuals with unique haplotype combinations are PCR 
amplified and cloned into separate pGL3 luciferase vectors or alternatively DNA from 
an individual, homozygous for all SNPs within the desired region, is cloned into a 
relevant pGL3 vector, after which site directed mutagenesis is performed on the 
construct to create all possible haplotype combinations. In this study the later strategy 
was used.
The genomic sequence of the DTNBPl 5’ flanking region (chr6:15771090-15773323) 
had previously been screened for variants as part of the analysis for chapter 3. Within 
the 2.2kb region selected for PCR amplification with rs2619538, five additional SNPs 
were identified (Table 5.4). Individuals 4, 5, 8, 9, 11, 12 and 13 were homozygous for 
all six SNPs and therefore were suitable to be used as a template for initial PCR 
amplification.
In order to clone either the DTNBPl 3’ flanking region or the 3’distal region, both of 
which contain rsl3198512 (chr6:15627534-15631184) was screened through 14 
unrelated schizophrenics. Details of this screening sample can be found in chapter
2.1.3. Screening of this 3.6kb region identified five polymorphisms (Table 5.5). Of the 
5 SNPs identified, two variants were novel (DTNBPl downstream indel and 
DTNBPl_downstream_SNPl). The remaining 3 polymorphisms had all been 
previously deposited in the dbSNP and HapMap databases. Individuals 1, 2, 7, 9, 11 
were homozygous for all five SNPs and therefore suitable for initial PCR amplification.
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Screening Set Individual
SNP ID Chromosomal Position Alleles CEU MAF 1 2 3 4 5 6 7 8 9 10 11 12 13 14
DTNBP1-C16 SNP1 15771705 C/G 0 CC CC CC CC CC CC CG CC CC CC CC CC CC CC
rs2619536 15771826 T/C 0.09 TT TT TC TT TT TT TT TT TT TT TT TT TT TT
DTNBP1-C16 SNP2
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rs2619538 15773188 T/A 0.39 AT |AA AA AA AA AT AA AA AA AT AA AA AA AA
Table 5.4. Screening results for chr6:15771090-15773323. Six SNPs were identified. Individual genotypes for the 14 subjects screened are given with heterozygous 
genotypes indicated in red. Chromosomal position is based on March 2006. Individuals 4, 5, 8, 9, 11, 12 and 13 are homozygous for all SNPs within this region. 
MAF = Minor Allele Frequency.
Screening Set Individual
SNP ID Chromosomal Position Alleles CEU MAF 1 2 3 4 5 6 7 8 9 10 11 12 13 14
rsl 047631 15631080 A/G 0.2 AA AA AA AG AG AG AA AA AA AA AA AA AA AA
DTNBP1 Downstream indell 15630460 Unknown N/A WT WT WT WT WT ID WT WT WT WT WT ID WT WT
DTNBP1_Downstream snpl 15629000 C/T N/A CC CC CC CC CC CC CC CT CC CC CC CC CC CC
rsl 3198533 15627893 A/G 0.255 AA GG AG AA AA AG AA GG GG AG GG GG AG AG
rs13198512 15627864 A/G 0.492 AA GG AG AA AA AG AA AG GG AG GG AG AG AG
Table 5.5. Screening results for chr6:15627534-15631184. Five SNPs were identified. Individual 
genotypes indicated in red. Chromosomal position is based on March 2006. MAF = Minor Allele 1 
1, 2, 7, 9 and 11 are homozygous for all SNPs within this region.
genotypes for the 14 subjects screened are given with heterozygous 
Frequency. ID = Insertion/Deletion. WT = Wild type. Individuals
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5.3.3 PCR Amplification and Gel Extraction
All three genomic regions (DTNBPl 5’flanking region, DTNBPl 3’flanking region and 
DTNBPl 3’distal region) were successfully amplified using the primers listed in Table
5.3. As each high fidelity PCR reaction produced multiple bands when visualised on an 
agarose gel (Figure 5.8) the correct size product for each PCR (noted by the arrows) 
was gel extracted.
3.6kb
744bp
Figure 5.8. High Fidelity PCR o f three regions (5’FR, 3’FR, 3 ’DR). A. 5’ flanking region PCR (2.2kb) 
B. 3’flanking region (3.6kb) and 3 ’ distal region (744bp). Arrows indicate PCR products o f the correct 
size which were subsequently gel extracted. Lanes immediately to the right o f each product are negative 
control runs.
5.3.4 pGEM-T® Vector Cloning
RE sites close to the end o f a sequence are often ineffectively cleaved by their 
respective enzymes [341]. For example Sail needs 3bp each side o f the recognition 
sequence to cut efficiently [342]. As the restriction enzyme sites incorporated into the 
PCR primers are located at the 3’ and 5’ ends o f each PCR fragment, direct enzymatic 
treatment o f the gel extracted PCR product would be likely to be inefficient.
As the pGEM-T® vector system (Figure 5.9) facilitates the direct cloning of PCR 
products without requiring prior enzymatic treatment, TA ligation o f the gel extracted 
PCR products into pGEM-T® was used as an intermediate step prior to restriction
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enzyme digestion and ligation into the appropriate pGL3 vector. Potential pGEM-T® 
recombinants were selected by an initial blue/white colony screen. In order to 
determine that the correct constructs had been produced, prospective recombinants 
(white colonies) were subjected to RE digest plus sequencing across the ligation 
boundary.
TA ligation site
112
T
Figure 5.9. pGEM-T® vector. Promega technical manual TM042.
While a control insert was used to determine that the ligation conditions were correct 
and a range of ligation ratios were attempted (insert:vector 1:1- 3:1) no white colonies 
were detected for the ligation reaction between pGEM-T® and DTNBPl 3’ flanking 
region.
As it is possible that the recombinant vector may not cause a frame shift in the lacZ 
gene and therefore white colonies will not be produced, a random selection of blue 
colonies were subjected to RE treatment and the predicted ligation boundaries 
sequenced. However all colonies analysed were re-ligated pGEM-T® vectors. This 
ligation failure may be due to the fact that the 3’flanking region (3.6kb) is larger than 
the pGEM-T® vector (3kb).
In contrast, the DTNBPl 3’ distal region was successfully cloned into the pGEM-T® 
vector (pGEMT-3’DR). This recombination vector was therefore used in all further 
experiments investigating the effect of rsl 3198512. The DTNBPl 5’ flanking region
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was also successfully cloned into a pGEM-T® vector (pGEMT-5’FR). Sequence traces 
o f boundaries o f all recombinants can be found in Appendix Figures 9.2.1 and 9.2.2.
5.3.5 Digested Promoter Insert and pGL3-Basic Cloning
After the successful cloning of the DTNBPl 5’ flanking region (chr6:15771090- 
15773323) into a pGEM-T® vector, an attempt was made to clone the 5’flanking 
region into a pGL3-Basic luciferase vector. Both the recombinant pGEMT® vector 
(pGEMT-5’ FR) and the pGL3 luciferase vector were digested with restriction enzymes 
Ncol and Mlu. In order to reduce the chance o f religation, the digested pGL3-Basic 
product was treated with CAP to dephosphorylate the 5’ DNA termini. Both the 
digested products o f pGEMT-5’ FR and pGL3 were run on an agarose gel where bands 
o f the expected size were observed and gel extracted (Figure 5.10).
Figure 5.10. Visualisation o f RE digest products. The sequential digestion o f pGL3-Basic and pGEMT- 
5’ FR are shown. A pGL3-Basic Ncol digest followed by Mlul. B pGL3-Basic Mlul digest followed by 
Ncol digest. C. pGEM T-5’ FR Ncol digest followed by Mlul. D. pGEMT-5’ FR Mlul digest followed by 
Ncol digest.
pGL3 5kb bands and 5’FR 2.2kb bands from A, B, C and D were gel extracted and subjected to a ligation 
reaction.
A B C D
pGL3 5 kb
5’FR 2.2kb
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5pi o f each gel extracted product was run on a second agarose gel to ensure a successful 
extraction had occurred. Ligation reactions were then performed with the remaining gel 
extracted products. A number of variations in ligation conditions were attempted 
including insert: vector ratios o f between 1:1 and 20:1, as well as three different ligation 
temperatures (10 minutes at room temperature, 4 hours at 16°C and 12-16 hours at 
4°C). Furthermore, transfection of all ligated products was attempted via heat shock 
and electroporation. Although a number a colonies were observed after incubation, 
digest and sequencing analysis determined that all colonies produced were reformed 
pGL3-Basic vector. Due to the failure o f the 5’ flanking region to be cloned into the 
pGL3-Basic vector functional analysis o f rs2619538 via reporter gene assay could not 
be performed.
5.3.6 Digested 3’Insert and pGL3 Promoter Cloning
The pGEMT-3’DR construct and a pGL3-Promoter (pGL3-P) luciferase vector were 
subjected to sequential digestion with REs BamHI and Sail. The digested products were 
subsequently run on an agarose gel (Figure 5.11) and the correct size products gel 
extracted.
DTNBPl-3’DR 
744bp
Figure 5.11. Product from BamHI and Sail sequential digestion o f A. pGL3-Promoter plasmid and B. 
pGEMT-3’DR. Expected product sizes were 5010bp for pG13-P digestion and 3000bp and 744bp for 
pGEMT-3’DR digestion. Digested products were run on separate gels and in separate tanks so as to avoid 
contamination. Bands at 5010bp and 744bp (depicted by arrows) were gel extracted, subjected to ligation 
and transformation into E.coli.
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A ligation reaction between the digested products was then performed. The DTNBP1 - 
3’DR was successfully cloned into the BamHI-Sall site of the pGL3-Promoter vector 
using a 14:1 insert:vector ratio. After transformation recombination was confirmed 
through digestion o f the extracted DNA with BamHI and Sail (Figure 5.12) and 
sequencing across the ligation boundaries (Appendix Figure 9.2.3). Thus the 744bp 
sequence downstream from DTNBPl, containing r s l3198512, was cloned 3’ to the 
luciferase gene within a pGL3-Promoter vector. The resultant plasmid was designated 
pGL3-P_3’DR.
pGL3-P 
5kb
D TNBPl-3’DR 
744bp
Figure 5.12. Result o f BamHI and Sail digestion o f extracted DNA from transformed colony. The 
expected product sizes o f 5010bp and 744bp are shown. Two controls are also shown. The 4th well 
contains a digest reaction without RE. The 5th well contains a negative control (RE digest with water 
replacing DNA).
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5.3.7 Site Directed Mutagenesis
In order to perform a comprehensive analysis of the potential regulatory effect of a 
SNP, all haplotypes with the inserted region were considered. Previous sequencing 
results found that in addition to rsl3198512, the DTNBPl 3’DR amplimer also 
contains rsl 3198533 (Figure 5.13). Therefore the haplotype frequencies of these SNPs 
were determined using the HapMap database.
Within the CEU population these two SNPs form one of three haplotype combinations 
(Table 5.6). The individual used for initial PCR amplification of the DTNBPl 3’DR 
(Sample 9 of the mutation detection sample) has the genotype GG for both SNPs. 
Consequently, site directed mutagenesis (G->A) was performed on both sites in order 
to produce the three haplotype combinations. The primers used for site directed 
mutagenesis are given in Table 5.7. After site directed mutagenesis all vectors were 
sequenced to determine that no base changes, other than rsl3198512 and rs l3198533, 
had occurred. The sequence traces of the three constructs are given in Appendix 9.2.4.
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Figure 5.13. Chromosomal position of the DTNBPl 3’distal region insert sequence (3’DR) and the relative location of the polymorphic SNPs rsl 3198512 and 
r s l3198533 within this region.
Haplotype rs13198512 rsl 3198533 Freq CEU Plasmid
1 G G 0.50 PGL3-P 3'DR GG
2 A G 0.26 pGL3-P_3'DR_AG
3 A A 0.24 pGL3-P_3'DR_AA
Table 5.6. Haplotypic analysis ofrsl3198512 and r s l3198533 within the CEU population.
Primer Name Sequence change Primer Sequence (5' to 3')
rs13198512 149GA F
cactgcctctaccacggagcactcagcaaagagacccagggg
ctttgttacatcctggatggtgacacaaatacccaagctacttga
ctcactttagctaccRgccactgaacctggcc
atgcaagtaaat[G>A]caaacacttctcaacctatacatatcc
ttgtaattcactcaagagaatcatttatctgtcggcaccaaaaac
5'-cctggccatgcaagtaaatacaaacacttctcaacct-3'
rs13198512 149GA R 5'-aggttgagaagtgtttgtatttacttgcatggccagg-3'
rs l3198533 120GA F
cactgcctctaccacggagcactcagcaaagagacccagggg
ctttgttacatcctggatggtgacacaaatacccaagctacttga
ctcactttagctacc[G>A]gccactgaacctggcc
atgcaagtaaatRcaaacacttctcaacctatacatatcc
ttgtaattcactcaagagaatcatttatctgtcggcaccaaaaac
5'-ctcactttagctaccagccactgaacctggc-3'
rs13198533 120GA R 5'-gccaggttcagtggctggtagctaaagtgag-3’
Table 5.7. Site directed mutagenesis primers.
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5.3.8 Luciferase Expression Analysis
In order to determine whether genetic variation at rs l3198512 affects transcription, the 
expression of the firefly luciferase reporter gene was quantified using the dual- 
luciferase® reporter assay system (Promega). In total five different vector constructs 
were assayed pGL3-Basic (negative control), pGL3-Promoter vector (positive control), 
pGL3-P 3’DR_GG, pGL3-P 3’DR_AG, pGL3-P 3’D RA A . Details of these constructs 
is given in Figure 5.14.
pSV40
pSV40
pSV40
polyA
LUC
LUC
pSV40
LUC
polyA
polyA
polyA
polyA
LUC
LUC 3’DR [rs13198512 (A), rsl 3198533 (G)]
3’DR [rs13198512 (A), rsl 3198533 (A)]
3’DR [rs13198512 (G), rsl 3198533 (G)]
pGL3-Basic
pGL3-Promoter
pGL3-P 3’DR_GG 
pGL3-P 3’DR_AG 
pGL3-P 3’DR_AA
Figure 5.14. Plasmids constructs assayed. pSV40 -  SV40 promoter, LUC = luciferase gene, polyA = 
SV40 polyadenylated signal, 3 ’DR = inserted sequence (SNP genotypes are given).
Results of the dual-luciferase® assay are illustrated in Figure 5.15. The 
luciferase/itettz7/tf expression ratio shown for each vector construct is derived from the 
average of two-three biological replicates, each of which comprises of at least 6 
technical replicates. The average ratios of each biological replicate are given in Table 
5.8. ANOVA of the luciferase expression levels for the biological replicates of pGL3-P 
3’D RG G , pGL3-P 3’DR_AG, pGL3-P 3’D R A A  revealed a significant difference in 
expression between the constructs (p=0.024). Post-hoc independent sample t-test were 
therefore performed. The Levene’s statistic for each t-test was non-significant therefore 
equal variance was assumed. All raw data (luciferase//te«z7/fl ratios and normalised 
results) from each technical and biological replicate can be found in Appendix Table 
9.2.5.
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ANOVA p=0.024
1.20 -
T-test p=0.009
S 50.80
</> (Z
cz ~  0.60
i  |  0.40
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PGL3 PGL3-P PGL3-P 3 ’DR_GG PGL3-P3'DR_AG PGL3-P3'DR_AA
PGL3 Construct
Figure 5.15. Graphical depiction o f the results from the dual-luciferase® reporter assay comparing pGL3- 
P 3 ’DR vectors containing the haplotypic variants o f  rsl 3198512 and rs 13198533 (G-G, A-G and A-A 
respectively). Negative (pGL3-Basic) and positive (pGL3-Promoter) controls are also given.
Biological Rep 1* Biological Rep 2 Biological Rep 3 Average
Post-hoc 
T-Test (P Value)
PGL3 0.03
PGL3-Promoter 1
PGL3-P 3'DR GG 0.847 0.945 0.896 GG vs AG (0.009)
PGL3-P 3'DR AG 0.367 0.269 0.252 0.296 AG vs AA ( 0.097)
PGL3-P 3'DR AA 0.469 0.692 0.976 0.712 AA vs GG( 0.339)
Table 5.8. Detailed results o f the dual-luciferase® reporter assay. The average luciferase/Renilla ratio is 
given for each biological replicate o f the different constructs. As an ANOVA test revealed a significant 
difference in luciferase expression level (p=0.024) post-hoc independent sample t-tests were performed. 
The p values for these t-tests (assuming equal variance) are given (pGL3-P 3’DR GG vs pGL3-P 
3’DR AG p=0.0009, pGL3-P 3’DR AG vs pGL3-P 3’DR AA p=0.097, pGL3-P 3 ’DR GG vs pGL3-P 
3’DR_AA p=0.339).
* Average o f three technical replication assays.
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Post-hoc independent samples t-test between pGL3-P 3’DR GG and pGL3-P 
3’DR AG indicated a significant difference in the luciferase expression levels (Table 
5.8) with a three fold increase in expression of the pGL3-P 3’D R G G  construct 
(average expression of pGL3-P 3’DR_ GG/_AG=3.03). Previous reports have 
suggested that an increase in expression above 1.5 fold is greater than any predicted 
assay variation and is highly reproducible in independent replication studies using fresh 
clones [343]. Therefore, the magnitude of the difference detected plus the number of 
replicates performed strongly suggests that rsl3198512 has a regulatory affect on 
transcription.
While the direct comparison of pGL3-P 3’DR GG and pGL3-P 3’DR AG indicates 
that rs l3 198512 is a regulatory variant, the results for pGL3-P 3’D R A A  are 
inconclusive. In order to analyse all common haplotypes within the insert, pGL3-P 
3’D R A A  (rsl3198512 A, rs l3 198533 A) was analysed in addition to pGL3-P 
3’DR AG (rsl3198512 A, rsl3198533 G). rsl3213814, a proxy for rsl3198533, was 
analysed in chapter 4 as part of the allelic expression correlation analysis. This SNP did 
not show an association with the allelic expression differences (p= 0.128) and therefore 
was not considered as a functional variant. Consequently, it was expected that pGL3-P 
3’DR_AG and pGL3-P 3’D R A A  would show similar luciferase expression results. 
However although there is no significant difference between pGL3-P 3’DR_AA and 
pGL3-P 3’DR AG (p=0.097), there is also no significant difference between pGL3-P 
3’D R A A  and pGL3-P 3’DR GG (p=0.339).
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5.4 Discussion
Association analysis between cortical dysbindin mRNA levels and putative regulatory 
polymorphisms, described in chapter 4, identified that genetic variation at rs2619538 
and rsl 3198512 is associated with reduced dysbindin expression. The aim of this 
chapter was to determine whether rs2619538 or rs l3198512 are genuine functional 
variants which have a cis-acting regulatory influence on gene expression. In addition, it 
was hoped that functional characterisation of these SNPs would provide evidence as to 
whether correlation analysis between putative regulatory polymorphisms and allelic 
expression data is an effective technique for identifying cis-acting variants.
In order to allow functional characterisation of rs2619538 and rs l3198512 an attempt 
was made to create pGL3 luciferase constructs which would determine the effect of 
each allelic variant of luciferase expression levels. Disappointingly, functional 
characterisation of rs2619538 could not be performed as cloning of the DTNBPl 5’FR, 
which contained rs2619538, into a pGL3 luciferase vector was unsuccessful. There are 
several reasons why this cloning attempt could have failed. These are summarised in 
Table 5.9. A number of steps were taken to resolve potential reasons for failure 
including ineffective RE digestion, relegation of vector, unoptimised ligation, 
inefficient transfection as well as individual error. However none of these resulted in 
successful cloning. This suggests that the DTNBPl 5’FR sequence may contain 
abnormalities, such as a complex secondary structure, that make it resistant to cloning.
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Possible Reason Steps taken
Ineffective digestion of vector/insert 
by restriction enzymes
Initial TA ligation into pGEMT vector.
Sequential RE digestion with heat inactivation after each reaction. 
Visualisation of bands of correct product size on agarose gel
Inhibitory complex in PCR product 
e.g. dATP PCR product gel purified prior to ligation
Pyridamine dimers formed UV exposure reduced to a minimum
Re-ligating vector CIP treatment of vector prior to ligation
The optimum vectoninsert not 
performed during ligation A wide range of ratios used from 1:1-20:1
The optimum ligation 
conditions not performed
Ligation attempted at 4°C, 16°C and room tempertaure 
for 16hrs, 4hrs and 10 minutes respectively
Heat shock transfection not suitable Electroportation attempted
Individual error Cloning experiment also attempted by Dr Liam Carrol
Sequence abnormalities in PCR fragment 
such as complex secondary structure/ 
GC content
Table 5.9. Summary o f possible reasons that the ligation o f  DTNBPl 5 ’FR and pGL3-Basic luciferase 
vector was unsuccessful and the steps taken to try and resolve them.
It was hypothesised that analysis of rs2619538, and potentially rs l3198512 through 
subcloning, in an expression vector with a native DTNBPl promoter, rather than an 
SV40 promoter, would be more likely to produce expression levels representative of in 
vivo dysbindin. For this reason, in addition to incorporating rs2619538 into a pGL3 
luciferase vector, a secondary objective of the cloning strategy was to insert the 
putative promoter of DTNBPl. An alternative approach, which may eliminate any 
incompatible structures, would be to clone ~lkb of sequence immediately surrounding 
rs2619538. Although this is likely to exclude the DTNBPl promoter, analysis of this 
sequence cloned into a pGL3-Promoter vector would allow a preliminary examination 
of the effect of rs2619538 on transcription. However due to time constraints, this 
alternative cloning strategy could not be attempted as part of this study.
As analysis of the effect of rs2619538 on expression could not be performed using a 
luciferase assay, publicly available eQTL datasets were examined. eQTL databases are 
created by the association mapping of genotypes to gene expression profiles, measured 
using microarray data [344]. Out of three datasets examined [345-347] only one had 
analysed rs2619538. The GENe Expression VARiation (GENEVAR) project analysed 
the gene expression profiles of the 270 individuals genotyped in the HapMap 
Consortium to elucidate the detailed features of genetic variation underlying gene
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expression [347]. However, rs2619538 was not significantly correlated with dysbindin 
expression in this dataset (p>0.215).
In contrast to rs2619538, rs l3198512 plus surrounding sequence was cloned into a 
pGL3 luciferase vector. Although one haplotype construct was inconclusive, the 
comparison of the expression levels of two other pGL3 luciferase plasmids, differing 
only by rs l3198512, revealed that genetic variation at this SNP had an affect on 
expression. The construct pGL3-P_3’DR_AG, which contains the A allele of 
rs l3198512, showed a significant reduction in luciferase expression compared to 
pGL3-P_3’DR_GG, a construct containing the G allele (p=0.009). This result is 
supported by the GENEVAR project which also found the A allele of rsl 3198512 to be 
significantly associated with reduced dysbindin expression within CEU individuals 
(p=0.03) [347].
However while these two studies support the hypothesis that rs l3198512 has a cis- 
acting influence on DTNBPl expression, the effect shown by the reporter assay is in 
the opposite direction to the correlation analysis described in chapter 4 which predicted 
that the G allele of rsl 3198512 would show reduced expression compared to the A 
allele. This variation in results could be explained by a number of factors. Firstly rather 
than using definite haplotypes, the allelic expression correlation analysis was based on 
haplotype probabilities. These probabilities were derived from the genotypes of the 
relatively small allelic expression sample (149 individuals). As a result the haplotype 
probabilities and consequently the allele(s) associated with reduced relative expression 
may be inaccurate. Secondly an allelic expression assay identifies any expression 
differences that were present in vivo at the time of extraction. In contrast a luciferase 
reporter assay is an in vitro assay which analyses the affect on the putative regulatory 
sequence/SNP on a surrogate gene. In addition the luciferase vector used for the 
analysis of rsl 3198512 contains a SV40 promoter rather than the native DTNBPl 
promoter. As discussed above one aim of this analysis was to replace the SV40 
promoter with the native DTNBPl promoter. However cloning of the putative 
DTNBPl promoter (DTNBPl 5’FR) into a luciferase vector was unsuccessful. Finally 
activity of a reporter gene may fail to reproduce the expression pattern of its
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endogenous equivalent owing to differences in chromatin context [348]. Naked DNA in 
a plasmid is highly unlikely to adopt a full chromatin structure. As chromatin 
modifications are important in modulating transcription, a reporter gene assay may miss 
true biological effects.
Finally, a difference between the reporter gene and allelic expression assays performed 
within this project, which could potentially explain the alternate alleles associated with 
reduced expression, is that the two assays were carried out within different tissues 
types. Luciferase expression was analysed using human embryo kidney cells (HEK). In 
contrast, allelic expression analysis was performed using RNA extracted from brain 
tissue. While advantageous for their transfection efficiency and ease of maintenance, 
HEK transformed cell lines do not provide the same sophisticated level of cellular 
architecture, subcellular organisation or biochemistry associated with native neuronal 
populations [337].
New research suggests that the majority of regulatory variants operate in an entirely 
cell-type specific manner [349]. Another group has determined that this cell-type 
specific regulation is particularly apparent in enhancer regions while promoter regions 
show a more consistent regulation across tissue types [350]. This may therefore be 
relevant to rs l3198512 which is found distal to the DTNBPl gene and could be located 
within an enhancer region.
As cell-type specific regulation is possible analysis of luciferase expression in neuronal 
cells may be needed to determine the true regulatory nature of both rsl 3198512 and 
rs2619538 in the brain. However again due to time constraints, this could not be 
performed as part of this project. While the GENE VAR project used lymphoblastoid 
cell lines derived from blood mononuclear cells, another study has performed 
expression profiling within brain tissue [346]. However this study did not genotype 
rs l3198512 or rs2619538.
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5.4.1 Possible Cis-acting Regulatory Mechanisms of rsl3198512
Though differing in the functional allele, the results from the luciferase reporter assay 
and the correlation analysis both indicate that rs l3198512 has a cis-acting regulatory 
influence on dysbindin expression. As noted in chapter 4, rs l3198512 is ~3kb 
downstream of DTNBPl, within an intron of JARID2. A number of SNPs 3’ to the 
target gene have been shown, via in vitro or in vivo techniques, to affect transcription 
however the majority of these are located within the 3’UTR of the gene [351]. This 
may be to be expected as recent findings suggest, in addition to post-translational 
modification and degradation [352, 353], the 3’UTR may also control mRNA activity 
[354] and affect several processes such as mRNA formation [351, 353], stability [355, 
356], transport, localisation [357] and translation [358]. Nonetheless a number of SNPs 
downstream of the 3’UTR have been found to be associated with expression [359-366]. 
This includes rs356219, a SNP 9kb downstream of the SNCA gene which is associated 
with in vivo SNCA mRNA levels [359]. However the mechanism by which SNPs 
downstream of the 3’UTR (often known as the 3’downstream sequence or 3’DSS) 
could affect transcription is not clear. At present all 3’DSS SNPs with a characterised 
mechanism of function are found within TFBSs. It is therefore likely that these SNPs 
are within enhancer and/or silencer regulatory elements and affect the binding of 
transcription factors. While rs l3198512 has not been found within a TFBS cluster, it 
may be possible that it disrupts a TFBS not predicted by the Cluster Buster program. As 
a result rsl 3198512 could alter the binding of an activator or a repressor. It is also 
possible that the sequence surrounding rs l3198512 is involved in the initial formation 
of the pre-initiation complex (PIC). In vivo footprinting and chromatin 
immunoprecipitation has shown RNA polymerase II binding to distal enhancer 
elements suggesting the PIC may initially form at a distal enhancer rather than at the 
core promoter [270]. Finally, rs l3198512 may alter transcription by affecting DNA 
curvature (the shape of the DNA sequence), flexibility (the ease with which the DNA 
can bend to allow interactions of different proteins bound to the DNA) or stability (the 
ease with which the DNA can become single stranded to allow transcription). Both 
curvature and flexibility have been shown to be important within DNA-promoter 
interactions [322]. These DNA attributes may therefore also have an affect on distal
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regulatory regions and the “looping-out” mechanism by which a distal regulatory 
region can interact with the DTNBP1 promoter may be disrupted by variation at 
rsl3198512.
The fact that rsl3198512 is within an intron of one gene (JARID2) but appears to affect 
the expression of a neighbouring gene (DTNBP1) is not unprecedented. Adlam and Siu 
identified an enhancer within the gene ISOT (also known as USP5) that is critical for 
the expression of a neighbouring gene CD4 [288]. CD4 transcription is closely coupled 
with T-cell development. While the enhancer maps to the first intron of ISOT, which is 
located 3’ to CD4, the enhancer does not appear to affect ISOT gene expression. 
Therefore, it is possible that rsl3198512, a variant that maps to the first intron of 
JARID2, a gene 3’ to DTNBP1, could have a regulatory effect on DTNBP1 but not 
JARID2. Alternatively, r s l3198512 could also have a regulatory effect on both genes 
as other variants have been shown to have a regulatory effect on more than one gene at 
a locus [344].
5.4.2 Implications of Luciferase Assay Results
This chapter set out to determine whether rs l3198512 and/or rs2619538 affect 
transcription in vitro. It was also hoped that this analysis would help establish whether 
the identification of putative regulatory SNPs and the correlation of these genotypes 
with allelic expression data is a viable way of identifying regulatory polymorphisms. 
Variation at rs l3198512 has been shown to be associated with differential expression of 
dysbindin mRNA and to affect luciferase expression levels. Although these two 
findings cannot be directly linked, they both support the hypothesis that DNA variants 
associated with differential allelic expression are regulatory variants. In contrast, 
rs 13198512 is not within a putative regulatory region identified by the methods 
described in chapter 3. It therefore appears that while initial screening of putative 
regulatory regions is advantageous in that it can substantially reduce the amount of 
screening and/or genotyping to be performed, it is likely to miss functional variants.
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However these observations have been made from the analysis of just one 
polymorphism. Other SNPs, both positively and negatively correlated with allelic 
expression data, plus those located within and outside putative regulatory regions, need 
to be analysed using reporter gene assays before any definite conclusions can be drawn.
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Chapter 6: An Examination of BLOC1S3 and MUTED 
as Schizophrenia Susceptibility Genes
6.1 Introduction
Although many studies have implicated DTNBP1 as a schizophrenia susceptibility gene 
[112, 113, 117, 121, 127, 129-138], the function of the dysbindin protein, specifically 
its role in schizophrenia pathology, remains largely unknown. Co-immunoprecipitation 
studies and yeast-two-hybrid analysis [208, 212] have shown that dysbindin is a 
member of the protein complex biogenesis of lysosome related organelles complex 1 
(BLOC-1). It is therefore reasonable to postulate that DTNBP1 could confer a risk to 
schizophrenia through disruption of this complex and that other BLOC-1 genes could 
themselves contribute to schizophrenia susceptibility.
Morris and colleagues [367] investigated this hypothesis by performing association 
analyses on seven BLOC-1 genes (MUTED, PLDN, CNO, SNAPAP, BLOC1S1, 
BLOC1S2, and BLOC1S3). All exonic regions plus lkb 5’ to each of the genes were 
screened for polymorphisms and a non-redundant set of SNPs were genotyped through 
their Irish case control sample. A significant association was observed for rsl2460985, 
a SNP 3’ of the BLOC 1 S3 gene (p=0.0028). However this result would not survive 
Bonferroni correction for the number of SNPs analysed. No other single marker within 
the BLOC-1 genes showed a significant association to schizophrenia.
Members of the BLOC-1 complex could potentially contribute to schizophrenia 
susceptibility either independently or alternatively through interaction with other 
members of the complex. Under this epistatic model any given mutation needs to be 
considered in the context of other polymorphisms [368]. Therefore in addition to an 
independent association analysis, Morris and colleagues also performed a gene x gene 
interaction analyses for all combinations of the BLOC-1 genes including DTNBP1.
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Although allelic and genotypic analysis did not show a significant association at the 
MUTED locus, gene based interaction analysis identified a significant interaction 
between SNPs at the DTNPB1 and MUTED loci (p=0.0009) [367]. Subsequent 
characterization of this gene x gene interaction using a standard logistic regression 
framework determined the strongest allele based signal to be between DTNBP1 
rs2619539 (PI 655) x MUTED rsl 0458217 (p=0.0094). A breakdown of the odds ratios 
(ORs) for each of the nine possible genotype combinations indicated that the majority 
of the significant interaction between these two SNPs could be accounted for by the 
genotype combination DTNBP1 GG x MUTED AA (Figure 6.1.).
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Figure 6.1. Breakdown o f the odds ratios from the nine possible genotype combinations o f the 
interacting SNPs DTNBP1 rs2619539 and MUTED r s l0458217 reported by Morris et al [367]. The ORs 
are relative to the double heterozygote which has been fixed as the reference (O R=l). The majority of 
the significant interaction between these two SNPs can be accounted for by the genotype combination 
DTNBP1 GG x MUTED AA.
The fact that Morris and colleagues observed a significant interaction with DTNBP1, 
but not a main effect at the MUTED locus, highlights the possibility that interaction 
analysis may have an important role in finding susceptibility genes. Although 
inconsistent results across association studies can be caused by both genetic 
heterogeneity and phenocopy, it is also possible that the conflicting results observed for 
DTNBP1 and other complex disorder susceptibility genes may partly be explained by 
epistasis. In support of this, Moore and Williams hypothesised that the lack of 
replication for single locus results in studies of another complex disease, essential 
hypertension, may be because epistatic effects are more important than independent 
main effects [369].
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In addition to the significant interaction between MUTED and DTNBP1 reported by 
Morris et al [367], significant evidence for association between markers at the MUTED 
locus and schizophrenia has been reported in abstract form. Straub and colleagues 
performed an association analysis on 17 MUTED SNPs. Of these, six were found to be 
significantly associated using the family base association test (FBAT) (rsl0458217 
p=0.0013, rs3734590 p=0.0003, rs3734591p=0.0002, rsl 1243223 p=0.0001, rs2815155 
p=0.01, rs2743986 p=0.008) [207].
While the effect sizes for the significant association and interaction reported at the 
BLOC 1 S3 and MUTED loci are modest, these studies support the involvement of 
BLOC-1 in the pathogenesis of schizophrenia. Interestingly, cell culture studies have 
shown that the knock down of MUTED by siRNA within human neuroblastoma cells 
causes a significant reduction in dysbindin protein (-65%, p=0.002) [229]. In addition, 
the knockdown of both DTNBP1 and MUTED can affect dopamine D2 receptor 
(DRD2) internalisation and signalling [229]. Iizuka and colleagues demonstrated this in 
DTNBP1 and MUTED siRNA transfected SH-SYSY cell lines. These cells showed an 
increase in cell surface DRD2 of 30% (p=0.004) and 20% (p=0.027) respectively 
compared with cells transfected with a control siRNA. These results provide a possible 
functional link between two members of the BLOC-1 complex and a neurotransmitter 
system implicated in schizophrenia pathogenesis.
The aim of this chapter was to attempt to replicate the association reported by Morris 
and colleagues between schizophrenia and the BLOC 1 S3 variant rs l2460985. In 
addition a detailed association analysis of the MUTED locus was performed in an 
attempt to replicate either the association reported by Straub and colleagues or Morris 
et al. This included genotyping a representative set of MUTED SNPs through our case 
control sample. In addition these markers were tested for evidence of interaction with 
15 SNPs at the DTNBP1 locus that had been previously genotyped in the same sample 
[134]. This included the pair of markers reported to show evidence for interaction in the 
study of Morris et al.
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6.2 Methods
6.2.1 Subjects
Mutation Screening was performed using a sample of 14 of unrelated schizophrenic 
subjects described in chapter 2.1.3. Individuals were chosen based on the criteria that 
they met the DSM-IV criteria for schizophrenia and each had at least 1 affected sibling. 
14 unrelated individuals from the same population should allow 95% power to detect 
alleles with a minor allele frequency of >0.1 and 80% power to detect alleles with a 
minor allele frequency of 0.05.
Informative SNPs were genotyped through the UK case control sample consisting of 
709 cases and 716 controls. The specific details of these individuals are described in 
chapter 2.1.1.
6.2.2 Identification of Putative Regulatory Regions
The genomic sequence of MUTED ±10kb (chr6:7949215-8019646) was analysed in 
silico to identify putative cis-acting regulatory regions. Three different strategies were 
used for identifying these regions; the protocol and the rationale for each is described in 
chapter 3. Briefly regions containing multiple transcription factor binding sites (TFBSs) 
were predicted using the web based programme Cluster Buster 
(http://zlab.bu.edu/cluster-buster/cbust.html) [315]. Evolutionary conserved sequence 
was identified using the ECR browser [317] (www.ECRbrowser.com) and the UCSC 
track “most conserved” [318]. Furthermore, as the sequence immediately 5’ to the TSS 
of MUTED is highly likely to contain promoter elements, the genomic sequence lkb 5’ 
to exon 1 of the MUTED transcript AK02544 was also included for polymorphism 
detection.
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6.2.3 Polymorphism Detection
The exonic structure of MUTED was ascertained according to AK02544 using the 
UCSC human genome reference sequence (March 2006 freeze). The genomic sequence 
of exonic and putative regulatory regions were subsequently derived and used to design 
PCR primers using Primer3 (http://www-genome.wi.mit.edu/cgi- 
bin/primer/primer3_www.cgi). Exonic and putative promoter PCR products were 
screened for sequence variation by Denaturing High Performance Liquid 
Chromatography (dHPLC) [245]. The protocol for which is described in chapter 2.5.1. 
Other putative regulatory regions were screened using HRMA (chapter 2.5.2).
6.2.4 Polymorphism Identification
PCR products from individuals showing chromatograms/melting profiles suggestive of 
heteroduplex formation were sequenced in both directions using Big-Dye terminator 
chemistry and the ABI3100 sequencer (Applied Biosystems, Foster City, USA), details 
of which are given in chapter 2.6.
6.2.5 SNP Selection
All DNA variants detected, as well as rs2743986, which had been reported to be 
associated to schizophrenia in previous studies [207, 367], were genotyped in the 30 
CEPH parent-offspring trios that constitute the HapMap CEU sample and their 
genotypes combined with all SNPs (n=163) of HapMap phase II (Jan 06) that span the 
MUTED locus (chr6:7950869-8017990, March 2006 freeze). Aggressive tagging via 
the Tagger function of Haploview was then used to select a set of tag SNPs which 
captured all alleles at this locus with an MAF >0.05 at an r2>0.8.
6.2.6 Genotyping
SNPs were genotyped using a Sequenom Mass ARRAY™ system [370] as described in 
chapter 2.7.1.
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6.2.7 Statistical Analysis
6.2.7.1 Association Analysis
Each marker was tested for allelic and genotypic association using %2 ld f and 2df tests. 
Goodness of fit tests for Hardy-Weinberg equilibrium (HWE) were performed in the 
cases and controls separately. All association and permutation analysis was performed 
in PLINK [256] apart from genotypic permutation analysis which was performed using 
CLUMP [321]. Analysis of all combinations of 2 and 3 marker haplotypes were 
performed using UNPHASED [371].
6.2.7.2 Imputation Analysis
Imputation analysis allows the prediction of individual genotypes for a specific sample, 
in this case the schizophrenia case control sample, with reference to the genotypic and 
linkage disequilibrium data from the HapMap dataset. A model based imputation 
method operated using PLINK [256] was used to predict genotypes of SNPs at the 
MUTED locus (chr6:7950869-8017990) that were included in the HapMap phase II 
CEU data but were not genotyped in this study.
6.2.7.3 Interaction Analysis
Gene x gene interaction analysis was performed using logistic regression [67] with 
Gene Interaction Tool designed by Dr. Valentina Moskvina 
(http://x001.psycm.uwcm.ac.uk/GIT/GIT.html). Markers were coded in terms of 
additive and dominance components of the genotype, and then two models (main 
effects and main effects plus interaction terms) were fitted and compared by using the 
likelihood ratio test. For marker combinations where the full interactive model could 
not be calculated, either due to a high standard error for the coefficient estimates or the 
presence of singularities in the model, stepwise reduction of the number of interaction 
terms was then used to find the largest model. For each between-gene marker pairing an 
empirical estimate of the significance was made by permuting affection status and
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determining whether and to what extent the model with interactive terms was 
significantly superior to that with main effects. Empirical p-values were then estimated 
by dividing the number of times the overall interaction effect p value was smaller in the 
simulated data set than in the specific marker-marker test by the number of simulated 
data sets (n=1000).
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6.3 Results
6.3.1 BLOC 1 S3 Association Analysis
Genotyping rs l2460985 through 709 cases and 719 controls produced a call rate of 
>95%. While HW equilibrium for both cases and controls showed p>0.001, the 
Armitage trend test was used to test for allelic association to compensate for even small 
deviations in HW. However, analysis of rsl 2460985 revealed no evidence for 
significant allelic or genotypic association (Table 6.1).
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rsID ChromosomalPosition Alleles
Frequency
Cases
Frequency
Controls
Arm Trend 
P-Value
Counts
Cases
Counts
Controls
HW Case 
and Controls
HW
Cases
HW
Controls
Genotypic
P-Value
rsl 2460985 Chr19: 50382729 CfT 0.17(C) 0.18 0.475 18/168/419 17/209/452 0.445 0.816 0.213 0.452
Table 6.1. Case/Control association analysis o f rsl260985 at the BLOC1S3 locus. SNP position is according to UCSC human genome chromosome 6 reference 
sequence (March 2006 freeze). Minor allele frequencies (MAF) are shown for the specific allele in parentheses.
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6.3.2 MUTED Putative Regulatory Region Identification
As no one comprehensive in silico method has been determined to detect cis-acting 
regulatory sequence, the identification o f putative regulatory regions at the MUTED 
locus was performed using a complimentary set of analyses. This consisted of 
identifying putative promoter region(s) plus determining regions containing TFBSs and 
evolutionary conserved sequence. Analysis o f chr6:7949215-8019646 identified 7 
MUTED putative regulatory regions (Figure 6.3). Exact chromosomal positions and 
PCR primers for mutation screening of these putative regulatory regions and all exonic 
sequence determined are given in Appendix Table 9.3.1. One “core promoter” region 
for all MUTED transcripts was identified. O f the remaining 6 regions, 5 contained 
highly conserved sequence which was determined using either ECR browser (n=l), 
USCS “most conserved” track (n=2) or both (n=2). Analysis using the web based 
program Cluster Buster predicted one region to contain multiple transcription factor 
binding sites.
cnr6 : I 79550001 79600001 79650001 79700001 79750001 79800001 79850001 7990000| 79950001 80000001 80050001 80100001 80150001
Core as
Conserved
7 I  6 |  4 |
S I
TFBS
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Figure 6.3. Analysis o f the MUTED locus by a combination o f methods identified 7 putative regulatory 
regions. The putative promoter sequence immediately 5 ’ to the transcription start site o f the MUTED 
isoforms is illustrated under the track named “Core”. Evolutionary conserved regions are given within 
the “Conserved” track. Regions identified by Cluster Buster as containing multiple TFBSs are shown 
under the track name “TFBS”.
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6.3.3 MUTED Polymorphism Identification
PCR optimisation was achieved for all exonic and putative regulatory regions except 
the regulatory region 3 (chr6: 7994178-7994348). Attempted genotyping of three 
dbSNPs within this region (rs9379158, rs9379159, rs9406083) also failed. Therefore 
polymorphisms within this region have not been included in the subsequent analysis. 
Analysis of this region in UCSC identified the sequence to be highly repetitive with a 2 
ALU elements plus a short repetitive sequence covering 91% of the region which may 
explain the problems encountered. dHPLC parameters for MUTED putative promoter 
and exonic regions are given in Appendix Table 9.3.2.
Screening all MUTED exons plus the remaining putative regulatory sequence identified 
17 sequence variants (Table 6.2), three of which were upstream of the MUTED gene 
and seven were detected within the 3’UTR. Seven SNPs were intronic, four of which 
were located within conserved non-coding sequence (CNC). Four variants had not been 
previously deposited in dbSNP (Muted_Ex5_snpl, Muted_Reg6_snpl, 
Muted_Reg2_snpl and Muted_Reg2_snp2).
Snp ID Chromosomal Position Alleles Location MAF
Muted_Ex5_snp1 7959444 C/G 3’ UTR 0.011 (C)
rs2748375 7959703 G/T 3' UTR Not typed
rs2815151 7959989 T/C 3' UTR 0.288 (T)
rs2748376 7960128 A/G 3' UTR 0.292 (A)
rsl 0458217 7960274 T/C 3’ UTR 0.175 (T)
rs3734590 7960719 G/A 3' UTR 0.175 (G)
rs3734591 7960820 G/A 3’ UTR 0.175 (G)
rs2057185 7961088 C/T Intron 4 0.117(C)
rsl 3202814 7961156 G/T Intron 4 0.195 (G)
rsl 0458106 7965466 T/C Intron 4 CNC 0.175 (T)
Muted_Reg6_snp1 7965521 A/G Intron 4 CNC 0(A )
rs2815128 7968461 G/T Intron 4 CNC 0.314 (G)
rs13191023 7968556 A/G Intron 4 CNC 0.175(A )
rs9328452 7971576 A/G Intron 4 0.305 (A)
Muted_Reg2_snp1 8009676 A/G Upstream Core Promoter Not typed
Muted Reg2_snp2 8010014 A/G Upstream Core Promoter 0.058 (A)
rs2815155 8010229 A/G Upstream Core Promoter 0.458 (A)
Table 6.2. Sequence variants identified at the MUTED locus.
SNP positions are according to UCSC human genome chromosome 6 reference sequence (March 2006 
freeze). Minor allele frequencies (MAF) in the HapMap CEU sample are shown for the specific allele in 
parenthesis. Muted_Ex5_snp 1, Muted_Reg6_snpl, Muted_Reg2_snpl and Muted_Reg2_snp2 are novel 
SNPs that were identified during this study.
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6.3.4 MUTED Association Analysis
Aggressive tagging via the Tagger function of Haploview selected a set of 19 tag SNPs 
which captured 94% alleles at the MUTED locus with an MAF >0.05 at an r2>0.8. Of 
the 19 tag SNPs genotyped in the UK case control sample, all had a call rate of >95%. 
Individuals were included in analysis if they had a genotype call rate >80%. This meant 
46 individuals were dropped from the original sample.
All markers were in HW equilibrium at p>0.001 for both cases and controls. However 
to compensate for even small deviations in HW, the Armitage trend test was used to 
test for allelic association.
While an Armitage trend test of rsl 002308 revealed no evidence for an allelic 
association (p=0.269), the test for genotypic association was nominally significant 
(p=0.022). However this would not survive Bonferroni correction for multiple testing 
(threshold p=0.002). Individual genotyping of the remaining 18 SNPs in the association 
sample of 709 schizophrenia cases and 716 controls revealed no evidence for 
significant allelic or genotypic association at any marker (Table 6.3). In reference to the 
previous association study by Straub et al [207], association analysis failed to replicate 
the allelic association previously observed at rsl04758217 (p=0.75), rs2815145( r2=l 
with rs2815155, p=0.97) and rs2743986 (p=0.91).
As tag SNP selection was based on aggressive tagging, 2 and 3 marker haplotype 
analysis is also important. However this also failed to identify any 2 or 3 marker 
haplotypes that were globally associated with schizophrenia (p min= 0 .08).
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No rsID
Chromosomal
Position Alleles
Frequency
Cases
Frequency
Controls
Arm T rend P 
(Emp P)
Counts
Cases
Counts
Controls
HW C ase 
and Controls
HW
Cases
HW
Controls
Genotypic P 
(Emp P)
1 rsl 002308 7955696 A/C 0.486 (A) 0.508 0.269 (0.268) 172/292/190 175/362/164 0.211 0.006 0.4063 0.020 (0.020)
2 Mutedex5_5snp1 7959444 G/C 0.014 (G) 0.017 0.486 (0.486) 1/16/638 0/24/678 0.275 0.112 1.000 NA (0.335)
3 rs2815151 7959989 T/C 0.343 (T) 0.351 0.669 (0.670) 91/262/294 85/323/294 0.118 0.011 0.8680 .115 (0.115)
4 rs10458217 7960274 T/C 0.166 (T) 0.162 0.756 (0.756) 23/173/462 19/190/495 0.279 0.204 0.890 0.683 (0.683)
5 rs2057185 7961088 C/T 0.180 (C) 0.190 0.502 (0.496) 30/174/447 30/205/462 0.015 0.023 0.267 0.545 (0.545)
6 rsl 3202814 7961156 G/T 0.139 (G) 0.154 0.276 (0.277) 9/164/481 16/183/500 0.447 0.325 1.000 0.392 (0.392)
7 rs2207720 7964196 C/T 0.492 (C) 0.473 0.353 (0.353) 156/296/166 157/324/193 0.164 0.296 0.354 0.646 (0.646)
8 rsl 0458106 7965466 T/C 0.167 (T) 0.162 0.702 (0.712) 22/174/456 18/190/491 0.488 0.323 1.000 0.683 (0.683)
9 rs2815128 7968461 G/T 0.366 (G) 0.373 0.702 (0.697) 89/298/264 106/307/283 0.198 0.736 0.144 0.679 (0.679)
10 rs13191023 7968556 A/G 0.136 (A) 0.156 0.138 (0.135) 9/157/479 16/185/496 0.511 0.403 0.8860 .281 (0.281)
11 rs9328452 7971576 T/C 0.365 (T) 0.369 0.837 (0.836) 88/300/264 102/311/285 0.349 0.866 0.256 0.792 (0.792)
12 rs9502675 7971924 T/C 0.192 m 0.186 0.719 (0.723) 26/199/430 24/213/464 0.790 0.614 1.000 0.866 (0.866)
13 rsl 3218209 7983148 A/G 0.306 (A) 0.317 0.530 (0.538) 63/273/317 63/316/319 0.568 0.712 0.255 0.439 (0.439)
14 rs2206098 7991601 G/A 0.149 (G) 0.159 0.477 (0.475) 16/163/477 19/184/497 0.531 0.643 0.671 0.774 (0.774)
15 rs2815145 7993302 T/C 0.489 (T) 0.489 0.973 (0.991) 156/325/170 175/335/191 0.414 1.000 0.257 0.735 (0.735)
16 rs2743986 8011954 T/C 0.501 (T) 0.499 0.910 (0.919) 162/329/161 179/334/181 0.586 0.876 0.324 0.689 (0.689)
17 rs2326975 8014321 C/T 0.056 (C) 0.052 0.687 (0.709) 2/69/586 2/69/630 1.000 1.000 0.711 NA (0.920)
18 rs9392958 8016561 T/C 0.338 (T) 0.342 0.802 (0.800) 69/299/279 75/325/294 0.201 0.430 0.312 0.961 (0.961)
19 rs9378519 8016671 A/T 0.258 (T) 0.266 0.598 (0.617) 41/256/359 46/281/373 0.401 0.683 0.562 0.864 (0.864)
Table 6.3. Case/Control association analysis o f 19 tag SNPs spanning the MUTED locus. SNP positions are according to UCSC human genome chromosome 6 
reference sequence (March 2006 freeze). Minor allele frequencies (MAF) are shown for the specific allele in parentheses. Allelic association results are shown with 
permutation (1000) p values in parentheses.
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6.3.5 MUTED Imputation Analysis
Imputation analysis relies on genotypic data from the HapMap CEU sample dataset. 
Genotypic data for two of the 19 tag SNPs genotyped in this study were not available 
on the HapMap CEU sample database (Muted_ex5snpl and rs2743986). These two 
SNPs were therefore not informative for imputation analysis. Imputation analysis of the 
remaining 17 tag SNPs allowed the genotypes of an additional 72 SNPs at the MUTED 
locus (chr6:7950869-8017990) to be predicted in our cases and controls with >80% 
probability (data not presented). Allelic and genotypic association analysis revealed that 
of these 72 SNPs, none were significantly associated with schizophrenia (imputed 
allelic p min = 0 .100, imputed genotypic pmjn=0.054).
6.3.6 MUTED and DTNBP1 Interaction Analysis
In an attempt to directly replicate the interaction reported by Morris et al [367] logistic 
regression was performed using the same markers reported to show a significant 
interaction (rsl0458217 (MUTED) and rs2619539 (DTNBP1)). However this failed to 
reveal any evidence for a significant locus/locus interaction (p=0.273, Appendix Table 
9.3.3A), nor at the specific allelic model that was reported (additive model p=0.078, 
Appendix Table 9.3.3B).
Subsequently all possible MUTED and DTNBP1 marker interactions were tested, using 
both additive and additive plus dominant models, with the 19 SNPs genotyped at the 
MUTED locus and 15 SNPs previously genotyped in the same sample at the DTNBP1 
locus [134]. This identified nominally significant evidence for interaction at 26 
different marker combinations using the full interaction model, five of which were 
significant at p<0.01 (rs2815151-SNPN p=0.0007, rs9328452-rs 12204704 p=0.002, 
rs 13218209-rs 12204704 p=0.006, rs2206098-rs 12204704 p=0.007, rs2815128- 
rsl2204704 p=0.002) (Appendix Table 9.3.3A). Six marker combinations were 
significant using the additive model (0.01<p<0.05) and one significant marker 
combination at p<0.01 (rs2815151-SNPN, p=0.0001, Appendix Table 9.3.3B). Under
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the full model no marker combinations were significant after multiple testing, however 
one significant result under the additive model was still associated after 1000 
permutations (rs2815151-SNPN, p=0.026).
6.3.6.1 rs2815151 and SNPN Significant Interaction
rs2815151 (MAF=0.29) is located in the 3’UTR of the MUTED gene (chr6:7959989). 
SNPN is a rare intronic polymorphism (MAF=0.04) located near the 3’ end of 
DTNBP1 (chr6:15658414). Further analysis of this SNP interaction (Table 6.4) 
indicates that the majority of the signal may be explained by genotypic combinations of 
very low frequency. The genotypic combination of MUTED rs2815151 (CC) x 
DTNBP1 SNPN (DEL/DEL) is the only combination which shows a difference 
between cases and controls where genotype frequencies are over 5% (14.5% in the 
cases and 10.5% in the controls, case/control ratio =1.41). The remaining genotypic 
combination ratios whose case/control ratio significantly differs from 1 (TT:G/DEL 
ratio =1.63, CT:G/DEL ratio = 0.361, CC:G/DEL ratio=0.298) have frequencies in both 
the cases and the controls of <0.05.
Case DTNBP1 SNPN
lO GG G/DEL DEL/DEL
lO TT 0.00391 (2) 0 .0 4 3  (22) 0 .395  (202)
00
CM CT 0 (0) 0 .0 1 5 6  (8) 0 .395  (202)
12 CC 0 (0) 0 .0040  (2) 0 .145  (74)
Control DTNBP1 SNPN
T-
in GG G/DEL DEL/DEL
in TT 0 (0) 0 .0263  (14) 0 .386  (206)
CO CT 0 .00563  (3) 0 .0432  (23) 0 .422  (225)
12 CC 0 (0) 0.0131 (7) 0 .103  (55)
Ratio Case/Control DTNBP1 SNPN
In GG G/DEL DEL/DEL
in TT INF 1.63 1.02
00 CT 0 0.361 0 .936
<2 CC NA 0.298 1.41
Table 6.4. Breakdown o f  significant interaction between Muted SNP rs2815151 and DTNBP1 SNPN 
under an additive model. The majority o f the interaction comes from very low frequency genotypes with 
the only common signal detected with CC:DEL/DEL which is 14.5% in cases and 10.3% in controls 
(ratio 1.41). Genotype counts are given in brackets.
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6.4 Discussion
A large body of genetic association data implicates DTNBP1 as a schizophrenia 
susceptibility gene, but its exact role in the pathogenesis of schizophrenia is currently 
unknown. Evidence supporting the involvement of DTNBP1 through its role in the 
BLOC-1 complex has come from genetic association studies of genes that code for 
proteins within the complex [207, 367, 372], but that evidence is not yet compelling. 
Significant evidence for an association between MUTED and schizophrenia has been 
reported [207, 372] and while a study by Morris and colleagues failed to identify any 
evidence for a main effect at MUTED, they did report evidence for interaction between 
MUTED and DTNBP1. Morris and colleagues also reported a significant association 
between a SNP at the BLOC 1 S3 locus and schizophrenia [367].
This chapter set out to analyse the significant association observed by Morris and 
colleagues for rsl2460985, as SNP 3’ to BLOC1S3 in addition to performing a detailed 
association analysis between common variation at the MUTED locus and 
schizophrenia. Analysis of rsl 2460985 within 709 cases and 719 controls revealed no 
evidence for association (p=0.475). Therefore we failed to replicate the findings of 
Morris et al.
Mutation screening of MUTED exons and putative regulatory sequence identified 17 
SNPs which were combined with 163 SNPs which spanned the MUTED locus 
(chr6:7950869-8017990) and had been genotyped in HapMap phase II. This defined a 
set of highly informative SNPs which captured the majority of common variation at this 
locus were then genotyped in a relatively ethnically homogeneous case-control sample. 
Analysis of allelic, genotypic plus 2 and 3 marker haplotype distributions in cases and 
controls failed to reveal evidence for association with schizophrenia after correction for 
multiple testing, as did imputation analysis of another 72 HapMap SNPs at the MUTED 
locus.
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In order to test for evidence of a significant interaction between MUTED and DTNBP1 
logistic regression analysis was performed between DTNBP1 and MUTED markers. 
The specific interaction analysis reported associated by Morris and colleagues [367] 
was not significant in our sample. Interaction analyses of all the other marker 
combinations identified one marker combination under the additive model which was 
still significant after multiple testing (rs2815151-SNPN p=0.026). However SNPN has 
a MAF=0.04 and the majority of the significant interaction appears to be accounted for 
by very low genotype counts (MAF<0.05).
In summary the data presented in this chapter provides no support for the hypothesis 
that either BLOC 1 S3 or MUTED are independent susceptibility genes for 
schizophrenia. However while we did not replicate the interaction found by Morris and 
colleagues [367], a weakly significant interaction was observed between DTNBP1 and 
MUTED with two other markers.
The presence of allelic heterogeneity at the DTNBP1 locus could dramatically 
influence the power of our study to replicate the locus-locus interaction analysis of 
Morris et al [367]. However given that the UK case-control sample used in this chapter 
is of similar ethnicity as the Irish sample used by Morris et al [367] and that the Irish 
sample has previously shown a significant association at the DTNBP1 locus with the 
same risk haplotype as the UK sample [134] this is not a particularly likely explanation.
Another potential explanation for the differing results is the fact that epistasis is 
difficult to detect and characterise using traditional parametric statistical methods. This 
includes logistic regression which has been used both in this chapter and in the Morris 
study [367]. This difficulty stems from the fact that when interaction between multiple 
polymorphisms, or polymorphisms of low frequency are considered, genotype 
combinations are produced that have very few or no data points. Logistic regression can 
also lead to either an increase in type I errors (i.e. false positives) due to the large 
standard errors, or an increase in type II errors (i.e. false negatives) and a decrease in 
power from attempting to fit the data to a regression model.
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While our study provides no definitive support for BLOC 1 S3 or MUTED as 
schizophrenia susceptibility genes, and thereby no support for the hypothesis that 
DTNBP1 contributes to susceptibility to schizophrenia through the BLOC-1 complex, 
the latter hypothesis cannot be rejected. Firstly, we have not tested every SNP in every 
BLOC-1 related gene. Our analysis of the BLOC 1 S3 gene only included the analysis of 
rsl2460985, a SNP reported as significantly associated with schizophrenia by Morris et 
al (p= 0.0028) [367]. Secondly, our sample, while relatively large in schizophrenia 
research and powered to identify association with common risk alleles at the BLOC 1 S3 
or MUTED locus (power >0.8 to detect association with a relative risk of 1.4 to alleles 
with a population frequency of 0.1 at p=0.05) it is underpowered to detect small effects 
(OR<1.4). Finally, while the hypothesis that DTNBP1 contributes to susceptibility to 
schizophrenia through the BLOC-1 complex would certainly be strengthened by clear 
demonstration of the involvement of another gene in that complex, it is not a 
requirement of the hypothesis that a susceptibility variant exists in any other member.
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Chapter 7: Allelic Expression Analysis of BLOC-1 
Genes
7.1 Introduction
As discussed in chapter 6, Morris and colleagues [373] performed an association 
analysis on all known BLOC-1 genes other than dysbindin (CNO, MUTED, PLDN, 
SNAPAP, BLOC1S1, BLOC1S2 and BLOC 1 S3). Though nominal significance was 
observed for MUTED and BLOC 1 S3, no association was reported between 
schizophrenia and the five remaining genes. This could suggest that either the Morris 
study was underpowered to detect association in the other BLOC-1 genes or that only 
certain genes within the complex are involved in schizophrenia pathology. It is also 
possible that the actual causal variants were not subjected to association analysis or in 
sufficient LD with the SNPs that were genotyped. Apart from Morris et al who 
analysed polymorphisms within the sequence immediately 5’ to each gene, no previous 
studies of BLOC-1 genes [207] have screened for DNA variants that have the potential 
to regulate expression. As discussed in previous chapters it is possible that dysbindin 
confers susceptibility to schizophrenia through altered expression. It is therefore also a 
valid hypothesis that alteration of expression of other BLOC-1 genes could confer 
susceptibility to schizophrenia. If this were true then risk variants may be located 
within cis-acting regulatory elements such as transcription factor binding sites.
Consequently allelic expression was performed to determine whether, in addition to 
dysbindin, any of the other known BLOC-1 genes are under the influence of cis-acting 
variation. Any genes showing differential expression were analysed for putative 
regulatory regions using the methods described in chapter 3. These regions plus all 
exonic sequence were screened for DNA variants which were subsequently subjected to 
association analysis with schizophrenia.
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7.2 Methods
7.2.1 Subjects
7.2.1.1 Caucasian Brain Sample
Allelic expression analysis was performed using the Caucasian Brain sample described 
in chapter 2.1.2. The initial analysis utilised a sample of 60 individuals obtained from 
the Stanley Medical Research Institute Brain Bank, Bethesda, USA. The remaining 88 
samples (which were assayed when a difference in allelic expression was detected in 
the first sample set) were obtained from three sources, the MRC London 
Neurodegenerative Diseases Brain Bank, London, UK; the Department of Clinical 
Neuroscience, Karolinska Institute, Sweden and the Mount Sinai School of Medicine, 
New York, USA.
7.2.1.2 UK Schizophrenia Case Control Association Sample
Informative SNPs for genes showing allelic expression differences were genotyped 
through the UK case control sample consisting of 709 cases and 716 controls. The 
specific details of these individuals are described in chapter 2.1.1.
7.2.2 BLOC-1 Gene Identification
After an initial literature search of the term “BLOC-1 complex”, members of the 
BLOC-1 complex were sourced from a number a publications (CNO [209], PLDN and 
MUTED [210], SNAPIN, BLOC1S1, BLOC1S2 and BLOC 1 S3 [211]).
7.2.3 Relative Allelic Expression Assay
Allelic expression analysis was performed as described in chapter 2.9. The allelic 
expression analysis of CNO was performed by Dr. Nicholas Bray.
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All ratios (corrected genomic or cDNA) were normalised via a natural log 
transformation. After conformation by the Kolmogorov-Smimov test that the 
transformed gDNA and cDNA data followed a normal distribution, gDNA and cDNA 
values were compared by a 2 independent sample t-test. To account for the possibility 
of weak LD between the assayed SNP and a potential regulatory SNP and/or multiple 
cis-acting variants the spread of the cDNA ratios and gDNA ratios were compared 
using the Levene’s test.
Evidence for differential allelic expression was deduced if an assay met the following 
criteria. Firstly, one or more samples had to show a differential expression of greater 
than 20% (0.8>ratio>1.2) after correction using the average genomic ratio. Secondly, a 
statistically significant difference (p<0.05) needed to be observed with either 2 
independent samples t-test or Levene’s test. More details of these criterion are given in 
chapter 2.9.1.
7.2.4 Power Detection
The calculation performed to determine the power of a sample to detect the effects of 
unknown regulatory variants is based on the binomial distribution. It assumes Hardy- 
Weinberg equilibrium at the regulatory SNP and no LD with the marker SNP [194]. 
The probability of an individual being homozygous at a putative regulatory locus with 
alleles in Hardy-Weinberg equilibrium is P2 + q2, where p and q are the two allele 
frequencies. Therefore the probability that, of n individuals assayed, all are 
homozygous for a regulatory polymorphism (meaning the regulatory variant will go 
undetected by the assay) is (p2 + q2)n. The power to detect at least one heterozygote at 
an unknown regulatory locus is therefore 1 - (p2 + q2)n. If the marker and regulatory 
SNP are in LD, then a higher proportion of people selected for heterozygosity at the 
allelic expression marker will also be heterozygous for the regulatory SNP and the 
power will be increased.
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7.2.5 Association Analysis
Any BLOC-1 genes showing common allelic expression differences (multiple 
individuals with ratio greater than 20% plus a significant independent sample t-test or 
Levene’s test) were subjected to association analysis with schizophrenia. Putative 
regulatory regions were identified as described in chapter 3.2.1. These regions plus 
exonic sequence were then screened for polymorphisms using high resolution DNA 
melting analysis technology and Sanger sequencing as described in chapters 2.5.2 and
2.6 respectively.
All detected DNA variants were genotyped in the 30 CEPH parent-offspring trios that 
constitute the HapMap CEU sample. SNPs were then combined with all SNPs of the 
HapMap phase II (Nov 08) that spans the assayed gene (largest transcript ± lkb). 
Pairwise tagging via the Tagger function of Haploview was then used to select a set of 
SNPs which captured all the alleles at the specified locus, plus any within distal 
putative regulatory regions identified, with a MAF >0.001 and at an r2>0.95. Tag SNPs 
were genotyped by Sequenom Mass Array (see chapter 2.7.1). If genotyping failed 
using Sequenom Mass Array, genotyping was attempted using Amplifluor (see chapter 
2.7.3).
7.2.5.1 Statistical Analysis for Association
Association analysis and Hardy-Weinberg equilibrium (HWE) tests were performed 
using plink software [256]. Each marker was tested for allelic association using the 
Armitage trend test. Genotypic association was performed using %2 2df tests. For SNPs 
whose genotype counts are less than 5 genotypic association analysis was performed 
using CLUMP with 10000 permutations [321]. Goodness of fit tests for HWE were 
performed in the cases and controls separately.
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7.3 Results
7.3.1 SNP Selection
In order to determine whether any BLOC-1 genes are under the influence of cis-acting 
variation, polymorphisms were identified for each BLOC-1 gene that a) were located 
within one or more predicted mRNA transcripts, b) were able to be assayed by primers 
that would amplify both genomic and cDNA and c) had frequency information for the 
CEU population. For each BLOC-1 gene the SNP with the highest minor allele 
frequency was selected for allelic expression analysis so as to maximise the number of 
heterozygotes studied. In order to have power to infer whether a gene is under common, 
relatively rare or no cis-acting variation, a minimum MAF threshold of 0.05 was 
specified for the assay SNP. It was estimated that, for the sample size used (n=60), this 
should provide at least 5 heterozygotes for analysis.
The rs#, chromosomal position and minor allele frequency of each SNP selected for 
allelic expression analysis of PLDN, SNAPAP, CNO, MUTED and BLOC 1 S3 are 
given in Table 7.1.
Gene SNP ID SNP Position Frequency in CEU
PLDN rs7181436 C>T chrl 5:43687710 0.183
MUTED rs3734590 T>C chr6:7960719 0.175
CNO rs3172604 T>G chr4:6769676 0.392
SNAPAP rs7345 C>A chrl: 151900682 0.467
BLOC1S3 rs758506 C>T chrl 9:50374664 0.075
Table 7.1. The rs#, chromosomal position and MAF o f each SNP selected for allelic expression analysis 
o f PLDN, SNAPAP, CNO, MUTED and BLOC 1 S3. SNP positions are according to UCSC human 
genome chromosome 6 reference sequence (March 2006 freeze).
BLOC1S1 and BLOC1S2 could not be examined for differential expression, as while 
the exonic or untranslated regions of BLOC1S1 and BLOC1S2 contain 3 and 11 
dbSNPs respectively, each of these SNPs either had no frequency information or a 
MAF<0.05 in the CEU population.
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According to dbSNP BLOC 1 S3 contains 7 exonic SNPs. As with BLOC1S1 and 
BLOC1S2 none of these reached the MAF threshold of 5%. However as BLOC 1 S3 had 
previously been identified as associated with schizophrenia [373], the coding SNP 
rs758506 (which previously has no frequency information) was genotyped through 
HapMap CEU sample in order to assess its potential for allelic expression analysis. In 
this population the MAF of rs758506 was 0.075. Consequently BLOC1S3 was 
subjected the allelic expression analysis with this SNP.
7.3.2 Allelic Expression Analysis
In total five BLOC-1 genes, PLDN, SNAPAP, BLOS1S3, MUTED and CNO were 
subjected to allelic expression analysis. An outline of the results can be found in Table
7.2. A more detailed summary of each gene is given below.
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Gene SNP ID Individuals genotyped # of hets assayed # of hets SD<0.2 SD/mean cDNA average Individuals >20% T-test P Levens P
PLDN rs7181436 60 15 10 0.033 0.964 0 N/A N/A
MUTED rs3734590 148 40* in duplicate 36 0.081 1.010 4 0.872 0.012
CNO rs3172604 60 20 in duplicate 18 0.045 1.227 11 2.423E-07 0.020
SNAPAP rs7345 60 29 21 0.082 1.010 0 N/A N/A
BLOS3 rs758506 60 7 6 0.050 0.941 0 N/A N/A
Table 7.2. Summary o f results allelic expression results for five BLOC-1 genes.
* Stanley and Extra samples genotyped. All other genes were analysed with just the Stanley sample.
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7.3.2.1 PLDN
The SNP rs7181436 was selected for allelic expression analysis of PLDN (see Figure
6.1 for chromosomal location). Genotyping of SNP rs7181436 in the gDNA of 60 
samples identified 15 heterozygotes. Allelic expression analysis was performed on 
cDNA generated from cerebral cortex post-mortem tissue of these 15 heterozygote 
individuals. Five samples showed a standard deviation >0.2 between duplicate RT 
reactions and so were removed from further analysis. The mean standard deviation for 
the remaining 10 samples was 0.033. Figure 7.2 shows the corrected genomic DNA 
ratios and the corrected cDNA averaged ratios (common allele/rare allele, C/T) for each 
sample.
No individuals showed differential expression of greater than 20% (1.2>C/T ratio>0.8), 
the predefined threshold to determine individuals showing allelic expression 
differences. No significant difference in variance between genomic and cDNA ratios 
was observed (Levene’s test p=0.822) though a nominal difference was observed 
between the mean of the corrected allele ratios for the gDNA versus cDNA 
(independent t-test p=0.031). However this significant difference was observed 
between C/T ratios of 1 for gDNA and 0.96 for cDNA. Therefore it can be concluded 
that PLDN does not show any evidence that it is under the influence of cis-acting 
variation.
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Figure 7.1. Chromosomal position o f rs7181436. Allelic expression analysis o f this SNP captures 
variation in expression o f all predicted mRNA transcripts.
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Figure 7.2. Relative allelic expression assay o f rs7181436, a SNP within the 3’UTR o f the PLDN gene. 
Both gDNA and cDNA were analysed in 10 heterozygote individuals using cDNA gained from the 
cerebral cortex. gDNA and cDNA allelic ratios (C/T) have been corrected by the mean gDNA ratio for 
all samples. Independent T-test p=0.031, Levene’s test =0.822.
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7.3.2.2 SNAPAP
The SNP rs7345 was selected for allelic expression analysis of SNAPAP (see Figure
7.3 for chromosomal location). Genotyping of this SNP in 60 individuals identified 29 
heterozygotes. After allelic expression analysis was performed on these 29 samples, 8 
samples showed a standard deviation >0.2 between duplicate RT reactions and so were 
removed from further analysis. The mean standard deviation between cDNA samples 
for the remaining 21 individuals was 0.082. Figure 7.4 shows the corrected genomic 
DNA ratios and the corrected cDNA averaged ratios (common allele/rare allele, C/A) 
for each sample.
No significant difference was observed between the mean of the corrected allele ratios 
for the gDNA versus cDNA (independent t-test p=0.786) though a nominal difference 
of the variance between genomic and cDNA ratios was observed (Levene’s test 
p=0.017). However no individuals showed differential expression of greater than 20%. 
This could suggest that rs7345 is in relatively low LD with a weak regulatory SNP. 
Nevertheless, using the previously set threshold of 20% as an indication of differential 
expression, this assay does not provide any evidence that SNAPAP is under the 
influence of cis-acting variation.
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Figure 7.3. Chromosomal position of rs7345. Allelic expression analysis o f this SNP will capture 
variation o f all SNAPAP predicted mRNA transcripts.
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Figure 7.4. Relative allelic expression assay o f rs7345, an exonic SNP within the SNAPAP gene. Both 
gDNA and cDNA were analysed in 21 heterozygote individuals. gDNA and cDNA allelic ratios (C/A) 
are corrected by the mean gDNA ratio for all samples. Independent T-test p=0.786, Levene’s test =0.017.
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rs758506 was selected for allelic expression analysis of BLOC1S3 (see Figure 7.5). 
Genotyping of this SNP in 60 individuals identified seven heterozygotes. Allelic 
expression analysis was therefore performed on these samples. One individual showed 
a standard deviation between duplicate RT reactions of >0.2 and so was removed from 
further analysis. The mean standard deviation for the remaining 6 samples was 0.050. 
Figure 7.6 shows the corrected genomic DNA ratios and the corrected cDNA averaged 
ratios (common allele/rare allele, C/T) for each sample.
No individuals showed differential expression of greater than 20% (1.2>C/T ratio>0.8) 
and no significant difference in variance between genomic and cDNA ratios was 
observed (Levene’s test p=0.344). A nominal difference was observed between the 
mean of the corrected allele ratios for the gDNA versus cDNA (independent t-test 
p=0.049). However as this was a difference between ratios of 1 for gDNA and 0.94 for 
cDNA it can be concluded that there is no evidence that BLOC 1 S3 is under the 
influence of cis-acting variation assayed by this polymorphism.
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Figure 7.5. Chromosomal position o f rs758506. Allelic expression analysis o f  this coding SNP captures 
variation at all BLOC 1 S3 predicted mRNA transcripts.
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Figure 7.6. Relative allelic expression assay o f  rs758506, a coding SNP within the BLOC 1 S3 gene. Both 
gDNA and cDNA were analysed in 6 heterozygote individuals. Corrected gDNA and cDNA allelic ratios 
(C/T) are shown. Independent T-test p=0.049, Levene’s test =0.344.
cDNA
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73.2.4 MUTED
Genotyping rs3734590, an exonic SNP within the MUTED gene (Figure 7.7) in 60 
individuals identified 17 heterozygotes. Allelic expression analysis was performed on 
these 17 heterozygote samples. Two samples showed a standard deviation between 
duplicate RT reactions of >0.2 and so were removed from further analysis. The mean 
standard deviation for the remaining 15 samples was 0.075. Two of these individuals 
showed allelic expression differences of >20% (T/C = 0.66 and 0.75 respectively). As 
allelic expression differences had been identified in only 2/15 individuals, rs3734590 
was genotyped in an additional 88 samples. This identified a further 23 heterozygotes 
which were also analysed for allelic expression differences. In total 40 individuals were 
analysed. Twelve of these showed a standard deviation between duplicate RT reactions 
of >0.2 and so were removed from further analysis. The mean standard deviation for 
the remaining 28 samples was 0.073. Four of these individuals showed allelic 
expression differences of >20%.
In order to ensure that these differences were due to cis-acting variation rather than, for 
example, experimental abnormalities, the assay was repeated for all heterozygotes. In 
total all 40 heterozygote cDNA samples were assayed four times and the corresponding 
genomic DNA twice. If a sample showed a standard deviation between duplicate RT 
reactions of >0.2 in one of the two assays, the allelic expression ratio was calculated 
from the one assay with the acceptable SD. After replication four samples showed a 
standard deviation between duplicate RT reactions of >0.2 in both assays and so were 
removed from further analysis. The mean standard deviation for the remaining 36 
samples was 0.081. The average corrected genomic DNA ratios and the average of 
either four or two corrected cDNA ratios (common allele/rare allele, T/C) for each 
sample are given in Figure 7.8.
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Figure 7.7. Chromosomal position o f rs3734590. Allelic expression analysis of this coding SNP captures 
variation at all MUTED predicted mRNA transcripts.
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Figure 7.8. Relative allelic expression assay o f rs3734590, an exonic SNP within the MUTED gene. 
Both gDNA and cDNA were analysed twice in 36 heterozygote individuals using cDNA gained from the 
cerebral cortex. Shown are the average gDNA and cDNA allelic ratios (T/C) corrected by the mean 
gDNA ratio for all samples. Independent T-test p=0.872, Levene’s test =0.012.
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Replication of the assay confirmed that four individuals were under the influence of cis- 
acting variation which caused differential expression of greater than 20% (1.2<C/T 
ratio<0.8).
Although differential expression was observed, the majority of individuals did not show 
allelic expression differences and no significant difference was observed between the 
mean of the corrected allele ratios for the gDNA versus cDNA (independent t-test 
p=0.872). A significant difference of the variance between genomic and cDNA ratios 
was observed however (Levene’s test p=0.012). Of the four individuals showing 
differential expression of greater than 20%, two show an increase of the T allele 
compared to the C alleles (ratios>l .2) and two show a relative increase of the C allele 
over the T allele (ratios <0.8).
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7.3.2.4.1 Individual Phenotypic Analysis
The sample used for allelic expression analysis consists of 76 cases (19 schizophrenia, 
15 bipolar, 16 depression, 4 alcohol or drug dependence, 22 Alzheimer’s disease) and 
73 controls. Therefore the variability in allelic expression ratios between individuals 
could be attributable to these phenotypic differences. In order to examine this 
hypothesis, the diagnosis of the four individuals showing allelic expression differences 
was examined, both between all four individuals and between the pairs showing over 
expression of the T allele (A199/88 and A296/95) and those showing under expression 
(G-19 and G-46). However no similarities were found at a phenotypic level (Table 7.3).
ID Sample AE ratio Gender Age Psycological Diagnosis
G-19 Stanley 0.657 Male 46 Depression
G-46 Stanley 0.748 Female 35 None
A199/88 Extra 1.306 Male 90 Alzheimer's disease
A296/95 Extra 1.386 Male 65 None
Table 7.3. Details o f  individuals showing allelic expression differences o f >20% for rs3734590. The 4 
samples do not show similarity on case/control status.
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7.3.2.5 CNO
Genotyping of rs3172604, an exonic SNP within the CNO gene (Figure 7.9), in the 
gDNA of 60 individuals identified 20 heterozygotes. Allelic expression analysis was 
performed on these 20 heterozygotes. Two samples showed a standard deviation 
between duplicate RT reactions of >0.2 and so were removed from further analysis. 
The mean standard deviation for the remaining 18 samples was 0.045. Figure 7.10 
shows the corrected genomic DNA ratios and the corrected cDNA averaged ratios 
(common allele/rare allele, T/G) for each sample.
A highly significant difference was observed between the mean corrected allele ratios 
for the gDNA versus cDNA with 11 out of 18 individuals showing allelic expression
fyj
differences greater than 20% (independent t-test p=2.42 x 10' ). This is indicative of a 
common cis-acting allele influencing the levels of the CNO gene. Further analysis of 
this data (see Figure 7.10) identified a relative decrease in the expression of the mRNA 
carrying the rarer G allele compared to the mRNA carrying the T allele. As this 
difference was observed in a high percentage of the individuals analysed (61%) there 
was no need to perform allelic expression in further samples.
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Figure 7.9. Chromosomal position o f rs3172604. Allelic expression analysis of this exonic SNP will 
capture variation at all CNO predicted mRNA transcripts.
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Figure 7.10. Relative allelic expression assay o f rs3172604, an exonic SNP within the CNO gene. The 
gDNA and cDNA allelic ratios (T/G) o f 18 heterozygotes were corrected by the mean gDNA ratio for all 
samples. Independent T-test p= 2.42E-07, Levene’s test p =0.02.
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7.3.3 CNO Association Analysis
CNO showed common allelic expression differences with over 60% of assayed 
individuals showing a 20% or more increase in mRNA carrying the G allele of 
rs3172604 compared to mRNA carrying the T allele. Consequently the CNO gene plus 
lOkb 5’ and 3’ (chr4:6,758,743-6,780,288) was screened for putative regulatory regions 
as described in chapter 3. While analysis for sequence of high conservation and DNase 
hypersensitivity did not identify any regions, Cluster Buster (http://zlab.bu.edu/cluster- 
buster) identified three regions predicted to contain multiple transcription factor 
binding sites. The core promoter was defined as lkb 5’ and 3’ to the CNO TSS. These 
regions, plus the CNO gene itself, which consists of just one exon (chr4:6768743- 
6770288) were screened for DNA variants. The regions identified are given in Table
7.3, as are the PCR primer sequences used for mutation screening.
The screening of these regions identified 10 SNPs and one indel (Table 7.4). Five SNPs 
were identified within putative regulatory regions and six polymorphisms within the 
exonic sequence.
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Name Chromosomal Positon (March 2006) Type of Region Method Relation to CNO Forward Reverse
CNO_Reg1 chr4:6766075-6766566 Regulatory Cluster buster 5’ T CTTACAT GAGGTT GCAGTCAA ctcatctacccaagacctgga
CNO_5'region1 chr4:6767761 -6768248 5' Core Promoter 5' actcccagttccaccatctg aaggtgaagttgagatgtgacg
CNO_5'region2 chr4:6768160-6768541 5’ Core Promoter 5' agtctaactgaatggtattctcagg tgtgcacattgatgactttgt
CNO exonla chr4:6768454-6768950 Exonic N/A N/A gttcatgggtgctggacat CTGT GGCT CT GGGAAACAGT
CNO exonib chr4:6768843-6769312 Exonic N/A N/A GGGTAGCTTTTCGGATGG CCTT GGT GACCT GCT CCTC
CNO exonic chr4:6769255-6769754 Exonic N/A N/A GCCTTCGTGAGGATGGTG GAGGTGGAAGGATCACTTGAG
CNO exonld chr4:6769702-6770176 Exonic N/A N/A TATGTT GCCCAGACT GTT CG TGGACAAAT GAAGACT GT GAGG
CNO exonle chr4:6770052-6770449 Exonic N/A N/A AACCT CCTATAGCGT GGATT G gaaaagaaatataccatgctctgaaa
CNO_3'region1 chr4:6770330-6770848 3' Core Promoter 3' CG IACTGCTGAIGIGCTTTI I CCGCAGGAAAATCCTAATACC
CNO_3‘region2 chr4:6770550-6771026 3' Core Promoter 3' cgttcacgccattctcct TCAGATT CTT CACAACACACAGC
CNO_Reg2 chr4:6771114-6771509 Regulatory Cluster buster 3' ggaactctgaatgtagaagctgaa ctcccgggttcacaccat
CNO Reg3 chr4:6777653-6778154 Regulatory Cluster buster 3' ggcactgtcagagcaccac tgcatgcatgtgtgatgtgt
Table 7.3. CNO exonic and putative regulatory regions screened for DNA variants. PCR primer sequences are also given.
SNP Chromosomal Position Alleles Region MAF CEU
CNO Exonl SNP1 chr4 6768674 G>C Exonic N/A
CNO Exonl SNP2 chr4 6769653 T>G Exonic N/A
rs3172604 chr4 6769676 G>T Exonic 0.4
rs11550047 chr4 6769712 A>G Exonic 0
CNO Exonl SNP3 chr4 6769908 C>T Exonic 0.008
CNO Exonl INDEL chr4:6770997-6770000 CAGT/- Exonic 0.37
rs4689525 chr4 6771473 A>T Regulatory2 N/A
rs4689526 chr4 6771482 T>A Regulatory2 N/A
rs12503163 chr4 6777760 C>T Regulatory3 0.57
rs12503199 chr4 6777877 C>T Regulatory3 0.57
rs12505863 chr4 6777940 A>G Regulatory3 0.69
Table 7.4. SNPs identified through screening o f exonic and putative regulatory regions o f CNO. Where frequency information was already known or where it has 
been possible to type these through the HapMap CEU sample, minor allele frequency (MAF) data is given.
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Of the 11 polymorphisms identified, four variants were not referenced in dbSNP 
(CNO_exonl_snpl, CNO_exonl_snp2, CNO_exonl_snp3 and CNO_exonl_indel). 
Only two polymorphic SNPs within the CNO locus have been deposited in the HapMap 
database (March 2008), both of which were detected in this screening (rs3172604 and 
rsl2503163). An attempt was made to genotype the remaining nine polymorphisms 
through the HapMap CEU sample. However four SNPs (See Table 7.4) detected 
through screening of the CNO gene and putative regulatory regions failed genotyping 
by both Sequenom MassARRAY and Amplifluor. All four of these SNPs fall in or near 
a repetitive element. These four SNPs have therefore not been captured in the 
subsequent study. Pairwise tagging of the remaining 7 polymorphisms selected a set of 
five tag snps which captured 100% of the variation at i^>0.95 and MAF>0.001. 
However due to genotyping failure of rs3172604 through the UKCC sample a final set 
of 4 tag SNPs were typed which captures 83% at r2>0.95 and MAF>0.001 of all DNA 
variants.
Of the 4 tag SNPs genotyped across the CNO locus and putative regulatory regions all 
had a call rate of >95%. Individuals were only included in analysis if they had 
genotypes for >2 of the 4 SNPs analysed. This meant 17 individuals were dropped from 
the original sample. All markers were in HW equilibrium at p>0.001 for both cases and 
controls. However to compensate for even small deviations in HW, the Armitage trend 
test was used to test for association (Table 7.5a). Of the four polymorphisms genotyped 
through the UKCC sample none showed allelic or genotypic association with 
schizophrenia (Table 7.5a and 7.5b).
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rsID
Chromosome 6 
Position Alleles
Frequency
Cases
Frequency
Controls Arm Trend P
Arm Trend Emp 
(10000)
CNO Exonl SNP3 6769908 C>T 0.002 0.001 0.948 0.5812
CNO Exonl INDEL 6770997-6771000 CAGT/- 0.366 0.387 0.248 0.2466
rs12503163 6777760 C>T 0.423 0.427 0.844 0.8468
rsi 2505863 6777940 A>G 0.311 0.315 0.828 0.8313
Table 7.5a. Allelic and genotypic results for CNO tag SNPs. Chromosomal positions are according to UCSC human genome chromosome 6 reference sequence 
(March 2006 freeze). Arm=Armitage.
rsID
Chromosome 6 
Position Alleles
Counts
Cases
Counts
Controls
HW
Cases
HW
Controls
Genotypic
P
Clump P 
(10000)
CNO Exonl SNP3 6769908 C>T 0/2/662 0/2/707 1.000 1.000 NA 0.998
CNO Exonl INDEL 6770997-6771000 CAGT/- 84/308/258 90/365/249 0.673 0.017 0.218 0.218
rs12503163 6777760 C>T 122/314/223 137/330/240 0.524 0.219 0.903 0.903
rs12505863 6777940 A>G 64/283/313 72/303/334 1.000 0.794 0.960 0.960
Table 7.5b. Genotypic results for CNO tag SNPs. Chromosomal positions are according to UCSC human genome chromosome 6 reference sequence (March 2006 
freeze). HW = Hardy-Weinberg P value.
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7.4 Discussion
This chapter attempted to determine whether the BLOC-1 genes PLDN, SNAPAP, 
MUTED, CNO or BLOC-1 subunits 1, 2, or 3 are under the influence of cis-acting 
variation. However allelic expression analysis could not be performed on BLOC1S1 or 
BLOCS2 as neither gene contains any exonic SNPs suitable for use as a copy-specific 
tag.
Of the five BLOC-1 genes assayed, PLDN, SNAPAP and BLOC 1 S3 did not show any 
evidence for differential expression between the mRNA from each chromosome using 
the criteria previously defined. Therefore this study provides no evidence of 
polymorphic cis-acting effects on these genes. A potential limitation of allelic 
expression analysis to detect cis-acting variants can be inadequate power at a locus due 
to the relatively small number of heterozygotes studied. Considering linkage 
equilibrium between the assayed polymorphisms and potential regulatory variants, the 
subsets of 10, 21 and 6 heterozygotes assayed for PLDN, SNAPAP and BLOC 1 S3 loci 
respectively yielded a power of approximately 86%, 98% and 70% to detect the effect 
of a regulatory variant present in the general population at a MAF of 0.1 (Table 7.6). In 
the presence of linkage disequilibrium between the putative regulatory variant and the 
assayed SNP, the corresponding power to detect a cis-acting variant is greater as the 
number of individuals heterozygous for the regulatory variant would be higher than that 
expected by chance. It is therefore unlikely that the PLDN, BLOC 1 S3, or SNAPAP loci 
contain common cis-acting polymorphisms or cis-acting epigenetic mechanisms which 
have a significant impact on mRNA expression in the cerebral cortex.
PLDN (10) SNAPIN (21) BLOS3 (6) MUTED (35) CNO (18)
M
A
F
0 .05 63 88 45 97 83
0.1 86 98 70 100 97
0.15 95 100 83 100 100
0.2 98 100 90 100 100
Table 7.7. Power (%) to detect a putative regulatory variant with varying MAF given the number o f 
samples assayed. Test assumes linkage equilibrium with the marker polymorphism. The number o f 
heterozygotes detected for each gene are given in brackets.
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One potential caveat of this conclusion is that primers designed for the allelic 
expression analysis were not cDNA specific and therefore susceptible to genomic DNA 
contamination. Any gDNA contamination has the potential to mask any cis-acting 
effects by normalising the data towards the genomic ratio of 1:1. In order to minimise 
this possibility, all RNA samples were DNase treated prior to RT-PCR samples.
Treated samples did not generate detectable PCR products with the “universal” primers 
in the absence of the reverse transcription cDNA synthesis step, suggesting that 
genomic contamination of cDNA was not an issue. Moreover, analysis of the two other 
BLOC-1 genes, MUTED and CNO, using the same gDNA and cDNA samples showed 
evidence for cis-acting influences and therefore also provided support against gDNA 
contamination.
Although allelic expression analysis of PLDN, BLOC 1 S3 and SNAPAP did not show 
any evidence for cis-acting variation, two BLOC-1 genes (MUTED and CNO) did 
show differential expression. Allelic expression of the MUTED gene demonstrated that 
the locus is likely to be under the influence of a rare cis-acting variant as, using a 
threshold previously defined by others [254], the majority of individuals do not show 
allelic expression differences. This possibility is further supported by the high number 
of heterozygotes assayed at this locus which provided a greater power to detect cis- 
acting effects (a power of approximately 97% to detect the effect of a regulatory variant 
present in the general population at a MAF of 0.1, Table 7.7). Furthermore, due to the 
spread of the data observed, the exonic polymorphism assayed rs3734590, appears to 
be in weak LD with the unknown regulatory polymorphism. In certain individuals the T 
allele is over-expressed and in others it is under expressed. This is suggestive of a 
switch in phase between the assayed SNP rs3734590 and the regulatory variant and 
therefore nominal linkage disequilibrium.
In comparison to MUTED, allelic expression analysis of CNO determined that the gene 
is under the influence of common cis-acting variation with 11/18 heterozygote 
individuals assayed showing differential expression of greater than 20%.
254
Although these genes have previously been analysed for association with schizophrenia 
[207, 373] no study has analysed putative regulatory SNPs for association. In order to 
test the hypothesis that CNO or MUTED could confer susceptibility to schizophrenia 
through altered expression, all putative regulatory polymorphisms plus exonic DNA 
variants at either locus were subjected to association analysis with schizophrenia. The 
results of the analysis of the CNO gene are described in this chapter while the analysis 
of MUTED is described in chapter 6. No allelic or genotypic association was observed 
for CNO, nor MUTED after correction for multiple testing. This suggests that while 
MUTED and CNO appear to be under the influence of cis-acting variation, this 
variation does not confer susceptibility to schizophrenia. Previous studies have shown 
that a high proportion of genes are likely to be under the influence of cis-acting 
variation and rather than being pathogenic, the majority of this cis-acting influence is 
responsible for population variation [184]. This could therefore be the case with CNO 
and MUTED.
On the other hand, it is possible the schizophrenia risk variants for MUTED or CNO 
and even the other BLOC-1 genes, have not yet been identified. Although an attempt 
was made to enrich for regulatory variants, only a small percentage of the genomic 
sequence surrounding both loci has been analysed. There may be other regularity 
variants not captured in the association analysis. It also must be noted that due to 
genotyping failure only 83% of the variation at the CNO locus has been captured. 
Furthermore, as discussed in chapter 6 the power of the schizophrenia UKCC to detect 
an association at a given locus (the sample is underpowered to detect effects with 
OR<1.4) must also be considered.
It is also possible that there may be risk variants at the MUTED or CNO loci which 
confer susceptibility through mechanisms not assayed by allelic expression or 
association analysis of coding regions. The allelic expression analysis described here 
does not address the possibility of post-transcriptional events such as translational 
efficiency.
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Nevertheless, the data described in this chapter, along with the association analysis of 
the MUTED locus described in chapter 6, does not support a role for the BLOC-1 
complex in schizophrenia pathology and suggests that dysbindin may confer 
susceptibility to schizophrenia via other pathways other than the BLOC-1 complex.
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Chapter 8: General Discussion
The purpose of this thesis was two fold. The first objective was to investigate the 
hypothesis that DTNBP1 risk variants contribute susceptibility to schizophrenia 
through cis-acting regulation of dysbindin expression. The second section of this thesis 
investigated the hypothesis that DTNBP1 could cause susceptibility to schizophrenia 
through is role within the BLOC-1 complex.
In regards to the first objective, four schizophrenia risk variants were identified at the 
DTNBP1 locus, though logistic regression suggests that these polymorphisms 
constitute the same association signal. Seven SNPs were found to be associated with 
differential expression of DTNBP1 mRNA with the majority of the expression 
differences were accounted for by variation at two loc, one of which was subsequently 
shown to affect transcription in vitro within a cell based system. However comparison 
of the SNPs associated with schizophrenia and those associated with differential 
expression suggests that a reduction in dysbindin expression through cis-acting 
variation may not be the primary aetiological factor in schizophrenia pathogenesis. The 
most significantly associated risk variant, rs4715984, was not correlated with allelic 
expression differences. In addition, further analysis of a risk haplotype previously 
reported to be associated with allelic expression differences, determined that the refined 
haplotype was no longer correlated.
While these findings suggest cis-acting regulation of DTNBP1 does not cause 
susceptibility to schizophrenia, there are a number of other possibilities that explain the 
data observed. Firstly, the association shown between rs4715984 and schizophrenia 
may be a false positive. Alternatively, rs4715984 may be truly associated with 
schizophrenia but may not be the causal variant. For example rs4715984 could show 
the greatest association to schizophrenia as it is in LD with two causal variants, one of 
which could be rs2619538 or rs9296989. rs2619538 showed the greatest correlation
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with allelic expression data and also showed association with schizophrenia. However 
unsuccessful cloning of rs2619538 into a luciferase vector meant that the SNP could 
not be assayed for an in vitro effect on expression. rs9296989 is also a candidate for the 
causal variant. Although it was less significantly associated with allelic expression 
differences than rs2619538 and located distal to DTNBP1, it was also significantly 
associated with schizophrenia.
Another potential explanation is that rs4715984 is the causal variant but the flipping of 
phase between rs4715984 and the allelic expression SNP rs 1047631 may prevent the 
detection of a significant correlation by the statistical methods employed in this thesis. 
However even this could not explain the differential expression shown by rs4715984 
homozygotes.
If rs4715984 is the causal variant, or in high LD with the causal variant, it may be that 
the allelic expression data used here is underpowered to assess the association between 
rs4715984 and differential expression. Another possibility is that cis-acting variation 
detected by rs 1047631 does not cause susceptibility to schizophrenia. As described 
previously rs 1047631 does not assay the expression differences of individual DTNBP1 
transcripts. It may be the case that while DTNBP1 is generally under the influence of 
cis-acting variation, it is only the altered expression of a specific transcript that causes 
susceptibility to disease.
As well as transcript specific expression differences, cell type specific differences also 
need to be considered. Dimas and colleagues performed gene expression profiling 
followed by association with DNA variants within three cell types (primary fibroblasts, 
lymphoblastoid cell lines and primary T-cells) of 75 individuals [349]. Although 
regulatory polymorphisms were detected it was determined that up to 80% of these 
variants operated in a cell-type specific manner. Therefore a potential hypothesis could 
be that rs4715984 only regulates expression of DTNBP1 in certain tissues/cell types.
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While these explanations are possible, the analyses performed in this study provide no 
evidence for cis-acting variation as a mechanism for the reduction in DTNBP1 mRNA 
expression observed in schizophrenic patients. Furthermore, the only previous evidence 
which linked these observations, that a schizophrenia risk haplotype was associated 
with reduced DTNBP1 expression, no longer appears to be the case. The reduction of 
DTNBP1 mRNA observed in schizophrenia patients [181-183] may therefore be caused 
by other non-cis processes. mRNA abundance is dependant on both transcription rates 
and mRNA stability. While both these aspects can be affected by cis-acting variation, 
other factors also exist. Epigenetic mechanisms, such as CpG methylation and histone 
modification can affect transcription rates [374]. In addition, trans-acting factors have 
been found to affect transcript stability either through mechanisms mediated by siRNAs 
or through protein-RNA interaction [375]. Finally, DNA variants at the DTNBP1 locus 
could affect alternative splicing and therefore the relative abundance of specific 
DTNBP1 transcripts.
8.1 Genome-wide Association Studies and Implications for DTNBP1
Until recently the evidence for association shown by DTNBP1 was unprecedented in 
schizophrenia and it was assumed that this was far beyond what could be attributed 
simply to chance. However results from recent studies, which have performed the first 
genome-wide association studies (GWAS) in schizophrenia, mean that DTNBP1 no 
longer shows the greatest evidence for association in schizophrenia research and the 
assumption that the association shown at DTNBP1 is not due to chance has been 
questioned. As the name suggests GWAS studies are able to survey the entire genome 
for common variants that might underlie a genetic disease in a single assay. These types 
of studies have become possible due to the completion of the human genome sequence, 
the deposition of millions of SNPs into public databases, the initiation of the HapMap 
project and the rapid improvements in SNP genotyping technology [77]. Currently the 
average number of SNPs that are analysed prior to QC is ~500,000. The scope of these 
studies is therefore unprecedented and will continue to increase with advances in SNP 
array technology.
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To date there have been eight schizophrenia GWAS studies published [143, 376-382]. 
Although it must be noted that the eight GWAS studies that have been published are 
not totally independent, due to some overlap in the samples used. One of the common 
features of all schizophrenia GWAS is that while a number of novel loci have been 
identified as putative susceptibility genes, the top hits observed by each study are not 
within previous schizophrenia candidate genes. This includes those genes with the most 
compelling previous evidence such as DTNBP1. Shi et al do report a significant 
association with rsl7619975, a SNP within JARID2, the gene adjacent to DTNBP1 
[379]. However this SNP does not survive correction for the number of SNPs assayed 
in the study and the significance decreases after meta-analysis with two additional 
GWAS studies [378, 381].
While this is initially discouraging, a number of explanations are possible in which 
DTNBP1 is a schizophrenia susceptibility gene. Firstly, the majority of schizophrenia 
GWAS studies have analysed less than 1000 cases and have therefore been 
underpowered to detect an association after accounting for the large number of SNPs
Q
assayed (known as genome-wide significance). Genome-wide significance (~p<10‘ ) 
has only been detected through meta-analysis of either several schizophrenia GWAS 
studies [378, 379, 381] or where schizophrenia and bipolar GWAS studies have been 
combined [377].
Due to multiple testing even a common SNP (MAF=0.2) with a relatively large effect 
size (OR=1.5) needs to be genotyped in a large sample (1500 cases and 1500 controls) 
to reach genome-wide significance and even this sample size would only have 80% 
power to detect the variant. As schizophrenia susceptibility is likely to be caused by 
multiple genes of weak effect (OR<1.5) even larger sample sizes will be needed to 
detect the majority of schizophrenia susceptibility variants, which may include 
DTNBP1.
Furthermore, while GWAS SNP arrays are designed to assay much of the common 
variation across the genome, the coverage of individual genes is unlikely to be 100%. 
The maximum coverage of DTNBP1 on the most technological advanced Affymetrix
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and Illumina arrays (Affymetrix 6 and Illumina 1M) is still only 77% and 88% 
respectively (r2>0.95, MAF>0.001). Moreover, these percentages do not take into 
account the removal of SNPs due to QC measures which would reduce this coverage 
further. It is also impossible to calculate the coverage of variants not genotyped as part 
of the HapMap project or variants that have yet to be identified. Therefore at present a 
negative or a non genome-wide significant association of a gene within a GWAS study 
is by no means conclusive.
8.2 Determining the Function of Susceptibility Variants Identified by GWAS
A major aim of this thesis was to identify putative DTNBP1 regulatory regions in 
which schizophrenia risk variants could be located. One advantage of GWAS studies is 
that due to the number of SNPs that can be assayed, the whole genome can be analysed 
in an unbiased way. Therefore no hypotheses are needed as to the function of 
susceptibility genes or the nature of the risk variants [77]. While a lack of functional 
annotation of the genome is not an initial hindrance in identifying associated 
polymorphisms, some of the strongest association signals detected in GWAS studies 
are within non-coding regions located in either large introns or far away from any 
annotated genes. As a result functional annotation is still, if not more, important than 
pre-GWAS.
Since the protocol which was used in this thesis for identifying putative regulatory 
regions was devised, significant advances have been made in the technology employed 
to identify putative regulatory sequence. The encyclopaedia of DNA elements 
(ENCODE) project aims to identify every sequence in the human genome with a 
functional role using a diverse set of techniques, including both computational analysis 
and “wet laboratory” technology [383]. The scale of the ENCODE project has meant 
several new technologies have been developed in order to generate high throughput 
data on functional elements. These techniques include several chromatin 
immunoprecipitation (ChIP) based methods. As discussed in section 3.1.2 chromatin 
immunoprecipitation allows the identification of protein-DNA interactions in vivo. By 
applying formaldehyde to cells, DNA-binding proteins, such as transcription factors,
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are cross-linked to the DNA with which they are bound. The DNA is then fragmented 
by sonication prior to immunoprecipitation by an antibody specific to the protein of 
interest [276]. Historically, analysis of the immunoprecipitated DNA has taken the form 
of PCR and sequencing either directly or within a plasmid vector. However recent 
advances in technology in the form of ChlP-Chip and ChlP-Seq have allowed the 
identification of protein binding sites on a genome-wide scale. ChlP-Chip combines 
chromatin immunoprecipitation with microarray technology whereby 
immunoprecipitated DNA is labelled with a fluorescent tag then hybridized to a DNA 
microarray [384]. Hybridisation patterns can then be analysed to determine the DNA 
binding sites of the protein examined in the ChIP stage. ChlP-Seq uses high throughput 
sequencing rather than microarray technology to determine the protein-DNA 
interactions detected by ChIP [385]. ChlP-Seq is often thought of as a preferential 
method to Chip-Chip as it is not affected by the bias introduced when using arrays, 
which are restricted in the number of probes that can be fixed to them. Both ChlP-chip 
and ChlP-Seq can be used to detect TFBSs, promoter regions, histone modifications 
and methylation within the genome.
Another technique being used by ENCODE to identify regulatory regions is 
chromosome conformation capture-carbon copy (5C) [386]. This technique allows the 
identification of physical interactions between distant DNA segments and of chromatin 
loops which are formed as a consequence of these interactions [387]. As with ChIP, 5C 
involves the treatment of cells with formaldehyde. This is followed by restriction 
enzyme digest, intramolecular ligation and reverse cross-linking. The 3C library 
produced can then be determined via microarrays analysis or high throughput 
sequencing [386].
A number of promoter prediction programs are available for the in silico identification 
of promoters. These include Promoterlnspector [388], FirstEF [389], McPromoter [390] 
and N-SCAN [391]. An assessment of these predictors [392], which used the ENCODE 
regions of the human genome as a point of reference, determined the best performing 
programs were those that combined promoter prediction with gene prediction, such as 
N-SCAN [391]. However the promoters predicted by these programs were inevitably
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biased towards transcribed regions. Therefore promoter prediction software needs to be 
developed which also considers intergenic sequence.
Since the advent of the ENCODE project [383] and other independent research groups 
performing similar analysis the experimental data stored on the UCSC database relating 
to gene expression has grown substantially [313]. Therefore the challenge in 
functionally annotating a locus is likely to be what data to use rather than a lack of 
information. However, even if putative regulatory regions can be identified more 
confidently, the affect of a SNP on gene expression still needs to be determined. 
Therefore, it is essential to have powerful and reliable methods to easily test the 
influence of DNA variants on gene expression.
The method of identifying putative cis-acting variants used in this thesis, the allelic 
expression assay, is relatively low-throughput with only one gene analysed at a time. 
With the advent of GWAS studies more high-throughput methods have been devised. 
These methods are based on the association mapping of genotypes to multiple gene 
expression profiles, measured using microarray technology. In a similar approach to 
GWAS studies, microarrays allow the simultaneous assessment of the expression of the 
majority of genes in the genome [393]. The capacity of microarrays means that the 
expression of specific transcripts can also be measured in one assay. As expression can 
be considered a quantitative trait, the expression levels of a gene or a specific transcript 
have been named expression Quantitative Trait Locus’ (eQTLs).
eQTL mapping is often performed in control individuals as this can significantly 
increase the power of an assay to detect expression differences relative to an assay 
which compares the expression of cases and controls. A number of eQTL studies are 
available publicly including the GENE VAR database [347] and the mRNA by SNP 
browser database [345]. While these two studies have performed expression profiling in 
lymphoblastoid cell lines, a number of eQTL studies have performed gene expression 
profiling in specific tissues including liver [394] and adipose tissue [395, 396]. 
However, potentially the most relevant eQTL study for researchers involved in 
schizophrenia is the study by Myers and colleagues [346]. This group performed gene 
expression analysis on RNA extracted from the cortex of 193 neuropathologically
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normal human brains. In addition, DNA from these brains was genotyped on the 
Affymetrix genechip human Mapping 500k array. After QC 366,140 SNPs were 
analysed for association with the expression of 14,078 gene transcripts.
These eQTL databases are a useful tool for researchers attempting to determine a 
putative function for SNPs identified through GWAS studies. For example, a GWAS 
study of asthma identified a series of SNPs strongly associated with the disease [397]. 
These SNPs were in high LD and spanned more than 200kb of chrl7q23. This region 
contained 19 genes, none of which were obvious candidates for disease. Examination of 
eQTL data derived from the same samples used in the GWAS showed that the disease- 
associated SNPs were highly significantly associated (p<10' ) with the expression of 
one gene in the region (ORMDL3) and showed a borderline significance with another 
(GSDML) [345]. Further research determined that these SNPs were cis-acting 
regulatory variants for both genes [344]. Additional studies have therefore focused on 
investigating the biological function of these two genes and their relationship to asthma 
[398-402].
As well as determining putative functions for risk variants, the combination of GWAS 
and eQTL mapping can identify putative susceptibility genes that would not have been 
identified by GWAS alone. A GWAS into Crohn’s disease (CD) identified markers on 
chromosome 5 which were strongly associated with CD. However as they resided 
within a 1.25Mb gene desert, a putative biological function could not be determined. 
Examination of a lymphoblastoid cell line eQTL database [344] showed that one or 
more of these associated SNPs act as long range cis-acting factors influencing 
expression of PTGER4, a gene over 250kb proximal to the associated region[403].
Another application of expression profiling is to compare the expression patterns of 
genes. By analysing the correlation in expression between genes, novel gene pathways 
or networks may be identified. This could result in the determination of additional 
functions for certain genes. At present DTNBP1 is known to function as part of the 
BLOC-1 and DPC complexes. While this thesis found no evidence to support the 
hypothesis that DTNBP1 causes susceptibility to schizophrenia through disruption of
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the BLOC-1 complex and no association has been found with members of the DPC 
complex [207], it is possible that DTNBP1 functions in other pathways and/or 
complexes that are currently unknown. Expression profiling may be able to produce 
clues as to these alternative functions.
While eQTL mapping is advantageous in that gene expression arrays can analyse 
thousands of gene simultaneously, there are limitations to this approach. Systematic 
bias’ can be introduced when using microarrays through differences in the hybridisation 
and measurement of expression, plus batch to batch variation in array manufacture and 
day to day variation in laboratory conditions [344].
The recent development of ultra-high throughput sequencing means that gene 
expression can be analysed without the limitations of microarray technology. Ultra-high 
throughput sequencing, also known as next generation sequencing, allows the parallel 
analysis of millions of sequence reads rather than the previous 96 which were possible 
with conventional capillary based systems. Next generation sequencers include the 
Illumina genome analyzer and Apllied Biosystems SOLiD sequencer. These systems 
can produce 13000-3000Mb of sequence per run. In contrast a single ABI 3730 can 
produce ~440kb of sequence per run [404].
The 1000 genome project has applied next generation sequencing technology to 
sequence ~1200 control human genomes (www.1000genomes.org). The project aims to 
discover >95 % of variants with minor allele frequencies as low as 1% across the 
genome and 0.1-0.5% in gene regions [405]. As with the International HapMap 
consortium [84], the 1000 genome project aims to estimate the population frequencies, 
haplotype backgrounds and linkage disequilibrium patterns of variant alleles identified. 
An alternative application for this technology is RNA-seq. RNA-seq uses high 
throughput sequencing technology to sequence cDNA in order to characterise the 
transcriptome and alternatively spliced transcripts [406, 407]. Sequence reads are 
individually mapped to the source genome and counted to obtain a density of reads 
corresponding to RNA from each known exon, splice event or new candidate gene 
[407]. However due to the size and complexity of the transcriptome and the low density
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of transcribed heterozygous SNPs (one every -3.3 kb), most informative SNPs are not 
covered at the sequencing depth sufficient to make accurate allelic quantification using 
RNA-seq [408]. Digital RNA allelotyping combines the sensitivity and quantitative 
accuracy of RNA-seq with the efficiency of targeted sequencing. Digital RNA 
allelotyping is based on large scale synthesis of padlock probes [409]. Padlock probes 
contain the flanking sequence of a transcribed SNP plus linker DNA sequence which 
contains the primer sites for multiplex PCR amplification and sequencing. Padlock 
probes therefore allow sequencing efforts to be focused on the specific fraction of the 
transcriptome carrying SNPs. As with an allelic expression assay SNP capture and 
single-molecule sequencing is performed on both genomic DNA and cDNA of the 
same individuals. RNA allelic ratios are then calculated and corrected by the gDNA 
allelic ratios [408].
8.3 Tissue Specific Expression
One major factor that will need to be considered in allelic expression, total gene 
expression analysis and transcriptome sequencing is the possibility of tissue specific 
expression. Some eQTL studies of specific human tissues have been carried out, 
notably of the liver, adipose and brain tissue [346, 394-396]. Furthermore, this thesis 
has shown that allelic expression analysis assaying RNA extracted from specific tissues 
such as the brain is also possible. However a potentially vital resource for determining 
the function of risk variants identified within GWAS studies will be the Genotype- 
Tissue Expression (GTEx) project [410]. This project aims to produce a database 
containing eQTL data on up to 1000 samples each assayed across 30 different tissues. 
Researchers will therefore be able to analyse whether their risk variants affect 
expression levels of genes, not only within human tissue rather than lymphoblastoid 
cell lines, but also in tissue(s) relevant to their disease.
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8.4 Biological Validation of Putative Regulatory Variants
While the technological advances described above are making the genome-wide 
analysis of regulatory variants a reality, it may still be necessary to determine whether a 
risk variant is a cis-acting variant and not just in high LD with functional 
polymorphism(s). In this thesis a luciferase reporter assay was used to determine 
whether SNPs correlated with allelic expression differences had an actual regulatory 
affect. However the development of luciferase reporter assay has not been as rapid as 
other methods described above such as association and expression analysis. While the 
ENCODE project is utilizing technology such as ChlP-chip and high throughput 
sequencing to identify putative regulatory regions, members of the consortium are 
using pGL3 luciferase constructs to test the transcriptional activity of putative 
promoters [383]. Details of the results of this analysis are available on the UCSC 
genome browser under the Stanford promoter activity track “Stanf Promoter”. While 
the low throughput of luciferase reporter assays remains an issue, pGL4 luciferase 
vectors have been developed which contain both luciferase and Renilla reporter gene 
technology within a single construct, therefore removing the necessity for dual 
transfection in order to normalise transfection rates [411].
The results of another project which uses reporter gene assays to functionally validate 
putative regulatory regions are available on the VISTA enhancer browser database 
(http://enhancer.lbl.gov/) [412]. Pennacchio and colleagues first performed a 
comparative analysis of genomic sequence between the human genome and a wide 
range of available species (mouse, rat, chicken, frog, fugu, tetraodon and zebrafish) 
using the Gumby program [413] to determine evolutionarily conserved regions (p <
0.001). Regions identified were then filtered for transcribed sequence. In addition they 
utilized other comparative genomic datasets of extreme conservation such as non­
coding "Ultra-conserved Elements" (defined as >200bp and 100% identical between 
human/mouse/rat) [309]. The enhancer activity of these regions has been assessed in 
transgenic mice using an in vivo lacZ reporter gene assay. As of September 2009 the 
group had tested nearly 2000 elements of which over 500 were observed to have 
enhancer activity.
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8.5 General Conclusions
Since the research described in this thesis was started advances have been made in 
identifying DNA variants associated with disease. However the challenge still remains 
in determining the mechanisms by which these risk variants cause susceptibility to 
complex diseases and the biological pathways involved. While this thesis had limited 
success in identifying the DTNBP1 causal variants, it has indicated that correlation 
analysis of genotypes with expression data is a potential method of identifying cis- 
acting variants. eQTL mapping and high throughput allele specific expression are 
therefore likely to be essential tools as GWAS studies become routine. However a 
number of issues still need to be addressed. These include tissue and temporal specific 
expression, epigenetic mechanisms, gene interactions and gene-environment 
interactions. Consequently in order to improve our understanding of the biology of 
complex diseases such as schizophrenia a coordinated effort will be required from a 
broad range of geneticists, functional biologists and statisticians.
268
Appendix
9.1 Chapter 3 Appendices
Region Chromosomal Position Size Subregion Method Forward Reverse
1 15623636-15624128 493 Cluster buster TTT C AAGCCAT CCTT CAG AAA GGACT ACAGGCGCT CAACAT
2 15631372-15631829 458 Cluster buster T CT G AGGG ATTT GG AACCT G CCGACTTT CT CAGCAGT GGT
3 15667548-15668039 492 Cluster buster AGTGGGT GCCTT AT GAGCT G CAGTT GGCGAGAGGT CAAGT
4 15691653-15692140 488 ECR ACAAACT CCAT CCCAGTT GC GGGGAATT GGCACTTT AACA
5 15703523-15704012 490 Cluster buster GGAGT GCAGCGGTGT GAT T GCT GTT CT GAAGT CT GTTT CC
6 15730941-15731413 473 Cluster buster GCCT GACAGCT GT GCAAAA GT CC AGGTT CCTTTCT G AGG
Alternative Transcript Promoter 15734658-15735135 478 P1 Putative promoter GGCAATATTAAAAACAGGAGGAGA GGATT GG AGAT CAAACAAACCT
15735038-15735511 474 P2 T CCT GCCT CAGT CT CC AGAA AAACAACTT GGGCAGGGTTT
15735451-15735934 484 P3 CCAGAATTT CAT GTGTT CCT GA TCATTTTTAAACTTTCTCTTCTGTGG
15735760-15736001 242 P4a TTTAAT GTTAT CTTTAACAACCCCT CT TCTAGATTT AGCTTTT CAAAT ACAT GG
15736061-15736390 330 P4b ACATAATTAACGGGT AATTA AAAACAGAATT GTCT GGG AGAAA
15736200-15736610 411 P5 GGAAACT GGCCAATT CCAGA AAGAACCTTAAT CTT GAG AT GT ACAAA
Main Transcript Promoter 15765956-15776344 10388 Putative promoter SEE APPENDIX TABLE 3.2.
19 15784237-15784635 399 DNase hyp GGGGCAAAGCAAGCT CAC AGT GACAGGAAT GACCAAACG
7 15786747-15787164 418 Cluster buster GAGAAAGGACTTCCCTAAAGAGG T GAAT CTATAAAACAAGGGCAAGA
8 15788437-15788915 479 Cluster buster CCAGCCAAT CT GACT AGGT AACA CCCTT AAGACT GCAGG AT GG
9 15790853-15791333 481 ECR GG AGCAATAAAAAT GAGCCATAA GCCAACT GGGAAGTT GCTTA
10 15794240-15794722 483 Cluster buster CATTT AT GCAT CCGTT GTCG GGGTT GCCT CCATACTTT G A
11 15798238-15798703 466 Cluster buster TTT CCAC AGAGGTT GCAT CA T CT CCTTT GACGGTTTTT CC
12 15800898-15801321 424 Cluster buster ACCAAGAGCT GAT GGAGT GG CCT GGCCAGTT CAG AAT CTT
13 15803413-15803903 491 Cluster buster T AT GT GACCCGGGAACCTT CTGTAT GG AAGT CATAAAT AGT GTCTG
14 15806380-15806876 497 ECR CCAGTAAGTT GCAGGATTT CG ACTTT CCAGCCACCAGAGT G
15 15820885-15821341 457 ECR/UCSC T GTT GTGTTCT CAAAGCTT GC GCAGCAT CT GCCCT CTTAT C
16 15841562-15841856 295 16a UCSC T GACATT CGAGAGATTTT CCT G T GTT GACAAT CCT GGCAGAC
15841724-15842119 396 16b TT GGTAAAAGAAAGAAGGTAG ACAA GCAAATGGTGGTGGTTCTTT
17 15842966-15843421 456 Cluster buster T CATTTT ACAGAT GAGGCAACAA AGCCT GGGCT ACAGAGT GAA
18 15843888-15844152 265 18a Cluster buster T AGGCT CAACT GCGAGAT GG AAACGT GGGAGG AAAT GAT G
15844048-15844446 399 18b GAGCT CAGT GCCT AGCACAT AAT TTT CCACCCACCT CT GCTAC
Table 9.1.1. Putative DTNBP1 regulatory regions identified by the methods described in chapter 3.2.1 are shown in chromosomal order. Chromosomal positions are 
according to UCSC human genome chromosome 6 reference sequence (March 2006 freeze). Forward and reverse refer to the primers used for mutation screening. 
The PCR primers used for the screening o f the putative promoter region o f three o f the main DTNBP1 transcripts are given in Appendix Table 9.2.
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Region Subregion Chromosomal Position Size Method Forward Reverse
Main Transcript Promoter chr6:15765956-15776344 10388 Putative Promoter
DYS CIS 1 493 GCCTGCCACATAGTAAGCACT TGCCAGTGCCAGACATTAGA
DYS CIS 2 493 TGAGCATATGGGCTCTCAAA TTTAGGCATGCAAACCCTT C
DYS CIS 3 490 GCAGCTGTAAACCCGTCAGT AAGGGCAGTGTAGAGATTACTGG
DYS CIS 4 491 CAAGGTTGACATAATT GTTACTACGC ACACTTGGTGGCAGAGCAAT
DYS CIS 5 482 CTGAGGCCTTCCATTCCAT TCACACCTGTAATCCCAGCA
DYS CIS 6 482 TAGTGGAGACGGGGTTTCAC GAGACGTGAGCTGCATCACTA
DYS CIS 7 500 AAAACAAATCTGATTATGGACTGC GGCCATTTTGGAGCTAGACA
DYS CIS 8 500 TTGTCAGCTGAAAGTGACCTG TTGCATTTTGITCTCCCTATTT
DYS CIS 9 497 CCATTT CAGCAT CACACCAA GGGATTACAGGCGTGTGC
DYS CIS 10 399 GGCAACAGAGCGAGAACTTG AATCCTGTTGGAGGATGCAC
DYS CIS 11 471 GGGGGAGAAATTTAAAACAGTATG CACCTGGGAACCTTTCAGAG
DYS CIS 12 457 CTTTAAAACGCCGTCTCCAG GCCCT GGAGGGAAGTCAT
DYS CIS 13 392 CGCACGAGCAGGTGTCTG CGACGAAAAGGGACCTGAG
DYS CIS 14 550 CCCGCAGGGACCTAAGTTAC GATAGGAATGAGCCGAGGAG
DYS CIS 15 500 AGGTGAAATCCTGCT GCAC TGTGCACATCGCCTATTGA
DYS CIS 16 481 TCCTTTGAGGGAAGTGTTGG GAGGCTGGACTGTAGCCTTG
DYS CIS 17 497 TCTGGTTCCCCTCTTTTCCT GGAGAAAAGTTT GT GAAAACACC
DYS CIS 18 500 ATCCACCAATTTGCTCAAGG AACCTGGAATTTT CTAAGAACACA
DYS CIS 19 497 TTTTCTAGCACTGTATCCAAATTGA T T GA1 AT TTT GTTCAT CACAG ATTTTT
DYS CIS 20 496 GGGAGCCAAAAAGCTCAGTA TGAATGCTCTTTGTTGGAAGTG
DYS CIS 21 500 GGAAGAGGTGACTACGATGATT GCTTTGTT GGAATGTAT GAAACTT
DYS CIS 22 472 TGAAAACCACAAGTACTGGGAAA TTTTGCCAATCCATCTTCCT
DYS CIS 23 482 GGACCAAGAGTTGAAGCATGT TGCCTGTAATCCCAGCATTT
DYS CIS 24 495 ATGTTGGACAGGCTGGTCTC GTTCGCTCTGATGGTGGTTT
DYS CIS 25 471 T GAGGATTT GGCGGAGTTAG AGGAATCGCCACACTGACTT
DYS CIS 26 491 AGGTGCTGGAGAGAATGTGG GCCCCAGTGTATGATGTTCC
DYS CIS 27 489 CAAACACCGCATGTTCTCAC TTGCTTCACGAGAAACATTTACA
DYS CIS 28 240 GCTTTGCAGGAACCTGACTT CTTTT CAAAAT GCT GTGCTGA
Table 9.1.2. PCR primer sequences for mutation detection within sequence 5kb 5’ and 3’ of the first exon o f three of the main DTNBP1 transcripts (DTNBPla, 
DTNBPlb and DTNBPlc). Chromosomal positions are according to UCSC human genome chromosome 6 reference sequence (March 2006 freeze). Forward and 
reverse refer to the primers used for mutation screening.
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Variables in the Equation
B S.E. Wald df Sia. Exd(B)
Step 1 rs4 7 15984 .366 .144 6.446 1 .011 1.443
rs9296989 -.111 .249 .198 1 .656 .895
rs 2619538 .026 .252 .010 1 .919 1.026
C onstant -.047 .496 .009 1 .924 .954
Table 9.1.3. Logistic Regression o f  DTNBP1 SNPs showing allelic association using the enter method. P 
values o f SNPs are adjusted for their correlation with all other SNPs in the model.
V ariab les  in th e  E quation
B S.E. Wald df Sia. Exd(B)
Step 1 rs4 7 15984 .428 .138 9.631 1 .002 1.533
C onstant -.159 .060 6.970 1 .008 .853
V ariab les  no t in th e  E quation
Score df Siq.
Step 1 Variables rs9296989 2.792 1 .095
rs2619538 2.605 1 .107
Overall Statistics 2.803 2 .246
Table 9.1.4. Forward Stepwise Logistic Regression o f DTNBP1 SNPs showing allelic association. SNPs 
included and removed from the model are given. P values o f SNPs removed are adjusted for their 
correlation with the other SNPs in the model.
Model if T erm  R em oved
Variable
Model Log 
Likelihood
Change in -2 
Log 
Likelihood df
Sig. of the 
C hanqe
Step 1 rs4 7 15984 -921.922 6.518 1 .011
rs9296989 -918.762 .198 1 .656
rs 2619538 -918.668 .010 1 .919
Step 2 rs4 7 15984 -922.069 6.802 1 .009
rs9296989 -920.064 2.792 1 .095
Step 3 rs4 7 15984 -924.953 9.778 1 .002
Table 9.1.5. Backward Stepwise Logistic Regression o f DTNBP1 SNPs showing allelic association. 
Variables entered in step 1: rs4715984, rs9296989 and rs2619538. P values o f  SNPs are adjusted for their 
correlation with all other SNPs in the model.
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pGEM-T vector DTNBP1 5’FR
lvtainP_seq1_8F_D01_KtoinPseq_plate107 Fragment base #77. Base 77 of 434
DTNBP1 5’FR pGEM-T vector
KteinP_seq6_8F_D 11 _K/binPseq_plate 1 0 7  Fragment base #297. Base 297 of 427
Figure 9.2.1, Sequencing traces o f the ligation junction in the pGEMT-5’flanking region (FR) construct.
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pGEM-T® vector DTNBP1 3’DR
UINBH1 E n h an cer ^K LltJ U INBP1_J .bpgem  I_seq_US l-ragm ent b a s e  na. b a s e  (\i ot bb«
DTNBP1 Enhancer 3R C04 DTNBP1 3.5pgemT seq 06
ia  a Fragm ent
DTNBP1 3’ DR pGEM-T® vector
base #269. Base 269 of 311
Figure 9.2.2. Sequencing traces of the ligation junction in the pGEMT-3’distal region (DR) construct.
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pGL3-Promoter Vector DTNBP1 3’DR
Pgl3 PF2~B~ BamHI FD1 E3 colony c h e c H l  Fragment base #55.V ase 55 of 574
T T T G G G G G T G A A A G G A A G  
T T T G C G G G T G R R R G G R R G
DTNBP1 3’DR pGL3-Promoter Vector
Pgl3_PF2_B_$all_F02_E3_colony_check12 Fragment base #415. Base 415 of 465
Figure 9.2.3. Sequencing traces o f the ligation junction in the pGL3-P 3’DR construct.
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rsl 3198533 rsl 3198512
A
B
PGL3 P_GG_9R D04 9F_seq_new_cols_08 Fragment base #323. Base 323 of 390
C T "G“ A A ~ C C T ■  G : C C A  T G C A
 T A : C : C : G G C
a n i a a a a a
PGL3_P_AG_9R_E04_9F_seq_new_cols 10 Fragment base #374. Base 374 of 441
C T “G A  A r C C T 19 G : C C A  T G C A A G T A A A T A  C A  t
T G f l T T  T f l T  3 T  T
G C T A : C : C:  A
i  a  r  t  a  a  t
PGL3_P_AA_9R_F04_9F_seq_neui_cols 12 Fragment base #372. Base 372 of 441
C T G A A : C C T Hi G : C C A  T G  C A  A
Figure 9.2.4. Sequencing traces of the three 3’DR inserted regions within their respective pGL3-P luciferase vectors after site directed mutagenesis. Genotypes for 
r s l3198512 and rsl3198533 are given for A. pGL3-P 3’DR GG, B. pGL3-P 3’DR AG, C. pGL3-P 3’DR AA.
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Assay 1 Assay 2 Assay 3
Construct 1 Construct 1 Construct 1 Construct 2 Construct 3 All Data
Ratio Normalised Average Ratio Normalised Average Ratio Normalised Average Ratio Normalised Average Ratio Normalised Average Average SEM
PGL3
0.01
0.01
0.01
0.01
0.01
0.01 0.01
0.05
0.05
0.05
0.05
0.05
0.05 0.05
0.020
0.022
0.024
0.026
0.026
0.029 0.02 0.03 0.004
PGL3-P
0.42 0.91 
0.43 0.93 
0.44 0.96 
0.46 1.01 
0.51 1.11 
0.49 1.07 1.00
1.99 1.00 
1.89 0.95 
1.96 0.99
1.94 0.98
1.95 0.98
2.21 1.11 1.00
1.075 0.932 
1.215 1.054 
1.007 0.874 
1.182 1.026 
1.184 1.027 
1.254 1.088 1.00 1.00 0.016
PGL3-P 3'DR GG
0.36 0.78 
0.31 0.68 
0.26 0.58 
0.28 0.61 
0.36 0.78 
0.31 0.69 0.68
1.43 0.72
1.49 0.75
1.49 0.75 
1.69 0.85 
1.67 0.84
1.66 0.83 0.79
1.061 0.920 
1.175 1.020 
1.230 1.067 
1.152 1.000 
1.354 1.174 
1.396 1.211 1.07
1.171 1.015 
0.872 0.757 
1.087 0.943 
1.094 0.949 
1.009 0.875 
1.304 1.131 0.95 0.87 0.050
PGL3-P 3'DR AG
0.03* 0.06*
0.11 0.24 
0.24 0.53 
0.29 0.64 
0.38 0.83 
0.19 0.41 0.53
0.36 0.18 
0.31 0.16 
0.58 0.29 
0.65 0.32 
0.94 0.47 
0.69 0.35 0.30
0.311 0.270 
0.252 0.219 
0.299 0.259 
0.303 0.263 
0.347 0.301 
0.382 0.332 0.27
0.281 0.244 
0.274 0.238 
0.290 0.251 
0.288 0.250 
0.345 0.299 
0.381 0.330 0.27
0.269 0.234 
0.252 0.218 
0.227 0.197 
0.314 0.272 
0.335 0.291 
0.348 0.302 0.25 0.32 0.027
PGL3-P 3'DR AA
0.18 0.39 
0.16 0.36 
0.15 0.32 
0.12 0.26 
0.18 0.39 
0.20 0.44 0.36
0.84 0.42 
0.77 0.39 
0.81 0.41 
0.71 0.36 
1.04 0.52 
0.84 0.42 0.42
0.697 0.604 
0.561 0.486 
0.807 0.700 
0.777 0.674 
0.742 0.643 
0.762 0.661 0.63
0.940 0.815 
0.691 0.599 
0.759 0.658 
0.750 0.651 
0.828 0.718 
0.817 0.709 0.69
0.987 0.856 
1.062 0.921 
1.119 0.971 
1.322 1.147 
0.987 0.856 
1.275 1.106 0.98 0.62 0.043
Table 9.2.5. Raw data for all biological and technical replicates o f the luciferase gene reporter assay. Normalised values based on the average pGL3-P ratio for each 
assay are given to the right o f each data point. SEM = Standard error o f the mean. * Value not included in analysis
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Name Chromosomal Positon (March 2006) Type of Region Method Relation to Muted Forward Reverse
MUTED_Reg1a 
MUTED_Reg1b 
MUTED R e g ie  
MUTED R egld
Chr6:8014289-8014779 
chr6:8014689-8015188 
chr6:8015117-8015479 
chr6:8015338-8015694
Regulatory ECR/UCSC 5’ gatgggggagaaggagaact
getggaaaagatgeaatget
ctctgcccagcaagagagat
gaaagaagaaatactgctctctgg
tgcttccattatcatgattcctt
gcactgggtgaattttattgc
tttctaacatttgacttaattcctttt
catgagagccctgctgaaat
MUTED_Reg2a 
MUTED_Reg2b 
MUTED Reg2c
chr6:8010138-8010637 
chr6:8009816-8010204 
chr6:8009603-8009894
Regulatory Promoter 5' ccattatgtaggcatagttggtt
aacagcccccagctaattg
caccagctttgagccaaata
cacagaaagtgaaacctcagataa
geggatgetgetagaatagg
actcatcccgaccagttcc
MUTED Exon 1 chr6:8009318-8009714 Exonic N/A N/A cgccctgtaatgacacacac gttgtggtgggacgcattt
MUTED Exon 2 chr6:8007685-8007929 Exonic N/A N/A tggggaagggagagagtaaaa aaaactggggaatttctcttctg
MUTED Reg3 Chr6: 7994178-7994348 Regulatory Cluster buster Intronic Could not PCR
MUTED Exon 3 chr6:7986262-7986549 Exonic N/A N/A aaaaaggaaaagacaccatatttatt ctgagcttccctctccctct
MUTED Exon 4 chr6:7971512-7971731 Exonic N/A N/A cacactcctcccccaggtat gagaattttctgatcaaaagcaa
MUTED Reg4a 
MUTED Reg4b
chr6:7968274-7968607
chr6:7968243-7968689
Regulatory ECR/UCSC Intronic ggcttcaaaagttgacacca
cttcataattacttccagtctggtt
tcttttatgtcaagacaatttgtgg
ccaccacacacggctaattt
MUTED Reg5 chr6:7965568-7966064 Regulatory UCSC Intronic gggtatggcatggacatctt gcacaatgctcttataactttagcc
MUTED _Reg6 chr6:7965259-7965708 Regulatory UCSC Intronic tcattccctaatgacatcacca tttgggggagaagaactgg
MUTED_Exon_5a 
MUTED Exon 5b 
MUTED Exon 5c 
MUTED_Exon_5d 
MUTED_Exon_5e 
MUTED Exon 5f
chr6:7960793-7961192 
chr6:7960455-7960915 
chr6:7960022-7960521 
chr6:7959593-7960092 
chr6:7959165-7959661 
chr6:7959094-7959487
Exonic N/A N/A tttggatattataacacaactttttcc
tggagaaggacctagcgaaa
caatagtttattattgtggcttaatgg
ctgttttgctgtgggtaagc
tgttggtgcacgcttgtaat
tttttatttgccataaaccaagc
agcagaggctaaacggtctg
aacagccaaggaggctatga
gattactcattaaacagtcgaaacat
cctcctgagttcaggtgattct
gaaagttggcagaagttcagtg
gcaagtgcgctttttagtcc
MUTED Reg7 Chr6:7958818-7959308 Regulatory ECR 3’ ttcacatgagatgaacacaaact gacaatgcctgcctgtgtaa
Table 9.3.1 All MUTED exons and putative regulatory regions identified by methods described in chapter 6.2.2 are shown. Chromosomal positions are according to 
UCSC human genome chromosome 6 reference sequence (March 2006 freeze). Forward and reverse refer to the PCR primers used for mutation screening.
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Assay 1 Assay 2 Assay 3 Assay 4
Region Chromosomal Position Tempi Gradl Grad2 Temp2 Gradl Grad2 Temp3 Gradl Grad2 Temp4 Gradl Grad2
Promoter FI (*1-6:8,010,138-8,010,637 55 33 25 60 40 32 62 38 30
Promoter F2 chr6:8,009,816-8,010,204 53 34 26 58 41 33 60 39 31
Promoter F3 chr6:8,009,603-8,009,894 63 46 38 65 44 36
Exonl chr6:8,009,318-8,009,714 64 42 34 66 40 32
Exon2 chr6:8,007,685-8,007,929 54 44 36 56 42 34
Exon3 chr6:7,986,262-7,986,549 52 47 39 57 44 36 59 42 34
Exon4 chr6:7,971,512-7,971,731 63 38 30 58 45 37 60 43 35
Exon5 FI chr6:7,960,793-7,961,192 52 33 25 57 40 32 59 38 30
Exon5 F2 chr6:7,960,455-7,960,915 56 39 31 58 37 29
Exon5 F3 chr6:7,960,022-7,960,521 49 37 29 54 34 26 59 41 33 61 39 31
Exon5 F4 chr6:7,959,593-7,960,099 55 34 26 60 41 33 62 39 31
Exon5 F5 chr6:7,959,165-7,959,661 56 38 30 60 43 35 62 41 33
Table 9.3.2 Parameters for dHPLC analysis o f MUTED exons and putative promoter. Temperature plus initial and final concentrations for buffer B are given for 
each assay. Optimal temperatures and corresponding elute gradients for each PCR fragment were selected using dHPLC Melt
(http://insertion.stanford.edu/melt.html). In addition to the temperature suggested by the software (n°C), each fragment was also run at n+2°C to ensure maximum 
sensitivity.
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rs909706 rs2619539 r s l 2524251 rs2619538 SNPK rs9476$88 r s l 047631 r s l 2525702 rs2743852 SNPN rs!213207 rs12204704 r s l 2527496 rs3829893 SNPO
rs1002308 0.814 (0.809) 0.713 (0.716) 0.735 (0.734) 0.846 (.850) 0.955 (0.949) 0.849 (0.956) 0.969 (0.980) 0.091 (0.907) 0.032 (0.351) 0.077 (0.088) 0.059 (0.624) 0.931 (0.928) 0.870 (0.859) 0.846 (0.824) N/A
Muted 5-5 N/A N/A N/A N/A 0.086 (0.999) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
r s t 0458217 0.646 (0.999) 0.273 (0.999) 0 820 (0.999) 0.607 (0.999) 0 988 (0.999) 0.332 (0.999) 0.508 (0.999) 0.783 (0.999) 0.188 (0.999) 0.112 (0.999) 0.205 (0.899) 0.535 (0.999) 0.956 (0.999) 0.964 (0.999) N/A
rs2057185 0.707 (0.999) 0.217 (0.999) 0 313 (0.999) 0.961 (0.999) 0.679 (0.999) 0.670 (0.999) 0.183 (0.999) 0.171 (0.999) 0.824 (0.999) 0.179 (0.999) 0.456 (0.999) 0.0161 (0.882) 0.478 (0.999) 0.451 (0.999) N/A
r s l 3202814 0.883 (0.999) 0.963 (0.999) 0.977 (0.999) 0.857 (0.999) 0.235 (0.999) 0.770 (0.999) 0.821 (0.999) 0.297 (0.999) 0.776 (0.999) 0.136 (0.099) 0.683 (0.899) 0.021 (0.884) 0.100 (0.999) 0.103 (0.999) N/A
rs2207720 0.806 (0.999) 0.660 (0.999) 0.061 (0.950) 0.044 (0.975) 0.568 (0.991) 0.189 (0.999) 0.147 (0.965) 0.212 (0.996) 0.105 (0.999) 0.357 (0.999) 0.627 (0.999) 0.527 (0.999) 0.217 (0.999) 0.222 (0.999) N/A
rs9328452 0.997 (0.999) 0.769 (0.999) 0.021 (0 830) 0.075 (0.996) 0.026 (0 999) 0.606 (0.999) 0.078 (0.999) 0.074 (0.999) 0.824 (0.999) 0.141 (0.999) 0.519 (0.999) 0.002 (0.289) 0.015 (0.798) 0.017 (0.831) N/A
rs9502$75 0.876 (0.999) 0.687 (0.999) 0.204 (0.999) 0.864 (0.999) 0.187 (0.999) 0.593 (0.999) 0.039 (0 999) 0.720 (0.999) 0.402 (0.999) 0.170 (0.999) 0.641 (0.989) 0.418 (0.999) 0.170 (0.999) 0.173 (0.999) N/A
r s l 3218209 0.760 (0.999) 0.454 (0.999) 0.149 (0.999) 0.546 (0.999) 0.644 (0.999) 0.254 (0.999) 0.564 (0.999) 0.810 (0.999) 0.787 (0.999) 0.079 (0.996) 0.858 (0.999) 0.006 (0.561) 0.688 (0.999) 0.619 (0.999) N/A
rs2206098 0.740 (0.999) 0.661 (0.999) 0.242 (0.999) 0.865 (0.999) 0.182 (0.999) 0.677 (0.999) 0.751 (0.999) 0.041 (0.971) 0.984 (0.999) 0.282 (0.999) 0.665 (0.999) 0.007 (0 569) 0.173 (0.999) 0.155 (0.999) N/A
rs2815145 0.924 (0.999) 0 368 (0.999) 0.183 (0.999) 0.135 (0.999) 0.068 (0.999) 0.386 (0.999) 0.141 (0.999) 0.084 (0.999) 0.297 (0.999) 0.041 (0.971) 0.444 (0.999) 0.012 (0.737) 0.196 (0.999) 0.186 (0.999) N/A
rs2743986 0.824 (0.999) 0.325 (0.999) 0.433 (0.999) 0.840 (0.999) 0.181 (0.999) 0.667 (0.999) 0.475 (0.999) 0.194 (0.999) 0.534 (0.999) 0.138 (0,999) 0.601 (0.999) 0.076 (0.998) 0.365 (0.999) 0.337 (0.999) N/A
rs2326975 0 104 (0.999) 0.438 (0.999) 0.815 (0.999) 0.354 (0.999) 0.098 (0.999) 0.817 (0.999) 0.559 (0.999) 0.164 (0.999) 0.333 (0.999) 0.486 (0.999) 0.812 (0.999) 0.302 (0.999) 0.529 (0.999) 0.592 (0.999) N/A
rs9392958 0.645 (0.999) 0.315 (0.999) 0.974 (0.999) 0.204 (0.999) 0.999 (0.999) 0.923 (0.999) 0.576 (0.999) 0.537 (0.999) 0.345 (0.999) 0.244 (0.999) 0.577 (0.999) 0.556 (0.999) 1.000 (0.999) 0.998 (0.999) N/A
rs9378519 0.571 (0.999) 0.117 (0.999) 0.644 (0.999) 0.944 (0.999) 0.662 (0.999) 0.943 (0.999) 0.378 (0.999) 0.354 (0.999) 0.414 (0.999) 0.445 (0.999) 0.215 (0.999) 0.418 (0.999) 0.629 (0.999) 0.601 (0.999) N/A
rs l  0458106 0.721 (0.999) 0.345 (0.999) 0.841 (0.999) 0.613 (0.999) 0.961 (0.999) 0.415 (0.999) 0.365 (0.999) 0.816 (0.999) 0.226 (0.999) 0.128 (0.999) 0.242 (0.999) 0.547 (0.999) 0.968 (0.999) 0.966 (0.999) N/A
rs13191023 0.948 (0.999) 0.976 (0.999) 0.982 (0.999) 0.892 (0.999) 0.192 (0.999) 0.541 (0.999) 0.736 (0.999) 0.297 (0.999) 0.839 (0.999) 0.115 (0.999) 0.763 (0.999) 0.015 (0.799) 0 084 (0.996) 0.087 (0 997) N/A
rs2815128 0.993 (0.999) 0.699 (0.999) 0.020 (0.856) 0.096 (0.997) 0 040 (0 980) 0.544 (0.999) 0.090 (0.997) 0.130 (0.999) 0.926 (0.999) 0.095 (0.997) 0.572 (0.999) 0.002 (0 207) 0.030 (0.945) 0.032 (0.954) N/A
rs2815151 0.893 (0.999) 0.891 (0.999) 0.966 (0.999) 0.613 (0.999) 0.968 (0.999) 0.377 (0.999) 0.342 (0.999) 0.750 (0.999) 0.370 (0.999) 0.0007 (0.106) 0.020 (0.735) 0.515 (0.999) 0.961 (0.999) 0.956 (0.999) N/A
Table 9.3.3A Interaction analysis between MUTED and DTNBP1 SNPs.
P-values are given uncorrected and amended for multiple testing in parentheses. Data was calculated using both the full additive model and dominant interactive 
model. Where the full interactive model could not be used a stepwise model was used to find the best term. These results are shaded in grey. N/A indicates that the 
marker pair could not be analysed as neither the specified interactive model nor any reduced model could be calculated. In these instances all interaction terms had 
either a high standard error for the coefficient estimates or singularities present. The ID’s o f the DTNBP1 SNPs are labelled as previously reported [134]. P values 
significantly associated are given in blue. Those still significant after permutation analysis are given in red.
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rs909706 rs2619539 rsl2624261 rs2619538 SNPK rs9476888 rs1047631 rs1262S702 rs2743852 SNPN rs3213207 rsl2204704 rsl2627496 rs3829893 SNPO
rs1002308 0.969 (0.999) 0.486 (0.999) 0.220 (0.999) 0.536 (0.999) 0.709 (0.999) 0.397 (0.999) 0.778 (0.999) 0.489 (0.999) 0.786 (0.999) 0.013 (0.774) 0.719 (0.999) 0.949 (0.999) 0.289 (0.999) 0.272 (0.999) N/A
Muted 5-5 0.885 (0.999) 0.670 (0.999) 0.809 (0.999) 0.731 (0.999) 0.847 (0.999) 0.098 (0.998) 0.920 (0.999) 0.382 (0.999) 0.177 (0.999) N/A 0.922 (0.999) 0.522 (0.999) 0.604 (0.999) 0.652 (0.999) N/A
rsl0458217 0.387 (0.999) 0.078 (0.997) 0.704 (0.999) 0.480 (0.999) 0.913 (0.999) 0.335 (0.999) 0.721 (0.999) 0.906 (0.999) 0.366 (0.999) 0.012 (0.757) 0.070 (0.995) 0.900 (0.999) 0.834 (0.999) 0.914 (0.999) N/A
rs2057185 0.205 (0.999) 0.384 (0.999) 0.174 (0.999) 0.954 (0.999) 0.680 (0.999) 0.887 (0.999) 0.728 (0.999) 0.341 (0.999) 0.940 (0.999) 0.069 (0.995) 0.583 (0.999) 0.799 (0.999) 0.279 (0.999) 0.305 (0.999) N/A
rs13202814 0.975 (0.999) 0.745 (0.999) 0.316 (0.999) 0.926 (0.999) 0.629 (0.999) 0.758 (0.999) 0.726 (0.999) 0.757 (0.999) 0.510 (0.999) 0.399 (0.999) 0.426 (0.999) 0.859 (0.999) 0.431 (0.999) 0.431 (0.999) N/A
rs2207720 0.570 (0.999) 0.389 (0.999) 0.040 (0.968) 0.830 (0.999) 0.284 (0.999) 0.309 (0.999) 0.234 (0.999) 0.353 (0.999) 0.188 (0.999) 0.538 (0.999) 0.135 (0.999) 0.317 (0.999) 0.114 (0.999) 0.088 (0.998) N/A
rs9328452 0.755 (0.999) 0.498 (0.999) 0.202 (0.999) 0.460 (0.999) 0.472 (0.999) 0.554 (0.999) 0.332 (0.999) 0.461 (0.999) 0.418 (0.999) 0.373 (0.999) 0.141 (0.999) 0.127 (0.999) 0.224 (0.999) 0.208 (0.999) N/A
rs9502675 0.737 (0.999) 0.933 (0.999) 0.654 (0.999) 0.369 (0.999) 0.690 (0.999) 0.593 (0.999) 0.576 (0.999) 0.858 (0.999) 0.443 (0.999) 0.535 (0.999) 0.421 (0.999) 0.105 (0.998) 0.748 (0.999) 0.710 (0.999) N/A
rsl3218209 0.469 (0.999) 0.205 (0.999) 0.534 (0.999) 0.519 (0.999) 0.765 (0.999) 0.282 (0.999) 0.951 (0.999) 0.721 (0.999) 0.829 (0.999) 0.235 (0.999) 0.304 (0.999) 0.951 (0.999) 0.540 (0.999) 0.480 (0.999) N/A
rs2206098 0.253 (0.999) 0.324 (0.999) 0.068 (0.995) 0.524 (0.999) 0.207 (0.999) 0.642 (0.999) 0.347 (0.999) 0.198 (0.999) 0.780 (0.999) 0.155 (0.999) 0.212 (0.999) 0.052 (0.984) 0.077 (0.997) 0.079 (0.997) N/A
rs2815145 0.945 (0.999) 0.560 (0.999) 0.234 (0.999) 0.124 (0.999) 0.390 (0.999) 0.145 (0.999) 0.380 (0.999) 0.539 (0.999) 0.971 (0.999) 0.020 (0.668) 0.977 (0.999) 0.019 (0.860) 0.238 (0.999) 0.183 (0.999) N/A
rsl3207958 0.955 (0.999) 0.924 (0.999) 0.421 (0.999) 0.723 (0.999) 0.983 (0.999) 0.995 (0.999) 0.790 (0.999) 0.805 (0.999) 0.746 (0.999) 0.069 (0.999) 0.967 (0.999) 0.174 (0.999) 0.662 (0.999) 0.693 (0.999) N/A
rs9392956 0.975 (0.999) 0.811 (0.999) 0.863 (0.999) 0.971 (0.999) 0.276 (0.999) 0.658 (0.999) 0.744 (0.999) 0.264 (0.999) 0.398 (0.999) 0.513 (0.999) 0.875 (0.999) 0.970 (0.999) 0.564 (0.999) 0.649 (0.999) N/A
rs9392958 0.378 (0.999) 0.184 (0.999) 0.571 (0.999) 0.512 (0.999) 0.886 (0.999) 0.827 (0.999) 0.498 (0.999) 0.779 (0.999) 0.521 (0.999) 0.062 (0.994) 0.549 (0.999) 0.397 (0.999) 0.992 (0.999) 0.952 (0.999) N/A
rs9378519 0.648 (0.999) 0.450 (0.999) 0.829 (0.999) 0.822 (0.999) 0.736 (0.999) 0.942 (0.999) 0.543 (0.999) 0.931 (0.999) 0.606 (0.999) 0.222 (0.999) 0.459 (0.999) 0.521 (0.999) 0.996 (0.999) 0.964 (0.999) N/A
rs10458106 0.366 (0.999) 0.092 (0.998) 0.875 (0.999) 0.428 (0.999) 0.802 (0.999) 0.486 (0.999) 0.795 (0.999) 0.935 (0.999) 0.312 (0.999) 0.014 (0.797) 0.079 (0.996) 0.820 (0.999) 0.923 (0.999) 0.892 (0.999) N/A
rs13191023 0.993 (0.999) 0.800 (0.999) 0.350 (0.999) 0.943 (0.999) 0.741 (0.999) 0.694 (0.999) 0.821 (0.999) 0.696 (0.999) 0.586 (0.999) 0.552 (0.999) 0.631 (0.999) 0.664 (0.999) 0.439 (0.999) 0.443 (0.999) N/A
rs2815128 0.601 (0.999) 0.455 (0.999) 0.171 (0.999) 0.423 (0.999) 0.498 (0.999) 0.768 (0.999) 0.393 (0.999) 0.548 (0.999) 0.534 (0.999) 0.520 (0.999) 0.157 (0.999) 0.082 (0.998) 0.262 (0.999) 0.239 (0.999) N/A
rs2815151 0.785 (0.999) 0.757 (0.999) 0.873 (0.999) 0.688 (0.999) 0.910 (0.999) 0.426 (0.999) 0.253 (0.999) 0.963 (0.999) 0.529 (0.999) 0.0001 (0.026) 0.917 (0.999) 0.741 (0.999) 0.832 (0.999) 0.868 (0.999) N/A
Table 9.3.3B. Interaction analysis between MUTED and DTNBP1 SNPs.
P-values are given uncorrected and amended for multiple testing in parenthesis. Data was calculated the additive model. N/A indicates that the marker pair could not 
be analysed as neither the specified interactive model nor any reduced model could be calculated. In these instances all interaction terms had either a high standard 
error for the coefficient estimates or singularities present. The ID’s o f the DTNBP1 SNPs are labelled as previously reported [134]. P values significantly associated 
are given in blue. Those still significant after permutation analysis are given in red.
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